QTL_RGD_ID SPECIES QTL_SYMBOL QTL_NAME CHROMOSOME_FROM_REF LOD P_VALUE VARIANCE FLANK_1_RGD_ID FLANK_1_SYMBOL FLANK_2_RGD_ID FLANK_2_SYMBOL PEAK_RGD_ID PEAK_MARKER_SYMBOL TRAIT_NAME SUBTRAIT_NAME TRAIT_METHODOLOGY PHENOTYPES ASSOCIATED_DISEASES CURATED_REF_RGD_ID CURATED_REF_PUBMED_ID CANDIDATE_GENE_RGD_IDS CANDIDATE_GENE_SYMBOLS INHERITANCE_TYPE RELATED_QTLS OMIM_ID MAP_POS_CHR MAP_POS_START MAP_POS_STOP MAP_POS_METHOD
1298408 human BP7_H Blood pressure QTL 7 (human) 12 3.44 1298193 D12S1715 1298188 D12S1591 1298164 D12S1682 Blood pressure hypertension susceptibility genome-wide scan for loci contributing to essential hypertension in a large Chinese kindred and 32 additional Chinese nuclear families with essential hypertension increased systemic arterial blood pressure Hypertension 738126 12761042 608742 12 16588250 23985107 1 - by flanking markers
1298409 human BP13_H Blood pressure QTL 13 (human) 18 2.09 1298119 D18S844 Blood pressure systolic genome-wide scan for loci contributing to blood pressure in a sample of Mexican American families chosen without regard to blood pressure status increased systemic arterial blood pressure Hypertension 738133 11255245 18 59483761 76117153 3 - by peak only
1298410 human OSTEAR24_H Osteoarthritis QTL 24 (human) 4 5.73 1298122 D4S408 1298175 D4S3051 1298155 D4S2924 Joint/bone inflammation Beukes hip dysplasia genome-wide scan was undertaken to find the gene responsible for Beukes hip dysplasia, an autosomal dominant form of premature degenerative osteoarthritis of the hip chronic joint inflammation Osteoarthritis, Hip 1298026 10053028 dominant 142669 4 185388083 188262156 1 - by flanking markers
1298411 human BFD2_H Body fluid distribution QTL 2 (human) 5 4.49 1298246 D5S1470 1298298 D5S2500 1298276 D5S623 Body fluid distribution impedance ratio genome-wide scan for loci affecting body fluid distribution (bioelectrical impedance ratio) in 150 African American affected sib pairs with essential hypertension abnormal water content Metabolic Syndrome X 738096 12411455 5 32528047 58733101 1 - by flanking markers
1298412 human RA1_H Rheumatoid arthritis QTL 1 (human) 1 0.0141 1298283 D2S396 Joint/bone inflammation rheumatoid arthritis genome-wide linkage scans were examined in families with at least two siblings diagnosed with rheumatoid arthritis with onset between 18 and 60 years of age chronic joint inflammation Arthritis, Rheumatoid 738125 11254450 dominant 180300 2 217392009 242951149 3 - by peak only
1298413 human OSTEAR18_H Osteoarthritis QTL 18 (human) 4 2.61 1298181 D4S2982 1298136 D4S3046 1298136 D4S3046 Joint/bone inflammation ideopathic hand osteoarthritis genome-wide scan of Icelandic patients diagnosed with ideopathic arthritis of the hand were compared with unrelated Icelandic control individuals chronic joint inflammation Osteoarthritis 738123 12736871 607850 4 161313902 163610518 1 - by flanking markers
1298414 human BFD5_H Body fluid distribution QTL 5 (human) 7 3.16 1298266 D7S2212 1298320 D7S821 1298256 D7S1813 Body fluid distribution impedance ratio genome-wide scan for loci affecting body fluid distribution (bioelectrical impedance ratio) in 150 African American affected sib pairs with essential hypertension abnormal water content Metabolic Syndrome X 738096 12411455 7 82634724 95895699 1 - by flanking markers
1298415 human BP24_H Blood pressure QTL 24 (human) 3 2.9 68977 AGTR1 Blood pressure hypertension susceptibility analysis of candidate genes for loci affecting susceptibility to essential hypertension in Finnish hypertensive affected sibling pairs increased systemic arterial blood pressure Hypertension 1298037 10082497 BP36_H 3 136920916 162920916 3 - by peak only
1298416 human OSTEAR13_H Osteoarthritis QTL 13 (human) 4 1.89 1.0E-4 733315 Il2 1298110 D4S1644 1298161 D4S2394 Joint/bone inflammation distal interphalangeal joint osteoarthritis genome-wide scan of 64 Finnish patients diagnosed with osteoarthritis of interphalangeal or metacarpophalangeal joints were compared with members of 16 unaffected Finnish core families chronic joint inflammation Osteoarthritis 738112 10486325 recessive 4 119063704 141971108 2 - by one flank and peak markers
1298417 human OSTEAR26_H Osteoarthritis QTL 26 (human) 4 3.1 1298324 D4S1600 1298331 D4S392 1298309 D4S3253 Joint/bone inflammation hip osteoarthritis genome-wide linkage scans were examined in families with at least two siblings who had undergone total hip or knee replacement for primary ideopathic osteoarthritis chronic joint inflammation Osteoarthritis, Hip 738108 14730605 OA21_H 4 62580246 70558137 1 - by flanking markers
1298418 human OSTEAR28_H Osteoarthritis QTL 28 (human) 16 1.9 Joint/bone inflammation hip osteoarthritis genome-wide linkage scans were examined in families with at least two siblings who had undergone total hip or knee replacement for primary ideopathic osteoarthritis chronic joint inflammation Osteoarthritis, Hip 738108 14730605
1298419 human OSTEAR20_H Osteoarthritis QTL 20 (human) 2 1.48 1298157 D2S175 1298100 D2S2201 1298125 D2S146 Joint/bone inflammation ideopathic hand osteoarthritis genome-wide scan of Icelandic patients diagnosed with ideopathic arthritis of the hand were compared with unrelated Icelandic control individuals chronic joint inflammation Osteoarthritis 738123 12736871 607850 2 19805423 21429675 1 - by flanking markers
1298420 human OSTEAR5_H Osteoarthritis QTL 5 (human) 11 1.6 1298156 D11S2371 1298202 D11S2002 1298156 D11S2371 Joint/bone inflammation hand osteoarthritis two generations of subjects from the Framingham Heart Study diagnosed with joint space narrowing in the hand underwent genome-wide scans for longitudinal study of hand osteoarthritis chronic joint inflammation Osteoarthritis 1285226 11953971 11 73182779 79643288 1 - by flanking markers
1298421 human BP35_H Blood pressure QTL 35 (human) 17 1.0E-4 1298263 D17S946 1298171 D17S949 1298308 D17S934 Blood pressure hypertension susceptibility analysis of affected sib pairs for loci affecting blood pressure in a region of human chromosome 17 that has homology to a rat chromosome 10 region containing blood pressure QTLs increased systemic arterial blood pressure Hypertension 1298214 9328471 603918 17 34106437 65977271 1 - by flanking markers
1298422 human RA14_H Rheumatoid arthritis QTL 14 (human) 8 0.0088 1298326 D8S277 Joint/bone inflammation rheumatoid arthritis genome-wide linkage scans were examined in families with at least two siblings diagnosed with rheumatoid arthritis with onset between 18 and 60 years of age chronic joint inflammation Arthritis, Rheumatoid 738125 11254450 dominant 180300 8 1 19504205 3 - by peak only
1298423 human OSTEAR23_H Osteoarthritis QTL 23 (human) 16 2.1 1298187 D16S407 1298200 D16S261 1298143 D16S287 Joint/bone inflammation hip osteoarthritis genome-wide linkage scans were examined in families with at least two siblings who had undergone total hip or knee replacement for primary ideopathic osteoarthritis chronic joint inflammation Osteoarthritis, Hip 1298025 10577938 16 10184882 47795700 1 - by flanking markers
1298424 human OSTEAR21_H Osteoarthritis QTL 21 (human) 4 3.9 1298147 D4S398 1298194 D4S250 Joint/bone inflammation hip osteoarthritis genome-wide linkage scans were examined in families with at least two siblings who had undergone total hip or knee replacement for primary ideopathic osteoarthritis chronic joint inflammation Osteoarthritis, Hip 1298025 10577938 4 61929562 139976238 2 - by one flank and peak markers
1298425 human OSTEAR29_H Osteoarthritis QTL 29 (human) 2 0.05 1298262 D2S111 1298284 D2S103 1298281 D2S326 Joint/bone inflammation nodal osteoarthritis genome-wide linkage scans were examined in affected sibling pairs diagnosed with polyarticular interphalangeal osteoartritis with Heberden's nodes in each hand chronic joint inflammation Osteoarthritis 1298211 8660106 2 165968478 179641996 2 - by one flank and peak markers
1298426 human BFD3_H Body fluid distribution QTL 3 (human) 6 2.79 1298273 D6S1270 1298206 D6S1021 1298306 D6S1056 Body fluid distribution impedance ratio genome-wide scan for loci affecting body fluid distribution (bioelectrical impedance ratio) in 150 African American affected sib pairs with essential hypertension abnormal water content Metabolic Syndrome X 738096 12411455 6 83527949 104780753 2 - by one flank and peak markers
1298427 human RA9_H Rheumatoid arthritis QTL 9 (human) 5 0.0066 1298299 D5S1457 Joint/bone inflammation rheumatoid arthritis genome-wide linkage scans were examined in families with at least two siblings diagnosed with rheumatoid arthritis with onset between 18 and 60 years of age chronic joint inflammation Arthritis, Rheumatoid 738125 11254450 dominant 180300 5 28069671 54069671 3 - by peak only
1298428 human BP8_H Blood pressure QTL 8 (human) 15 1.6E-5 1298146 D15S203 Blood pressure diastolic multipoint linkage analysis of affected sibling pairs for loci affecting blood pressure in rural Chinese sib pairs concordant for extreme low diastolic blood pressure increased systemic arterial blood pressure Hypertension 738127 10556304 604329 15 84446609 100338915 3 - by peak only
1298429 human BP23_H Blood pressure QTL 23 (human) 2 3.36 1298264 D2S324 1298231 D2S325 Blood pressure diastolic genome wide scan for loci affecting blood pressure in Old Order Amish population increased systemic arterial blood pressure Hypertension 1298033 10859286 2 179364489 207979229 1 - by flanking markers
1298430 human RA27_H Rheumatoid arthritis QTL 27 (human) 17 0.0053 1298314 D17S1308 1298294 D17S1298 Joint/bone inflammation rheumatoid arthritis genome-wide linkage scans were examined in families with at least two siblings diagnosed with rheumatoid arthritis with onset between 18 and 60 years of age chronic joint inflammation Arthritis, Rheumatoid 738125 11254450 dominant 180300 17 569917 6656925 2 - by one flank and peak markers
1298431 human RA11_H Rheumatoid arthritis QTL 11 (human) 6 2.4E-6 1298151 D6S1959 1298131 D6S291 1298191 D6S265 Joint/bone inflammation rheumatoid arthritis genome-wide linkage scans were examined in families with at least two siblings diagnosed with rheumatoid arthritis with onset between 18 and 60 years of age chronic joint inflammation Arthritis, Rheumatoid 738125 11254450 dominant 180300 6 17127552 43127552 3 - by peak only
1298432 human OSTEAR10_H Osteoarthritis QTL 10 (human) 2 2.34 1.0E-4 1298207 D2S2209 1298149 D2S293 735430 IL1R1 Joint/bone inflammation distal interphalangeal joint osteoarthritis genome-wide scan of 64 Finnish patients diagnosed with osteoarthritis of interphalangeal or metacarpophalangeal joints were compared with members of 16 unaffected Finnish core families chronic joint inflammation Osteoarthritis 738112 10486325 dominant OA11_H;OA12_H 140600 2 100608635 106640386 1 - by flanking markers
1298433 human BP17_H Blood pressure QTL 17 (human) 1 0.0162 1298303 D1S1612 Blood pressure hypertension susceptibility nonparametric analysis of markers near 18 candidate genes for loci affecting young-onset hypertension in Han Chinese affected sib pairs increased systemic arterial blood pressure Hypertension 1298024 11071381 1 1 21040628 3 - by peak only
1298434 human BP1_H Blood pressure QTL 1 (human) 4 3.9 1298103 D4S2366 1298180 D4S2397 1298204 D4S2639 Blood pressure systolic genome-wide scan for blood pressure variation in 18 Dutch families with familial combined hyperlipidemia (FCH) in which affected individuals have lipid abnormalities, hypertension, and elevated fasting insulin levels increased circulating free fatty acid level;increased systemic arterial blood pressure Hypertension;Hyperlipidemia, Familial Combined 738095 11641285 144250 4 6535686 26867101 1 - by flanking markers
1298435 human OSTEAR6_H Osteoarthritis QTL 6 (human) 12 1298109 D12S1045 1298101 D12S392 1298101 D12S392 Joint/bone inflammation hand osteoarthritis two generations of subjects from the Framingham Heart Study diagnosed with joint space narrowing in the hand underwent genome-wide scans for longitudinal study of hand osteoarthritis chronic joint inflammation Osteoarthritis 1285226 11953971 12 128963691 132349534 4 - by one flank marker only
1298436 human OSTEAR8_H Osteoarthritis QTL 8 (human) 19 1.82 1298168 D19S433 Joint/bone inflammation hand osteoarthritis two generations of subjects from the Framingham Heart Study diagnosed with joint space narrowing in the hand underwent genome-wide scans for longitudinal study of hand osteoarthritis chronic joint inflammation Osteoarthritis 1285226 11953971 19 22108969 48108969 3 - by peak only
1298437 human BW19_H Body weight QTL 19 (human) 1 3.7 1298271 D1S518 1298247 D1S3465 1298252 D1S1660 Body weight body mass index body weight and body mass index, plasma insulin, and pancreatic morphology were assessed; body mass index was calculated from body weight and nasoanal body length; plasma glucose concentration was determined by glucose oxidase assay increased body mass index Obesity 738096 12411455 1 185816911 205426124 1 - by flanking markers
1298438 human BP4_H Blood pressure QTL 4 (human) 6 2.5 1298134 D6S1017 1298206 D6S1021 1298166 D6S1031 Blood pressure diastolic genome-wide scan for blood pressure variation in 18 Dutch families with familial combined hyperlipidemia (FCH) in which affected individuals have lipid abnormalities, hypertension, and elevated fasting insulin levels increased systemic arterial blood pressure Hypertension 738095 11641285 144250 6 41785174 104780753 1 - by flanking markers
1298439 human BP30_H Blood pressure QTL 30 (human) 3 2.03 1298321 D3S2432 1298277 D3S2387 Blood pressure systolic genome-wide linkage scan for loci affecting blood pressure in rural Chinese sibling pairs with blood pressure extremes abnormal systemic arterial blood pressure 1298213 10330357 145500 3 1 32140379 2 - by one flank and peak markers
1298440 human OSTEAR11_H Osteoarthritis QTL 11 (human) 2 2.51 1298183 D2S1896 1298113 D2S2254 1298137 D2S410 Joint/bone inflammation distal interphalangeal joint osteoarthritis genome-wide scan of 64 Finnish patients diagnosed with osteoarthritis of interphalangeal or metacarpophalangeal joints were compared with members of 16 unaffected Finnish core families chronic joint inflammation Osteoarthritis 738112 10486325 dominant OA10_H;OA12_H 140600 2 112409640 119705531 1 - by flanking markers
1298441 human RA2_H Rheumatoid arthritis QTL 2 (human) 1 0.0048 1298318 D1S235 Joint/bone inflammation rheumatoid arthritis genome-wide linkage scans were examined in families with at least two siblings diagnosed with rheumatoid arthritis with onset between 18 and 60 years of age chronic joint inflammation Arthritis, Rheumatoid 738125 11254450 dominant 180300 1 220960531 246960531 3 - by peak only
1298442 human RA7_H Rheumatoid arthritis QTL 7 (human) 4 1.0E-4 1298248 D4S1647 Joint/bone inflammation rheumatoid arthritis genome-wide linkage scans were examined in families with at least two siblings diagnosed with rheumatoid arthritis with onset between 18 and 60 years of age chronic joint inflammation Arthritis, Rheumatoid 738125 11254450 dominant 180300 4 86654067 112654067 3 - by peak only
1298443 human BP15_H Blood pressure QTL 15 (human) 17 0.025 1298144 D17S799 Blood pressure hypertension susceptibility chromosome 17 linkage scan for loci contributing to essential hypertension in 177 affected sibpairs of British descent increased systemic arterial blood pressure Hypertension 1298023 11702222 145500 17 111790 26111790 3 - by peak only
1298444 human BP32_H Blood pressure QTL 32 (human) 15 2.69 1298332 D15S822 1298311 D15S657 Blood pressure diastolic genome-wide linkage scan for loci affecting blood pressure in rural Chinese sibling pairs with blood pressure extremes abnormal systemic arterial blood pressure Hypertension 1298213 10330357 BP8_H 604329 15 24973428 100338915 2 - by one flank and peak markers
1298447 human RA17_H Rheumatoid arthritis QTL 17 (human) 9 0.0244 1298236 D9S2157 Joint/bone inflammation rheumatoid arthritis genome-wide linkage scans were examined in families with at least two siblings diagnosed with rheumatoid arthritis with onset between 18 and 60 years of age chronic joint inflammation Arthritis, Rheumatoid 738125 11254450 dominant 180300 9 122025441 140273252 3 - by peak only
1298404 human OSTEAR25_H Osteoarthritis QTL 25 (human) 2 1.23 0.0086 1298259 D2S157 1298257 D2S117 1298255 D2S272 Joint/bone inflammation hip osteoarthritis genome-wide scans were conducted in affected sib pairs who had undergone total hip or knee replacement for primary ideopathic osteoarthritis chronic joint inflammation Osteoarthritis, Hip 734502 10817769 2 195327241 210914566 1 - by flanking markers
1298405 human OSTEAR19_H Osteoarthritis QTL 19 (human) 3 1.79 1298116 D3S1562 1298196 D3S1274 1298160 D3S3551 Joint/bone inflammation ideopathic hand osteoarthritis genome-wide scan of Icelandic patients diagnosed with ideopathic arthritis of the hand were compared with unrelated Icelandic control individuals chronic joint inflammation Osteoarthritis 738123 12736871 607850 3 71306508 78954026 1 - by flanking markers
1298406 human BP16_H Blood pressure QTL 16 (human) 17 4.0E-4 730951 NOS2 Blood pressure hypertension susceptibility chromosome 17 candidate gene analysis for loci contributing to essential hypertension in 177 affected sibpairs of British descent increased systemic arterial blood pressure Hypertension 1298023 11702222 145500 17 10129800 36129800 3 - by peak only
1298407 human BFD4_H Body fluid distribution QTL 4 (human) 6 2.52 1298251 D6S474 1298296 D6S1009 1298242 D6S1040 Body fluid distribution impedance ratio genome-wide scan for loci affecting body fluid distribution (bioelectrical impedance ratio) in 150 African American affected sib pairs with essential hypertension abnormal water content Metabolic Syndrome X 738096 12411455 6 112985799 137344123 1 - by flanking markers
1298448 human BP6_H Blood pressure QTL 6 (human) 10 2.5 1298105 D10S189 1298189 D10S1423 Blood pressure hypertension susceptibility genome-wide scan for loci affecting blood pressure in 1425 sib pairs (concordant and discordant) of Chinese and Japanese origins increased systemic arterial blood pressure Hypertension 738098 12559686 10 6761916 19478134 1 - by flanking markers
1298449 human UAE2_H Urinary albumin excretion QTL 2 (human) 12 2.0 0.005 735410 PAH Urinary albumin excretion urine albumin:creatinine ratio (ACR) genome-wide scan for loci affecting urinary albumin excretion in 2589 individuals from 805 hypertensive families in the Family Blood Pressure Program albuminuria Albuminuria 738099 12925555 12 101756234 127756234 4 - by one flank marker only
1298450 human RA8_H Rheumatoid arthritis QTL 8 (human) 5 0.043 1298334 D5S2848 Joint/bone inflammation rheumatoid arthritis genome-wide linkage scans were examined in families with at least two siblings diagnosed with rheumatoid arthritis with onset between 18 and 60 years of age chronic joint inflammation Arthritis, Rheumatoid 738125 11254450 dominant 180300 5 13811395 39811395 3 - by peak only
1298451 human OSTEAR17_H Osteoarthritis QTL 17 (human) 11 2.4 4.0E-4 1298224 TNFRSF1B Joint/bone inflammation osteoarthritis genome-wide scans were conducted in affected sib pairs who had undergone total hip or knee replacement for primary ideopathic osteoarthritis chronic joint inflammation Osteoarthritis 1285222 10364529 165720 1 1 25170755 3 - by peak only
1298500 human RA19_H Rheumatoid arthritis QTL 19 (human) 11 0.0258 1298235 D11S1998 Joint/bone inflammation rheumatoid arthritis genome-wide linkage scans were examined in families with at least two siblings diagnosed with rheumatoid arthritis with onset between 18 and 60 years of age chronic joint inflammation Arthritis, Rheumatoid 738125 11254450 dominant 180300 11 104203048 130203048 3 - by peak only
1298501 human RA25_H Rheumatoid arthritis QTL 25 (human) 16 0.0042 1298329 D16S403 Joint/bone inflammation rheumatoid arthritis genome-wide linkage scans were examined in families with at least two siblings diagnosed with rheumatoid arthritis with onset between 18 and 60 years of age chronic joint inflammation Arthritis, Rheumatoid 738125 11254450 dominant 180300 16 9945229 35945229 3 - by peak only
1298502 human OSTEAR3_H Osteoarthritis QTL 3 (human) 7 2.32 1298142 D7S1806 1298099 D7S2846 1298114 D7S817 Joint/bone inflammation hand osteoarthritis two generations of subjects from the Framingham Heart Study diagnosed with joint space narrowing in the hand underwent genome-wide scans for longitudinal study of hand osteoarthritis chronic joint inflammation Osteoarthritis 1285226 11953971 7 29472317 38101569 1 - by flanking markers
1298503 human BW20_H Body weight QTL 20 (human) 8 3.43 1298265 D8S1179 1298150 D8S373 1298230 D8S1128 Body weight body mass index body weight and body mass index, plasma insulin, and pancreatic morphology were assessed; body mass index was calculated from body weight and nasoanal body length; plasma glucose concentration was determined by glucose oxidase assay increased body mass index Obesity 738096 12411455 8 125976261 144296716 1 - by flanking markers
1298504 human OSTEAR15_H Osteoarthritis QTL 15 (human) 9 2.23 0.03 1298108 D9S1850 1298115 DBH 1298165 D9S915 Joint/bone inflammation distal interphalangeal joint osteoarthritis genome-wide scan of 64 Finnish patients diagnosed with osteoarthritis of interphalangeal or metacarpophalangeal joints were compared with members of 16 unaffected Finnish core families chronic joint inflammation Osteoarthritis 738112 10486325 recessive 9 122490084 140273252 2 - by one flank and peak markers
1298506 human RA15_H Rheumatoid arthritis QTL 15 (human) 8 0.0187 1298285 D8S1110 Joint/bone inflammation rheumatoid arthritis genome-wide linkage scans were examined in families with at least two siblings diagnosed with rheumatoid arthritis with onset between 18 and 60 years of age chronic joint inflammation Arthritis, Rheumatoid 738125 11254450 dominant 180300 8 40343661 66343661 3 - by peak only
1298507 human BW8_H Body weight QTL 8 (human) 5 1.9 0.0017 1298186 D5S817 Body weight body mass index Genome wide scan for obesity in African Americans who were recruited as part of a blood pressure program obese;increased body mass index Obesity 738103 11812767 5 1 24638615 3 - by peak only
1298508 human RA10_H Rheumatoid arthritis QTL 10 (human) 5 0.0079 1298254 D5S1501 1298261 D5S1462 Joint/bone inflammation rheumatoid arthritis genome-wide linkage scans were examined in families with at least two siblings diagnosed with rheumatoid arthritis with onset between 18 and 60 years of age chronic joint inflammation Arthritis, Rheumatoid 738125 11254450 dominant 180300 5 78504210 114308558 2 - by one flank and peak markers
1298509 human RA21_H Rheumatoid arthritis QTL 21 (human) 12 0.0051 1298304 D12S398 Joint/bone inflammation rheumatoid arthritis genome-wide linkage scans were examined in families with at least two siblings diagnosed with rheumatoid arthritis with onset between 18 and 60 years of age chronic joint inflammation Arthritis, Rheumatoid 738125 11254450 dominant 180300 12 38483417 64483417 3 - by peak only
1298510 human RA28_H Rheumatoid arthritis QTL 28 (human) 17 0.0054 1298272 D17S2180 Joint/bone inflammation rheumatoid arthritis genome-wide linkage scans were examined in families with at least two siblings diagnosed with rheumatoid arthritis with onset between 18 and 60 years of age chronic joint inflammation Arthritis, Rheumatoid 738125 11254450 dominant 180300 17 31028167 57028167 3 - by peak only
1298511 human RA3_H Rheumatoid arthritis QTL 3 (human) 3 0.0139 1298316 D3S3038 Joint/bone inflammation rheumatoid arthritis genome-wide linkage scans were examined in families with at least two siblings diagnosed with rheumatoid arthritis with onset between 18 and 60 years of age chronic joint inflammation Arthritis, Rheumatoid 738125 11254450 dominant 180300 3 8924608 34924608 3 - by peak only
1298512 human RA29_H Rheumatoid arthritis QTL 29 (human) 17 0.0017 1298312 D17S1301 Joint/bone inflammation rheumatoid arthritis genome-wide linkage scans were examined in families with at least two siblings diagnosed with rheumatoid arthritis with onset between 18 and 60 years of age chronic joint inflammation Arthritis, Rheumatoid 738125 11254450 dominant 180300 17 57192606 78774742 3 - by peak only
1298513 human BP22_H Blood pressure QTL 22 (human) 11 0.004 1298323 D11S934 Blood pressure hypertension susceptibility genome wide scan for loci affecting susceptibility to essential hypertension in Caucasian affected sib pairs from East Anglia UK increased systemic arterial blood pressure Hypertension 1298032 10856279 11 112585636 134452384 3 - by peak only
1298514 human RA13_H Rheumatoid arthritis QTL 13 (human) 6 0.0075 1298206 D6S1021 Joint/bone inflammation rheumatoid arthritis genome-wide linkage scans were examined in families with at least two siblings diagnosed with rheumatoid arthritis with onset between 18 and 60 years of age chronic joint inflammation Arthritis, Rheumatoid 738125 11254450 dominant 180300 6 91780683 117780683 3 - by peak only
1298515 human PREECLM1_H Pre-eclampsia/eclampsia QTL 1 (human) 2 4.7 1298163 D2S292 1298130 D2S329 1298185 D2S286 Pre-eclampsia/elampsia pre-eclampsia susceptibility genome-wide scan for loci contributing to pre-eclampsia in Icelandic families with 343 affected women proteinuria;increased systemic arterial blood pressure Pre-Eclampsia 738129 10441346 189800 2 70555586 79235045 1 - by flanking markers
1298452 human OSTEAR16_H Osteoarthritis QTL 16 (human) 6 1.85 0.0016 1298223 COL9A1 Joint/bone inflammation hip osteoarthritis eleven candidate genes were examined in families with at least two siblings who had undergone total hip or knee replacement for primary ideopathic osteoarthritis chronic joint inflammation Osteoarthritis, Hip 738111 10788539 6 58026011 84026011 3 - by peak only
1298453 human BP11_H Blood pressure QTL 11 (human) 8 1.92 1298150 D8S373 Blood pressure diastolic genome-wide scan for loci contributing to blood pressure in a sample of Mexican American families chosen without regard to blood pressure status increased systemic arterial blood pressure Hypertension 738133 11255245 8 131296611 146274826 3 - by peak only
1298455 human RA30_H Rheumatoid arthritis QTL 30 (human) 18 0.0433 1298292 D18S858 Joint/bone inflammation rheumatoid arthritis genome-wide linkage scans were examined in families with at least two siblings diagnosed with rheumatoid arthritis with onset between 18 and 60 years of age chronic joint inflammation Arthritis, Rheumatoid 738125 11254450 dominant 180300 18 40048190 66048190 3 - by peak only
1298457 human RA18_H Rheumatoid arthritis QTL 18 (human) 10 0.0462 1298228 D10S1419 1298280 D10S2327 Joint/bone inflammation rheumatoid arthritis genome-wide linkage scans were examined in families with at least two siblings diagnosed with rheumatoid arthritis with onset between 18 and 60 years of age chronic joint inflammation Arthritis, Rheumatoid 738125 11254450 dominant 180300 10 67382154 93382154 3 - by peak only
1298458 human BW9_H Body weight QTL 9 (human) 6 2.7 2.0E-4 1298151 D6S1959 Body fat amount Genome wide scan for obesity in African Americans who were recruited as part of a blood pressure program obese;abnormal lateral ganglionic eminence morphology Obesity 738103 11812767
1298459 human BP19_H Blood pressure QTL 19 (human) 8 0.0284 1298274 D8S1145 Blood pressure hypertension susceptibility nonparametric analysis of markers near 18 candidate genes for loci affecting young-onset hypertension in Han Chinese affected sib pairs increased systemic arterial blood pressure Hypertension 1298024 11071381 8 5396942 31396942 3 - by peak only
1298460 human OSTEAR7_H Osteoarthritis QTL 7 (human) 13 1.61 1298148 D13S325 Joint/bone inflammation hand osteoarthritis two generations of subjects from the Framingham Heart Study diagnosed with joint space narrowing in the hand underwent genome-wide scans for longitudinal study of hand osteoarthritis chronic joint inflammation Osteoarthritis 1285226 11953971 13 29071455 55071455 3 - by peak only
1298461 human BP20_H Blood pressure QTL 20 (human) 17 0.0256 1298335 D17S2193 Blood pressure hypertension susceptibility nonparametric analysis of markers near 18 candidate genes for loci affecting young-onset hypertension in Han Chinese affected sib pairs increased systemic arterial blood pressure Hypertension 1298024 11071381 17 51059427 77059427 3 - by peak only
1298462 human OSTEAR14_H Osteoarthritis QTL 14 (human) 7 1.38 0.001 1298179 D7S2201 1298159 D7S673 1298140 D7S513 Joint/bone inflammation distal interphalangeal joint osteoarthritis genome-wide scan of 64 Finnish patients diagnosed with osteoarthritis of interphalangeal or metacarpophalangeal joints were compared with members of 16 unaffected Finnish core families chronic joint inflammation Osteoarthritis 738112 10486325 dominant 7 5597181 23815161 1 - by flanking markers
1298463 human BP9_H Blood pressure QTL 9 (human) 1 3.9 1298224 TNFRSF1B Blood pressure hypertension susceptibility study of association between TNFRSF1B and essential hypertension in 200 affected Anglo-Celtic Caucasian sib pairs increased systemic arterial blood pressure Hypertension 738128 10942422 145500 1 1 25170755 3 - by peak only
1298464 human BP18_H Blood pressure QTL 18 (human) 1 0.0263 1298297 D1S547 Blood pressure hypertension susceptibility nonparametric analysis of markers near 18 candidate genes for loci affecting young-onset hypertension in Han Chinese affected sib pairs increased systemic arterial blood pressure Hypertension 1298024 11071381 1 226822702 247249719 3 - by peak only
1298465 human BP14_H Blood pressure QTL 14 (human) 17 1.9 0.0029 1298171 D17S949 Blood pressure hypertension susceptibility chromosome 17 linkage scan for loci contributing to essential hypertension in 177 affected sibpairs of British descent increased systemic arterial blood pressure Hypertension 1298023 11702222 145500 17 52977161 78774742 3 - by peak only
1298466 human RA22_H Rheumatoid arthritis QTL 22 (human) 12 0.0227 1298293 D12S1052 Joint/bone inflammation rheumatoid arthritis genome-wide linkage scans were examined in families with at least two siblings diagnosed with rheumatoid arthritis with onset between 18 and 60 years of age chronic joint inflammation Arthritis, Rheumatoid 738125 11254450 dominant 180300 12 60895805 86895805 3 - by peak only
1298467 human OSTEAR9_H Osteoarthritis QTL 9 (human) 19 1.83 1298198 D19S178 Joint/bone inflammation hand osteoarthritis two generations of subjects from the Framingham Heart Study diagnosed with joint space narrowing in the hand underwent genome-wide scans for longitudinal study of hand osteoarthritis chronic joint inflammation Osteoarthritis 1285226 11953971 19 36097564 62097564 3 - by peak only
1298468 human BP34_H Blood pressure QTL 34 (human) 17 2.16 1298314 D17S1308 1298335 D17S2193 1298244 D17S1303 Blood pressure systolic genome-wide linkage scan for loci affecting blood pressure in rural Chinese sibling pairs with blood pressure extremes abnormal systemic arterial blood pressure Hypertension 1298213 10330357 145500 17 569917 64059498 1 - by flanking markers
1298469 human RA23_H Rheumatoid arthritis QTL 23 (human) 14 0.0174 1298288 D14S1280 Joint/bone inflammation rheumatoid arthritis genome-wide linkage scans were examined in families with at least two siblings diagnosed with rheumatoid arthritis with onset between 18 and 60 years of age chronic joint inflammation Arthritis, Rheumatoid 738125 11254450 dominant 180300 14 12725778 38725778 3 - by peak only
1298471 human OSTEAR4_H Osteoarthritis QTL 4 (human) 9 2.29 1298167 D9S1122 1298120 D9S922 1298167 D9S1122 Joint/bone inflammation hand osteoarthritis two generations of subjects from the Framingham Heart Study diagnosed with joint space narrowing in the hand underwent genome-wide scans for longitudinal study of hand osteoarthritis chronic joint inflammation Osteoarthritis 1285226 11953971 9 78878447 82158418 1 - by flanking markers
1298472 human BP21_H Blood pressure QTL 21 (human) 5 0.0785 1298302 D5S1480 Blood pressure hypertension susceptibility nonparametric analysis of markers near 18 candidate genes for loci affecting young-onset hypertension in Han Chinese affected sib pairs increased systemic arterial blood pressure Hypertension 1298024 11071381 5 131124026 157124026 3 - by peak only
1298473 human RA12_H Rheumatoid arthritis QTL 12 (human) 6 0.0043 1298229 D6S2427 1298275 D6S2439 Joint/bone inflammation rheumatoid arthritis genome-wide linkage scans were examined in families with at least two siblings diagnosed with rheumatoid arthritis with onset between 18 and 60 years of age chronic joint inflammation Arthritis, Rheumatoid 738125 11254450 dominant 180300 6 39583335 65583335 4 - by one flank marker only
1298474 human OSTEAR30_H Osteoarthritis QTL 29 (human) 2 0.05 1298289 D2S128 1298283 D2S396 1298307 D2S126 Joint/bone inflammation nodal osteoarthritis genome-wide linkage scans were examined in affected sibling pairs diagnosed with polyarticular interphalangeal osteoartritis with Heberden's nodes in each hand chronic joint inflammation Osteoarthritis 1298211 8660106 2 214800624 230392178 1 - by flanking markers
1298475 human RA6_H Rheumatoid arthritis QTL 6 (human) 3 0.0408 1298243 D3S1311 Joint/bone inflammation rheumatoid arthritis genome-wide linkage scans were examined in families with at least two siblings diagnosed with rheumatoid arthritis with onset between 18 and 60 years of age chronic joint inflammation Arthritis, Rheumatoid 738125 11254450 dominant 180300 3 185502595 199501827 3 - by peak only
1298476 human BP3_H Blood pressure QTL 3 (human) 19 2.4 1298192 D19S1034 1298107 D19S1166 Blood pressure systolic genome-wide scan for blood pressure variation in 18 Dutch families with familial combined hyperlipidemia (FCH) in which affected individuals have lipid abnormalities, hypertension, and elevated fasting insulin levels increased circulating LDL cholesterol level;increased systemic arterial blood pressure Hyperlipidemia, Familial Combined;Hypertension 738095 11641285 144250 19 1 6064482 2 - by one flank and peak markers
1298477 human OSTEAR1_H Osteoarthritis QTL 1 (human) 1 2.96 1298097 D1S1665 1298097 D1S1665 Joint/bone inflammation hand osteoarthritis two generations of subjects from the Framingham Heart Study diagnosed with joint space narrowing in the hand underwent genome-wide scans for longitudinal study of hand osteoarthritis chronic joint inflammation Osteoarthritis 1285226 11953971 1 61002091 87002091 3 - by peak only
1298478 human BP12_H Blood pressure QTL 12 (human) 21 2.82 1298173 D21S1440 Blood pressure systolic genome-wide scan for loci contributing to blood pressure in a sample of Mexican American families chosen without regard to blood pressure status increased systemic arterial blood pressure Hypertension 738133 11255245 21 25063577 46944323 3 - by peak only
1298479 human RA5_H Rheumatoid arthritis QTL 5 (human) 3 0.0288 1298282 D3S3023 Joint/bone inflammation rheumatoid arthritis genome-wide linkage scans were examined in families with at least two siblings diagnosed with rheumatoid arthritis with onset between 18 and 60 years of age chronic joint inflammation Arthritis, Rheumatoid 738125 11254450 dominant 180300 3 109374882 135374882 3 - by peak only
1298480 human RA20_H Rheumatoid arthritis QTL 20 (human) 12 0.0031 1298300 D12S373 Joint/bone inflammation rheumatoid arthritis genome-wide linkage scans were examined in families with at least two siblings diagnosed with rheumatoid arthritis with onset between 18 and 60 years of age chronic joint inflammation Arthritis, Rheumatoid 738125 11254450 180300 12 3906370 29906370 3 - by peak only
1298481 human OSTEAR2_H Osteoarthritis QTL 2 (human) 2 2.23 1298117 D2S405 1298195 D2S1788 1298117 D2S405 Joint/bone inflammation joint space narrowing genome-wide scan for longitudinal study of hand osteoarthritis in two generations of subjects from the Framingham Heart Study chronic joint inflammation Osteoarthritis 1285226 11953971 2 29330151 36113999 1 - by flanking markers
1298482 human BP2_H Blood pressure QTL 2 (human) 8 1.8 70836 LPL Blood pressure diastolic genome-wide scan for blood pressure variation in 18 Dutch families with familial combined hyperlipidemia (FCH) in which affected individuals have lipid abnormalities, hypertension, and elevated fasting insulin levels increased systemic arterial blood pressure Hypertension 738095 11641285 144250 8 6855053 32855053 3 - by peak only
1298483 human BP10_H Blood pressure QTL 10 (human) 2 3.92 1298104 D2S1790 Blood pressure diastolic genome-wide scan for loci contributing to blood pressure in a sample of Mexican American families chosen without regard to blood pressure status increased systemic arterial blood pressure Hypertension 738133 11255245 2 71928947 97928947 3 - by peak only
1298484 human RA16_H Rheumatoid arthritis QTL 16 (human) 8 0.0084 1298150 D8S373 Joint/bone inflammation rheumatoid arthritis genome-wide linkage scans were examined in families with at least two siblings diagnosed with rheumatoid arthritis with onset between 18 and 60 years of age chronic joint inflammation Arthritis, Rheumatoid 738125 11254450 180300 8 131296611 146274826 3 - by peak only
1298485 human RA24_H Rheumatoid arthritis QTL 24 (human) 14 0.0373 1298291 D14S587 Joint/bone inflammation rheumatoid arthritis genome-wide linkage scans were examined in families with at least two siblings diagnosed with rheumatoid arthritis with onset between 18 and 60 years of age chronic joint inflammation Arthritis, Rheumatoid 738125 11254450 dominant 180300
1298487 human BFD1_H Body fluid distribution QTL 1 (human) 3 3.94 1298321 D3S2432 1298245 D3S2406 1298325 D3S2409 Body fluid distribution impedance ratio genome-wide scan for loci affecting body fluid distribution (bioelectrical impedance ratio) in 150 African American affected sib pairs with essential hypertension abnormal water content;increased systemic arterial blood pressure Hypertension 738096 12411455 3 32140243 73341388 1 - by flanking markers
1298488 human RA26_H Rheumatoid arthritis QTL 26 (human) 16 0.0316 1298327 D16S2624 1298258 D16S516 Joint/bone inflammation rheumatoid arthritis genome-wide linkage scans were examined in families with at least two siblings diagnosed with rheumatoid arthritis with onset between 18 and 60 years of age chronic joint inflammation Arthritis, Rheumatoid 738125 11254450 dominant 180300 16 70292632 88827254 4 - by one flank marker only
1298489 human RA4_H Rheumatoid arthritis QTL 4 (human) 3 0.0283 1298239 D3S1768 1298237 D3S2384 Joint/bone inflammation rheumatoid arthritis genome-wide linkage scans were examined in families with at least two siblings diagnosed with rheumatoid arthritis with onset between 18 and 60 years of age chronic joint inflammation Arthritis, Rheumatoid 738125 11254450 dominant 180300 3 34599409 60599409 4 - by one flank marker only
1298490 human OSTEAR22_H Osteoarthritis QTL 22 (human) 6 2.9 1298106 D6S1610 1298112 D6S314 1298111 D6S462 Joint/bone inflammation hip osteoarthritis genome-wide linkage scans were examined in families with at least two siblings who had undergone total hip or knee replacement for primary ideopathic osteoarthritis chronic joint inflammation Osteoarthritis, Hip 1298025 10577938 OA16_H 6 39367582 140056474 1 - by flanking markers
1298491 human BP5_H Blood pressure QTL 5 (human) 1 2.96 1298129 D1S1679 Blood pressure diastolic genome-wide scan for loci affecting blood pressure in 160 white families from the GenNet network of the NHLBI sponsored Family Blood Pressure Program increased systemic arterial blood pressure Hypertension 738097;1298218 12559684;11034945 1 147628616 173628616 3 - by peak only
1298492 human BP31_H Blood pressure QTL 31 (human) 11 2.07 1298253 D11S1392 1298267 D11S4464 1298333 D11S1985 Blood pressure systolic genome-wide linkage scan for loci affecting blood pressure in rural Chinese sibling pairs with blood pressure extremes abnormal systemic arterial blood pressure Obesity 1298213;1285225 10330357;11923912 145500 11 34596653 123132075 1 - by flanking markers
1298493 human RA31_H Rheumatoid arthritis QTL 31 (human) X 0.016 1298286 DXS6807 Joint/bone inflammation rheumatoid arthritis genome-wide linkage scans were examined in families with at least two siblings diagnosed with rheumatoid arthritis with onset between 18 and 60 years of age chronic joint inflammation Arthritis, Rheumatoid 738125 11254450 dominant 180300 X 1 17753515 3 - by peak only
1298494 human OSTEAR12_H Osteoarthritis QTL 12 (human) 2 1.48 7.0E-4 1298197 D2S397 1298121 D2S2184 1298132 D2S1399 Joint/bone inflammation distal interphalangeal joint osteoarthritis genome-wide scan of 64 Finnish patients diagnosed with osteoarthritis of interphalangeal or metacarpophalangeal joints were compared with members of 16 unaffected Finnish core families chronic joint inflammation Osteoarthritis 738112 10486325 dominant OA10_H;OA11_H 140600 2 139830058 148886473 1 - by flanking markers
1298495 human OSTEAR27_H Osteoarthritis QTL 27 (human) 16 1.7 Joint/bone inflammation hip osteoarthritis genome-wide linkage scans were examined in families with at least two siblings who had undergone total hip or knee replacement for primary ideopathic osteoarthritis chronic joint inflammation Osteoarthritis, Hip 738108 14730605
1298496 human BW11_H Body weight QTL 11 (human) 3 4.3 4.0E-6 1298124 D3S3676 1298169 D3S2427 Body weight body mass index genome-wide linkage analysis for obesity in African American individuals increased body mass index;obese Obesity 738104 12716766 3 177267732 177871155 1 - by flanking markers
1298497 human BW10_H Body weight QTL 10 (human) 3 1.8 0.002 1298153 D3S2477 Body weight body mass index genome wide scan for obesity in African Americans who were recruited as part of a blood pressure program obese;increased body mass index Obesity 738103 11812767 3 32313469 58313469 3 - by peak only
1298498 human BP33_H Blood pressure QTL 33 (human) 16 2.74 1298279 D16S748 1298322 D16S2824 1298287 D16S3396 Blood pressure systolic genome-wide linkage scan for loci affecting blood pressure in rural Chinese sibling pairs with blood pressure extremes abnormal systemic arterial blood pressure Hypertension 1298213 10330357 145500 16 12046946 87452910 2 - by one flank and peak markers
1298499 human UAE1_H Urinary albumin excretion QTL 1 (human) 19 2.73 9.0E-4 1298107 D19S1166 Urinary albumin excretion urine albumin:creatinine ratio (ACR) genome-wide scan for loci affecting urinary albumin excretion in 2589 individuals from 805 hypertensive families in the Family Blood Pressure Program albuminuria Albuminuria 738099 12925555 19 1 16026900 3 - by peak only
1299997 human BW17_H Body weight QTL 17 (human) 20 1.5 1298199 D20S178 1298154 D20S149 Body weight body mass index pairwise correlation analyses were conducted on alleles shared identical by descent for independent obese affected sibling pairs increased body mass index Obesity 738100 12478478 601665 20 45985389 54947834 1 - by flanking markers
1299999 human BW26_H Body weight QTL 26 (human) 7 2.36 1299890 D7S2847 Body weight body mass index genome wide linkage scan for body mass index in HyperGEN (black) subjects from the National Heart, Lung, and Blood Insititute Family Blood Pressure Program 1285225 11923912 7 105606840 131606840 3 - by peak only
1300000 human BP54_H Blood pressure QTL 54 (human) 14 1.43 0.00514 1299943 D14S283 Blood pressure systolic genome-wide scan for loci affecting blood pressure in random and obese families in the Quebec Family Study increased systemic arterial blood pressure Hypertension 1298218 11034945 14 8757439 34757439 3 - by peak only
1300001 human BP26_H Blood pressure QTL 26 (human) 4 3.2 1299893 D4S1572 Blood pressure systolic genome wide scan for loci affecting blood pressure in white Australian sibling pairs from the Victorian Family Heart Study increased systemic arterial blood pressure Hypertension 1298042 11875187 4 90989222 116989222 3 - by peak only
1300002 human BW28_H Body weight QTL 28 (human) 14 2.15 1299930 D14S617 Body weight body mass index genome wide linkage scan for body mass index in HyperGEN (black) subjects from the National Heart, Lung, and Blood Insititute Family Blood Pressure Program increased body mass index Obesity 1285225 11923912 14 78272613 104272613 3 - by peak only
1300004 human BP47_H Blood pressure QTL 47 (human) 5 2.8 1.6E-4 1299894 D5S2488 1298299 D5S1457 1299891 D5S1986 Blood pressure systolic genome-wide scan for loci affecting blood pressure in random and obese families in the Quebec Family Study increased systemic arterial blood pressure Hypertension 1298218 11034945 5 180431 41069726 1 - by flanking markers
1300005 human BP49_H Blood pressure QTL 49 (human) 8 2.24 6.6E-4 1299947 D8S1136 1299931 D8S556 730946 CRH Blood pressure systolic genome-wide scan for loci affecting blood pressure in random and obese families in the Quebec Family Study increased systemic arterial blood pressure Hypertension 1298218 11034945 8 28324754 106179670 2 - by one flank and peak markers
1300006 human BW16_H Body weight QTL 16 (human) 10 1.46 1298123 D10S1646 Body weight body mass index pairwise correlation analyses were conducted on alleles shared identical by descent for independent obese affected sibling pairs increased body mass index Obesity 738100 12478478 607514 10 55292953 81292953 3 - by peak only
1300007 human BP29_H Blood pressure QTL 29 (human) 20 736622 PTGIS Blood pressure hypertension susceptibility candidate gene analysis of prostacyclin synthase (human PTGIS) variant in members of a Japanese family with essential hypertension, analysis of other individuals with essential hypertension, and in normal individuals increased systemic arterial blood pressure Hypertension 1298040 12372404 145500 20 34585966 60585966 3 - by peak only
1300008 human BP28_H Blood pressure QTL 28 (human) X 3.3 1299932 DXS993 Blood pressure systolic genome wide scan for loci affecting blood pressure in white Australian sibling pairs from the Victorian Family Heart Study increased systemic arterial blood pressure Hypertension 1298042 11875187 X 28032779 54032779 3 - by peak only
1300009 human BW22_H Body weight QTL 22 (human) 10 2.32 1299888 D10S582 1299925 D10S1766 1299953 ZEB1 Body weight body mass index genome-wide scan for linkage to body weight in German obese individuals increased body mass index Obesity 1298038 10946912 10 24522666 50415680 1 - by flanking markers
1300010 human BP27_H Blood pressure QTL 27 (human) 16 3.2 1299892 D16S3068 Blood pressure systolic genome wide scan for loci affecting blood pressure in white Australian sibling pairs from the Victorian Family Heart Study increased systemic arterial blood pressure Hypertension 1298042 11875187 16 12468197 38468197 3 - by peak only
1300011 human BW24_H Body weight QTL 24 (human) 3 2.03 1299906 D3S1259 Body weight body mass index genome wide linkage scan for body mass index in HyperGEN (white) subjects from the National Heart, Lung, and Blood Insititute Family Blood Pressure Program increased body mass index Obesity 1285225 11923912 3 1 25073826 3 - by peak only
1300012 human BP52_H Blood pressure QTL 52 (human) 10 1.41 0.00547 1299918 D10S2325 Blood pressure systolic genome-wide scan for loci affecting blood pressure in random and obese families in the Quebec Family Study increased systemic arterial blood pressure Hypertension 1298218 11034945
1300013 human BP37_H Blood pressure QTL 37 (human) 2 2.96 1298264 D2S324 Blood pressure hypertension susceptibility genome-wide scan for loci affecting hypertension in Finnish affected sib pairs increased systemic arterial blood pressure Hypertension 1298217 11081770 2 166364621 192364621 3 - by peak only
1300014 human BP48_H Blood pressure QTL 48 (human) 7 2.26 6.3E-4 1299946 D7S1875 1299920 D7S3070 1299901 D7S530 Blood pressure systolic genome-wide scan for loci affecting blood pressure in random and obese families in the Quebec Family Study increased systemic arterial blood pressure Hypertension 1298218 11034945 7 127537916 151198240 1 - by flanking markers
1300015 human BP51_H Blood pressure QTL 51 (human) 3 1.27 0.00787 1299926 D3S3045 Blood pressure systolic genome-wide scan for loci affecting blood pressure in random and obese families in the Quebec Family Study increased systemic arterial blood pressure Hypertension 1298218 11034945 3 95472703 121472703 3 - by peak only
1300016 human BW18_H Body weight QTL 18 (human) 7 2.26 6.0E-4 1298158 D7S796 1298178 D7S794 1298139 D7S692 Body weight body mass index linkage and linkage disequilibrium mapping to body mass index in European American families increased body mass index Obesity 738105 12765970 7 103290039 143354787 1 - by flanking markers
1300017 human BW32_H Body weight QTL 32 (human) 18 2.3 9.7E-4 1299911 D18S471 1299942 D18S843 Body weight body mass index genome-wide linkage analysis to identify linkage to obesity in type 2 diabetic Dutch Caucasian siblings hyperglycemia Obesity;Diabetes Mellitus, Non-Insulin-Dependent 1298537 12727978 125853 18 5971902 8603953 1 - by flanking markers
1300018 human BW15_H Body weight QTL 15 (human) 4 4.5 3.0E-6 1298204 D4S2639 1298182 D4S1581 1298170 D4S2912 Body weight body mass index genome wide scan for linkage to obesity related traits in Mexican Americans increased circulating leptin level;obese;increased body mass index;hyperglycemia Obesity 738107 14740316 608410 4 18454351 37814020 1 - by flanking markers
1300019 human BP25_H Blood pressure QTL 25 (human) 1 3.5 1299923 D1S2890 Blood pressure systolic genome wide scan for loci affecting blood pressure in white Australian sibling pairs from the Victorian Family Heart Study increased systemic arterial blood pressure Hypertension 1298042 11875187 1 44646082 70646082 3 - by peak only
1300020 human BW31_H Body weight QTL 31 (human) 17 1.87 1299928 D17S2196 Body weight body mass index genome wide linkage scan for body mass index in GENOA (Mexican American) subjects from the National Heart, Lung, and Blood Insititute Family Blood Pressure Program increased body mass index Obesity 1285225 11923912 17 4205275 30205275 3 - by peak only
1300021 human BP45_H Blood pressure QTL 45 (human) 1 1.77 0.00218 735332 ATP1A1 Blood pressure systolic genome-wide scan for loci affecting blood pressure in random and obese families in the Quebec Family Study increased systemic arterial blood pressure Hypertension 1298218 11034945 1 103733139 129733139 3 - by peak only
1300022 human BW27_H Body weight QTL 27 (human) 7 1.29 1299935 D7S1824 Body weight body mass index genome wide linkage scan for body mass index in GENOA (Mexican American) subjects from the National Heart, Lung, and Blood Insititute Family Blood Pressure Program increased body mass index Obesity 1285225 11923912 7 126659122 152659122 3 - by peak only
1300023 human BP46_H Blood pressure QTL 46 (human) 2 2.26 6.2E-4 1299910 D2S2114 1299945 D2S434 1299886 D2S2972 Blood pressure systolic genome-wide scan for loci affecting blood pressure in random and obese families in the Quebec Family Study increased systemic arterial blood pressure Hypertension 1298218 11034945 2 75683889 218285001 1 - by flanking markers
1300024 human BW25_H Body weight QTL 25 (human) 7 2.66 1299933 D7S3051 Body weight body mass index genome wide linkage scan for body mass index in SAPPHIRe (Asian) subjects from the National Heart, Lung, and Blood Insititute Family Blood Pressure Program increased body mass index Obesity 1285225 11923912 7 5251125 31251125 3 - by peak only
1300025 human BP39_H Blood pressure QTL 39 (human) X 2.41 1298241 DXS6810 Blood pressure hypertension susceptibility genome-wide scan for loci affecting hypertension in Finnish affected sib pairs increased systemic arterial blood pressure Hypertension 1298217 11081770 X 29803744 55803744 3 - by peak only
1300026 human BP36_H Blood pressure QTL 36 (human) 3 4.04 1298249 D3S1308 68977 AGTR1 Blood pressure hypertension susceptibility genome-wide scan for loci affecting hypertension in affected sib pairs from the Finnish Twin Cohort Study increased systemic arterial blood pressure Hypertension 1298217 11081770 BP24_H 3 149324821 150517011 2 - by one flank and peak markers
1300027 human BW34_H Body weight QTL 34 (human) 19 1.5 0.0063 1299912 D19S400 1299939 D19S245 Body weight body mass index genome-wide linkage analysis to identify linkage to obesity in type 2 diabetic Dutch Caucasian siblings hyperglycemia Obesity;Diabetes Mellitus, Non-Insulin-Dependent 1298537 12727978 125853 19 38790201 46219373 1 - by flanking markers
1300028 human BP53_H Blood pressure QTL 53 (human) 12 1.33 0.00673 1299937 D12S372 Blood pressure systolic genome-wide scan for loci affecting blood pressure in random and obese families in the Quebec Family Study increased systemic arterial blood pressure Hypertension 1298218 11034945 12 1 16457710 3 - by peak only
1300030 human BW23_H Body weight QTL 23 (human) 3 3.45 1299921 D3S1764 Body weight body mass index genome wide linkage scan for body mass index in GENOA (black) subjects from the National Heart, Lung, and Blood Insititute Family Blood Pressure Program increased body mass index Obesity 1285225 11923912 3 127671173 153671173 3 - by peak only
1300031 human BP55_H Blood pressure QTL 55 (human) 22 1.54 0.00383 1299924 D22S274 Blood pressure diastolic genome-wide scan for loci affecting blood pressure in random and obese families in the Quebec Family Study increased systemic arterial blood pressure Hypertension 1298218 11034945 22 30647918 49691432 3 - by peak only
1300032 human BW33_H Body weight QTL 33 (human) 2 1.5 0.0075 1299938 D2S436 1299936 D2S1888 Body weight body mass index genome-wide linkage analysis to identify linkage to obesity in type 2 diabetic Dutch Caucasian siblings hyperglycemia Obesity;Diabetes Mellitus, Non-Insulin-Dependent 1298537 12727978 125853 2 106609665 111111693 1 - by flanking markers
1300033 human BP38_H Blood pressure QTL 38 (human) 22 2.07 1298301 D22S685 Blood pressure hypertension susceptibility genome-wide scan for loci affecting hypertension in Finnish affected sib pairs increased systemic arterial blood pressure Hypertension 1298217 11081770 22 19925686 45925686 3 - by peak only
1300034 human BP50_H Blood pressure QTL 50 (human) 19 2.1 9.4E-4 735594 LDLR 1299905 D19S247 Blood pressure systolic genome-wide scan for loci affecting blood pressure in random and obese families in the Quebec Family Study increased systemic arterial blood pressure Hypertension 1298218 11034945 19 1 11105490 2 - by one flank and peak markers
1300035 human BW30_H Body weight QTL 30 (human) 17 2.47 1299913 D17S947 Body weight body mass index genome wide linkage scan for body mass index in GENOA (white) subjects from the National Heart, Lung, and Blood Insititute Family Blood Pressure Program increased body mass index Obesity 1285225 11923912 17 1 25747231 3 - by peak only
1300036 human BW29_H Body weight QTL 29 (human) 16 2.55 1299900 D16S2620 Body weight body mass index genome wide linkage scan for body mass index in GENOA (white) subjects from the National Heart, Lung, and Blood Insititute Family Blood Pressure Program increased body mass index Obesity 1285225 11923912 16 47671096 73671096 3 - by peak only
1331632 human COPD7_H Chronic obstructive pulmonary disease QTL 7 (human) 1 2.24 1331563 G15725 1331570 G15727 Chronic airflow obstruction post-bronchodilator FEV1 genome wide scan for loci affecting persistent airflow obstruction in 72 pedigrees with probands having severe early onset COPD abnormal respiratory function Pulmonary Disease, Chronic Obstructive 1331518;1331521 12719384;15374838 606963 1 93083097 119083097 3 - by peak only
1331633 human COPD23_H Chronic obstructive pulmonary disease QTL 23 (human) 19 1.47 1298168 D19S433 1299939 D19S245 1331583 D19S559 Chronic airflow obstruction FEV1/FVC ratio genome-wide scan for irreversible airflow obstruction in relatives of probands with severe early-onset COPD; COPD was measured by spirometric indices, including forced expiratory volume at 1 second (FEV1) and the ratio of FEV1 to forced vital capacity (FVC) abnormal respiratory function;abnormal pulmonary ventilation;abnormal airway resistance;abnormal lung volume;decreased pulmonary ventilation Pulmonary Disease, Chronic Obstructive 1331521;1331515;1331517 15374838;11914989;11897646 606963 19 35108867 38790201 1 - by flanking markers
1331634 human AASTH1_H Allergic/atopic asthma related QTL 1 (human) 4 2.74 2.0E-4 1331597 D4S2417 1298122 D4S408 Reversible airflow obstruction genome-wide scan for linkage to childhood atopic allergy to the house-dust mite Dermatophagoides farinae; affected individuals showed Df-specific RAST scores >3 and total serum IgE levels >1 standard deviation above the age-matched population mean increased IgE level Asthma 1331538 10860660 600807 4 159388311 185388311 4 - by one flank marker only
1331635 human COPD19_H Chronic obstructive pulmonary disease QTL 19 (human) 2 4.12 1331574 D1S1649 1331557 D2S2968 1331561 D2S1363 Chronic airflow obstruction FEV1/FVC ratio genome-wide scan for irreversible airflow obstruction in relatives of probands with severe early-onset COPD; COPD was measured by spirometric indices, including forced expiratory volume at 1 second (FEV1) and the ratio of FEV1 to forced vital capacity (FVC) abnormal airway resistance;abnormal vital capacity;decreased pulmonary ventilation Pulmonary Disease, Chronic Obstructive 1331521;1331515 15374838;11914989 606963 2 214288152 237743384 1 - by flanking markers
1331636 human COPD13_H Chronic obstructive pulmonary disease QTL 13 (human) 4 1.56 1298203 D4S1592 1299895 D4S2951 1331573 D4S1625 Chronic airflow obstruction post-BD FEV1 minus pre-BD FEV1 genome wide scan for loci affecting persistent airflow obstruction in 72 pedigrees with probands having severe early onset COPD abnormal respiratory function Pulmonary Disease, Chronic Obstructive 1331518 12719384 606963 4 57376574 183397294 1 - by flanking markers
1331637 human COPD2_H Chronic obstructive pulmonary disease QTL 2 (human) 8 1.36 1331569 D8S507 Chronic airflow obstruction FEV1 <80% predicted and FEV/FVC<90% predicted genome-wide multipoint non-parametric linkage analysis performed on 585 members of 72 pedigree that had early-onset COPD probands without severe alpha1-antitrypsin deficiency abnormal forced expiratory flow rates;decreased pulmonary ventilation;abnormal vital capacity;abnormal airway resistance Pulmonary Disease, Chronic Obstructive 1331521;1331516 15374838;11912177 8 46301528 72301528 3 - by peak only
1331638 human COPD14_H Chronic obstructive pulmonary disease QTL 14 (human) 3 1.5 1299934 D3S1561 1298169 D3S2427 1331571 D3S4529 Chronic airflow obstruction post-BD FEV1 minus pre-BD FEV1 genome wide scan for loci affecting persistent airflow obstruction in 72 pedigrees with probands having severe early onset COPD abnormal respiratory function Pulmonary Disease, Chronic Obstructive 1331521;1331518 15374838;12719384 606963 3 36459185 177267732 1 - by flanking markers
1331639 human COPD3_H Chronic obstructive pulmonary disease QTL 3 (human) 19 1.54 1331582 D19S432 Chronic airflow obstruction FEV1 <80% predicted and FEV/FVC<90% predicted genome-wide multipoint non-parametric linkage analysis performed on 585 members of 72 pedigree that had early-onset COPD probands without severe alpha1-antitrypsin deficiency abnormal forced expiratory flow rates;decreased pulmonary ventilation;abnormal vital capacity;abnormal airway resistance Pulmonary Disease, Chronic Obstructive 1331521;1331516 15374838;11912177 19 2543318 28543318 3 - by peak only
1331640 human COPD11_H Chronic obstructive pulmonary disease QTL 11 (human) 1 2.52 1331568 D1S551 1331563 G15725 Chronic airflow obstruction post-bronchodilator FEV1/FVC genome wide scan for loci affecting persistent airflow obstruction in 72 pedigrees with probands having severe early onset COPD abnormal respiratory function Pulmonary Disease, Chronic Obstructive 1331518 12719384 606963 1 82667884 108667884 4 - by one flank marker only
1331641 human COPD25_H Chronic obstructive pulmonary disease QTL 25 (human) 6 2.4 24.0 1331585 D6S953 1331575 D6S1590 1331575 D6S1590 Chronic airflow obstruction FEV1 genome wide scan for lung function where spirometric measurements of FEV1, FVC and ratio of FEV1 to FVC were taken during adulthood in each generation of these pedigrees abnormal respiratory function;abnormal pulmonary ventilation Pulmonary Disease, Chronic Obstructive 1331517 11897646 608852 6 157601898 170899992 3 - by peak only
1331642 human AASTH6_H Allergic/atopic asthma related QTL 6 (human) 12 2.46 4.0E-4 1331611 PAH 1299944 D12S2070 1299944 D12S2070 Reversible airflow obstruction post-bronchodilator FEV1 segregation analysis and variance-component analysis for high total serum IgE performed on 108 probands and their families increased IgE level Asthma 1331539 11023809 recessive 12 101567143 127567143 3 - by peak only
1331643 human COPD16_H Chronic obstructive pulmonary disease QTL 16 (human) 3 1.07 1298237 D3S2384 1331560 D3S1746 Chronic airflow obstruction post-BD FEV1 minus pre-BD FEV1/pre-BD FEV1 x 100 genome wide scan for loci affecting persistent airflow obstruction in 72 pedigrees with probands having severe early onset COPD abnormal respiratory function Pulmonary Disease, Chronic Obstructive 1331518 12719384 606963 3 140212555 166212555 3 - by peak only
1331644 human AASTH7_H Allergic/atopic asthma related QTL 7 (human) 12 2.29 1331605 D12S357 1331602 D12S92 1331609 D12S97 Reversible airflow obstruction asthma score linkage analysis was performed on a population that was evaluated for asthma related qualitative scores. They were evaluated by written and video questionaire, wheezing, skin prick testing, bronchial reactivity, FEV1 ratio, Eczema, Hay fever, total IgE, specific IgE, Asthma score(combination of wheezing, video questionaire, bronchial response, and FEV1 ratio) and Asthma affection (Asthma score with predisposition among normals and severity factored in) abnormal respiratory function;abnormal pulmonary ventilation;abnormal respiratory sounds;dermatitis;abnormal cranial nerve morphology Asthma 1331541 9799590 600807 12 72420181 132349534 2 - by one flank and peak markers
1331645 human COPD18_H Chronic obstructive pulmonary disease QTL 18 (human) 1 1.92 1298097 D1S1665 1331565 D1S1653 1331563 G15725 Chronic airflow obstruction FEV1/FVC ratio genome-wide scan for irreversible airflow obstruction in relatives of probands with severe early-onset COPD; COPD was measured by spirometric indices, including forced expiratory volume at 1 second (FEV1) and the ratio of FEV1 to forced vital capacity (FVC) abnormal airway resistance;decreased pulmonary ventilation;abnormal lung volume Pulmonary Disease, Chronic Obstructive 1331515 11914989 606963 1 74001979 156199505 1 - by flanking markers
1331646 human COPD21_H Chronic obstructive pulmonary disease QTL 21 (human) 12 2.43 1331584 D12S1581 1331577 D12S1066 1331548 D12S1630 Chronic airflow obstruction FEV1 genome-wide scan for irreversible airflow obstruction in relatives of probands with severe early-onset COPD; COPD was measured by spirometric indices, including forced expiratory volume at 1 second (FEV1) and the ratio of FEV1 to forced vital capacity (FVC) abnormal airway resistance;abnormal lung volume;decreased pulmonary ventilation Pulmonary Disease, Chronic Obstructive 1331521;1331515 15374838;11914989 606963 12 12975624 21630770 1 - by flanking markers
1331647 human COPD4_H Chronic obstructive pulmonary disease QTL 4 (human) 22 1.37 1331587 D22S278 Chronic airflow obstruction FEV1 <80% predicted and FEV/FVC<90% predicted genome-wide multipoint non-parametric linkage analysis performed on 585 members of 72 pedigree that had early-onset COPD probands without severe alpha1-antitrypsin deficiency abnormal forced expiratory flow rates Pulmonary Disease, Chronic Obstructive 1331521;1331516 15374838;11912177 22 21736717 47736717 3 - by peak only
1331648 human COPD8_H Chronic obstructive pulmonary disease QTL 8 (human) 8 2.01 1331581 D8S1108 1298150 D8S373 1298150 D8S373 Chronic airflow obstruction post-bronchodilator FEV1 genome wide scan for loci affecting persistent airflow obstruction in 72 pedigrees with probands having severe early onset COPD abnormal respiratory function Pulmonary Disease, Chronic Obstructive 1331518 12719384 606963 8 136360837 144296716 1 - by flanking markers
1331649 human COPD22_H Chronic obstructive pulmonary disease QTL 22 (human) 17 2.68 1331576 D17S1294 1298272 D17S2180 1298272 D17S2180 Chronic airflow obstruction FEV1/FVC ratio genome-wide scan for irreversible airflow obstruction in relatives of probands with severe early-onset COPD; COPD was measured by spirometric indices, including forced expiratory volume at 1 second (FEV1) and the ratio of FEV1 to forced vital capacity (FVC) abnormal airway resistance;abnormal lung volume;decreased pulmonary ventilation Pulmonary Disease, Chronic Obstructive 1331521;1331515 15374838;11914989 606963 17 25406301 44028226 1 - by flanking markers
1331650 human COPD15_H Chronic obstructive pulmonary disease QTL 15 (human) 4 1.28 1298203 D4S1592 1298155 D4S2924 1298103 D4S2366 Chronic airflow obstruction post-BD FEV1 minus pre-BD FEV1/pre-BD FEV1 x 100 genome wide scan for loci affecting persistent airflow obstruction in 72 pedigrees with probands having severe early onset COPD abnormal respiratory function Pulmonary Disease, Chronic Obstructive 1331521;1331518 15374838;12719384 606963 4 57376574 186689238 1 - by flanking markers
1331651 human COPD12_H Chronic obstructive pulmonary disease QTL 12 (human) 17 2.44 1298244 D17S1303 1298335 D17S2193 1298272 D17S2180 Chronic airflow obstruction post-bronchodilator FEV1/FVC genome wide scan for loci affecting persistent airflow obstruction in 72 pedigrees with probands having severe early onset COPD abnormal respiratory function Pulmonary Disease, Chronic Obstructive 1331521;1331518 15374838;12719384 606963 17 10800103 64059498 1 - by flanking markers
1331652 human COPD17_H Chronic obstructive pulmonary disease QTL 17 (human) 1 1.28 1298138 D1S468 1331547 D1S3669 1298303 D1S1612 Chronic airflow obstruction FEV1 genome-wide scan for irreversible airflow obstruction in relatives of probands with severe early-onset COPD; COPD was measured by spirometric indices, including forced expiratory volume at 1 second (FEV1) and the ratio of FEV1 to forced vital capacity (FVC) abnormal lung volume;decreased pulmonary ventilation;abnormal airway resistance Pulmonary Disease, Chronic Obstructive 1331515 11914989 606963 1 3574817 17656435 1 - by flanking markers
1331653 human AASTH5_H Allergic/atopic asthma related QTL 5 (human) 7 3.36 4.0E-5 39.0 1331594 D7S820 1298320 D7S821 1298320 D7S821 Reversible airflow obstruction post-bronchodilator FEV1 segregation analysis and variance-component analysis for high total serum IgE performed on 108 probands and their families increased IgE level Asthma 1331539 11023809 recessive 7 83627328 95895699 1 - by flanking markers
1331654 human COPD28_H Chronic obstructive pulmonary disease QTL 28 (human) 18 2.88 1298292 D18S858 Chronic airflow obstruction FVC genome-wide scan for linkage of FEV1, FVC, and FEV1/FVC measurements was performed on 2,178 individuals in 391 pedigrees participating in the NHLBI Family Heart Study, as well as 702 additional individuals who contributed genotyping data. abnormal forced expiratory flow rates Pulmonary Disease, Chronic Obstructive 1331519 12637344 COPD26_H 18 40048190 66048190 3 - by peak only
1331655 human COPD20_H Chronic obstructive pulmonary disease QTL 20 (human) 11 1.53 1298156 D11S2371 1299908 D11S2000 1298202 D11S2002 Chronic airflow obstruction FVC genome-wide scan for irreversible airflow obstruction in relatives of probands with severe early-onset COPD; COPD was measured by spirometric indices, including forced expiratory volume at 1 second (FEV1) and the ratio of FEV1 to forced vital capacity (FVC) abnormal airway resistance;abnormal lung volume Pulmonary Disease, Chronic Obstructive 1331515 11914989 606963 11 73182779 105064165 1 - by flanking markers
1331656 human COPD26_H Chronic obstructive pulmonary disease QTL 26 (human) 21 2.6 26.0 1298173 D21S1440 Chronic airflow obstruction FVC genome wide scan for lung function where spirometric measurements of FEV1, FVC and ratio of FEV1 to FVC were taken during adulthood in each generation of these pedigrees abnormal forced expiratory flow rates Pulmonary Disease, Chronic Obstructive 1331517 11897646 21 12063658 38063658 4 - by one flank marker only
1331657 human COPD9_H Chronic obstructive pulmonary disease QTL 9 (human) 19 1.94 1299977 D19S221 1331606 D19S404 1331586 D19S246 Chronic airflow obstruction post-bronchodilator FEV1 genome wide scan for loci affecting persistent airflow obstruction in 72 pedigrees with probands having severe early onset COPD abnormal respiratory function Pulmonary Disease, Chronic Obstructive 1331521;1331518 15374838;12719384 606963 19 12573944 62224940 1 - by flanking markers
1331658 human COPD27_H Chronic obstructive pulmonary disease QTL 27 (human) 18 2.31 1299942 D18S843 Chronic airflow obstruction FEV1 genome-wide scan for linkage of FEV1, FVC, and FEV1/FVC measurements was performed on 2,178 individuals in 391 pedigrees participating in the NHLBI Family Heart Study, as well as 702 additional individuals who contributed genotyping data. abnormal forced expiratory flow rates Pulmonary Disease, Chronic Obstructive 1331519 12637344 COPD25_H 18 1 21603861 3 - by peak only
1331659 human AASTH4_H Allergic/atopic asthma related QTL 4 (human) 5 2.73 2.0E-4 37.0 1331601 D5S666 1331598 D5S402 Reversible airflow obstruction post-bronchodilator FEV1 segregation analysis and variance-component analysis for high total serum IgE performed on 108 probands and their families increased IgE level Asthma 1331539 11023809 recessive 5 118021324 144021324 4 - by one flank marker only
1331660 human AASTH3_H Allergic/atopic asthma related QTL 3 (human) 5 3.73 1.7E-5 1331599 D5S2040 1331595 D5S1456 1331600 D5S1471 Reversible airflow obstruction genome-wide scan for linkage to childhood atopic allergy to the house-dust mite Dermatophagoides farinae; affected individuals showed Df-specific RAST scores >3 and total serum IgE levels >1 standard deviation above the age-matched population mean increased IgE level Asthma 1331538 10860660 AASTH2_H 600807 5 165001554 168965291 1 - by flanking markers
1331661 human COPD10_H Chronic obstructive pulmonary disease QTL 10 (human) 2 4.42 1299945 D2S434 1331561 D2S1363 Chronic airflow obstruction post-bronchodilator FEV1/FVC genome wide scan for loci affecting persistent airflow obstruction in 72 pedigrees with probands having severe early onset COPD abnormal respiratory function Pulmonary Disease, Chronic Obstructive 1331521;1331518 15374838;12719384 606963 2 218284736 226738038 1 - by flanking markers
1331662 human COPD29_H Chronic obstructive pulmonary disease QTL 29 (human) 4 3.51 1331562 D4S1511 1331564 D4S403 Chronic airflow obstruction FEV1/FVC ratio genome-wide scan for linkage of FEV1, FVC, and FEV1/FVC measurements was performed on 2,178 individuals in 391 pedigrees participating in the NHLBI Family Heart Study, as well as 702 additional individuals who contributed genotyping data. abnormal forced expiratory flow rates Pulmonary Disease, Chronic Obstructive 1331519 12637344 4 11993119 14727189 2 - by one flank and peak markers
1331663 human COPD1_H Chronic obstructive pulmonary disease QTL 1 (human) 12 2.61 1331555 D12S269 1298164 D12S1682 1298193 D12S1715 Chronic airflow obstruction FEV1 <80% predicted and FEV/FVC<90% predicted genome-wide multipoint non-parametric linkage analysis performed on 585 members of 72 pedigree that had early-onset COPD probands without severe alpha1-antitrypsin deficiency abnormal forced expiratory flow rates Pulmonary Disease, Chronic Obstructive 1331521;1331516 15374838;11912177 dominant 12 13497722 20571160 1 - by flanking markers
1331664 human COPD6_H Chronic obstructive pulmonary disease QTL 6 (human) 8 3.3 1331550 D8S1458 1331550 D8S1458 Chronic airflow obstruction post-bronchodilator FEV1 genome wide scan for loci affecting persistent airflow obstruction in 72 pedigrees with probands having severe early onset COPD abnormal forced expiratory flow rates Pulmonary Disease, Chronic Obstructive 1331518 12719384 606963 8 1 16421238 3 - by peak only
1331665 human AASTH2_H Allergic/atopic asthma related QTL 2 (human) 5 4.73 1.3E-6 1331607 D5S2013 1331608 D5S422 1331610 D5S820 Reversible airflow obstruction genome-wide scan for linkage to childhood atopic allergy to the house-dust mite Dermatophagoides farinae; affected individuals showed Df-specific RAST scores >3 and total serum IgE levels >1 standard deviation above the age-matched population mean increased IgE level Asthma 1331538 10860660 AASTH3_H 600807 5 149563530 162086586 1 - by flanking markers
1331666 human COPD5_H Chronic obstructive pulmonary disease QTL 5 (human) 19 3.3 1331567 D19S215 1331580 D19S589 1331558 D19S220 Chronic airflow obstruction pre-bronchodilator FEV1 fine mapping of a QTL found in the genome-wide scan of a group of families participating in the Boston Early-Onset COPD Study. Measurements included pre- and post-bronchodilator forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC) and the ratio FEV1/FCV decreased pulmonary ventilation;abnormal vital capacity;abnormal airway resistance Pulmonary Disease, Chronic Obstructive 1331520 15175276 19 21474514 58475389 1 - by flanking markers
1331667 human COPD24_H Chronic obstructive pulmonary disease QTL 24 (human) 4 1.6 1331603 D4S416 Chronic airflow obstruction FEV1 genome wide scan for lung function where spirometric measurements of FEV1, FVC and ratio of FEV1 to FVC were taken during adulthood in each generation of these pedigrees abnormal respiratory function;abnormal pulmonary ventilation Pulmonary Disease, Chronic Obstructive 1331517 11897646 4 40307951 66307951 4 - by one flank marker only
1357356 human BW59_H Body weight QTL 59 (human) 8 2.0 0.001 1299947 D8S1136 1340571 D8S1746 1299931 D8S556 Body weight BMI before exercise training genome-wide scan for linkage to body composition before and after exercise training in Caucasians from the HERITAGE study decreased body mass index Obesity 1354706 11299268 8 77047395 135311775 2 - by one flank and peak markers
1357357 human BW56_H Body weight QTL 56 (human) 17 2.33 1337206 D17S1293 Body weight body mass index genome-wide scan for linkage to body mass index in families of Mexican-American heritage increased body mass index Obesity 1354698 10480620 17 16584420 42584420 3 - by peak only
1357358 human COHEN2_H Cohen syndrome QTL 2 (human) 8 3.237 1335449 D8S270 1336716 D8S514 1341757 D8S267 Cohen syndrome linkage analysis via homozygosity mapping was performed on two brothers and a cousin displaying a phenotype of microcephaly, mental retardation, postnatal growth deficiency, and hypotonia delayed brain development;microcephaly Obesity;Muscle Hypotonia;Microcephaly;Mental Retardation 1357204;1357226 10842298;7920642 recessive 216550 8 93089665 123811633 1 - by flanking markers
1357360 human COHEN1_H Cohen syndrome QTL 1 (human) 8 4.48 1335449 D8S270 1341722 D8S521 1342282 D8S559 Cohen syndrome linkage analysis via homozygosity mapping was performed on Finnish families with affected individuals displaying a phenotype of microcephaly, mental retardation, postnatal growth deficiency, and hypotonia delayed brain development;microcephaly Mental Retardation;Obesity;Microcephaly;Muscle Hypotonia 1357226 7920642 8 93089665 102375438 1 - by flanking markers
1357361 human BW37_H Body weight QTL 37 (human) 12 4.08 1.0E-5 735410 PAH 1338691 D12S349 1337908 D12S1339 Body fat amount genome-wide scan for obesity related traits in a European-American population; percent fat measured by bioelectric impedence, BMI and waist circumference also measured increased body mass index Obesity 1334490 14988268 216550 12 91589001 117589001 4 - by one flank marker only
1357362 human BW54_H Body weight QTL 54 (human) 6 1.53 1334598 D6S1719 Body weight body mass index genome-wide scan for linkage to body mass index in families of Mexican-American heritage increased body mass index Obesity 1354698 10480620 6 152989781 170899992 3 - by peak only
1357363 human BW55_H Body weight QTL 55 (human) 17 1.34 1335610 D17S945 Body weight body mass index genome-wide scan for linkage to body mass index in families of Mexican-American heritage increased body mass index Obesity;Obesity 1354698;1354706 10480620;11299268 17 1 22764060 3 - by peak only
1357365 human HRTRT1_H Heart rate QTL 1 (human) 4 3.9 0.00435 1338978 D4S2623 1298110 D4S1644 1298161 D4S2394 Heart rate resting heart rate Genomic screen for genes controlling resting heart rate in a population of primarily Northern European ancestry. Resting heart rate by radial pulse was measured in triplicate after resting for 15 minutes, for 60 seconds each measurement. Mean of second and third heart rate measurements was used for analysis. Normal heart rate defined as 0.5 SD from mean; elevated heart rate >2 SD from mean. increased heart rate Hypertension 1302896;1554330 14993199;12189495 4 111109155 141971108 1 - by flanking markers
1357366 human BW69_H Body weight QTL 69 (human) 8 0.0065 1357236 D8S1132 Body weight body mass index genome-wide scan for linkage of body mass index in Old Order Amish families increased body mass index Obesity 1354707 12888987 601665 8 94398122 120398122 3 - by peak only
1357367 human BW53_H Body weight QTL 53 (human) 2 1.16 1298195 D2S1788 Body weight body mass index genome-wide scan for linkage to body mass index in families of Mexican-American heritage increased body mass index Obesity 1354698 10480620 2 23113904 49113904 3 - by peak only
1357368 human BW52_H Body weight QTL 52 (human) 8 3.21 1299947 D8S1136 1335208 D8S1477 1335043 D8S1791 Body weight body mass index genome-wide scan for linkage to body mass index in families of Mexican-American heritage increased body mass index Obesity 1354698 10480620 8 32186709 44359965 2 - by one flank and peak markers
1357378 human BW72_H Body weight QTL 72 (human) 5 0.0039 1337571 D5S408 Body weight body mass index percentile genome-wide scan for linkage of Body mass index in Old Order Amish families increased body mass index Obesity 1354707 12888987 601665 5 166921015 180857866 3 - by peak only
1357379 human BW70_H Body weight QTL 70 (human) 11 0.0079 1299908 D11S2000 Body weight body mass index genome-wide scan for linkage of body mass index in Old Order Amish families increased body mass index Obesity 1354707 12888987 601665 11 92064058 118064058 3 - by peak only
1357380 human BW64_H Body weight QTL 64 (human) 11 2.2 1338714 D11S1321 1336203 D11S4089 69170 UCP2 Body weight percent fat after exercise training genome-wide scan for linkage to body composition before and after exercise training in Caucasians from the HERITAGE study decreased body mass index Obesity 1354706 11299268 11 75339935 120495085 1 - by flanking markers
1357381 human BW57_H Body weight QTL 57 (human) 1 1.0 1.0E-4 1334872 D1S435 1334886 D1S2762 1349517 S100A1 Body weight fat free mass after exercise training genome-wide scan for linkage to body composition before and after exercise training in Caucasians from the HERITAGE study decreased body mass index Obesity 1354706 11299268 1 91331358 165222998 1 - by flanking markers
1357382 human SLEP2_H Serum leptin level QTL 2 (human) 2 4.95 9.0E-7 1334898 D2S1360 1357238 D2S441 1298195 D2S1788 Hormone level leptin genome-wide scan for serum leptin concentration and fat mass was conducted in Mexican American families increased circulating leptin level Obesity 1357228 9054940 601694 2 17355438 68092661 1 - by flanking markers
1357383 human BW61_H Body weight QTL 61 (human) 5 2.4 4.0E-4 1335880 D5S493 1342371 D5S434 1298261 D5S1462 Body weight BMI after exercise training genome-wide scan for linkage to body composition before and after exercise training in Caucasians from the HERITAGE study decreased body mass index 1354706 11299268 5 34987917 147295674 1 - by flanking markers
1357384 human BW71_H Body weight QTL 71 (human) 1 0.0099 1340396 D1S3721 Body weight body mass index genome-wide scan for linkage of body mass index in Old Order Amish families increased body mass index Obesity 1354707 12888987 601665 1 28499186 54499186 3 - by peak only
1357385 human BW60_H Body weight QTL 60 (human) 1 2.2 6.0E-4 1342270 D1S445 1336446 D1S2891 1298252 D1S1660 Body weight fat mass after exercise training genome-wide scan for linkage to body composition before and after exercise training in Caucasians from the HERITAGE study decreased body mass index 1354706 11299268 1 166221024 206519383 1 - by flanking markers
1357386 human BW66_H Body weight QTL 66 (human) 14 2.4 1341752 D14S70 1337378 D14S1032 1298288 D14S1280 Body weight BMI before exercise training genome-wide scan for linkage to body composition before and after exercise training in Caucasians from the HERITAGE study decreased body mass index Obesity 1354706 11299268 14 25281346 33528945 1 - by flanking markers
1357288 human AASTH30_H Allergic/atopic asthma related QTL 30 (human) 2 3.16 36.0 1336601 D2S442 1335148 D2S1384 1298319 D2S2314 Serum IgE titer fine mapping of linkage between a region on chromosome 2q and elevated serum IgE levels using 9 additional dinucleotide microsatellite markers increased IgE level Asthma 1331588;1331539 12417883;11023809 2 136975836 204935512 1 - by flanking markers
1357289 human AASTH31_H Allergic/atopic asthma related QTL 31 (human) 11 2.0 1340959 D11S905 1339134 D11S1396 1340887 D11S1337 Reversible airflow obstruction Asthmatic African-American families with an ashtma phenotype from the Johns Hopkins center of the Collaborative Study on the Genetics of Asthma (CSGA)were included in the study. Asthma was determined by spirometry and methacholine challenge. abnormal forced expiratory flow rates Asthma 1331546 12664305 600807 11 40930877 81252157 1 - by flanking markers
1357290 human AASTH52_H Allergic/atopic asthma related QTL 52 (human) 21 0.0012 Reversible airflow obstruction genome-wide scan for loci affecting asthma susceptibility in the Hutterites, a religious isolate of European ancestry; individuals were tested according to the Collaborative Study on the Genetics of Asthma (CSGA) protocol abnormal forced expiratory flow rates;increased susceptibility to type I hypersensitivity reaction;increased IgE level 1331840 9700192 600807
1357291 human AASTH48_H Allergic/atopic asthma related QTL 48 (human) 9 0.0093 1298120 D9S922 Reversible airflow obstruction genome-wide scan for loci affecting asthma susceptibility in the Hutterites, a religious isolate of European ancestry; individuals were tested according to the Collaborative Study on the Genetics of Asthma (CSGA) protocol abnormal forced expiratory flow rates;increased susceptibility to type I hypersensitivity reaction;increased IgE level 1331840 9700192 600807 9 69158292 95158292 3 - by peak only
1357292 human AASTH34_H Allergic/atopic asthma related QTL 34 (human) 6 2.61 1298131 D6S291 Atopy reversible airflow obstruction genome-wide scan to find loci that influence asthma susceptibility; this study focused on the quantitative traits atopy, broadly defined as an allergic response, and RASTI, the RAdioallergoSorbent Test specific for serum IgE antibodies to dust mite and Timothy grass abnormal airway resistance;abnormal cranial nerve morphology Asthma 1331675 11793670
1357293 human AASTH20_H Allergic/atopic asthma related QTL 20 (human) 12 1.13 1299944 D12S2070 Reversible airflow obstruction post-bronchodilator FEV1 genome-wide nonparametric multipoint analysis for marker allele frequencies in 3 ethnic groups (African American, European American and Hispanic) decreased pulmonary ventilation Asthma 1331533 11349227 12 101567143 127567143 3 - by peak only
1357294 human AASTH40_H Allergic/atopic asthma related QTL 40 (human) 5 3.61 3.0E-4 1339413 D5S393 1337935 D5S410 1338437 D5S436 Serum IgE titer total serum IgE titer segregation analysis and linkage analysis for total serum IgE levels performed on 538 probands decreased pulmonary ventilation Asthma 1331847;1331851;1331673 7835897;8590328;11888952 recessive 5 135729237 152755350 1 - by flanking markers
1357295 human AASTH14_H Allergic/atopic asthma related QTL 14 (human) 13 2.4 1339038 D13S175 1340637 D13S217 Reversible airflow obstruction chromosome 13 marker scan for loci affecting atopic asthma in 86 Japanese families whose probands are asthmatic children increased IgE level Asthma 1331589;1331538 10400996;10860660 13 19746506 45746506 4 - by one flank marker only
1357296 human AASTH9_H Allergic/atopic asthma related QTL 9 (human) 1 1.17 1336170 D1S2844 1337678 D1S2693 1341449 D1S1663 Reversible airflow obstruction ETS negative genome-wide scan among affected siblings with asthma; study attempts to find loci that influence asthma susceptibility based on exposure to environmental tobacco smoke during infancy (ETS positive or negative) abnormal airway resistance;abnormal lung volume;decreased pulmonary ventilation Asthma 1331535 12704367 1 161215450 242367128 1 - by flanking markers
1357297 human AASTH21_H Allergic/atopic asthma related QTL 21 (human) 11 2.0 0.002 1298333 D11S1985 Reversible airflow obstruction post-bronchodilator FEV1 genome-wide nonparametric multipoint analysis for marker allele frequencies in African American decreased pulmonary ventilation Asthma 1331533 11349227
1357298 human AASTH25_H Allergic/atopic asthma related QTL 25 (human) 20 1.07 1336081 D20S473 Reversible airflow obstruction post-bronchodilator FEV1 genome-wide nonparametric multipoint analysis for marker allele frequencies in European American group decreased pulmonary ventilation Asthma 1331533 11349227 20 1 16413530 3 - by peak only
1357299 human AASTH47_H Allergic/atopic asthma related QTL 47 (human) 9 2.8E-4 1335858 G10361 Reversible airflow obstruction genome-wide scan for loci affecting asthma susceptibility in the Hutterites, a religious isolate of European ancestry; individuals were tested according to the Collaborative Study on the Genetics of Asthma (CSGA) protocol abnormal forced expiratory flow rates;increased susceptibility to type I hypersensitivity reaction;increased IgE level 1331840 9700192 600807
1357300 human AASTH39_H Allergic/atopic asthma related QTL 39 (human) 20 3.93 1339552 D14S74 1340797 D20S849 1337861 D20S842 Reversible airflow obstruction BHR genome-wide scan among families with siblings diagnosed with asthma; criteria for selection included doctor's diagnosis and current medication use; dichotomized variants for analysis included bronchial hyperresponsiveness (BHR) and an age-specific cutoff for elevated serum IgE levels in response to specific antigens abnormal airway resistance;abnormal cranial nerve morphology;increased IgE level;abnormal bronchial provocation Asthma 1331674 12110844 600807
1357301 human AASTH17_H Allergic/atopic asthma related QTL 17 (human) 5 2.18 7.0E-4 1336709 D5S642 1336064 D5S209 1341400 D5S479 Reversible airflow obstruction atopy score fine mapping of linkages of multicomponent factors to the chromosome 5 q31-q33 region; atopy score consists of total serum IgE and physician-diagnosed rhinitis as well as hypersensitivity in skin tests to 7 common allergens increased susceptibility to type I hypersensitivity reaction;increased IgE level 1331534 11692103 5 128219438 152529735 1 - by flanking markers
1357302 human AASTH35_H Allergic/atopic asthma related QTL 35 (human) 7 2.25 1299901 D7S530 Atopy reversible airflow obstruction genome-wide scan to find loci that influence asthma susceptibility; this study focused on the quantitative traits atopy, broadly defined as an allergic response, and RASTI, the RAdioallergoSorbent Test specific for serum IgE antibodies to dust mite and Timothy grass abnormal airway resistance;abnormal cranial nerve morphology Asthma 1331675 11793670 7 115989737 141989737 3 - by peak only
1357303 human AASTH38_H Allergic/atopic asthma related QTL 38 (human) 6 3.56 2.6E-5 1339515 D6S290 1331554 D6S305 Reversible airflow obstruction wheezing age of onset genome wide scan for loci affecting asthma or wheezing age of onset in 97 German families with two or more asthmatic children abnormal respiratory sounds Asthma 1331671 11793663 6 153126004 162115529 1 - by flanking markers
1357304 human AASTH26_H Allergic/atopic asthma related QTL 25 (human) 1 2.92 2.0E-4 1340128 D1S2134 Reversible airflow obstruction post-bronchodilator FEV1 genome-wide nonparametric multipoint analysis for marker allele frequencies in Hispanics decreased pulmonary ventilation Asthma 1331533 11349227 1 35053998 61053998 3 - by peak only
1357305 human AASTH49_H Allergic/atopic asthma related QTL 49 (human) 12 0.0081 1341685 D12S375 Reversible airflow obstruction genome-wide scan for loci affecting asthma susceptibility in the Hutterites, a religious isolate of European ancestry; individuals were tested according to the Collaborative Study on the Genetics of Asthma (CSGA) protocol abnormal forced expiratory flow rates;increased susceptibility to type I hypersensitivity reaction;increased IgE level 1331840 9700192 600807 12 54231106 80231106 3 - by peak only
1357306 human AASTH50_H Allergic/atopic asthma related QTL 50 (human) 13 0.0025 1342079 D13S787 Reversible airflow obstruction genome-wide scan for loci affecting asthma susceptibility in the Hutterites, a religious isolate of European ancestry; individuals were tested according to the Collaborative Study on the Genetics of Asthma (CSGA) protocol abnormal forced expiratory flow rates;increased susceptibility to type I hypersensitivity reaction;increased IgE level 1331840 9700192 600807 13 10278863 36278863 3 - by peak only
1357307 human AASTH12_H Allergic/atopic asthma related QTL 12 (human) 9 1.18 0.009 1337739 D9S1780 1336114 D9S170 1337783 D9S910 Reversible airflow obstruction ETS negative genome-wide scan among affected siblings with asthma; study attempts to find loci that influence asthma susceptibility based on exposure to environmental tobacco smoke during infancy (ETS positive or negative) abnormal airway resistance;abnormal lung volume;decreased pulmonary ventilation Asthma 1331535 12704367 9 81058770 118107315 1 - by flanking markers
1357308 human AASTH23_H Allergic/atopic asthma related QTL 23 (human) 8 1.06 1336611 D8S1130 Reversible airflow obstruction post-bronchodilator FEV1 genome-wide nonparametric multipoint analysis for marker allele frequencies in European American group decreased pulmonary ventilation Asthma 1331533 11349227
1357309 human AASTH55_H Allergic/atopic asthma related QTL 5 (human) 5 1.0E-4 1339413 D5S393 Atopy reversible airflow obstruction Atopy was characterized in Japanese subjects three years of age and older, and defined as follows: total serum IgE levels more than one standard deviation above the normal Japanese population and/or increased serum IgE for various allergens. This QTL is also linked to asthma, characterized by clinical evidence of both recurrent episodes of wheezing an shortness of breath in the preceding year and spontaneous or bronchodilator-mediated reversible wheezing and dyspnea increased IgE level;increased susceptibility to type I hypersensitivity reaction Asthma 1331846 9372650 600807 5 122729319 148729319 3 - by peak only
1357310 human AASTH42_H Allergic/atopic asthma related QTL 42 (human) 2 0.004 1339630 D2S1328 Reversible airflow obstruction genome-wide scan for loci affecting asthma susceptibility in the Hutterites, a religious isolate of European ancestry; individuals were tested according to the Collaborative Study on the Genetics of Asthma (CSGA) protocol abnormal forced expiratory flow rates;increased susceptibility to type I hypersensitivity reaction;increased IgE level 1331840 9700192 600807 2 112903275 138903275 3 - by peak only
1357311 human AASTH13_H Allergic/atopic asthma related QTL 13 (human) 17 1.12 0.016 1298314 D17S1308 1338603 D17S1824 1298314 D17S1308 Reversible airflow obstruction ETS positive genome-wide scan among affected siblings with asthma; study attempts to find loci that influence asthma susceptibility based on exposure to environmental tobacco smoke during infancy (ETS positive or negative) abnormal airway resistance;abnormal lung volume;decreased pulmonary ventilation Asthma 1331535 12704367 17 569917 23684317 1 - by flanking markers
1357312 human AASTH11_H Allergic/atopic asthma related QTL 11 (human) 6 1.45 1339819 D6S1640 1341200 D6S1616 1337397 D6S1281 Reversible airflow obstruction ETS negative genome-wide scan among affected siblings with asthma; study attempts to find loci that influence asthma susceptibility based on exposure to environmental tobacco smoke during infancy (ETS positive or negative) abnormal airway resistance;abnormal lung volume;decreased pulmonary ventilation Asthma 1331535 12704367 6 7354389 40705949 1 - by flanking markers
1357313 human AASTH36_H Allergic/atopic asthma related QTL 36 (human) 13 4.32 1334923 D13S153 Atopy reversible airflow obstruction genome-wide scan to find loci that influence asthma susceptibility; this study focused on the quantitative traits atopy, broadly defined as an allergic response, and RASTI, the RAdioallergoSorbent Test specific for serum IgE antibodies to dust mite and Timothy grass abnormal airway resistance;abnormal cranial nerve morphology Asthma 1331675 11793670 AASTH33_H 13 34788891 60788891 3 - by peak only
1357314 human AASTH54_H Allergic/atopic asthma related QTL 54 (human) 5 3.56 3.0E-4 735276 IL9 732897 PDGFRB 1339413 D5S393 Reversible airflow obstruction total serum IgE single-region scan on chromosome 5q among families with affected sib-pairs for asthma; affected sib-pair analysis was used to test for linkage to bronchial hyperresponsiveness (BHR) and total serum IgE levels specific to house dust mite and grass mix abnormal airway resistance;abnormal cranial nerve morphology;increased IgE level 1331848 8590353 5 135255834 149515615 1 - by flanking markers
1357315 human AASTH51_H Allergic/atopic asthma related QTL 51 (human) 19 5.0E-4 1298198 D19S178 Reversible airflow obstruction genome-wide scan for loci affecting asthma susceptibility in the Hutterites, a religious isolate of European ancestry; individuals were tested according to the Collaborative Study on the Genetics of Asthma (CSGA) protocol abnormal forced expiratory flow rates;increased susceptibility to type I hypersensitivity reaction;increased IgE level 1331840 9700192 600807 19 36097564 62097564 3 - by peak only
1357316 human AASTH33_H Allergic/atopic asthma related QTL 33 (human) 13 3.12 1334923 D13S153 RASTI reversible airflow obstruction genome-wide scan to find loci that influence asthma susceptibility; this study focused on the quantitative traits atopy, broadly defined as an allergic response, and RASTI, the RAdioallergoSorbent Test specific for serum IgE antibodies to dust mite and Timothy grass abnormal airway resistance;increased IgE level Asthma 1331675 11793670 AASTH36_H 13 34788891 60788891 3 - by peak only
1357317 human AASTH19_H Allergic/atopic asthma related QTL 19 (human) 5 0.98 1298302 D5S1480 Reversible airflow obstruction post-bronchodilator FEV1 genome-wide nonparametric multipoint analysis for marker allele frequencies in 3 ethnic groups (African American, European American and Hispanic) decreased pulmonary ventilation Asthma 1331533 11349227 5 131124026 157124026 3 - by peak only
1357318 human AASTH43_H Allergic/atopic asthma related QTL 43 (human) 3 0.001 1298321 D3S2432 Reversible airflow obstruction genome-wide scan for loci affecting asthma susceptibility in the Hutterites, a religious isolate of European ancestry; individuals were tested according to the Collaborative Study on the Genetics of Asthma (CSGA) protocol abnormal forced expiratory flow rates;increased susceptibility to type I hypersensitivity reaction;increased IgE level 1331840 9700192 600807 3 19140311 45140311 3 - by peak only
1357319 human AASTH8_H Allergic/atopic asthma related QTL 8 (human) 1 1.29 1339661 D1S2677 1334783 D1S2776 1298097 D1S1665 Reversible airflow obstruction ETS positive genome-wide scan among affected siblings with asthma; study attempts to find loci that influence asthma susceptibility based on exposure to environmental tobacco smoke (ETS) during infancy abnormal airway resistance;abnormal lung volume;decreased pulmonary ventilation Asthma 1331535 12704367 1 45564670 92982869 1 - by flanking markers
1357320 human AASTH27_H Allergic/atopic asthma related QTL 27 (human) 18 2.61 1335600 G15802 1337075 D18S1095 1298119 D18S844 Serum IgE titer reversible airflow obstruction genome-wide scan to find loci that influence total serum IgE titers in families with siblings diagnosed with asthma, adjusted for gender, age and Allergy Index (based on skin test sensitivity to common allergens); variance components analysis used to compartmentalize the asthma-correlated component of IgE titer abnormal airway resistance;abnormal cranial nerve morphology;increased IgE level Asthma 1331669 11255243 18 59543512 75349452 1 - by flanking markers
1357321 human AASTH53_H Allergic/atopic asthma related QTL 53 (human) 21 0.0096 1298173 D21S1440 Reversible airflow obstruction genome-wide scan for loci affecting asthma susceptibility in the Hutterites, a religious isolate of European ancestry; individuals were tested according to the Collaborative Study on the Genetics of Asthma (CSGA) protocol abnormal forced expiratory flow rates;increased susceptibility to type I hypersensitivity reaction;increased IgE level 1331840 9700192 600807 21 25063577 46944323 3 - by peak only
1357322 human AASTH44_H Allergic/atopic asthma related QTL 44 (human) 3 0.0012 1298239 D3S1768 Reversible airflow obstruction genome-wide scan for loci affecting asthma susceptibility in the Hutterites, a religious isolate of European ancestry; individuals were tested according to the Collaborative Study on the Genetics of Asthma (CSGA) protocol abnormal forced expiratory flow rates;increased susceptibility to type I hypersensitivity reaction;increased IgE level 1331840 9700192 600807 3 21599501 47599501 3 - by peak only
1357323 human AASTH18_H Allergic/atopic asthma related QTL 18 (human) 14 1.23 0.017 1338763 D14S749 Reversible airflow obstruction post-bronchodilator FEV1 genome-wide nonparametric multipoint analysis for marker allele frequencies in 3 ethnic groups (African American, European American and Hispanic) decreased pulmonary ventilation Asthma 1331533 11349227 14 80449597 106368585 3 - by peak only
1357324 human AASTH16_H Allergic/atopic asthma related QTL 16 (human) 13 1.4 1342302 D13S285 1338959 D13S293 Reversible airflow obstruction chromosome 13 marker scan for loci affecting atopic asthma in 86 Japanese families whose probands are asthmatic children increased IgE level Asthma 1331589 10400996 147050 13 111843434 113332527 1 - by flanking markers
1357325 human AASTH15_H Allergic/atopic asthma related QTL 15 (human) 13 2.0 1334923 D13S153 1341348 D13S156 Reversible airflow obstruction chromosome 13 marker scan for loci affecting atopic asthma in 86 Japanese families whose probands are asthmatic children increased IgE level Asthma 1331589 10400996 147050 13 47788774 73555775 1 - by flanking markers
1357326 human AASTH37_H Allergic/atopic asthma related QTL 37 (human) 14 2.88 1339552 D14S74 Atopy reversible airflow obstruction genome-wide scan to find loci that influence asthma susceptibility; this study focused on the quantitative traits atopy, broadly defined as an allergic response, and RASTI, the RAdioallergoSorbent Test specific for serum IgE antibodies to dust mite and Timothy grass abnormal airway resistance;abnormal cranial nerve morphology Asthma 1331675 11793670 14 64728351 90728351 3 - by peak only
1357327 human AASTH45_H Allergic/atopic asthma related QTL 45 (human) 3 0.0053 1298169 D3S2427 Reversible airflow obstruction genome-wide scan for loci affecting asthma susceptibility in the Hutterites, a religious isolate of European ancestry; individuals were tested according to the Collaborative Study on the Genetics of Asthma (CSGA) protocol abnormal forced expiratory flow rates;increased susceptibility to type I hypersensitivity reaction;increased IgE level 1331840 9700192 600807 3 164267613 190267613 3 - by peak only
1357328 human AASTH24_H Allergic/atopic asthma related QTL 24 (human) 19 1.02 1336425 D19S198 Reversible airflow obstruction post-bronchodilator FEV1 genome-wide nonparametric multipoint analysis for marker allele frequencies in European American group decreased pulmonary ventilation Asthma 1331533 11349227 19 33844982 59844982 3 - by peak only
1357329 human AASTH46_H Allergic/atopic asthma related QTL 46 (human) 5 0.0079 1298302 D5S1480 Reversible airflow obstruction genome-wide scan for loci affecting asthma susceptibility in the Hutterites, a religious isolate of European ancestry; individuals were tested according to the Collaborative Study on the Genetics of Asthma (CSGA) protocol abnormal forced expiratory flow rates;increased susceptibility to type I hypersensitivity reaction;increased IgE level 1331840 9700192 600807 5 131124026 157124026 3 - by peak only
1357330 human AASTH22_H Allergic/atopic asthma related QTL 22 (human) 6 1.91 0.003 1337397 D6S1281 Reversible airflow obstruction post-bronchodilator FEV1 genome-wide nonparametric multipoint analysis for marker allele frequencies in European American group decreased pulmonary ventilation Asthma 1331533 11349227 6 12405100 38405100 3 - by peak only
1357331 human AASTH10_H Allergic/atopic asthma related QTL 10 (human) 5 1.23 1339439 D5S620 1340017 D5S487 1336959 D5S1505 Reversible airflow obstruction ETS positive genome-wide scan among affected siblings with asthma; study attempts to find loci that influence asthma susceptibility based on exposure to environmental tobacco smoke during infancy (ETS positive or negative) abnormal airway resistance;abnormal lung volume;decreased pulmonary ventilation Asthma 1331535 12704367 5 81708802 155600921 1 - by flanking markers
1357387 human BW58_H Body weight QTL 58 (human) 12 2.3 1.0E-4 1341595 D12S819 1335398 D12S809 70506 IGF1 Body weight fat free mass after exercise training genome-wide scan for linkage to body composition before and after exercise training in Caucasians from the HERITAGE study decreased body mass index Obesity 1354706 11299268 12 88356130 114356130 3 - by peak only
1357388 human BW62_H Body weight QTL 62 (human) 9 2.3 1341061 D9S173 1339367 D9S158 1339367 D9S158 Body weight BMI before exercise training genome-wide scan for linkage to body composition before and after exercise training in Caucasians from the HERITAGE study decreased body mass index Obesity 1354706 11299268
1357389 human BW68_H Body weight QTL 68 (human) 7 0.0011 1338834 D7S1804 1299920 D7S3070 1339157 D7S495 Body weight body mass index genome-wide scan for loci affecting body mass index in Old Order Amish families increased body mass index Obesity 1354707 12888987 601665 7 131930166 151198240 1 - by flanking markers
1357390 human BW67_H Body weight QTL 67 (human) 18 1.9 0.001 1338440 D18S381 1342398 D18S877 Body weight fat mass after exercise training genome-wide scan for linkage to body composition before and after exercise training in Caucasians from the HERITAGE study decreased body mass index Obesity 1354706 11299268 18 24979303 53574374 1 - by flanking markers
1357391 human BW63_H Body weight QTL 63 (human) 10 2.7 1342188 D10S1751 1335224 D10S249 1298105 D10S189 Body weight BMI before exercise training genome-wide scan for linkage to body composition before and after exercise training in Caucasians from the HERITAGE study decreased body mass index Obesity 1354706 11299268 10 271015 7235765 1 - by flanking markers
1357406 human SLEP1_H Serum leptin level QTL 1 (human) 8 3.4 4.0E-5 1341834 D8S592 1298265 D8S1179 1298265 D8S1179 Hormone level leptin genome-wide scan for genotype-by-smoking interaction QTLs related to serum leptin levels (measured by radioimmunoassay) in Caucasian families of Northern European ancestry in the Midwestern US increased circulating leptin level Obesity 1334493;1354707 12629560;12888987 8 118525332 125976441 1 - by flanking markers
1358213 human BW88_H Body weight QTL 88 (human) 3 3.54 0.009 1340885 D3S3656 1298243 D3S1311 1298169 D3S2427 Body weight hip circumference genome-wide scan to identify loci affecting a number of phenotypes of the metabolic syndrome including body mass index (BMI), waist and hip circumferance, glucose concentration, insulin level, and leptin level; serum glucose concentration was measured using the glucose oxidase procedure, plasma insulin and leptin levels were each measured using RIA. increased body weight;abnormal circulating insulin level;abnormal circulating glucose level Obesity 1298041 11121050 605552 3 172385638 198502655 1 - by flanking markers
1358214 human AASTH29_H Allergic/Atopic asthma related QTL 29 (human) 4 2.12 1298136 D4S3046 Serum IgE titer reversible airflow obstruction genome-wide multipoint analysis for total serum IgE was performed on a population with asthma increased IgE level Asthma 1331668 11793664 4 150610470 176610470 3 - by peak only
1358215 human SLEP3_H Serum leptin level QTL 3 (human) 17 4.97 3.0E-4 1299913 D17S947 1341434 D17S805 1299913 D17S947 Hormone level leptin genome-wide scan to identify loci affecting a number of phenotypes of the metabolic syndrome including body mass index (BMI), waist and hip circumferance, glucose concentration, insulin level, and leptin level. Serum glucose concentration was measured using the glucose oxidase procedure, plasma insulin and leptin levels were each measured using RIA. abnormal circulating leptin level;increased body weight Obesity 1298041 11121050 605552 17 12747096 19316276 1 - by flanking markers
1358216 human BW65_H Body weight QTL 65 (human) 12 2.2 1339029 D12S328 1336551 D12S85 Body fat amount fat mass before exercise training genome-wide scan for linkage to body composition before and after exercise training in Caucasians from the HERITAGE study decreased body mass index 1354706 11299268 12 5221529 45623114 1 - by flanking markers
1358217 human AASTH56_H Allergic/Atopic asthma related QTL 32 (human) 10 1.74 1336158 D10S191 Serum IgE titer reversible airflow obstruction genome-wide multipoint linkage analysis for serum IgE levels in Caucasian families with asthma increased IgE level Asthma 1331668 11793664 10 1599737 27599737 3 - by peak only
1358218 human AASTH32_H Allergic/Atopic asthma related QTL 32 (human) 10 1.31 1338104 D10S1743 Serum IgE titer reversible airflow obstruction genome-wide multipoint linkage analysis for serum IgE levels in African American families increased IgE level Asthma 1331668 11793664 10 54097269 80097269 3 - by peak only
1358219 human AASTH41_H Allergic/Atopic asthma related QTL 41 (human) 5 4.67 1339413 D5S393 1338437 D5S436 1338437 D5S436 Serum IgE titer reversible airflow obstruction linkage analysis to identify loci affecting serum IgE levels in individuals with asthma from a group of families from Holland. Testing on probands and family included a standardized respiratory questionairre, pulmonary function testing, broncial responsiveness to inhaled histamine and allergic status (skin tests, total serum IgE, specific IgE levels) increased IgE level Asthma 1331850 7668269 147061 5 135729237 145184396 1 - by flanking markers
1358220 human AASTH28_H Allergic/Atopic asthma related QTL 28 (human) 4 2.41 1339710 D4S3022 Serum IgE titer reversible airflow obstruction genome-wide multipoint analysis for total serum IgE was performed on a population with asthma increased IgE level Asthma 1331668 11793664 4 12223704 38223704 3 - by peak only
1358827 human MULTSCL22_H Multiple sclerosis susceptibility QTL 22 (human) 12 735410 PAH Multiple sclerosis susceptibility genome wide scan for loci affecting multiple sclerosis susceptibility, probands and siblings meet criteria for definite diagnosis of multiple sclerosis demyelination;neurodegeneration;abnormal inflammatory response Multiple Sclerosis 1358641 15069025 12 88795872 114795872 3 - by peak only
1358828 human MULTSCL2_H Multiple sclerosis susceptibility QTL 2 (human) 1 1298297 D1S547 Multiple sclerosis susceptibility genome wide scan for loci affecting multiple sclerosis susceptibility in families with individuals defined as definite multiple sclerosis status by clinical criteria, MRI scanning, and evoked-response testing neurodegeneration;abnormal nerve conduction;abnormal inflammatory response Multiple Sclerosis 1358640 15494893 126200 1 226822702 247249719 3 - by peak only
1358829 human MULTSCL33_H Multiple sclerosis susceptibility QTL 33 (human) 10 2.5 1335224 D10S249 1340909 D10S197 1339177 D10S591 Multiple sclerosis susceptibility chromsome 10 marker scan for fine-mapping of loci affecting multiple sclerosis susceptibility; study is a follow up to multiple genome wide screens suggesting linkage to chromosome 10 abnormal nerve conduction;abnormal inflammatory response;neurodegeneration Multiple Sclerosis 1358654 14575911 10 270898 26567069 1 - by flanking markers
1358830 human MULTSCL21_H Multiple sclerosis susceptibility QTL 21 (human) 11 1335533 D11S929 Multiple sclerosis susceptibility genome wide scan for loci affecting multiple sclerosis susceptibility, probands and siblings meet criteria for definite diagnosis of multiple sclerosis neurodegeneration;abnormal inflammatory response;demyelination Multiple Sclerosis 1358641 15069025 11 12808743 38808743 3 - by peak only
1358831 human MULTSCL12_H Multiple sclerosis susceptibility QTL 12 (human) 18 1299942 D18S843 Multiple sclerosis susceptibility genome wide scan for loci affecting multiple sclerosis susceptibility in families with individuals defined as definite multiple sclerosis status by clinical criteria, MRI scanning, and evoked-response testing neurodegeneration;abnormal nerve conduction;abnormal inflammatory response Multiple Sclerosis 1358640 15494893 126200 18 1 21603861 3 - by peak only
1358832 human MULTSCL7_H Multiple sclerosis susceptibility QTL 7 (human) 9 1340005 D9S282 Multiple sclerosis susceptibility genome wide scan for loci affecting multiple sclerosis susceptibility in families with individuals defined as definite multiple sclerosis status by clinical criteria, MRI scanning, and evoked-response testing neurodegeneration;abnormal nerve conduction;abnormal inflammatory response Multiple Sclerosis 1358640 15494893 126200 9 112848784 138848784 3 - by peak only
1358833 human MULTSCL25_H Multiple sclerosis susceptibility QTL 25 (human) 21 1339309 D21S1446 Multiple sclerosis susceptibility genome wide scan for loci affecting multiple sclerosis susceptibility, probands and siblings meet criteria for definite diagnosis of multiple sclerosis neurodegeneration;abnormal inflammatory response;demyelination Multiple Sclerosis 1358641 15069025 21 33862123 46944323 3 - by peak only
1358834 human MULTSCL29_H Multiple sclerosis susceptibility QTL 29 (human) 5 1.1 1340441 D5S1981 1337476 D5S419 Multiple sclerosis susceptibility genome wide scan for loci affecting multiple sclerosis susceptibility, affected individuals meet criteria for clinical, radiological (MRI), and immunological diagnosis of multiple sclerosis neurodegeneration;demyelination Multiple Sclerosis 1358652 14575909 recessive 5 1207429 26694521 1 - by flanking markers
1358835 human MULTSCL27_H Multiple sclerosis susceptibility QTL 27 (human) 18 1.9 1334759 D18S68 1340498 D18S70 1335010 D18S1161 Multiple sclerosis susceptibility genome wide scan for loci affecting multiple sclerosis susceptibility, affected individuals meet criteria for clinical, radiological (MRI), and immunological diagnosis of multiple sclerosis neurodegeneration;demyelination Multiple Sclerosis 1358652 14575909 18 59688675 75965487 1 - by flanking markers
1358836 human MULTSCL14_H Multiple sclerosis susceptibility QTL 14 (human) 3 1340974 D3S2418 Multiple sclerosis susceptibility genome wide scan for loci affecting multiple sclerosis susceptibility in families with individuals defined as definite multiple sclerosis status by clinical criteria, MRI scanning, and evoked-response testing neurodegeneration;abnormal nerve conduction;abnormal inflammatory response Multiple Sclerosis 1358640 15494893 126200 3 180799751 199501827 3 - by peak only
1358837 human MULTSCL9_H Multiple sclerosis susceptibility QTL 9 (human) 16 1341614 D16S2622 Multiple sclerosis susceptibility genome wide scan for loci affecting multiple sclerosis susceptibility in families with individuals defined as definite multiple sclerosis status by clinical criteria, MRI scanning, and evoked-response testing abnormal inflammatory response;neurodegeneration;abnormal nerve conduction Multiple Sclerosis 1358640 15494893 126200 16 1 16649765 3 - by peak only
1358838 human MULTSCL8_H Multiple sclerosis susceptibility QTL 8 (human) 13 1339038 D13S175 Multiple sclerosis susceptibility genome wide scan for loci affecting multiple sclerosis susceptibility in families with individuals defined as definite multiple sclerosis status by clinical criteria, MRI scanning, and evoked-response testing neurodegeneration;abnormal nerve conduction;abnormal inflammatory response Multiple Sclerosis 1358640 15494893 126200 13 6746562 32746562 3 - by peak only
1358839 human MULTSCL5_H Multiple sclerosis susceptibility QTL 5 (human) 6 1349823 HLA-DRB1 Multiple sclerosis susceptibility genome wide scan for loci affecting multiple sclerosis susceptibility in families with individuals defined as definite multiple sclerosis status by clinical criteria, MRI scanning, and evoked-response testing abnormal nerve conduction;abnormal inflammatory response;neurodegeneration Multiple Sclerosis 1358640 15494893 126200 6 19660043 45660043 3 - by peak only
1358840 human MULTSCL23_H Multiple sclerosis susceptibility QTL 23 (human) 18 1341022 D18S53 Multiple sclerosis susceptibility genome wide scan for loci affecting multiple sclerosis susceptibility, probands and siblings meet criteria for definite diagnosis of multiple sclerosis neurodegeneration;abnormal inflammatory response;demyelination Multiple Sclerosis 1358641 15069025 18 1 24482826 3 - by peak only
1358841 human MULTSCL6_H Multiple sclerosis susceptibility QTL 6 (human) 6 1298251 D6S474 Multiple sclerosis susceptibility genome wide scan for loci affecting multiple sclerosis susceptibility in families with individuals defined as definite multiple sclerosis status by clinical criteria, MRI scanning, and evoked-response testing neurodegeneration;abnormal nerve conduction;abnormal inflammatory response Multiple Sclerosis 1358640 15494893 126200 6 99985879 125985879 3 - by peak only
1358842 human MULTSCL11_H Multiple sclerosis susceptibility QTL 11 (human) 18 1336163 D18S391 Multiple sclerosis susceptibility genome wide scan for loci affecting multiple sclerosis susceptibility in families with individuals defined as definite multiple sclerosis status by clinical criteria, MRI scanning, and evoked-response testing neurodegeneration;abnormal nerve conduction;abnormal inflammatory response Multiple Sclerosis 1358640 15494893 126200 18 1 18771314 3 - by peak only
1358843 human MULTSCL24_H Multiple sclerosis susceptibility QTL 24 (human) 18 1340498 D18S70 Multiple sclerosis susceptibility genome wide scan for loci affecting multiple sclerosis susceptibility, probands and siblings meet criteria for definite diagnosis of multiple sclerosis neurodegeneration;abnormal inflammatory response;demyelination Multiple Sclerosis 1358641 15069025 18 62965430 76117153 3 - by peak only
1358844 human MULTSCL15_H Multiple sclerosis susceptibility QTL 15 (human) 5 1340849 D5S816 Multiple sclerosis susceptibility genome wide scan for loci affecting multiple sclerosis susceptibility in families with individuals defined as definite multiple sclerosis status by clinical criteria, MRI scanning, and evoked-response testing neurodegeneration;abnormal nerve conduction;abnormal inflammatory response Multiple Sclerosis 1358640 15494893 126200 5 122329530 148329530 3 - by peak only
1358845 human MULTSCL13_H Multiple sclerosis susceptibility QTL 13 (human) 22 1340346 D22S689 Multiple sclerosis susceptibility genome wide scan for loci affecting multiple sclerosis susceptibility in families with individuals defined as definite multiple sclerosis status by clinical criteria, MRI scanning, and evoked-response testing neurodegeneration;abnormal nerve conduction;abnormal inflammatory response Multiple Sclerosis 1358640 15494893 126200 22 14186571 40186571 3 - by peak only
1358846 human MULTSCL30_H Multiple sclerosis susceptibility QTL 30 (human) 19 0.89 1336308 D19S209 1335819 D19S919 Multiple sclerosis susceptibility genome wide scan for loci affecting multiple sclerosis susceptibility, affected individuals meet criteria for clinical, radiological (MRI), and immunological diagnosis of multiple sclerosis neurodegeneration;demyelination Multiple Sclerosis 1358652 14575909 recessive 19 3265332 34603056 1 - by flanking markers
1358847 human MULTSCL28_H Multiple sclerosis susceptibility QTL 28 (human) 8 1.2 1337367 D8S264 1339606 D8S1113 Multiple sclerosis susceptibility genome wide scan for loci affecting multiple sclerosis susceptibility, affected individuals meet criteria for clinical, radiological (MRI), and immunological diagnosis of multiple sclerosis neurodegeneration;demyelination Multiple Sclerosis 1358652 14575909 recessive 8 2117752 59871002 1 - by flanking markers
1358848 human MULTSCL16_H Multiple sclerosis susceptibility QTL 16 (human) 1 1340437 D1S552 Multiple sclerosis susceptibility genome wide scan for loci affecting multiple sclerosis susceptibility in families with individuals defined as definite multiple sclerosis status by clinical criteria, MRI scanning, and evoked-response testing neurodegeneration;abnormal nerve conduction;abnormal inflammatory response Multiple Sclerosis 1358640 15494893 126200 1 6139677 32139677 3 - by peak only
1358849 human MULTSCL18_H Multiple sclerosis susceptibility QTL 18 (human) 5 1339692 D5S2005 Multiple sclerosis susceptibility genome wide scan for loci affecting multiple sclerosis susceptibility, probands and siblings meet criteria for definite diagnosis of multiple sclerosis neurodegeneration;abnormal inflammatory response;demyelination Multiple Sclerosis 1358641 15069025 5 1 14395192 3 - by peak only
1358850 human MULTSCL10_H Multiple sclerosis susceptibility QTL 10 (human) 16 1298258 D16S516 Multiple sclerosis susceptibility genome wide scan for loci affecting multiple sclerosis susceptibility in families with individuals defined as definite multiple sclerosis status by clinical criteria, MRI scanning, and evoked-response testing neurodegeneration;abnormal nerve conduction;abnormal inflammatory response Multiple Sclerosis 1358640 15494893 126200
1358851 human MULTSCL31_H Multiple sclerosis susceptibility QTL 31 (human) 18 1.84 1340121 D18S59 1341022 D18S53 Multiple sclerosis susceptibility genome wide scan for loci affecting multiple sclerosis susceptibility, affected individuals meet criteria for clinical, radiological (MRI), and immunological diagnosis of multiple sclerosis neurodegeneration;demyelination Multiple Sclerosis 1358652 14575909 recessive 18 636461 11482915 1 - by flanking markers
1358852 human MULTSCL3_H Multiple sclerosis susceptibility QTL 3 (human) 2 1335148 D2S1384 Multiple sclerosis susceptibility genome wide scan for loci affecting multiple sclerosis susceptibility in families with individuals defined as definite multiple sclerosis status by clinical criteria, MRI scanning, and evoked-response testing neurodegeneration;abnormal nerve conduction;abnormal inflammatory response Multiple Sclerosis 1358640 15494893 126200 2 191935442 217935442 3 - by peak only
1358853 human MULTSCL20_H Multiple sclerosis susceptibility QTL 20 (human) 9 1337019 D9S301 Multiple sclerosis susceptibility genome wide scan for loci affecting multiple sclerosis susceptibility, probands and siblings meet criteria for definite diagnosis of multiple sclerosis abnormal inflammatory response;demyelination;neurodegeneration Multiple Sclerosis 1358641 15069025 9 59992657 85992657 3 - by peak only
1358854 human MULTSCL4_H Multiple sclerosis susceptibility QTL 4 (human) 6 1298151 D6S1959 Multiple sclerosis susceptibility genome wide scan for loci affecting multiple sclerosis susceptibility in families with individuals defined as definite multiple sclerosis status by clinical criteria, MRI scanning, and evoked-response testing neurodegeneration;abnormal nerve conduction;abnormal inflammatory response Multiple Sclerosis 1358640 15494893 126200
1358855 human MULTSCL32_H Multiple sclerosis susceptibility QTL 32 (human) 13 1.1 1336078 D13S218 1342302 D13S285 Multiple sclerosis susceptibility genome wide scan for loci affecting multiple sclerosis susceptibility, affected individuals meet criteria for clinical, radiological (MRI), and immunological diagnosis of multiple sclerosis neurodegeneration;demyelination;neurodegeneration;demyelination Multiple Sclerosis;Multiple Sclerosis 1358652;1358654 14575909;14575911 13 37930331 111843529 1 - by flanking markers
1358856 human MULTSCL17_H Multiple sclerosis susceptibility QTL 17 (human) 2 1341363 D2S140 Multiple sclerosis susceptibility genome wide scan for loci affecting multiple sclerosis susceptibility, probands and siblings meet criteria for definite diagnosis of multiple sclerosis abnormal inflammatory response;demyelination;neurodegeneration Multiple Sclerosis 1358641 15069025 2 228388212 242951149 3 - by peak only
1358857 human MULTSCL19_H Multiple sclerosis susceptibility QTL 19 (human) 6 1349823 HLA-DRB1 Multiple sclerosis susceptibility genome wide scan for loci affecting multiple sclerosis susceptibility, probands and siblings meet criteria for definite diagnosis of multiple sclerosis neurodegeneration;abnormal inflammatory response;demyelination Multiple Sclerosis 1358641 15069025 6 19660043 45660043 3 - by peak only
1358858 human MULTSCL26_H Multiple sclerosis susceptibility QTL 26 (human) 1 1342061 D1S230 Multiple sclerosis susceptibility genome wide scan for loci affecting multiple sclerosis susceptibility, probands and siblings meet criteria for definite diagnosis of multiple sclerosis neurodegeneration;abnormal inflammatory response;demyelination Multiple Sclerosis 1358641 15069025
1549941 human BW21_H Body weight QTL 21 (human) 5 1.73 1299969 D5S418 1299941 D5S407 Body weight body mass index Sib Pair linkage analysis of French families for gene linkage to morbid obesity increased body mass index Obesity 1298039 10334320 5 40051556 56030638 1 - by flanking markers
1559411 human SCL107_H Serum cholesterol level QTL 107 (human) 15 3.88 736139 GABRB3 1335361 D15S165 Lipid level triglyceride genome wide scan for loci affecting plasma triglyceride concentration in Mexican Americans; fasting blood samples were tested for glucose, triglyceride, and HDL cholesterol levels 1556737 10729112 15 24339786 29048110 1 - by flanking markers
1581521 human BP67_H Blood pressure QTL 67 (human) 5 2.7 0.001 1331600 D5S1471 Blood pressure pulse pressure genome-wide scan for linkage to loci influencing pulse pressure, the difference between systolic and diastolic pressure 1578727 16286574 5 153809133 179809133 3 - by peak only
1581523 human BP61_H Blood pressure QTL 61 (human) 18 3.2 0.001 1331553 D18S851 Blood pressure pulse pressure genome-wide scan for linkage to loci influencing pulse pressure, the difference between systolic and diastolic pressure 1578727 16286574 18 35361535 61361535 3 - by peak only
1581524 human BP80_H Blood pressure QTL 80 (human) 21 2.1 0.001 1336642 D21S1896 Blood pressure pulse pressure genome-wide scan for linkage to loci influencing pulse pressure, the difference between systolic and diastolic pressure 1578727 16286574 21 13746105 39746105 3 - by peak only
1581525 human BP63_H Blood pressure QTL 63 (human) 17 3.6 0.001 1298335 D17S2193 Blood pressure pulse pressure genome-wide scan for linkage to loci influencing pulse pressure, the difference between systolic and diastolic pressure 1578727 16286574 17 51059427 77059427 3 - by peak only
1581526 human BP77_H Blood pressure QTL 77 (human) 1 2.7 0.001 1298252 D1S1660 Blood pressure pulse pressure genome-wide scan for linkage to loci influencing pulse pressure, the difference between systolic and diastolic pressure 1578727 16286574 1 183878083 209878083 3 - by peak only
1581527 human BP70_H Blood pressure QTL 70 (human) 16 2.2 0.001 1298327 D16S2624 Blood pressure pulse pressure genome-wide scan for linkage to loci influencing pulse pressure, the difference between systolic and diastolic pressure 1578727 16286574 16 57292706 83292706 3 - by peak only
1581528 human BP64_H Blood pressure QTL 64 (human) 21 4.3 0.001 1336270 D21S1437 Blood pressure pulse pressure genome-wide scan for linkage to loci influencing pulse pressure, the difference between systolic and diastolic pressure 1578727 16286574 21 7568770 33568770 3 - by peak only
1581529 human BP71_H Blood pressure QTL 71 (human) 22 2.0 0.001 732324 CABIN1 Blood pressure pulse pressure genome-wide scan for linkage to loci influencing pulse pressure, the difference between systolic and diastolic pressure 1578727 16286574 22 9821180 35821180 3 - by peak only
1581530 human BP69_H Blood pressure QTL 69 (human) 19 2.3 0.001 1331586 D19S246 Blood pressure pulse pressure genome-wide scan for linkage to loci influencing pulse pressure, the difference between systolic and diastolic pressure 1578727 16286574 19 42647559 63811651 3 - by peak only
1581531 human BP78_H Blood pressure QTL 78 (human) 19 2.3 0.001 1298198 D19S178 Blood pressure pulse pressure genome-wide scan for linkage to loci influencing pulse pressure, the difference between systolic and diastolic pressure 1578727 16286574 19 36097564 62097564 3 - by peak only
1581532 human BP74_H Blood pressure QTL 74 (human) 21 2.2 0.001 1336270 D21S1437 Blood pressure pulse pressure genome-wide scan for linkage to loci influencing pulse pressure, the difference between systolic and diastolic pressure 1578727 16286574 21 7568770 33568770 3 - by peak only
1581533 human BP66_H Blood pressure QTL 66 (human) 7 3.1 0.001 1342229 D7S3046 Blood pressure pulse pressure genome-wide scan for linkage to loci influencing pulse pressure, the difference between systolic and diastolic pressure 1578727 16286574 7 55190426 81190426 3 - by peak only
1581534 human BP76_H Blood pressure QTL 76 (human) 19 2.0 0.001 1334592 D19S591 Blood pressure pulse pressure genome-wide scan for linkage to loci influencing pulse pressure, the difference between systolic and diastolic pressure 1578727 16286574
1581535 human BP65_H Blood pressure QTL 65 (human) 19 3.1 0.001 1334592 D19S591 Blood pressure pulse pressure genome-wide scan for linkage to loci influencing pulse pressure, the difference between systolic and diastolic pressure 1578727 16286574
1581536 human BP68_H Blood pressure QTL 68 (human) 3 2.5 0.001 1340780 D3S1763 Blood pressure pulse pressure genome-wide scan for linkage to loci influencing pulse pressure, the difference between systolic and diastolic pressure 1578727 16286574 3 155722527 181722527 3 - by peak only
1581537 human BP72_H Blood pressure QTL 72 (human) 3 2.1 0.001 1298245 D3S2406 Blood pressure pulse pressure genome-wide scan for linkage to loci influencing pulse pressure, the difference between systolic and diastolic pressure 1578727 16286574 3 60341229 86341229 3 - by peak only
1581538 human BP62_H Blood pressure QTL 62 (human) 20 4.4 0.001 1339243 D20S481 Blood pressure pulse pressure genome-wide scan for linkage to loci influencing pulse pressure, the difference between systolic and diastolic pressure 1578727 16286574 20 30201813 56201813 3 - by peak only
1581539 human BP75_H Blood pressure QTL 75 (human) 1 2.4 0.001 1339881 D1S1728 Blood pressure pulse pressure genome-wide scan for linkage to loci influencing pulse pressure, the difference between systolic and diastolic pressure 1578727 16286574
1581540 human BP60_H Blood pressure QTL 60 (human) 1 1337647 D1S413 1341324 D1S199 1299923 D1S2890 Blood pressure hypertension susceptibility genome-wide scan for linkage to quantitative traits of systolic and diastolic blood pressure and to qualitative trait of hypertension susceptibility in hypertensive families from China 1578730 15638827 1 19829731 196887027 1 - by flanking markers
1581542 human BP73_H Blood pressure QTL 73 (human) 21 3.2 0.001 1335360 D21S272 Blood pressure pulse pressure genome-wide scan for linkage to loci influencing pulse pressure, the difference between systolic and diastolic pressure 1578727 16286574 21 11300530 37300530 3 - by peak only
1581543 human BP79_H Blood pressure QTL 79 (human) 1 2.2 0.001 1338648 D1S202 Blood pressure pulse pressure genome-wide scan for linkage to loci influencing pulse pressure, the difference between systolic and diastolic pressure 1578727 16286574 1 172232096 198232096 3 - by peak only
1559336 human BW84_H Body weight QTL 84 (human) 18 2.1 0.004 1340121 D18S59 1338314 D18S464 1299942 D18S843 Body weight body mass index genome-wide scan for loci affecting body mass index and possible genetic imprinting effects in children and young adults from the Rochester Family Heart Study increased body weight 1357973 12774034 18 636461 9951557 1 - by flanking markers
1559337 human SCL86_H Serum cholesterol level QTL 86 (human) 2 1.54 0.004 1334801 D2S220 Lipid level total cholesterol genome wide linkage analysis to identify loci that influence serum lipid levels, including fasting total serum cholesterol, high density lipoprotein cholesterol and triglycerides, in participants in the Amish Family Diabetes Study Hypercholesterolemia 1559071 15177127 2 7949584 33949584 3 - by peak only
1559338 human BW83_H Body weight QTL 83 (human) 16 1.82 0.006 1342205 G10252 Body weight body mass index genome-wide scan for loci affecting body mass index and possible genetic imprinting effects in children and young adults from the Rochester Family Heart Study increased body weight 1357973 12774034
1559339 human BW45_H Body weight QTL 45 (human) 14 1.95 0.002 1338735 D14S742 Body weight body mass index genome-wide scan for loci affecting body mass index and possible genetic imprinting effects in children and young adults from the Rochester Family Heart Study increased body weight 1357973 12774034 14 8271015 34271015 3 - by peak only
1559340 human SCL85_H Serum cholesterol level QTL 85 (human) 2 2.17 8.0E-4 1335620 D2S312 Lipid level LDL cholesterol genome wide linkage analysis to identify loci that influence serum lipid levels, including fasting total serum cholesterol, high density lipoprotein cholesterol and triglycerides, in participants in the Amish Family Diabetes Study Hypercholesterolemia 1559071 15177127 2 2144862 28144862 3 - by peak only
1559341 human BW46_H Body weight QTL 46 (human) 15 1.87 0.004 1341689 D15S1007 Body weight body mass index genome-wide scan for loci affecting body mass index and possible genetic imprinting effects in children and young adults from the Rochester Family Heart Study increased body weight 1357973 12774034 15 18525141 44525141 3 - by peak only
1559342 human BW42_H Body weight QTL 42 (human) 8 1.98 0.003 1298326 D8S277 Body weight body mass index genome-wide scan for loci affecting body mass index and possible genetic imprinting effects in children and young adults from the Rochester Family Heart Study increased body weight 1357973 12774034 8 1 19504205 3 - by peak only
1559343 human BW41_H Body weight QTL 41 (human) 4 1.84 0.005 1331597 D4S2417 Body weight body mass index genome-wide scan for loci affecting body mass index and possible genetic imprinting effects in children and young adults from the Rochester Family Heart Study increased body weight 1357973 12774034
1559344 human SCL89_H Serum cholesterol level QTL 89 (human) 9 1.61 0.003 1342068 D9S290 Lipid level total cholesterol genome wide linkage analysis to identify loci that influence serum lipid levels, including fasting total serum cholesterol, high density lipoprotein cholesterol and triglycerides, in participants in the Amish Family Diabetes Study Hypercholesterolemia 1559071 15177127 9 117567367 140273252 3 - by peak only
1559345 human BW82_H Body weight QTL 82 (human) 12 1.83 0.006 1337710 G08254 Body weight body mass index genome-wide scan for loci affecting body mass index and possible genetic imprinting effects in children and young adults from the Rochester Family Heart Study increased body weight 1357973 12774034 12 1 21048975 3 - by peak only
1559346 human SCL94_H Serum cholesterol level QTL 94 (human) 19 1.54 0.004 1298168 D19S433 Lipid level total cholesterol genome wide linkage analysis to identify loci that influence serum lipid levels, including fasting total serum cholesterol, high density lipoprotein cholesterol and triglycerides, in participants in the Amish Family Diabetes Study Hypercholesterolemia 1559071 15177127 19 22108969 48108969 3 - by peak only
1559347 human SCL92_H Serum cholesterol level QTL 92 (human) 19 2.15 8.0E-4 1299977 D19S221 Lipid level LDL cholesterol genome wide linkage analysis to identify loci that influence serum lipid levels, including fasting total serum cholesterol, high density lipoprotein cholesterol and triglycerides, in participants in the Amish Family Diabetes Study Hypercholesterolemia 1559071 15177127 19 1 25573976 3 - by peak only
1559348 human LDLPS1_H Low density lipoprotein particle size QTL 1 (human) 6 2.1 0.025 1298242 D6S1040 1340196 D6S972 1338844 D6S2436 LDL particle size genome-wide scan for linkage to LDL size and triglyceride levels in participants of the Genetic Epidemiology of Hypertriglyceridemia Study 1556572 12923221 6 131027446 157027446 4 - by one flank marker only
1559349 human SCL88_H Serum cholesterol level QTL 88 (human) 3 1.67 0.003 1341208 D3S1263 Lipid level total cholesterol genome wide linkage analysis to identify loci that influence serum lipid levels, including fasting total serum cholesterol, high density lipoprotein cholesterol and triglycerides, in participants in the Amish Family Diabetes Study Hypercholesterolemia 1559071 15177127 3 1 24492378 3 - by peak only
1559350 human SCL90_H Serum cholesterol level QTL 90 (human) 11 1.7 0.003 1336607 D11S902 Lipid level triglyceride genome wide linkage analysis to identify loci that influence serum lipid levels, including fasting total serum cholesterol, high density lipoprotein cholesterol and triglycerides, in participants in the Amish Family Diabetes Study Hypertriglyceridemia 1559071 15177127 11 4445155 30445155 3 - by peak only
1559351 human SCL93_H Serum cholesterol level QTL 93 (human) 19 2.23 7.0E-4 1298168 D19S433 Lipid level LDL cholesterol genome wide linkage analysis to identify loci that influence serum lipid levels, including fasting total serum cholesterol, high density lipoprotein cholesterol and triglycerides, in participants in the Amish Family Diabetes Study Hypercholesterolemia 1559071 15177127 19 22108969 48108969 3 - by peak only
1559352 human BW80_H Body weight QTL 80 (human) 5 2.48 6.0E-4 1331600 D5S1471 Body weight body mass index genome-wide scan for loci affecting body mass index and possible genetic imprinting effects in children and young adults from the Rochester Family Heart Study increased body weight 1357973 12774034 5 153809133 179809133 3 - by peak only
1559353 human SCL95_H Serum cholesterol level QTL 95 (human) 22 1.55 0.004 1336957 D22S315 Lipid level HDL cholesterol genome wide linkage analysis to identify loci that influence serum lipid levels, including fasting total serum cholesterol, high density lipoprotein cholesterol and triglycerides, in participants in the Amish Family Diabetes Study Hypercholesterolemia 1559071 15177127 22 11345958 37345958 3 - by peak only
1559354 human LDLPS4_H Low density lipoprotein particle size QTL 4 (human) 15 2.2 0.019 735789 ACTC1 1341623 D15S153 1340590 D15S659 LDL particle size genome-wide scan for linkage to HDL cholesterol levels and LDL particle size in Dutch families abnormal cholesterol homeostasis;hyperlipidemia Hyperlipidemia 1556550 10681408 15 32869723 64347234 1 - by flanking markers
1559355 human BW43_H Body weight QTL 43 (human) 8 2.05 0.00135 1339606 D8S1113 Body weight body mass index genome-wide scan for loci affecting body mass index and possible genetic imprinting effects in children and young adults from the Rochester Family Heart Study increased body weight 1357973 12774034 8 46870882 72870882 3 - by peak only
1559356 human SCL96_H Serum cholesterol level QTL 96 (human) 9 2.63 1337281 D9S167 Lipid level HDL cholesterol genome wide linkage analysis to identify loci that influence serum lipid levels, including fasting total serum cholesterol, high density lipoprotein cholesterol and triglycerides, in participants in the Amish Family Diabetes Study Hypercholesterolemia 1559071 15177127 9 71974017 97974017 3 - by peak only
1559357 human BW81_H Body weight QTL 81 (human) 10 1.89 0.005 1337710 G08254 Body weight body mass index genome-wide scan for loci affecting body mass index and possible genetic imprinting effects in children and young adults from the Rochester Family Heart Study increased body weight 1357973 12774034 12 1 21048975 3 - by peak only
1559358 human SCL91_H Serum cholesterol level QTL 91 (human) 11 2.03 0.001 1340832 D11S1345 Lipid level triglyceride genome wide linkage analysis to identify loci that influence serum lipid levels, including fasting total serum cholesterol, high density lipoprotein cholesterol and triglycerides, in participants in the Amish Family Diabetes Study Hypertriglyceridemia 1559071 15177127 11 108803119 134452384 3 - by peak only
1559359 human BW39_H Body weight QTL 39 (human) 20 3.55 1.6E-4 1357241 D20S482 Body weight body mass index genome-wide scan for loci affecting body mass index and possible genetic imprinting effects in children and young adults from the Rochester Family Heart Study increased body weight 1357973 12774034 20 1 17454357 3 - by peak only
1576335 human MYI15_H Myocardial infarction susceptibility QTL 15 (human) 13 3.61 1338935 D13S796 Myocardial infarction susceptibility early-onset genome-wide scan for susceptibility genes for myocardial infarction in families with familial premature coronary artery disease and myocardial infarction coronary artery stenosis Myocardial Infarction 1554326 14732905 13 93687047 114142980 3 - by peak only
1576336 human MYI12_H Myocardial infarction susceptibility QTL 12 (human) 5 3.73 1334571 D5S2845 Myocardial infarction susceptibility early-onset genome-wide scan for susceptibility genes for myocardial infarction in families with familial premature coronary artery disease and myocardial infarction coronary artery stenosis Myocardial Infarction 1554326 14732905 5 9426481 35426481 3 - by peak only
1576337 human MYI13_H Myocardial infarction susceptibility QTL 13 (human) 7 3.59 1299899 D7S1799 Myocardial infarction susceptibility early-onset genome-wide scan for susceptibility genes for myocardial infarction in families with familial premature coronary artery disease and myocardial infarction coronary artery stenosis Myocardial Infarction 1554326 14732905 7 90982330 116982330 3 - by peak only
1576338 human MYI6_H Myocardial infarction susceptibility QTL 6 (human) 12 5.62 1298109 D12S1045 Myocardial infarction susceptibility early-onset genome-wide scan for susceptibility genes for myocardial infarction in families with familial premature coronary artery disease and myocardial infarction coronary artery stenosis Myocardial Infarction 1554326 14732905 12 115963729 132349534 3 - by peak only
1576339 human LVC3_H Left ventricular contractility QTL 3 (human) 22 2.83 67.0 1339581 D22S420 Left ventricular contractility genome-wide scan for loci affecting variation in stress-corrected midwall shortening (an index of left ventricular contractility) in subjects participating in the HyperGEN study 1556478 11641284 22 3239551 29239551 3 - by peak only
1576340 human MYI16_H Myocardial infarction susceptibility QTL 16 (human) 14 4.24 1336875 D14S592 Myocardial infarction susceptibility early-onset genome-wide scan for susceptibility genes for myocardial infarction in families with familial premature coronary artery disease and myocardial infarction coronary artery stenosis Myocardial Infarction 1554326 14732905 14 47466722 73466722 3 - by peak only
1576341 human MYI5_H Myocardial infarction susceptibility QTL 5 (human) 7 3.74 1299899 D7S1799 Myocardial infarction susceptibility early-onset genome-wide scan for susceptibility genes for myocardial infarction in families with familial premature coronary artery disease and myocardial infarction coronary artery stenosis Myocardial Infarction 1554326 14732905 7 90982330 116982330 3 - by peak only
1576342 human MYI11_H Myocardial infarction susceptibility QTL 11 (human) 4 4.41 1340836 D4S2431 Myocardial infarction susceptibility early-onset genome-wide scan for susceptibility genes for myocardial infarction in families with familial premature coronary artery disease and myocardial infarction coronary artery stenosis Myocardial Infarction 1554326 14732905 4 162057363 188057363 3 - by peak only
1576343 human COARD4_H Coronary artery disease susceptibility QTL 4 (human) 1 2.17 0.006 1338350 D1S397 1341225 D1S229 1298271 D1S518 Coronary artery disease susceptibility early-onset Genome-wide scan for early-onset coronary artery disease in participants of the GENECARD Study coronary artery stenosis Coronary Arteriosclerosis 1556750 15272420 1 165776192 215160455 1 - by flanking markers
1576344 human COARD1_H Coronary artery disease susceptibility QTL 1 (human) 3 3.5 0.001 1298245 D3S2406 1299921 D3S1764 1339257 D3S2460 Coronary artery disease susceptibility early-onset Genome-wide scan for early-onset coronary artery disease in participants of the GENECARD Study coronary artery stenosis Coronary Arteriosclerosis 1556750 15272420 3 73341071 140671289 1 - by flanking markers
1576345 human LVC1_H Left ventricular contractility QTL 1 (human) 11 3.93 1338255 D11S1975 1339123 G27260 1337563 D11S1993 Left ventricular contractility genome-wide scan for loci affecting variation in stress-corrected midwall shortening (an index of left ventricular contractility) in subjects participating in the HyperGEN study 1556478 11641284 11 17052575 70080991 2 - by one flank and peak markers
1576346 human MYI10_H Myocardial infarction susceptibility QTL 10 (human) 2 3.3 1298104 D2S1790 Myocardial infarction susceptibility early-onset genome-wide scan for susceptibility genes for myocardial infarction in families with familial premature coronary artery disease and myocardial infarction coronary artery stenosis Myocardial Infarction 1554326 14732905 2 71928947 97928947 3 - by peak only
1576347 human COARD3_H Coronary artery disease susceptibility QTL 3 (human) 3 2.42 1298245 D3S2406 1341424 D3S2322 1339257 D3S2460 Coronary artery disease susceptibility early-onset Genome-wide scan for early-onset coronary artery disease in participants of the GENECARD Study coronary artery stenosis Coronary Arteriosclerosis 1556750 15272420 3 73341071 134169100 1 - by flanking markers
1559360 human BW79_H Body weight QTL 79 (human) 4 1.89 0.005 1341136 D4S1629 Body weight body mass index genome-wide scan for loci affecting body mass index and possible genetic imprinting effects in children and young adults from the Rochester Family Heart Study increased body weight 1357973 12774034 4 145556329 171556329 3 - by peak only
1559361 human BW40_H Body weight QTL 40 (human) 20 4.08 4.6E-5 1338506 D20S851 Body weight body mass index genome-wide scan for loci affecting body mass index and possible genetic imprinting effects in children and young adults from the Rochester Family Heart Study increased body weight 1357973 12774034 20 1 21810009 3 - by peak only
1559362 human BW49_H Body weight QTL 49 (human) 16 2.2 0.003 1339571 D16S3103 Body weight body mass index genome-wide scan for loci affecting body mass index and possible genetic imprinting effects in children and young adults from the Rochester Family Heart Study increased body weight 1357973 12774034 16 4381168 30381168 3 - by peak only
1559363 human SCL87_H Serum cholesterol level QTL 87 (human) 3 2.47 4.0E-4 1341208 D3S1263 Lipid level LDL cholesterol genome wide linkage analysis to identify loci that influence serum lipid levels, including fasting total serum cholesterol, high density lipoprotein cholesterol and triglycerides, in participants in the Amish Family Diabetes Study Hypercholesterolemia 1559071 15177127 3 1 24492378 3 - by peak only
1559364 human BW44_H Body weight QTL 44 (human) 9 1.85 0.004 1298120 D9S922 Body weight body mass index genome-wide scan for loci affecting body mass index and possible genetic imprinting effects in children and young adults from the Rochester Family Heart Study increased body weight 1357973 12774034 9 69158292 95158292 3 - by peak only
1559365 human BW48_H Body weight QTL 48 (human) 16 2.45 6.0E-4 1335387 D16S764 Body weight body mass index genome-wide scan for loci affecting body mass index and possible genetic imprinting effects in children and young adults from the Rochester Family Heart Study increased body weight 1357973 12774034 16 3554365 29554365 3 - by peak only
1559366 human BW85_H Body weight QTL 85 (human) 18 2.31 0.002 1338314 D18S464 1336700 D18S1126 1339328 D18S478 Body weight body mass index genome-wide scan for loci affecting body mass index and possible genetic imprinting effects in children and young adults from the Rochester Family Heart Study increased body weight 1357973 12774034 18 9951411 45610730 1 - by flanking markers
1559367 human BW47_H Body weight QTL 47 (human) 16 3.12 2.5E-4 1335604 D16S404 Body weight body mass index genome-wide scan for loci affecting body mass index and possible genetic imprinting effects in children and young adults from the Rochester Family Heart Study increased body weight 1357973 12774034 16 1 22625957 3 - by peak only
1559368 human BW76_H Body weight QTL 76 (human) 2 1.77 0.006 1298137 D2S410 Body weight body mass index genome-wide scan for loci affecting body mass index and possible genetic imprinting effects in children and young adults from the Rochester Family Heart Study increased body weight 1357973 12774034 2 102957477 128957477 3 - by peak only
1559369 human BW77_H Body weight QTL 77 (human) 2 2.4 0.00146 1336601 D2S442 Body weight body mass index genome-wide scan for loci affecting body mass index and possible genetic imprinting effects in children and young adults from the Rochester Family Heart Study increased body weight 1357973 12774034 2 123975936 149975936 3 - by peak only
1559370 human BW78_H Body weight QTL 78 (human) 3 1.77 0.0065 1340467 D3S3601 1298321 D3S2432 1298316 D3S3038 Body weight body mass index genome-wide scan for loci affecting body mass index and possible genetic imprinting effects in children and young adults from the Rochester Family Heart Study increased body weight 1357973 12774034 3 10643524 32140379 1 - by flanking markers
1576325 human MYI1_H Myocardial infarction susceptibility QTL 1 (human) 1 11.68 1.0E-12 1336052 D1S1597 1338435 ATA79C10 2181539 D1S3720 Myocardial infarction susceptibility early-onset genome-wide scan for susceptibility genes for myocardial infarction in families with familial premature coronary artery disease and myocardial infarction coronary artery stenosis Myocardial Infarction 1554326 14732905 1 13656774 27912392 2 - by one flank and peak markers
1576326 human MYI3_H Myocardial infarction susceptibility QTL 3 (human) 4 5.08 1340836 D4S2431 Myocardial infarction susceptibility early-onset genome-wide scan for susceptibility genes for myocardial infarction in families with familial premature coronary artery disease and myocardial infarction coronary artery stenosis Myocardial Infarction 1554326 14732905 4 162057363 188057363 3 - by peak only
1576327 human LVC2_H Left ventricular contractility QTL 2 (human) 12 1.97 1298304 D12S398 Left ventricular contractility genome-wide scan for loci affecting variation in stress-corrected midwall shortening (an index of left ventricular contractility) in subjects participating in the HyperGEN study 1556478 11641284 12 38483417 64483417 3 - by peak only
1576328 human MYI4_H Myocardial infarction susceptibility QTL 4 (human) 5 4.3 1334571 D5S2845 Myocardial infarction susceptibility early-onset genome-wide scan for susceptibility genes for myocardial infarction in families with familial premature coronary artery disease and myocardial infarction coronary artery stenosis Myocardial Infarction 1554326 14732905 5 9426481 35426481 3 - by peak only
1576329 human MYI9_H Myocardial infarction susceptibility QTL 9 (human) 1 12.0 1336052 D1S1597 1338435 ATA79C10 2181539 D1S3720 Myocardial infarction susceptibility early-onset genome-wide scan for susceptibility genes for myocardial infarction in families with familial premature coronary artery disease and myocardial infarction coronary artery stenosis Myocardial Infarction 1554326 14732905 1 13656774 27912392 2 - by one flank and peak markers
1576330 human MYI8_H Myocardial infarction susceptibility QTL 8 (human) 14 3.64 1336875 D14S592 Myocardial infarction susceptibility early-onset genome-wide scan for susceptibility genes for myocardial infarction in families with familial premature coronary artery disease and myocardial infarction coronary artery stenosis Myocardial Infarction 1554326 14732905 14 47466722 73466722 3 - by peak only
1576331 human MYI7_H Myocardial infarction susceptibility QTL 7 (human) 13 3.86 1338935 D13S796 Myocardial infarction susceptibility early-onset genome-wide scan for susceptibility genes for myocardial infarction in families with familial premature coronary artery disease and myocardial infarction coronary artery stenosis Myocardial Infarction 1554326 14732905 13 93687047 114142980 3 - by peak only
1576332 human MYI14_H Myocardial infarction susceptibility QTL 14 (human) 12 4.44 1298109 D12S1045 Myocardial infarction susceptibility early-onset genome-wide scan for susceptibility genes for myocardial infarction in families with familial premature coronary artery disease and myocardial infarction coronary artery stenosis Myocardial Infarction 1554326 14732905 12 115963729 132349534 3 - by peak only
1576333 human COARD2_H Coronary artery disease susceptibility QTL 2 (human) 3 3.16 1298245 D3S2406 1299921 D3S1764 1339257 D3S2460 Coronary artery disease susceptibility early-onset Genome-wide scan for early-onset coronary artery disease in participants of the GENECARD Study coronary artery stenosis Coronary Arteriosclerosis 1556750 15272420 3 73341071 140671289 1 - by flanking markers
1576334 human MYI2_H Myocardial infarction susceptibility QTL 2 (human) 2 3.82 1298104 D2S1790 Myocardial infarction susceptibility early-onset genome-wide scan for susceptibility genes for myocardial infarction in families with familial premature coronary artery disease and myocardial infarction coronary artery stenosis Myocardial Infarction 1554326 14732905 2 71928947 97928947 3 - by peak only
1558685 human SCL3_H Serum cholesterol level QTL 3 (human) 2 1.3 1340264 D2S172 1339325 D2S427 Lipid level HDL cholesterol genome-wide scan for linkage to high-density lipoprotein cholesterol levels in Mexican Americans subjects Non-insulin dependent diabetes Diabetes Mellitus, Non-Insulin-Dependent 1554327 11743583 2 230880823 231914752 1 - by flanking markers
1558686 human HRTRT5_H Heart rate QTL 5 (human) 4 1.91 1341279 D4S2688 1340394 D4S2952 1298122 D4S408 Heart rate genome-wide scan for linkage to heart rate among Caucasian and African-American families with at lease two siblings with mild to severe hypertension hypertension Hypertension 1554330 12189495 4 166675084 191273063 2 - by one flank and peak markers
1558687 human SCL13_H Serum cholesterol level QTL 13 (human) 2 3.5 1338989 D2S1334 Lipid level HDL cholesterol genome-wide scan for linkage to body mass index and high-density lipoprotein cholesterol levels in participants from the Framingham Heart study increased circulating HDL cholesterol level 1556548 14975120 2 123173055 149173055 3 - by peak only
1558688 human HRTRT12_H Heart rate QTL 12 (human) 3 1.56 1298243 D3S1311 Heart rate genome-wide scan for linkage to heart rate among Caucasian and African-American families with at lease two siblings with mild to severe hypertension hypertension Hypertension 1554330 12189495 3 185502595 199501827 3 - by peak only
1558689 human SCL2_H Serum cholesterol level QTL 2 (human) 9 2.4 1338296 D9S257 1336259 D9S1118 1337019 D9S301 Lipid level HDL cholesterol genome-wide scan for linkage to high-density lipoprotein cholesterol levels in Mexican Americans subjects who are part of the San Antonio Family Heart Study Non-insulin dependent diabetes Diabetes Mellitus, Non-Insulin-Dependent 1554327 11743583 9 31915500 89480562 1 - by flanking markers
1558690 human HRTRT2_H Heart rate QTL 2 (human) 4 3.18 1341279 D4S2688 1340394 D4S2952 1298122 D4S408 Heart rate genome-wide scan for linkage to heart rate among Caucasian and African-American families with at least two siblings with mild to severe hypertension hypertension Hypertension 1554330 12189495 4 166675084 191273063 2 - by one flank and peak markers
1558691 human SCL8_H Serum cholesterol level QTL 8 (human) 11 1.2 1337036 D11S1331 736606 HBB Lipid level HDL cholesterol genome-wide scan for linkage to high-density lipoprotein cholesterol levels in Mexican Americans subjects who are part of the San Antonio Family Diabetes Study Non-insulin dependent diabetes Diabetes Mellitus, Non-Insulin-Dependent 1554327 11743583 11 5204877 7248595 1 - by flanking markers
1558692 human SCL14_H Serum cholesterol level QTL 14 (human) 6 2.7 1298251 D6S474 1338844 D6S2436 1298296 D6S1009 Lipid level HDL cholesterol genome-wide scan for linkage to body mass index and high-density lipoprotein cholesterol levels in participants from the Framingham Heart study 1556548 14975120 6 112985799 161702209 2 - by one flank and peak markers
1558693 human SCL9_H Serum cholesterol level QTL 9 (human) 20 1.4 1338506 D20S851 1340191 D20S186 Lipid level HDL cholesterol genome-wide scan for linkage to high-density lipoprotein cholesterol levels in Mexican Americans subjects who are part of the San Antonio Family Diabetes Study Non-insulin dependent diabetes Diabetes Mellitus, Non-Insulin-Dependent 1554327 11743583 20 8809944 11471932 1 - by flanking markers
1558694 human HRTRT8_H Heart rate QTL 8 (human) 16 2.05 1336829 D16S3076 Heart rate genome-wide scan for linkage to heart rate among Caucasian and African-American families with at lease two siblings with mild to severe hypertension hypertension Hypertension 1554330 12189495 16 9942264 35942264 3 - by peak only
1558695 human BW149_H Body weight QTL 149 (human) 6 3.9 0.0072 1298242 D6S1040 1338844 D6S2436 1298296 D6S1009 Body weight BMI BMI more than 35 kg/m2 increased circulating HDL cholesterol level;increased body mass index 1556548;1642950 14975120;15220211 6 131027446 143660562 2 - by one flank and peak markers
1558696 human HRTRT7_H Heart rate QTL 7 (human) 5 1.9 1340969 D5S2501 Heart rate genome-wide scan for linkage to heart rate among Caucasian and African-American families with at lease two siblings with mild to severe hypertension hypertension Hypertension 1554330 12189495 5 97064369 123064369 3 - by peak only
1558697 human HRTRT6_H Heart rate QTL 6 (human) 5 2.29 1298299 D5S1457 Heart rate genome-wide scan for linkage to heart rate among Caucasian and African-American families with at lease two siblings with mild to severe hypertension hypertension Hypertension 1554330 12189495 5 28069671 54069671 3 - by peak only
1558698 human HRTRT3_H Heart rate QTL 3 (human) 10 2.01 1334681 D10S1682 1337655 D10S1703 1335092 D10S587 Heart rate genome-wide scan for linkage to heart rate among Caucasian families with at lease two siblings with mild to severe hypertension hypertension Hypertension 1554330 12189495 10 113310818 128487143 1 - by flanking markers
1558699 human HRV2_H Heart rate variability QTL 2 (human) 2 1.81 1338867 D2S2315 1338024 D2S2208 1336280 D2S2324 Heart rate variability low-frequency power genome-wide scan for heart rate variability in participants of the Framingham Heart Study decreased heart rate variability 1554329 12480036 2 59145280 208433251 1 - by flanking markers
1558700 human HRV1_H Heart rate variability QTL 1 (human) 15 1.84 1340721 D15S540 1342279 D15S531 1341623 D15S153 Heart rate variability very low-frequency power genome-wide scan for heart rate variability in participants of the Framingham Heart Study decreased heart rate variability 1554329 12480036 15 51347128 77347128 3 - by peak only
1558701 human SCL7_H Serum cholesterol level QTL 7 (human) 9 1.4 1335834 D9S1675 Lipid level HDL cholesterol genome-wide scan for linkage to high-density lipoprotein cholesterol levels in Mexican Americans subjects who are part of the San Antonio Family Diabetes Study Non-insulin dependent diabetes Diabetes Mellitus, Non-Insulin-Dependent 1554327 11743583 9 99129064 125129064 3 - by peak only
1558702 human HRTRT9_H Heart rate QTL 9 (human) 16 1.92 1336829 D16S3076 Heart rate genome-wide scan for linkage to heart rate among Caucasian and African-American families with at lease two siblings with mild to severe hypertension hypertension Hypertension 1554330 12189495 16 9942264 35942264 3 - by peak only
1558703 human SCL6_H Serum cholesterol level QTL 1 (human) 8 1.2 1338138 D8S136 732290 FGFR1 Lipid level HDL cholesterol genome-wide scan for linkage to high-density lipoprotein cholesterol levels in Mexican Americans subjects who are part of the San Antonio Family Diabetes Study Non-insulin dependent diabetes Diabetes Mellitus, Non-Insulin-Dependent 1554327 11743583 8 22489340 38445293 1 - by flanking markers
1558704 human HRTRT4_H Heart rate QTL 4 (human) 4 2.14 1341279 D4S2688 1340394 D4S2952 1298122 D4S408 Heart rate genome-wide scan for linkage to heart rate among Caucasian and African-American families with at lease two siblings with mild to severe hypertension hypertension Hypertension 1554330 12189495 4 166675084 191273063 2 - by one flank and peak markers
1558705 human BP57_H Blood pressure QTL 57 (human) 18 2.25 1.0E-4 1341313 ATA82B02 Blood pressure systolic genome-wide scan for the rate of change of systolic blood pressure over time in subjects in the Framingham Heart Study increased systemic arterial systolic blood pressure Hypertension 1554328 14975154 18 54064591 76117153 3 - by peak only
1558706 human HRTRT10_H Heart rate QTL 10 (human) 20 2.15 1336443 D20S211 Heart rate genome-wide scan for linkage to heart rate among Caucasian and African-American families with at lease two siblings with mild to severe hypertension hypertension Hypertension 1554330 12189495 20 38602151 62435964 3 - by peak only
1558707 human HRTRT11_H Heart rate QTL 11 (human) 20 1.55 1336443 D20S211 Heart rate genome-wide scan for linkage to heart rate among Caucasian and African-American families with at lease two siblings with mild to severe hypertension hypertension Hypertension 1554330 12189495 20 38602151 62435964 3 - by peak only
1549953 human MULTSCL1_H Multiple sclerosis susceptibility QTL 1 (human) 18 3.42 736262 MBP Multiple sclerosis susceptibility linkage and association analysis of a candidate gene affecting multiple sclerosis susceptibility in families with MS defined by clinical, laboratory, or MRI criteria, unrelated individuals with definite MS, and unaffected controls abnormal nerve conduction;abnormal inflammatory response;neurodegeneration Multiple Sclerosis 1358926 1383661 dominant 18 59896769 76117153 3 - by peak only
1558708 human SCL5_H Serum cholesterol level QTL 5 (human) 7 1.6 1342170 D7S653 1337313 D7S479 Lipid level HDL cholesterol genome-wide scan for linkage to high-density lipoprotein cholesterol levels in Mexican Americans subjects who are part of the San Antonio Family Diabetes Study Non-insulin dependent diabetes Diabetes Mellitus, Non-Insulin-Dependent 1554327 11743583 7 71480281 96171304 1 - by flanking markers
1558709 human SCL4_H Serum cholesterol level QTL 4 (human) 3 1.6 1298169 D3S2427 1337822 D3S1617 Lipid level HDL cholesterol genome-wide scan for linkage to high-density lipoprotein cholesterol levels in Mexican Americans subjects who are part of the San Antonio Family Diabetes Study Non-insulin dependent diabetes Diabetes Mellitus, Non-Insulin-Dependent 1554327 11743583 3 177267495 187367336 1 - by flanking markers
1558710 human SCL10_H Serum cholesterol level QTL 10 (human) 20 1.0 1339271 D20S470 1341027 D20S195 Lipid level HDL cholesterol genome-wide scan for linkage to high-density lipoprotein cholesterol levels in Mexican Americans subjects who are part of the San Antonio Family Diabetes Study Non-insulin dependent diabetes Diabetes Mellitus, Non-Insulin-Dependent 1554327 11743583 20 17320490 31289609 1 - by flanking markers
1558711 human BP56_H Blood pressure QTL 56 (human) 7 2.24 2.0E-6 1335908 D7S1818 Blood pressure systolic genome-wide scan for the rate of change of systolic blood pressure over time in subjects in the Framingham Heart Study increased systemic arterial systolic blood pressure Hypertension 1554328 14975154 7 36359513 62359513 3 - by peak only
1558712 human SCL1_H Serum cholesterol level QTL 1 (human) 9 3.4 4.0E-5 1334533 D9S1687 1299940 D9S1874 Lipid level HDL cholesterol genome-wide scan for linkage to high-density lipoprotein cholesterol levels in Mexican Americans subjects who are part of the San Antonio Family Diabetes Study Non-insulin dependent diabetes Diabetes Insipidus, Nephrogenic;Diabetes Mellitus, Non-Insulin-Dependent 1554327 11743583 9 12965149 37212493 1 - by flanking markers
1559390 human SCL100_H Serum cholesterol level QTL 100 (human) 2 1.7 0.0023 1298195 D2S1788 Lipid level triglyceride genome-wide linkage analysis to identify loci that influence total and HDL cholesterol levels and triglyceride levels in a Pima Indian population Hypertriglyceridemia 1559166 11116067 2 23113904 49113904 3 - by peak only
1559391 human SCL109_H Serum cholesterol level QTL 109 (human) 7 1.86 1299935 D7S1824 1339951 D7S688 Lipid level triglyceride genome wide scan for loci affecting plasma triglyceride concentration in Mexican Americans in the San Antonio Family Diabetes Study; fasting blood samples were tested for glucose, triglyceride, and HDL cholesterol levels 1556737 10729112 7 139659034 148174965 1 - by flanking markers
1559392 human SCL108_H Serum cholesterol level QTL 108 (human) 7 2.05 1341881 D7S691 1337313 D7S479 Lipid level triglyceride genome wide scan for loci affecting plasma triglyceride concentration in Mexican Americans in the San Antonio Family Diabetes Study; fasting blood samples were tested for glucose, triglyceride, and HDL cholesterol levels 1556737 10729112 7 41996228 96171304 1 - by flanking markers
1559393 human SCL103_H Serum cholesterol level QTL 103 (human) 2 4.25 1339630 D2S1328 1340813 D2S1776 Lipid level total cholesterol genome wide scan for loci affecting serum lipid levels in two distinct, isolated Sardinian populations 1556735 15478097 2 125903199 169353753 1 - by flanking markers
1559394 human SCL111_H Serum cholesterol level QTL 111 (human) 1 2.43 1298152 D1S214 Lipid level LDL cholesterol genome wide scan for loci affecting lipid related traits in families with at least two diabetic siblings; total, HDL, LDL cholesterol and triglyceride levels were determined from fasting blood samples 1556738 11812765 1 1 19884730 3 - by peak only
1559395 human SCL116_H Serum cholesterol level QTL 116 (human) 13 2.01 1341263 D13S171 Lipid level HDL cholesterol genome wide scan for loci affecting lipid related traits in families with at least two diabetic siblings; total, HDL, LDL cholesterol and triglyceride levels were determined from fasting blood samples 1556738 11812765 13 19152052 45152052 3 - by peak only
1559396 human SCL102_H Serum cholesterol level QTL 102 (human) 5 1.59 1338291 D5S1720 Lipid level triglyceride genome-wide linkage analysis to identify loci that influence total and HDL cholesterol levels and triglyceride levels in a Pima Indian population Hypertriglyceridemia 1559166 11116067 5 101246696 127246696 3 - by peak only
1559397 human SCL105_H Serum cholesterol level QTL 105 (human) 2 1.6 1298118 D2S347 1338107 D2S1353 Lipid level total cholesterol genome wide scan for loci affecting serum lipid levels in two distinct isolated Sardinian populations 1556735 15478097 2 123966318 159267328 1 - by flanking markers
1559398 human SCL99_H Serum cholesterol level QTL 99 (human) 20 1.51 1342251 D20S102 Lipid level HDL cholesterol genome-wide linkage analysis to identify loci that influence total and HDL cholesterol levels and triglyceride levels in a Pima Indian population Hypercholesterolemia 1559166 11116067
1559399 human SCL104_H Serum cholesterol level QTL 104 (human) 2 3.87 1339630 D2S1328 1340813 D2S1776 Lipid level LDL cholesterol genome wide scan for loci affecting serum lipid levels in two distinct isolated Sardinian populations 1556735 15478097 2 125903199 169353753 1 - by flanking markers
1559400 human SCL97_H Serum cholesterol level QTL97 (human) 19 3.89 2.0E-5 1298192 D19S1034 Lipid level total cholesterol genome-wide linkage analysis to identify loci that influence total and HDL cholesterol levels and triglyceride levels in a Pima Indian population Hypercholesterolemia 1559166 11116067 19 1 19064369 3 - by peak only
1559401 human SCL106_H Serum cholesterol level QTL 106 (human) 2 2.2 1298118 D2S347 1338107 D2S1353 Lipid level LDL cholesterol genome wide scan for loci affecting serum lipid levels in two distinct isolated Sardinian populations 1556735 15478097 2 123966318 159267328 1 - by flanking markers
1559402 human SCL110_H Serum cholesterol level QTL 110 (human) 7 1.67 1342170 D7S653 1342252 D7S471 1337313 D7S479 Lipid level HDL cholesterol genome wide scan for loci affecting plasma triglyceride concentration in Mexican Americans in the San Antonio Family Diabetes Study; fasting blood samples were tested for glucose, triglyceride, and HDL cholesterol levels 1556737 10729112 7 71480281 120862203 2 - by one flank and peak markers
1559403 human SCL118_H Serum cholesterol level QTL 118 (human) 19 3.16 1298198 D19S178 Lipid level triglyceride genome wide scan for loci affecting lipid related traits in families with at least two diabetic siblings; total, HDL, LDL cholesterol and triglyceride levels were determined from fasting blood samples 1556738 11812765 19 36097564 62097564 3 - by peak only
1559404 human SCL117_H Serum cholesterol level QTL 117 (human) 19 2.05 1299905 D19S247 Lipid level triglyceride-HDL ratio genome wide scan for loci affecting lipid related traits in families with at least two diabetic siblings; total, HDL, LDL cholesterol and triglyceride levels were determined from fasting blood samples 1556738 11812765 19 1 16091092 3 - by peak only
1559405 human SCL98_H Serum cholesterol level QTL 98 (human) 3 2.64 4.0E-4 1341099 D3S3053 Lipid level HDL cholesterol genome-wide linkage analysis to identify loci that influence total and HDL cholesterol levels and triglyceride levels in a Pima Indian population Hypercholesterolemia 1559166 11116067 3 160233676 186233676 3 - by peak only
1559406 human SCL115_H Serum cholesterol level QTL 115 (human) 5 1.97 1341886 D5S211 Lipid level LDL cholesterol genome wide scan for loci affecting lipid related traits in families with at least two diabetic siblings; total, HDL, LDL cholesterol and triglyceride levels were determined from fasting blood samples 1556738 11812765 5 160181041 180857866 3 - by peak only
1559407 human SCL113_H Serum cholesterol level QTL 113 (human) 2 2.31 1338037 D2S338 Lipid level LDL-HDL ratio genome wide scan for loci affecting lipid related traits in families with at least two diabetic siblings; total, HDL, LDL cholesterol and triglyceride levels were determined from fasting blood samples 1556738 11812765 2 223900295 242951149 3 - by peak only
1559408 human SCL101_H Serum cholesterol level QTL 101 (human) 3 1.77 0.0033 1298245 D3S2406 Lipid level triglyceride genome-wide linkage analysis to identify loci that influence total and HDL cholesterol levels and triglyceride levels in a Pima Indian population Hypertriglyceridemia 1559166 11116067 3 60341229 86341229 3 - by peak only
1559409 human SCL114_H Serum cholesterol level QTL 114 (human) 5 2.09 1339745 D5S427 Lipid level total cholesterol genome wide scan for loci affecting lipid related traits in families with at least two diabetic siblings; total, HDL, LDL cholesterol and triglyceride levels were determined from fasting blood samples 1556738 11812765 5 49939016 75939016 3 - by peak only
1559410 human SCL112_H Serum cholesterol level QTL 112 (human) 1 2.11 1334530 D1S233 Lipid level LDL-HDL ratio genome wide scan for loci affecting lipid related traits in families with at least two diabetic siblings; total, HDL, LDL cholesterol and triglyceride levels were determined from fasting blood samples 1556738 11812765 1 18256665 44256665 3 - by peak only
1578593 human SCL134_H Serum cholesterol level QTL 134 (human) 16 2.1 1298279 D16S748 Lipid level total cholesterol genome wide scan for loci affecting plasma lipid variation in families with at least two obese siblings Hypercholesterolemia 1559420 14754912 16 1 25047040 3 - by peak only
1578594 human LDLPS19_H Low density lipoprotein particle size QTL 19 (human) 1 2.56 9.0E-5 735832 LEPR LDL particle size genome-wide scan for linkage to LDL peak particle diameter in participants of the Quebec Family Study 1559066 12732599 1 52767158 78767158 3 - by peak only
1578595 human COARD6_H Coronary artery disease susceptibility QTL 6 (human) 2 2.64 1331557 D2S2968 1338037 D2S338 Coronary artery disease susceptibility genome-wide scan for linkage to acute cornary syndrome (myocardial infarction and unstable angina)in patients from 8 metropolitan Melbourne hospitals coronary artery stenosis Coronary Arteriosclerosis 1566427 12006406 2 236057206 237743384 2 - by one flank and peak markers
1578596 human LDLPS12_H Low density lipoprotein particle size QTL 12 (human) 5 2.4 4.0E-6 1298254 D5S1501 LDL particle size genome-wide scan for linkage to LDL peak particle diameter in participants of the Quebec Family Study 1559066 12732599 5 65504264 91504264 3 - by peak only
1578597 human LDLPS17_H Low density lipoprotein particle size QTL 17 (human) 2 2.11 2.6E-4 1335148 D2S1384 LDL particle size genome-wide scan for linkage to LDL peak particle diameter in participants of the Quebec Family Study 1559066 12732599 2 191935442 217935442 3 - by peak only
1578598 human SCL126_H Serum cholesterol level QTL 126 (human) 20 1.7 1335995 D20S103 1335922 D20S196 Lipid level triglyceride-HDL ratio genome wide scan for loci influencing the triglyceride/HDL cholesterol ratio in families from the Framingham Heart Study increased circulating triglyceride level;increased circulating HDL cholesterol level Hypercholesterolemia;Hypertriglyceridemia 1559419 10814713 20 507258 48995328 1 - by flanking markers
1578599 human SCL131_H Serum cholesterol level QTL 131 (human) 15 2.3 1341663 D15S643 Lipid level HDL cholesterol genome wide scan for loci affecting plasma lipid variation in families with at least two obese siblings Hypercholesterolemia 1559420 14754912 15 44501222 70501222 3 - by peak only
1578600 human SCL129_H Serum cholesterol level QTL 129 (human) 6 2.2 1339853 G15833 1338844 D6S2436 Lipid level LDL cholesterol genome wide scan for loci affecting plasma lipid variation in families with at least two obese siblings Hypercholesterolemia 1559420 14754912 6 148008762 170899992 4 - by one flank marker only
1578601 human LDLPS11_H Low density lipoprotein particle size QTL 11 (human) 5 2.34 3.0E-6 1298254 D5S1501 LDL particle size genome-wide scan for linkage to LDL peak particle diameter in participants of the Quebec Family Study 1559066 12732599 5 65504264 91504264 3 - by peak only
1578602 human LDLPS21_H Low density lipoprotein particle size QTL 21 (human) 1 2.05 3.7E-4 735832 LEPR LDL particle size genome-wide scan for linkage to LDL peak particle diameter in participants of the Quebec Family Study 1559066 12732599 1 52767158 78767158 3 - by peak only
1578603 human LDLPS14_H Low density lipoprotein particle size QTL 14 (human) 4 2.22 0.01891 1298180 D4S2397 LDL particle size genome-wide scan for linkage to LDL peak particle diameter in participants of the Quebec Family Study 1559066 12732599 4 13867033 39867033 3 - by peak only
1578604 human LDLPS10_H Low density lipoprotein particle size QTL 10 (human) 5 2.1 8.0E-6 1298254 D5S1501 LDL particle size genome-wide scan for linkage to LDL peak particle diameter in participants of the Quebec Family Study 1559066 12732599 5 65504264 91504264 3 - by peak only
1578605 human LDLPS9_H Low density lipoprotein particle size QTL 9 (human) 14 2.79 6.0E-5 1337546 D14S53 LDL particle size genome-wide scan for linkage to LDL peak particle diameter in participants of the Quebec Family Study 1559066 12732599
1578606 human LDLPS8_H Low density lipoprotein particle size QTL 8 (human) 14 2.65 9.0E-5 1337546 D14S53 LDL particle size genome-wide scan for linkage to LDL peak particle diameter in participants of the Quebec Family Study 1559066 12732599
1578607 human COARD5_H Coronary artery disease susceptibility QTL 5 (human) 2 2.63 2.0E-4 1340605 D2S2318 1336468 D2S2285 1331557 D2S2968 Coronary artery disease susceptibility genome-wide scan for linkage to acute cornary syndrome (myocardial infarction and unstable angina)in patients from 8 metropolitan Melbourne hospitals coronary artery stenosis Coronary Arteriosclerosis 1566427 12006406 2 198422894 240550427 1 - by flanking markers
1578608 human SCL133_H Serum cholesterol level QTL 133 (human) 7 2.3 1331594 D7S820 Lipid level total cholesterol genome wide scan for loci affecting plasma lipid variation in families with at least two obese siblings Hypercholesterolemia 1559420 14754912 7 70627440 96627440 3 - by peak only
1578609 human SCL125_H Serum cholesterol level QTL 125 (human) 16 1.5 1340592 D16S423 1339638 D16S539 Lipid level triglyceride genome wide scan for loci influencing the triglyceride/HDL cholesterol ratio in families from the Framingham Heart Study increased circulating triglyceride level Hypertriglyceridemia 1559419 10814713 16 5983322 84943914 1 - by flanking markers
1578610 human SCL128_H Serum cholesterol level QTL 128 (human) 7 2.2 1299922 D7S559 1299935 D7S1824 1335278 D7S3058 Lipid level LDL cholesterol genome wide scan for loci affecting plasma lipid variation in families with at least two obese siblings Hypercholesterolemia 1559420 14754912 7 139659211 156165886 1 - by flanking markers
1578611 human SCL132_H Serum cholesterol level QTL 132 (human) 2 2.0 1336092 D2S1394 Lipid level HDL cholesterol genome wide scan for loci affecting plasma lipid variation in families with at least two obese siblings Hypercholesterolemia 1559420 14754912 2 59992782 85992782 3 - by peak only
1578612 human SCL122_H Serum cholesterol level QTL 122 (human) 7 1.8 1338834 D7S1804 1299920 D7S3070 1335302 D7S1805 Lipid level triglyceride-HDL ratio genome wide scan for loci influencing the triglyceride/HDL cholesterol ratio in families from the Framingham Heart Study increased circulating triglyceride level;increased circulating HDL cholesterol level Hypertriglyceridemia 1559419 10814713 7 131930166 151198240 1 - by flanking markers
1578613 human SCL123_H Serum cholesterol level QTL 123 (human) 7 2.5 1299935 D7S1824 1299920 D7S3070 1335302 D7S1805 Lipid level triglyceride genome wide scan for loci influencing the triglyceride/HDL cholesterol ratio in families from the Framingham Heart Study increased circulating triglyceride level Hypertriglyceridemia 1559419 10814713 7 139659034 151198240 1 - by flanking markers
1578614 human LDLPS13_H Low density lipoprotein particle size QTL 13 (human) 4 2.11 0.03278 1298180 D4S2397 LDL particle size genome-wide scan for linkage to LDL peak particle diameter in participants of the Quebec Family Study 1559066 12732599 4 13867033 39867033 3 - by peak only
1578615 human LDLPS18_H Low density lipoprotein particle size QTL 18 (human) 2 1.91 3.6E-4 1335148 D2S1384 LDL particle size genome-wide scan for linkage to LDL peak particle diameter in participants of the Quebec Family Study 1559066 12732599 2 191935442 217935442 3 - by peak only
1578616 human LDLPS6_H Low density lipoprotein particle size QTL 6 (human) 17 4.7 1.0E-6 1334672 D17S790 1341934 D17S1351 1298312 D17S1301 LDL particle size genome-wide scan for linkage to LDL peak particle diameter in participants of the Quebec Family Study 1559066 12732599 17 50153867 68183919 1 - by flanking markers
1578617 human LDLPS15_H Low density lipoprotein particle size QTL 15 (human) 4 2.14 0.02079 1298180 D4S2397 LDL particle size genome-wide scan for linkage to LDL peak particle diameter in participants of the Quebec Family Study 1559066 12732599 4 13867033 39867033 3 - by peak only
1578618 human SCL127_H Serum cholesterol level QTL 127 (human) 7 3.7 1299922 D7S559 1299935 D7S1824 1335278 D7S3058 Lipid level triglyceride genome wide scan for loci affecting plasma lipid variation in families with at least two obese siblings Hypertriglyceridemia 1559420 14754912 7 139659211 156165886 1 - by flanking markers
1578619 human SCL124_H Serum cholesterol level QTL 124 (human) 3 1.8 1298245 D3S2406 1299926 D3S3045 1331571 D3S4529 Lipid level triglyceride-HDL ratio genome wide scan for loci influencing the triglyceride/HDL cholesterol ratio in families from the Framingham Heart Study increased circulating triglyceride level;increased circulating HDL cholesterol level Hypertriglyceridemia 1559419 10814713 3 73341071 108472798 1 - by flanking markers
1578620 human LDLPS20_H Low density lipoprotein particle size QTL 21 (human) 1 2.04 4.6E-4 735832 LEPR LDL particle size genome-wide scan for linkage to LDL peak particle diameter in participants of the Quebec Family Study 1559066 12732599 1 52767158 78767158 3 - by peak only
1578621 human LDLPS7_H Low density lipoprotein particle size QTL 7 (human) 17 4.72 1.0E-6 1334672 D17S790 1341934 D17S1351 1298312 D17S1301 LDL particle size genome-wide scan for linkage to LDL peak particle diameter in participants of the Quebec Family Study 1559066 12732599 17 50153867 68183919 1 - by flanking markers
1578622 human SCL130_H Serum cholesterol level QTL 130 (human) 12 2.6 1340016 D12S391 1298304 D12S398 1298300 D12S373 Lipid level HDL cholesterol genome wide scan for loci affecting plasma lipid variation in families with at least two obese siblings Hypercholesterolemia 1559420 14754912 12 12341197 51483480 1 - by flanking markers
1578623 human LDLPS5_H Low density lipoprotein particle size QTL 5 (human) 17 6.76 1.0E-6 1334672 D17S790 1341934 D17S1351 1298312 D17S1301 LDL particle size genome-wide scan for linkage to LDL peak particle diameter in participants of the Quebec Family Study 1559066 12732599 17 50153867 68183919 1 - by flanking markers
1578624 human LDLPS16_H Low density lipoprotein particle size QTL 16 (human) 2 2.27 0.00278 1335148 D2S1384 LDL particle size genome-wide scan for linkage to LDL peak particle diameter in participants of the Quebec Family Study 1559066 12732599 2 191935442 217935442 3 - by peak only
1559096 human SCL18_H Serum cholesterol level QTL 18 (human) 12 4.06 7.46E-4 1341904 D12S334 Lipid level HDL cholesterol genome-wide scan for linkage to genes influencing lipid and lipoprotein levels in participants of the Quebec Family study increased body weight;increased circulating HDL cholesterol level Obesity 1556570 14679165 12 46421673 72421673 3 - by peak only
1559097 human SCL17_H Serum cholesterol level QTL 17 (human) 13 3.08 1336345 D13S1300 1339747 D13S1266 1334720 D13S1267 Lipid level LDL cholesterol genome-wide scan for linkage to LDL levels in a Syrian family with hypercholesterolemia hyperlipidemia Hyperlipidemia 1556551 12016260 recessive 13 91409212 101908082 1 - by flanking markers
1559098 human SCL43_H Serum cholesterol level QTL 43 (human) 7 2.4 0.09 1298140 D7S513 Lipid level LDL-apoB genome-wide scan for linkage to baseline and after training LDL cholesterol and apolipoprotein B levels in participants of the HERITAGE Family Study increased circulating LDL cholesterol level 1556749 15576847 7 1 24617972 3 - by peak only
1559099 human SCL44_H Serum cholesterol level QTL 44 (human) 12 2.1 0.45 1339759 D12S1691 Lipid level LDL cholesterol genome-wide scan for linkage to baseline and after training LDL cholesterol and apolipoprotein B levels in participants of the HERITAGE Family Study increased circulating LDL cholesterol level 1556749 15576847 12 42792235 68792235 3 - by peak only
1559100 human SCL33_H Serum cholesterol level QTL 33 (human) 5 1.89 1335537 D5S635 1340441 D5S1981 1339871 D5S2849 Lipid level LDL cholesterol genome-wide scan for linkage to variation in LDL cholesterol levels in participants of the NHLBI Family Heart Study coronary artery stenosis Coronary Arteriosclerosis 738093 12215839 5 1207692 6365760 1 - by flanking markers
1559101 human SCL39_H Serum cholesterol level QTL 39 (human) 1 2.1 0.4 1337995 D1S2703 Lipid level LDL cholesterol genome-wide scan for linkage to baseline and after training LDL cholesterol and apolipoprotein B levels in participants of the HERITAGE Family Study increased circulating LDL cholesterol level 1556749 15576847 1 198156185 224156185 3 - by peak only
1559102 human SAPOB1_H Serum apolipoprotein B level QTL 1 (human) 1 2.9 0.06 1338967 D1S456 1339695 D1S2649 1338647 D1S2860 Apolipoprotein level apolipoprotein B genome-wide scan for linkage to baseline and after training LDL-cholesterol and apolipoprotein B levels in participants of the HERITAGE Family Study 1556749 15576847 1 203725107 233445625 1 - by flanking markers
1559103 human SCL21_H Serum cholesterol level QTL 21 (human) 15 3.11 2.88E-4 1340735 D15S652 Lipid level LDL cholesterol genome-wide scan for linkage to genes influencing lipid and lipoprotein levels in participants of the Quebec Family study increased body weight;increased circulating HDL cholesterol level Obesity 1556570 14679165 15 77318513 100338915 3 - by peak only
1559104 human SCL15_H Serum cholesterol level QTL 15 (human) 11 2.6 0.06 1338236 D11S1981 1298202 D11S2002 1337584 D11S1324 Lipid level hyperlipidemia susceptibility genome-wide scan for linkage to Familial Combined Hyperlipidemia in 35 Dutch families and sibling pairs abnormal circulating cholesterol level;increased triglyceride level;hyperlipidemia Hyperlipidemia 1556549 10417282 11 17042780 79643288 1 - by flanking markers
1559105 human SCL40_H Serum cholesterol level QTL 40 (human) 8 3.6 0.01 1336061 D8S1802 1340645 D8S1740 1337130 D8S1774 Lipid level LDL cholesterol genome-wide scan for linkage to baseline and after training LDL cholesterol and apolipoprotein B levels in participants of the HERITAGE Family Study increased circulating LDL cholesterol level 1556749 15576847 8 120938365 134045227 2 - by one flank and peak markers
1559106 human SAPOB2_H Serum apolipoprotein B level QTL 2 (human) 8 2.5 0.15 1336061 D8S1802 1340645 D8S1740 1337130 D8S1774 Apolipoprotein level apolipoprotein B genome-wide scan for linkage to baseline and after training LDL cholesterol and apolipoprotein B levels in participants of the HERITAGE Family Study 1556749 15576847 8 120938365 134045227 2 - by one flank and peak markers
1559107 human SCL32_H Serum cholesterol level QTL 32 (human) 11 3.27 1338255 D11S1975 1337584 D11S1324 1337563 D11S1993 Lipid level LDL cholesterol genome-wide scan for linkage to variation in LDL cholesterol levels in participants of the NHLBI Family Heart Study coronary artery stenosis Coronary Arteriosclerosis 738093 12215839 11 28870554 70080881 1 - by flanking markers
1559108 human SCL37_H Serum cholesterol level QTL 37 (human) 21 2.74 1335114 D21S2058 1342316 D21S1891 1340425 D21S1246 Lipid level LDL cholesterol genome-wide scan for linkage to variation in LDL cholesterol levels in participants of the NHLBI Family Heart Study coronary artery stenosis Coronary Arteriosclerosis 738093 12215839 21 39343403 46792460 1 - by flanking markers
1559109 human SCL41_H Serum cholesterol level QTL 41 (human) 8 3.3 0.02 1336061 D8S1802 1340645 D8S1740 1337130 D8S1774 Lipid level LDL-apoB genome-wide scan for linkage to baseline and after training LDL cholesterol and apolipoprotein B levels in participants of the HERITAGE Family Study increased circulating LDL cholesterol level 1556749 15576847 8 120938365 134045227 2 - by one flank and peak markers
1559110 human SCL22_H Serum cholesterol level QTL 22 (human) 19 3.59 2.41E-4 736378 APOE Lipid level LDL cholesterol genome-wide scan for linkage to genes influencing lipid and lipoprotein levels in participants of the Quebec Family study increased body weight;increased circulating HDL cholesterol level Obesity 1556570 14679165 19 37102684 63102684 3 - by peak only
1559111 human SCL25_H Serum cholesterol level QTL 25 (human) 15 2.56 0.002 1340590 D15S659 1338210 D15S1028 1341663 D15S643 Lipid level triglyceride genome-wide scan for linkage to LDL size and triglyceride levels in participants of the Genetic Epidemiology of Hypertriglyceridemia Study increased triglyceride level Hyperlipoproteinemia Type IV 1556572 12923221 15 44161300 46784448 1 - by flanking markers
1559112 human SCL36_H Serum cholesterol level QTL 36 (human) 21 2.66 1335114 D21S2058 1342316 D21S1891 1340425 D21S1246 Lipid level LDL cholesterol genome-wide scan for linkage to variation in LDL cholesterol levels in participants of the NHLBI Family Heart Study coronary artery stenosis Coronary Arteriosclerosis 738093 12215839 21 39343403 46792460 1 - by flanking markers
1559113 human SCL31_H Serum cholesterol level QTL 31 (human) 11 3.72 1338255 D11S1975 1337584 D11S1324 1337563 D11S1993 Lipid level LDL cholesterol genome-wide scan for linkage to variation in LDL cholesterol levels in participants of the NHLBI Family Heart Study coronary artery stenosis Coronary Arteriosclerosis 738093 12215839 11 28870554 70080881 1 - by flanking markers
1559114 human SCL45_H Serum cholesterol level QTL 45 (human) 20 2.2 1341108 D20S840 Lipid level LDL-apoB genome-wide scan for linkage to baseline and after training LDL cholesterol and apolipoprotein B levels in participants of the HERITAGE Family Study increased circulating LDL cholesterol level 1556749 15576847 20 38580839 62435964 3 - by peak only
1559115 human SCL20_H Serum cholesterol level QTL 20 (human) 11 3.22 0.001213 736796 DRD2 Lipid level LDL cholesterol genome-wide scan for linkage to genes influencing lipid and lipoprotein levels in participants of the Quebec Family study increased body weight;increased circulating HDL cholesterol level Obesity 1556570 14679165 11 99818309 125818309 3 - by peak only
1559116 human SCL24_H Serum cholesterol level QTL 24 (human) 11 2.11 9.0E-6 1298253 D11S1392 Lipid level triglyceride genome-wide scan for linkage to genes influencing lipid and lipoprotein levels in participants of the Quebec Family study increased body weight;increased circulating HDL cholesterol level Obesity 1556570 14679165 11 21596755 47596755 3 - by peak only
1559117 human SCL30_H Serum cholesterol level QTL 30 (human) 18 2.02 0.029 1336700 D18S1126 1337583 D18S1163 1342398 D18S877 Lipid level HDL adjusted for triglyceride, LDL particle size genome-wide scan for linkage to LDL size and triglyceride levels in participants of the Genetic Epidemiology of Hypertriglyceridemia Study increased triglyceride level Hyperlipoproteinemia Type IV 1556572 12923221 18 7462548 45610471 1 - by flanking markers
1559118 human SCL34_H Serum cholesterol level QTL 34 (human) 10 2.47 1338976 D10S219 1339124 D10S542 1338636 D10S521 Lipid level LDL cholesterol genome-wide scan for linkage to variation in LDL cholesterol levels in participants of the NHLBI Family Heart Study coronary artery stenosis Coronary Arteriosclerosis 738093 12215839 10 80522873 120742566 1 - by flanking markers
1559119 human SCL29_H Serum cholesterol level QTL 29 (human) 18 1.9 0.045 1335304 D18S78 1335856 D18S474 1342398 D18S877 Lipid level HDL cholesterol adjusted for LDL particle size genome-wide scan for linkage to LDL size and triglyceride levels in participants of the Genetic Epidemiology of Hypertriglyceridemia Study increased triglyceride level Hyperlipoproteinemia Type IV 1556572 12923221 18 5931014 46948943 1 - by flanking markers
1559120 human SCL27_H Serum cholesterol level QTL 27 (human) 8 1.97 0.004 1335008 D8S1757 1337871 D8S508 1298265 D8S1179 Lipid level HDL cholesterol genome-wide scan for linkage to LDL size and triglyceride levels in participants of the Genetic Epidemiology of Hypertriglyceridemia Study increased triglyceride level Hyperlipoproteinemia Type IV 1556572 12923221 8 81202412 127415934 1 - by flanking markers
1559121 human SCL38_H Serum cholesterol level QTL 38 (human) 1 3.7 0.01 1338967 D1S456 1339695 D1S2649 1338647 D1S2860 Lipid level LDL-apoB genome-wide scan for linkage to baseline and after training LDL cholesterol and apolipoprotein B levels in participants of the HERITAGE Family Study increased circulating LDL cholesterol level 1556749 15576847 1 203725107 233445625 1 - by flanking markers
1559122 human SCL42_H Serum cholesterol level QTL 42 (human) 2 2.3 0.09 1336962 D2S131 Lipid level LDL cholesterol genome-wide scan for linkage to baseline and after training LDL cholesterol and apolipoprotein B levels in participants of the HERITAGE Family Study increased circulating LDL cholesterol level 1556749 15576847 2 285154 26285154 3 - by peak only
1559123 human LDLPS3_H Low density lipoprotein particle size QTL 3 (human) 4 4.1 23.0 1339490 D4S2975 LDL particle size genome-wide scan for linkage to LDL particle size and serum P-selectin level in participants of the San Antonio Family Heart Study 1556751 10865820 4 112665188 138665188 3 - by peak only
1559124 human SCL23_H Serum cholesterol level QTL 23 (human) 19 3.24 6.17E-4 1298198 D19S178 Lipid level LDL cholesterol genome-wide scan for linkage to genes influencing lipid and lipoprotein levels in participants of the Quebec Family study increased body weight;increased circulating HDL cholesterol level Obesity 1556570 14679165 19 36097564 62097564 3 - by peak only
1559125 human SPSL2_H Serum P-selectin level QTL 2 (human) 12 2.59 1299944 D12S2070 1340016 D12S391 735410 PAH Serum P-selectin level genome-wide scan for linkage to LDL particle size and serum P-selectin level in participants of the San Antonio Family Heart Study 1556751 10865820 12 12341421 114567092 1 - by flanking markers
1559126 human SCL53_H Serum cholesterol level QTL 53 (human) 2 2.32 1357238 D2S441 Lipid level triglyceride genome-wide scan for linkage to genes influencing lipid and lipoprotein levels in participants of the Quebec Family study 1556570 14679165 2 55092581 81092581 3 - by peak only
1559127 human SCL54_H Serum cholesterol level QTL 54 (human) 11 1.93 1298267 D11S4464 Lipid level triglyceride genome-wide scan for linkage to genes influencing lipid and lipoprotein levels in participants of the Quebec Family study 1556570 14679165 11 110131956 134452384 3 - by peak only
1559128 human SCL28_H Serum cholesterol level QTL 28 (human) 15 1.95 0.013 1337586 D15S152 1338739 D15S1034 1298311 D15S657 Lipid level HDL cholesterol adjusted for triglyceride genome-wide scan for linkage to LDL size and triglyceride levels in participants of the Genetic Epidemiology of Hypertriglyceridemia Study increased triglyceride level Hyperlipoproteinemia Type IV 1556572 12923221 15 83684056 95672981 1 - by flanking markers
1559129 human SPSL1_H Serum P-selectin level QTL 1 (human) 15 3.8 1.4E-5 1298311 D15S657 1341623 D15S153 1340735 D15S652 Serum P-selectin level genome-wide scan for linkage to LDL particle size and serum P-selectin level in participants of the San Antonio Family Heart Study 1556751 10865820 15 64347234 94505852 1 - by flanking markers
1559130 human SCL16_H Serum cholesterol level QTL 16 (human) 1 3.07 0.002 1339307 D1S2826 1340283 D1S513 1337350 D1S2843 Lipid level LDL cholesterol genome-wide scan for linkage to LDL levels in a Syrian family with hypercholesterolemia hyperlipidemia Hyperlipidemia 1556551 12016260 1 18306011 31104509 1 - by flanking markers
1559131 human SCL19_H Serum cholesterol level QTL 19 (human) 1 2.5 7.8E-5 1298297 D1S547 Lipid level LDL cholesterol genome-wide scan for linkage to genes influencing lipid and lipoprotein levels in participants of the Quebec Family study increased body weight;increased circulating HDL cholesterol level Obesity 1556570 14679165 1 226822702 247249719 3 - by peak only
1559132 human SAPOB3_H Serum apolipoprotein B level QTL 3 (human) 7 2.0 0.4 69038 IGFBP1 Apolipoprotein level apolipoprotein B genome-wide scan for linkage to baseline and after training LDL cholesterol and apolipoprotein B levels in participants of the HERITAGE Family Study 1556749 15576847 7 32897138 58897138 3 - by peak only
1559133 human SCL26_H Serum cholesterol level QTL 26 (human) 15 2.44 0.002 1337510 D15S655 1338210 D15S1028 1340811 D15S211 Lipid level triglyceride genome-wide scan for linkage to LDL size and triglyceride levels in participants of the Genetic Epidemiology of Hypertriglyceridemia Study increased triglyceride level Hyperlipoproteinemia Type IV 1556572 12923221 15 46784448 85777069 1 - by flanking markers
1559134 human SCL35_H Serum cholesterol level QTL 35 (human) 17 2.33 1335934 D17S940 1339370 D17S745 1339370 D17S745 Lipid level LDL cholesterol genome-wide scan for linkage to variation in LDL cholesterol levels in participants of the NHLBI Family Heart Study coronary artery stenosis Coronary Arteriosclerosis 738093 12215839 17 64590012 78774742 4 - by one flank marker only
1559135 human LDLPS2_H Low density lipoprotein particle size QTL 2 (human) 3 4.1 22.8 1342261 D3S2320 LDL particle size genome-wide scan for linkage to LDL particle size and serum P-selectin level in participants of the San Antonio Family Heart Study 1556751 10865820
1559213 human SCL71_H Serum cholesterol level QTL 71 (human) 7 3.46 1335278 D7S3058 Lipid level triglyceride genome-wide scan for fasting serum triglyceride levels in 380 obese nuclear families increased body weight Obesity 1556856 15604520
1559214 human SCL64_H Serum cholesterol level QTL 64 (human) 6 3.1 1341977 D6S1635 1340330 D6S264 1335494 D6S1637 Lipid level HDL cholesterol and triglyceride genome-wide scan for linkage to plasma triglyceride and HDL cholesterol levels in participants of the Framingham Heart Study 1556855 14975115 6 108058593 166629361 1 - by flanking markers
1559215 human SCL80_H Serum cholesterol level QTL 80 (human) 20 2.48 1340914 D20S164 Lipid level triglyceride genome-wide scan for fasting serum triglyceride levels in 380 obese nuclear families increased body weight Obesity 1556856 15604520 20 43486856 62435964 3 - by peak only
1559216 human SCL61_H Serum cholesterol level QTL 61 (human) 2 2.6 1338141 D2S2376 Lipid level HDL cholesterol genome-wide scan for linkage to plasma triglyceride and HDL cholesterol levels in participants of the Framingham Heart Study 1556855 14975115 2 124278454 150278454 3 - by peak only
1559217 human SCL48_H Serum cholesterol level QTL 48 (human) 5 2.4 1336959 D5S1505 Lipid level HDL cholesterol genome-wide scan for linkage to HDL cholesterol levels and LDL particle size in Dutch families increased circulating HDL cholesterol level;hyperlipidemia Hyperlipidemia 1556550 10681408 5 106129673 132129673 3 - by peak only
1559218 human SCL69_H Serum cholesterol level QTL 69 (human) 7 3.41 0.002 1339951 D7S688 1335278 D7S3058 1335278 D7S3058 Lipid level triglyceride genome-wide scan for fasting serum triglyceride levels in 380 obese nuclear families increased body weight Obesity 1556856 15604520 7 148174826 158821424 4 - by one flank marker only
1559219 human SCL55_H Serum cholesterol level QTL 55 (human) 21 3.9 0.001 1338345 D21S1260 1335114 D21S2058 1341166 D21S1897 Lipid level LDL cholesterol and triglyceride genome-wide scan for linkage to LDL cholesterol and triglyceride concentration among participants of the Hypertension Genetic Epidemiology Network (HyperGEN) hypertension Hypertension 1556857 15721017 21 41717912 46792645 1 - by flanking markers
1559220 human SCL50_H Serum cholesterol level QTL 50 (human) 13 4.23 1334556 D13S158 1341348 D13S156 1341756 D13S794 Lipid level LDL cholesterol scan for linkage to LDL levels to identify a postulated cholesterol lowering gene in a family with familial hypercholesterolemia that has heterozygous individuals with normal LDL and homozygous individuals with LDL levels that matched those with heterozygous familial hypercholesterolemia hyperlipidemia Hyperlipidemia 1556854 10631147 13 73555775 102774399 1 - by flanking markers
1559221 human SCL67_H Serum cholesterol level QTL 67 (human) 7 2.98 0.002 1339951 D7S688 1335278 D7S3058 1335278 D7S3058 Lipid level triglyceride genome-wide scan for fasting serum triglyceride levels in 380 obese nuclear families increased body weight Obesity 1556856 15604520 7 148174826 158821424 4 - by one flank marker only
1559222 human SAPOA2_H Serum apolipoprotein A level QTL 2 (human) 4 2.35 1340166 D4S1564 1341725 D4S1523 1338059 D4S2368 Apolipoprotein level apolipoprotein A-II level genome-wide scan for linkage to plasma lipid levels and apolipoprotein levels in participants of the Rochester Family Heart study 1556852 11397706 4 108595994 190677330 1 - by flanking markers
1559223 human SCL65_H Serum cholesterol level QTL 65 (human) 20 2.1 1340535 D20S863 Lipid level triglyceride genome-wide scan for linkage to plasma triglyceride and HDL cholesterol levels in participants of the Framingham Heart Study 1556855 14975115 20 17041591 43041591 3 - by peak only
1559224 human FBRL1_H Fibrinogen level QTL 1 (human) 2 1.5 1335896 D2S2237 1339458 D2S2338 1335500 D2S2205 Fibrinogen level genome-wide scan to identify loci contributing to circulating fibrinogin levels in participants of the Framingham Heart Study 1559049 12877910 2 205337639 242951149 2 - by one flank and peak markers
1559225 human SCL78_H Serum cholesterol level QTL 78 (human) 16 3.66 1298287 D16S3396 Lipid level triglyceride genome-wide scan for fasting serum triglyceride levels in 380 obese nuclear families increased body weight Obesity 1556856 15604520 16 36749928 62749928 3 - by peak only
1559226 human SLEP4_H Serum leptin concentration QTL 4 (human) 1 3.4 1339881 D1S1728 1340128 D1S2134 1298097 D1S1665 Hormone level leptin genome-wide scan for plasma leptin, soluble TNFRSF1A and TNFRSF1B levels, and body mass index; quantitative phenotypes of adiposity in Dutch dyslipidemic families 1334495 11126332 1 48053855 99950327 2 - by one flank and peak markers
1559227 human SCL82_H Serum cholesterol level QTL 82 (human) 6 3.7 1335021 D6S1647 1337095 D6S473 1337954 D6S975 Lipid level HDL cholesterol subfraction 3 genome-wide scan for linkage to HDL cholesterol subfraction 3 levels in subjects from the Framingham Heart Study 1559028 15805549 6 111045347 155287577 1 - by flanking markers
1559228 human SCL75_H Serum cholesterol level QTL 75 (human) 20 2.34 1340914 D20S164 Lipid level triglyceride genome-wide scan for fasting serum triglyceride levels in 380 obese nuclear families increased body weight Obesity 1556856 15604520 20 43486856 62435964 3 - by peak only
1559229 human SCL84_H Serum cholesterol level QTL 84 (human) 11 2.2 1336419 D11S1358 Lipid level HDL cholesterol subfraction 2 genome-wide scan for linkage to HDL cholesterol subfraction 2 levels in subjects from the Framingham Heart Study 1559028 15805549 11 77005769 103005769 3 - by peak only
1559230 human SAPOE1_H Serum apolipoprotein E level QTL 1 (human) 19 4.2 1299939 D19S245 1335633 D19S254 1331586 D19S246 Apolipoprotein level apolipoprotein E level genome-wide scan for linkage to plasma lipid levels and apolipoprotein levels in participants of the Rochester Family Heart study 1556852 11397706 19 38789997 62358877 1 - by flanking markers
1559231 human SCL79_H Serum cholesterol level QTL 79 (human) 16 2.62 1341462 D16S3144 Lipid level triglyceride genome-wide scan for fasting serum triglyceride levels in 380 obese nuclear families increased body weight Obesity 1556856 15604520 16 64917007 88827254 3 - by peak only
1559232 human SCL66_H Serum cholesterol level QTL 66 (human) 7 2.98 0.002 1335278 D7S3058 Lipid level triglyceride genome-wide scan for fasting serum triglyceride levels in 320 obese nuclear families increased body weight Obesity 1556856 15604520
1559233 human BW38_H Body weight QTL 38 (human) 10 3.3 1342103 D10S169 1342195 D10S212 1342195 D10S212 Body weight body mass index genome-wide scan for plasma leptin, soluble TNFRSF1A and TNFRSF1B levels, and body mass index; quantitative phenotypes of adiposity in Dutch dyslipidemic families 1334495 11126332 10 132411616 134299779 1 - by flanking markers
1559238 human SCL63_H Serum cholesterol level QTL 63 (human) 6 2.4 1341977 D6S1635 1340330 D6S264 1340789 D6S1699 Lipid level HDL cholesterol genome-wide scan for linkage to plasma triglyceride and HDL cholesterol levels in participants of the Framingham Heart Study 1556855 14975115 6 108058593 166629361 1 - by flanking markers
1559239 human SCL52_H Serum cholesterol level QTL 52 (human) 13 2.0E-4 1334556 D13S158 1341348 D13S156 1337854 D13S1241 Lipid level LDL cholesterol scan for linkage to LDL cholesterol levels in normotensive white monozygotic and dizygotic twins in Germany hyperlipidemia Hyperlipidemia 1556854 10631147 13 73555775 102774399 1 - by flanking markers
1559240 human SCL47_H Serum cholesterol level QTL 47 (human) 16 1.9 0.01 1342205 G10252 Lipid level total cholesterol genome-wide scan for linkage to apolipoprotein B, cholesterol, and triglycerides in families from the Netherlands with familial combined hyperlipidemia hyperlipidemia Hyperlipidemia 1556569 15308552
1559241 human SCL77_H Serum cholesterol level QTL 77 (human) 13 2.68 1334883 D13S1295 Lipid level triglyceride genome-wide scan for fasting serum triglyceride levels in 380 obese nuclear families increased body weight Obesity 1556856 15604520 13 99142528 114142980 3 - by peak only
1559242 human FBRL6_H Fibrinogen level QTL 6 (human) 17 1.5 1298244 D17S1303 1334706 D17S928 1298312 D17S1301 Fibrinogen level genome-wide scan to identify loci contributing to circulating fibrinogin levels in participants of the Framingham Heart Study 1559049 12877910 17 10800103 77846317 1 - by flanking markers
1559243 human SAPOB4_H Serum apolipoprotein B level QTL 4 (human) 1 2.2 9.0E-6 1298097 D1S1665 1334896 D1S1627 1334896 D1S1627 Apolipoprotein level apolipoprotein B genome-wide scan for linkage to apolipoprotein B, cholesterol, and triglycerides in families from the Netherlands with familial combined hyperlipidemia hyperlipidemia Hyperlipidemia 1556569 15308552 1 74001979 106765300 1 - by flanking markers
1559244 human SCL56_H Serum cholesterol level QTL 56 (human) 21 2.0 0.001 1334541 D21S1893 1335114 D21S2058 1340174 D21S1912 Lipid level LDL cholesterol and triglyceride genome-wide scan for linkage to LDL cholesterol and triglyceride concentration among participants of the Hypertension Genetic Epidemiology Network (HyperGEN) hypertension Hypertension 1556857 15721017 21 40278478 46792645 1 - by flanking markers
1559245 human SAPOE2_H Serum apolipoprotein E level QTL 2 (human) 12 1.5 1336387 D12S1692 Apolipoprotein level apolipoprotein E genome-wide scan for linkage to plasma lipid levels and apolipoprotein levels in participants of the Rochester Family Heart study 1556852 11397706 12 19879113 45879113 3 - by peak only
1559246 human FBRL4_H Fibrinogen level QTL 4 (human) 10 2.4 1339504 D10S548 1338891 D10S1709 1338111 G10336 Fibrinogen level genome-wide scan to identify loci contributing to circulating fibrinogin levels in participants of the Framingham Heart Study 1559049 12877910 10 18761298 99475525 1 - by flanking markers
1559247 human SCL51_H Serum cholesterol level QTL 51 (human) 6 1.95 1337496 D6S257 Lipid level LDL cholesterol scan for linkage to LDL levels to identify a postulated cholesterol lowering gene in a family with familial hypercholesterolemia that has heterozygous individuals with normal LDL and homozygous individuals with LDL levels that matched those with heterozygous familial hypercholesterolemia hyperlipidemia Hyperlipidemia 1556854 10631147 6 43026623 69026623 3 - by peak only
1559251 human SCL76_H Serum cholesterol level QTL 76 (human) 9 2.29 1337783 D9S910 Lipid level triglyceride genome-wide scan for fasting serum triglyceride levels in 380 obese nuclear families increased body weight Obesity 1556856 15604520
1559252 human FBRL2_H Fibrinogen level QTL 2 (human) 2 2.1 1335896 D2S2237 1339458 D2S2338 1336488 D2S2348 Fibrinogen level genome-wide scan to identify loci contributing to circulating fibrinogin levels in participants of the Framingham Heart Study 1559049 12877910 2 205337639 242951149 2 - by one flank and peak markers
1559253 human SCL83_H Serum cholesterol level QTL 83 (human) 3 1.8 1298277 D3S2387 Lipid level HDL cholesterol subfraction 3 genome-wide scan for linkage to HDL cholesterol subfraction 3 levels in subjects from the Framingham Heart Study 1559028 15805549 3 1 14011366 3 - by peak only
1559254 human SCL57_H Serum cholesterol level QTL 57 (human) 6 2.0 1342013 D6S280 1338991 D6S1582 1337620 D6S295 Lipid level LDL cholesterol and triglyceride genome-wide scan for linkage to LDL cholesterol and triglyceride concentration among participants of the Hypertension Genetic Epidemiology Network (HyperGEN) hypertension Hypertension 1556857 15721017 6 43206837 73802393 1 - by flanking markers
1559255 human FBRL7_H Fibrinogen level QTL 7 (human) 20 1.5 1335158 D20S478 1342071 D20S171 1336000 D20S480 Fibrinogen level genome-wide scan to identify loci contributing to circulating fibrinogin levels in participants of the Framingham Heart Study 1559049 12877910 20 36665442 57241563 1 - by flanking markers
1559256 human SCL59_H Serum cholesterol level QTL 59 (human) 17 2.48 1340339 D17S1843 1334706 D17S928 1334706 D17S928 Lipid level total cholesterol genome-wide scan for linkage to plasma lipid levels and apolipoprotein levels in participants of the Rochester Family Heart study 1556852 11397706 17 16005240 77846317 1 - by flanking markers
1559257 human SOTNFR1_H Soluble tumor necrosis factor receptor level QTL 1 (human) 8 2.8 0.013 1334926 D8S2324 1335208 D8S1477 1298285 D8S1110 Hormone level TNFRSF1A genome-wide scan for plasma leptin, soluble TNFRSF1A and TNFRSF1B levels, and body mass index; quantitative phenotypes of adiposity in Dutch dyslipidemic families 1334495 11126332 8 32186878 74416883 1 - by flanking markers
1559258 human SCL74_H Serum cholesterol level QTL 74 (human) 13 2.0 1334883 D13S1295 Lipid level triglyceride genome-wide scan for fasting serum triglyceride levels in 380 obese nuclear families increased body weight Obesity 1556856 15604520 13 99142528 114142980 3 - by peak only
1559259 human SCL46_H Serum cholesterol level QTL 46 (human) 12 3.7 1.0E-4 1331555 D12S269 1299937 D12S372 1299937 D12S372 Lipid level total cholesterol genome-wide scan for linkage to apolipoprotein B, cholesterol, and triglycerides in families from the Netherlands with familial combined hyperlipidemia hyperlipidemia Hyperlipidemia 1556569 15308552 12 3457798 13497722 1 - by flanking markers
1559260 human SCL81_H Serum cholesterol level QTL 81 (human) 13 5.22 1337026 D13S254 Lipid level LDL cholesterol scan for linkage to LDL levels to identify a postulated cholesterol lowering gene in a family with familial hypercholesterolemia that has heterozygous individuals with normal LDL and homozygous individuals with LDL levels that matched those with heterozygous familial hypercholesterolemia hyperlipidemia Hyperlipidemia 1556854 10631147 13 82754913 108754913 3 - by peak only
1559261 human SAPOA3_H Serum apolipoprotein A level QTL 3 (human) 5 2.13 1340441 D5S1981 1334895 D5S1373 1298298 D5S2500 Apolipoprotein level apolipoprotein A -II level genome-wide scan for linkage to plasma lipid levels and apolipoprotein levels in participants of the Rochester Family Heart study 1556852 11397706 5 1207429 116258621 2 - by one flank and peak markers
1559262 human SAPOB5_H Serum apolipoprotein B level QTL 5 (human) 17 3.7 9.0E-5 1299928 D17S2196 1338084 D17S1299 1331576 D17S1294 Apolipoprotein level apolipoprotein B genome-wide scan for linkage to apolipoprotein B, cholesterol, and triglycerides in families from the Netherlands with familial combined hyperlipidemia hyperlipidemia Hyperlipidemia 1556569 15308552 17 17205207 36248135 1 - by flanking markers
1559263 human SCL72_H Serum cholesterol level QTL 72 (human) 7 3.25 1335278 D7S3058 Lipid level triglyceride genome-wide scan for fasting serum triglyceride levels in 380 obese nuclear families increased body weight Obesity 1556856 15604520
1559264 human SCL68_H Serum cholesterol level QTL 68 (human) 7 3.1 0.002 1339951 D7S688 1335278 D7S3058 1335278 D7S3058 Lipid level triglyceride genome-wide scan for fasting serum triglyceride levels in 380 obese nuclear families increased body weight Obesity 1556856 15604520 7 148174826 158821424 4 - by one flank marker only
1559265 human SCL49_H Serum cholesterol level QTL 49 (human) 13 4.82 1.26E-6 1334556 D13S158 1341348 D13S156 1337854 D13S1241 Lipid level LDL cholesterol scan for linkage to LDL levels to identify a postulated cholesterol lowering gene in a family with familial hypercholesterolemia that has heterozygous individuals with normal LDL and homozygous individuals with LDL levels that matched those with heterozygous familial hypercholesterolemia hyperlipidemia Hyperlipidemia 1556854 10631147 13 73555775 102774399 1 - by flanking markers
1559234 human SCL73_H Serum cholesterol level QTL 73 (human) 9 1.9 1337783 D9S910 Lipid level triglyceride genome-wide scan for fasting serum triglyceride levels in 380 obese nuclear families increased body weight Obesity 1556856 15604520
1559235 human SCL62_H Serum cholesterol level QTL 62 (human) 6 2.9 1341977 D6S1635 1340330 D6S264 1341174 D6S1564 Lipid level HDL cholesterol genome-wide scan for linkage to plasma triglyceride and HDL cholesterol levels in participants of the Framingham Heart Study 1556855 14975115 6 108058593 166629361 1 - by flanking markers
1559236 human FBRL3_H Fibrinogen level QTL 3 (human) 2 1.7 1335896 D2S2237 1339458 D2S2338 1341606 D2S2344 Fibrinogen level genome-wide scan to identify loci contributing to circulating fibrinogin levels in participants of the Framingham Heart Study 1559049 12877910 2 205337639 242951149 2 - by one flank and peak markers
1559237 human SCL70_H Serum cholesterol level QTL 70 (human) 7 3.52 0.002 1339951 D7S688 1335278 D7S3058 1335278 D7S3058 Lipid level triglyceride genome-wide scan for fasting serum triglyceride levels in 380 obese nuclear families increased body weight Obesity 1556856 15604520 7 148174826 158821424 4 - by one flank marker only
1559248 human SAPOA1_H Serum apolipoprotein A level QTL 1 (human) 12 2.02 1337348 D12S362 1336385 D12S2342 1336905 D12S1718 Apolipoprotein level apolipoprotein A-I genome-wide scan for linkage to plasma lipid levels and apolipoprotein levels in participants of the Rochester Family Heart study 1556852 11397706 12 94236546 132349534 2 - by one flank and peak markers
1559249 human FBRL5_H Fibrinogen level QTL 5 (human) 10 2.0 1339504 D10S548 1338891 D10S1709 1338111 G10336 Fibrinogen level genome-wide scan to identify loci contributing to circulating fibrinogin levels in participants of the Framingham Heart Study 1559049 12877910 10 18761298 99475525 1 - by flanking markers
1559250 human SCL60_H Serum cholesterol level QTL 60 (human) 11 1.84 1340365 D11S904 Lipid level total cholesterol genome-wide scan for linkage to plasma lipid levels and apolipoprotein levels in participants of the Rochester Family Heart study 1556852 11397706 11 13637273 39637273 3 - by peak only
1643038 human BW184_H Body weight QTL 184 (human) 20 2.59 0.0031 1341566 D20S120 Body weight BMI Body mass index (BMI) measured as kg/m2; linkage to the discrete trait assessed using dichotomized phenotypes with individuals having BMI>=30 considered "affected" and those having lower BMI considered "unaffected" increased body mass index Obesity 1642891 9915959 69199;736916;736208;69093;1345990;1347922 ASIP;GNAS;CEBPB;HNF4A;MC3R;PCK1 20 39439006 62435964 3 - by peak only
1643040 human BW159_H Body weight QTL 159 (human) 10 0.0256 1335092 D10S587 Body fat amount percent body fat Percent body fat (%fat) measured by bioelectric impedance (BIA) increased body weight;increased percent body fat Obesity 1642891 9915959 10 112178704 135374737 3 - by peak only
1643042 human BW153_H Body weight QTL 153 (human) 7 0.0265 1298114 D7S817 Body weight BMI Body mass index (BMI) measured as kg/m2 increased body mass index Obesity 1642891 9915959 7 19103000 45103000 3 - by peak only
1643044 human BW151_H Body weight QTL 151 (human) 2 0.0045 1341482 D2S439 Body fat amount percent body fat Percent body fat (%fat) measured by bioelectric impedance (BIA) increased body weight;increased percent body fat Obesity 1642891 9915959 2 215888541 241888541 3 - by peak only
1643045 human BW169_H Body weight QTL 169 (human) 20 0.0256 1335976 D20S471 Body fat amount percent body fat Percent body fat (%fat) measured by bioelectric impedance; linkage to the quantitative trait assessed using untransformed values increased percent body fat;increased body weight Obesity 1642891 9915959 69199;736916;736208;69093;1345990;1347922 ASIP;GNAS;CEBPB;HNF4A;MC3R;PCK1 20 6779702 32779702 3 - by peak only
1643047 human BW167_H Body weight QTL 167 (human) 20 0.0106 1298154 D20S149 Body fat amount percent body fat Percent body fat (%fat) measured by bioelectric impedance (BIA) increased body weight;increased percent body fat Obesity 1642891 9915959 20 41947690 62435964 3 - by peak only
1643048 human BW175_H Body weight QTL 175 (human) 20 0.0118 1335922 D20S196 Body fat amount percent body fat Percent body fat (%fat) measured by bioelectric impedance; linkage to the discrete trait assessed using dichotomized phenotypes with individuals having %fat>=40 considered "affected" and those having lower %fat considered "unaffected" increased body weight;increased percent body fat Obesity 1642891 9915959 69199;736916;736208;69093;1345990;1347922 ASIP;GNAS;CEBPB;HNF4A;MC3R;PCK1 20 35995245 61995245 3 - by peak only
1643050 human BW164_H Body weight QTL 164 (human) 20 0.0056 1338523 D20S200 Body weight BMI Body mass index (BMI) measured as kg/m2 increased body mass index Obesity 1642891 9915959 18 45704691 71704691 3 - by peak only
1643051 human BW116_H Body Weight QTL 116 (human) 17 2.48 3.6E-4 1299971 D17S784 Body weight obesity insulin factor (Obesity-INS) was determined by factor analysis which was performed on 10 risk factors using maximum likelihood method obese Obesity 1642885 16172425 17 62416927 78774742 3 - by peak only
1643053 human BW117_H Body Weight QTL 117 (human) 2 2.4 4.4E-4 1339308 D2S2944 Body weight obesity insulin factor (Obesity-INS) was determined by factor analysis which was performed on 10 risk factors using maximum likelihood method obese Obesity 1642885 16172425
1643054 human BW180_H Body weight QTL 180 (human) 20 0.0421 1341108 D20S840 Body weight BMI Body mass index (BMI) measured as kg/m2; linkage to the discrete trait assessed using dichotomized phenotypes with individuals having BMI>=30 considered "affected" and those having lower BMI considered "unaffected" increased body mass index Obesity 1642891 9915959 69199;736916;736208;69093;1345990;1347922 ASIP;GNAS;CEBPB;HNF4A;MC3R;PCK1 20 38580839 62435964 3 - by peak only
1643055 human BW115_H Body Weight QTL 115 (human) 16 2.59 2.8E-4 1298327 D16S2624 Body weight obesity insulin factor (Obesity-INS) was determined by factor analysis which was performed on 10 risk factors using maximum likelihood method obese Obesity 1642885 16172425 16 57292706 83292706 3 - by peak only
1643056 human BW172_H Body weight QTL 172 (human) 20 0.008 1298199 D20S178 Body fat amount percent body fat Percent body fat (%fat) measured by bioelectric impedance; linkage to the discrete trait assessed using dichotomized phenotypes with individuals having %fat>=40 considered "affected" and those having lower %fat considered "unaffected" increased body weight;increased percent body fat Obesity 1642891 9915959 69199;736916;736208;69093;1345990;1347922 ASIP;GNAS;CEBPB;HNF4A;MC3R;PCK1 20 32985515 58985515 3 - by peak only
1643057 human BW170_H Body weight QTL 170 (human) 20 0.0215 1338523 D20S200 Body weight BMI Body mass index (BMI) measured as kg/m2; linkage to the quantitative trait was assessed using untransformed values increased body mass index Obesity 1642891 9915959 69199;736916;736208;69093;1345990;1347922 ASIP;GNAS;CEBPB;HNF4A;MC3R;PCK1 18 45704691 71704691 3 - by peak only
1643059 human BW183_H Body weight QTL 183 (human) 20 2.44 0.005 1341423 D20S913 Body weight BMI Body mass index (BMI) measured as kg/m2; linkage to the discrete trait assessed using dichotomized phenotypes with individuals having BMI>=30 considered "affected" and those having lower BMI considered "unaffected" increased body mass index Obesity 1642891 9915959 69199;736916;736208;69093;1345990;1347922 ASIP;GNAS;CEBPB;HNF4A;MC3R;PCK1 20 38934587 62435964 3 - by peak only
1643077 human BW176_H Body weight QTL 176 (human) 20 0.0349 1341293 D20S869 Body weight BMI Body mass index (BMI) measured as kg/m2; linkage to the discrete trait assessed using dichotomized phenotypes with individuals having BMI>=30 considered "affected" and those having lower BMI considered "unaffected" increased body mass index Obesity 1642891 9915959 69199;736916;736208;69093;1345990;1347922 ASIP;GNAS;CEBPB;HNF4A;MC3R;PCK1 20 35990149 61990149 3 - by peak only
1643078 human BW163_H Body weight QTL 163 (human) 17 0.039 1338613 D17S796 Body weight BMI Body mass index (BMI) measured as kg/m2 increased body mass index Obesity 1642891 9915959 17 1 19192397 3 - by peak only
1643079 human BW118_H Body Weight QTL 118 (human) 8 2.39 4.6E-5 1338138 D8S136 Body weight obesity insulin factor (Obesity-INS) was determined by factor analysis which was performed on 10 risk factors using maximum likelihood method obese Obesity 1642885 16172425 8 9489374 35489374 3 - by peak only
1643080 human BW182_H Body weight QTL 182 (human) 20 1.59 0.003391 1336443 D20S211 Body fat amount percent body fat Percent body fat (%fat) measured by bioelectric impedance; linkage to the discrete trait assessed using dichotomized phenotypes with individuals having %fat>=40 considered "affected" and those having lower %fat considered "unaffected" increased body weight;increased percent body fat Obesity 1642891 9915959 69199;736916;736208;69093;1345990;1347922 ASIP;GNAS;CEBPB;HNF4A;MC3R;PCK1 20 38602151 62435964 3 - by peak only
1643081 human BP91_H Blood pressure QTL 91 (human) 4 1.95 0.00138 1642896 D4S3243 Blood pressure blood pressure factor (BP) was determined by factor analysis which was performed on 10 risk factors using maximum likelihood method hypertension Hypertension 1642885 16172425
1643082 human BW190_H Body weight QTL 190 (human) 10 0.005 1340909 D10S197 Body weight BMI Body mass index (BMI) measured as kg/m2; linkage to the qualitative trait assessed using dichotomized phenotypes with individuals having BMI>=27 considered affected increased body mass index Obesity 1642915 11317669 10 13566984 39566984 3 - by peak only
1643083 human BW122_H Body Weight QTL 122 (human) 3 2.61 2.7E-4 1299921 D3S1764 Body weight central obesity factor (Central-OBS) was determined by factor analysis which was performed on 10 risk factors using maximum likelihood method obese Obesity 1642885 16172425 3 127671173 153671173 3 - by peak only
1643084 human BW114_H Body Weight QTL 114 (human) 18 3.94 1.0E-5 1331566 D18S976 1298292 D18S858 1341022 D18S53 Body weight obesity insulin factor (Obesity-INS) was determined by factor analysis which was performed on 10 risk factors using maximum likelihood method obese Obesity 1642885 16172425 732421 MC5R 18 5238944 53048289 1 - by flanking markers
1643085 human BW185_H Body weight QTL 185 (human) 20 0.0056 1341566 D20S120 Body fat amount percent body fat Percent body fat (%fat) measured by bioelectric impedance; linkage to the discrete trait assessed using dichotomized phenotypes with individuals having %fat>=40 considered "affected" and those having lower %fat considered "unaffected" increased body weight;increased percent body fat Obesity 1642891 9915959 69199;736916;736208;69093;1345990;1347922 ASIP;GNAS;CEBPB;HNF4A;MC3R;PCK1 20 39439006 62435964 3 - by peak only
1643086 human BW160_H Body weight QTL 160 (human) 12 0.0226 1298300 D12S373 Body weight BMI Body mass index (BMI) measured as kg/m2 increased body mass index Obesity 1642891 9915959 12 3906370 29906370 3 - by peak only
1643087 human BW181_H Body weight QTL 181 (human) 20 3.16 6.9E-5 1336443 D20S211 Body weight BMI Body mass index (BMI) measured as kg/m2; linkage to the discrete trait assessed using dichotomized phenotypes with individuals having BMI>=30 considered "affected" and those having lower BMI considered "unaffected" increased body mass index Obesity 1642891 9915959 69199;736916;736208;69093;1345990;1347922 ASIP;GNAS;CEBPB;HNF4A;MC3R;PCK1 20 38602151 62435964 3 - by peak only
1643088 human BW154_H Body weight QTL 154 (human) 8 0.0239 1338538 D8S560 Body fat amount percent body fat Percent body fat (%fat) measured by bioelectric impedance (BIA) increased body weight;increased percent body fat Obesity 1642891 9915959 8 8646323 34646323 3 - by peak only
1643089 human BW188_H Body weight QTL 188 (human) 10 0.03 1298290 D10S208 Body weight BMI Body mass index (BMI) measured as kg/m2; linkage to the qualitative trait assessed using dichotomized phenotypes with individuals having BMI>=27 considered affected increased body mass index Obesity 1642915 11317669 10 18720195 44720195 3 - by peak only
1643090 human BW152_H Body weight QTL 152 (human) 3 0.0112 1336766 D3S1286 Body fat amount percent body fat Percent body fat (%fat) measured by bioelectric impedance (BIA) increased percent body fat;increased body weight Obesity 1642891 9915959 3 2794331 28794331 3 - by peak only
1643091 human BP90_H Blood pressure QTL 90 (human) 17 1.5 0.0043 1298312 D17S1301 Blood pressure blood pressure factor (BP) was determined by factor analysis which was performed on 10 risk factors using maximum likelihood method hypertension Hypertension 1642885 16172425 737323;1345363 ACE;ITGB3 17 57192606 78774742 3 - by peak only
1643092 human BW171_H Body weight QTL 171 (human) 20 0.0014 1334643 D20S107 Body weight BMI Body mass index (BMI) measured as kg/m2; linkage to the quantitative trait was assessed using untransformed values increased body mass index Obesity 1642891 9915959 69199;736916;736208;69093;1345990;1347922 ASIP;GNAS;CEBPB;HNF4A;MC3R;PCK1 20 25316105 51316105 3 - by peak only
1643093 human BW168_H Body weight QTL 168 (human) 20 0.0279 1298154 D20S149 Body weight BMI Body mass index (BMI) measured as kg/m2 increased body mass index Obesity 1642891 9915959 20 41947690 62435964 3 - by peak only
1643094 human BW165_H Body weight QTL 165 (human) 20 0.0032 1334643 D20S107 Body weight BMI Body mass index (BMI) measured as kg/m2 increased body mass index Obesity 1642891 9915959 20 25316105 51316105 3 - by peak only
1643095 human BW187_H Body weight QTL 187 (human) 20 2.04 0.001085 1298154 D20S149 Body fat amount percent body fat Percent body fat (%fat) measured by bioelectric impedance; linkage to the discrete trait assessed using dichotomized phenotypes with individuals having %fat>=40 considered "affected" and those having lower %fat considered "unaffected" increased body weight;increased percent body fat Obesity 1642891 9915959 69199;736916;736208;69093;1345990;1347922 ASIP;GNAS;CEBPB;HNF4A;MC3R;PCK1 20 41947690 62435964 3 - by peak only
1643096 human BW173_H Body weight QTL 173 (human) 20 2.24 0.0087 1338093 D20S887 Body weight BMI Body mass index (BMI) measured as kg/m2; linkage to the discrete trait assessed using dichotomized phenotypes with individuals having BMI>=30 considered "affected" and those having lower BMI considered "unaffected" increased body mass index Obesity 1642891 9915959 69199;736916;736208;69093;1345990;1347922 ASIP;GNAS;CEBPB;HNF4A;MC3R;PCK1 20 34106786 60106786 3 - by peak only
1643060 human BW123_H Body Weight QTL 123 (human) 20 2.46 3.8E-4 1341151 D20S604 Body weight obese Obesity 1642885 16172425 20 1 25532381 3 - by peak only
1643061 human BW157_H Body weight QTL 157 (human) 10 0.0148 1341909 D10S537 Body weight BMI Body mass index (BMI) measured as kg/m2 increased body mass index Obesity 1642891 9915959 10 59065420 85065420 3 - by peak only
1643062 human BW162_H Body weight QTL 162 (human) 16 0.0207 1339638 D16S539 Body fat amount percent body fat Percent body fat (%fat) measured by bioelectric impedance (BIA) increased body weight;increased percent body fat Obesity 1642891 9915959 16 71943836 88827254 3 - by peak only
1643063 human BW179_H Body weight QTL 179 (human) 20 0.0351 1336794 D20S839 Body weight BMI Body mass index (BMI) measured as kg/m2; linkage to the discrete trait assessed using dichotomized phenotypes with individuals having BMI>=30 considered "affected" and those having lower BMI considered "unaffected" increased body mass index Obesity 1642891 9915959 69199;736916;736208;69093;1345990;1347922 ASIP;GNAS;CEBPB;HNF4A;MC3R;PCK1 20 37455319 62435964 3 - by peak only
1643064 human BW186_H Body weight QTL 186 (human) 20 2.18 0.0104 1298154 D20S149 Body weight BMI Body mass index (BMI) measured as kg/m2; linkage to the discrete trait assessed using dichotomized phenotypes with individuals having BMI>=30 considered "affected" and those having lower BMI considered "unaffected" increased body mass index Obesity 1642891 9915959 69199;736916;736208;69093;1345990;1347922 ASIP;GNAS;CEBPB;HNF4A;MC3R;PCK1 20 41947690 62435964 3 - by peak only
1643065 human BW120_H Body Weight QTL 120 (human) 13 1.95 0.00138 1342079 D13S787 Body weight obesity insulin factor (Obesity-INS) was determined by factor analysis which was performed on 10 risk factors using maximum likelihood method obese Obesity 1642885 16172425 13 10278863 36278863 3 - by peak only
1643066 human BW189_H Body weight QTL 189 (human) 10 0.014 1299888 D10S582 Body weight BMI Body mass index (BMI) measured as kg/m2; linkage to the qualitative trait assessed using dichotomized phenotypes with individuals having BMI>=27 considered affected increased body mass index Obesity 1642915 11317669 10 11522736 37522736 3 - by peak only
1643068 human BW155_H Body weight QTL 155 (human) 9 0.0499 1338087 D9S1863 Body weight BMI Body mass index (BMI) measured as kg/m2 increased body mass index Obesity 1642891 9915959 9 119489789 140273252 3 - by peak only
1643069 human BW121_H Body Weight QTL 121 (human) 13 2.67 2.3E-4 1339782 D13S779 Body weight central obesity factor (Central-OBS) was determined by factor analysis which was performed on 10 risk factors using maximum likelihood method obese Obesity 1642885 16172425 13 87302049 113302049 3 - by peak only
1643071 human BW174_H Body weight QTL 174 (human) 20 0.0389 1335922 D20S196 Body weight BMI Body mass index (BMI) measured as kg/m2; linkage to the discrete trait assessed using dichotomized phenotypes with individuals having BMI>=30 considered "affected" and those having lower BMI considered "unaffected" increased body mass index Obesity 1642891 9915959 69199;736916;736208;69093;1345990;1347922 ASIP;GNAS;CEBPB;HNF4A;MC3R;PCK1 20 35995245 61995245 3 - by peak only
1643072 human BW150_H Body weight QTL 150 (human) 1 0.0297 1339028 D1S194 Body fat amount percent body fat Percent body fat (%fat) measured by bioelectric impedance (BIA) increased body weight;increased percent body fat Obesity 1642891 9915959 1 150704011 176704011 3 - by peak only
1643073 human BW119_H Body Weight QTL 119 (human) 17 2.35 5.0E-4 1331576 D17S1294 Body weight obesity insulin factor (Obesity-INS) was determined by factor analysis which was performed on 10 risk factors using maximum likelihood method obese Obesity 1642885 16172425 17 12406428 38406428 3 - by peak only
1643074 human BW161_H Body weight QTL 161 (human) 13 0.0245 1335883 D13S168 Body fat amount percent body fat Percent body fat (%fat) measured by bioelectric impedance (BIA) increased body weight;increased percent body fat Obesity 1642891 9915959 13 33709521 59709521 3 - by peak only
1643075 human BP89_H Blood pressure QTL 89 (human) 17 3.22 5.9E-5 0.37 1338084 D17S1299 1298312 D17S1301 1341644 D17S1290 Blood pressure blood pressure factor (BP) was determined by factor analysis which was performed on 10 risk factors using maximum likelihood method hypertension Hypertension 1642885 16172425 17 36247937 70192683 1 - by flanking markers
1643256 human BW127_H Body Weight QTL 127 (human) 4 1.31 0.007 735842 FABP2 Body weight body mass index log-transformed BMI (lnBMI) 1334498 12502515 4 107460309 133460309 3 - by peak only
1643257 human BW136_H Body weight QTL 136 (human) 6 3.72 1.75E-5 1337640 D6S1053 1298166 D6S1031 Body weight genome-wide scan for linkage to birth weight in Mexican-Americans using the data from the San Antonio Family Birth Weight Study 1642884 16611675 1318965 COL19A1 6 64648238 77518319 1 - by flanking markers
1643258 human BW205_H Body weight QTL 205 (human) 12 4.08 1.0E-5 1337908 D12S1339 Body fat amount percent body fat Percent body fat (%fat) measured by bioelectric impedance; linkage to the quantitative trait was assessed using untransformed values increased percent body fat;increased susceptibility to weight gain Obesity 1334490 14988268 70506;731908;731886 IGF1;ACACB;PMCH
1643260 human BW191_H Body weight QTL 191 (human) 7 0.0039 1299899 D7S1799 Body weight BMI Body mass index (BMI) measured as (weight in kg)/(height in meters)2; linkage to the qualitative trait assessed using dichotomized phenotypes with individuals having BMI>=27 considered affected increased body mass index;increased susceptibility to weight gain Obesity 1334490 14988268 69123 LEP 7 90982330 116982330 3 - by peak only
1643262 human BW207_H Body weight QTL 207 (human) 2 1.7 0.003 1334898 D2S1360 Body weight BMI Body mass index (BMI) measured as (weight in kg)/(height in meters)2; linkage to the quantitative trait was assessed using untransformed values increased body mass index;increased susceptibility to weight gain Obesity 1642925 15470360 730864;735787;10069;1316957;1352097 SDC1;APOB;ACP1;LPIN1;POMC 2 4355507 30355507 3 - by peak only
1643264 human BW195_H Body weight QTL 195 (human) 12 0.0151 735410 PAH Body weight BMI Body mass index (BMI) measured as (weight in kg)/(height in meters)2; linkage to the qualitative trait assessed using dichotomized phenotypes with individuals having BMI>=30 considered affected increased body mass index;increased susceptibility to weight gain Obesity 1334490 14988268 12 88795872 114795872 3 - by peak only
1643266 human BW201_H Body weight QTL 201 (human) 12 3.79 1.0E-5 1299944 D12S2070 Body fat amount percent body fat Percent body fat (%fat) measured by bioelectric impedance; linkage to the quantitative trait was assessed using untransformed values increased percent body fat;increased susceptibility to weight gain Obesity 1334490 14988268 70506;731908;731886 IGF1;ACACB;PMCH 12 101567143 127567143 3 - by peak only
1643267 human SADIPOQ6_H Serum adiponectin level QTL 6 (human) 17 1.32 1298312 D17S1301 Hormone level serum adiponectin level Serum adiponectin concentration was measured by radioimmunoassay 1642892 17495197 17 57192606 78774742 3 - by peak only
1643269 human SADIPOQ5_H Serum adiponectin level QTL 5 (human) 11 2.89 1338308 D11S1986 Hormone level serum adiponectin level Serum adiponectin concentration was measured by radioimmunoassay 1642892 17495197 11 97728932 123728932 3 - by peak only
1643270 human BW198_H Body weight QTL 198 (human) 12 3.57 3.0E-5 1299944 D12S2070 Body weight BMI Body mass index (BMI) measured as (weight in kg)/(height in meters)2; linkage to the quantitative trait was assessed using untransformed values increased body mass index;increased susceptibility to weight gain Obesity 1334490 14988268 70506;731908;731886 IGF1;ACACB;PMCH 12 101567143 127567143 3 - by peak only
1643271 human BW214_H Body weight QTL 214 (human) 2 2.12 0.0021 1338979 D2S2952 Body weight BMI Body mass index (BMI) measured as (weight in kg)/(height in meters)2; linkage to the qualitative trait assessed using dichotomized phenotypes with individuals having BMI>=35 considered affected increased body mass index;increased susceptibility to weight gain Obesity 1642925 15470360 730864;735787;10069;1316957;1352097 SDC1;APOB;ACP1;LPIN1;POMC 2 1 20995586 3 - by peak only
1643273 human BW330_H Body Weight QTL 330 (human) 15 1.05 0.014 736048 GABRA5 1335361 D15S165 Body weight body mass index log-transformed BMI (lnBMI) 1334498 12502515 15 24742696 29048110 1 - by flanking markers
1643274 human BW209_H Body weight QTL 209 (human) 3 1.5 0.005 1298169 D3S2427 Body weight BMI Body mass index (BMI) measured as (weight in kg)/(height in meters)2; linkage to the quantitative trait was assessed using untransformed values increased body mass index;increased susceptibility to weight gain Obesity 1642925 15470360 3 164267613 190267613 3 - by peak only
1643275 human BW331_H Body Weight QTL 331 (human) 16 1.41 0.005 1335387 D16S764 Body weight body mass index log-transformed BMI (lnBMI) 1334498 12502515 16 3554365 29554365 3 - by peak only
1643276 human BW200_H Body weight QTL 200 (human) 13 2.82 2.0E-4 1339782 D13S779 Body weight BMI Body mass index (BMI) measured as (weight in kg)/(height in meters)2; linkage to the quantitative trait was assessed using untransformed values increased body mass index;increased susceptibility to weight gain Obesity 1334490 14988268 736204 IRS2 13 87302049 113302049 3 - by peak only
1643277 human BW203_H Body weight QTL 203 (human) 12 3.05 9.0E-5 1299944 D12S2070 Body morphometry waist circumference Waist circumference in centimeters was measured at the same time blood samples were taken for analysis abnormal adipose tissue distribution;abnormal lateral ganglionic eminence morphology;increased susceptibility to weight gain Obesity 1334490 14988268 70506;731908;731886 IGF1;ACACB;PMCH 12 101567143 127567143 3 - by peak only
1643279 human BW192_H Body weight QTL 192 (human) 12 0.0128 1337710 G08254 Body weight BMI Body mass index (BMI) measured as (weight in kg)/(height in meters)2; linkage to the qualitative trait assessed using dichotomized phenotypes with individuals having BMI>=27 considered affected increased body mass index;increased susceptibility to weight gain Obesity 1334490 14988268 12 1 21048975 3 - by peak only
1643280 human BW202_H Body weight QTL 202 (human) 21 4.27 1.0E-5 1339309 D21S1446 Body fat amount percent body fat Percent body fat (%fat) measured by bioelectric impedance; linkage to the quantitative trait was assessed using untransformed values increased percent body fat;increased susceptibility to weight gain Obesity 1334490 14988268 21 33862123 46944323 3 - by peak only
1643281 human BW210_H Body weight QTL 210 (human) 7 0.0077 1298320 D7S821 Body weight BMI Body mass index (BMI) measured as (weight in kg)/(height in meters)2; linkage to the qualitative trait assessed using dichotomized phenotypes with individuals having BMI>=35 considered affected increased body mass index;increased susceptibility to weight gain Obesity 1642925 15470360 7 82895575 108895575 3 - by peak only
1643282 human BW199_H Body weight QTL 199 (human) 13 2.7 2.0E-4 1340767 D13S800 Body weight BMI Body mass index (BMI) measured as (weight in kg)/(height in meters)2; linkage to the quantitative trait was assessed using untransformed values increased body mass index;increased susceptibility to weight gain Obesity 1334490 14988268 734107 HTR2A 13 59772840 85772840 3 - by peak only
1643283 human BW333_H Body Weight QTL 333 (human) 17 1.17 0.01 1341260 D17S921 1331576 D17S1294 Body weight body mass index log-transformed BMI (lnBMI) 1334498 12502515 17 14201430 25406556 1 - by flanking markers
1643284 human BW332_H Body Weight QTL 332 (human) 17 1.41 0.005 1298312 D17S1301 Body weight body mass index log-transformed BMI (lnBMI) 1334498 12502515 17 57192606 78774742 3 - by peak only
1643285 human SADIPOQ1_H Serum adiponectin level QTL 1 (human) 11 2.33 1298267 D11S4464 Hormone level serum adiponectin level Serum adiponectin concentration was measured by radioimmunoassay 1642892 17495197 11 110131956 134452384 3 - by peak only
1643286 human BW211_H Body weight QTL 211 (human) 13 0.0215 1341616 D13S1493 Body weight BMI Body mass index (BMI) measured as (weight in kg)/(height in meters)2; linkage to the qualitative trait assessed using dichotomized phenotypes with individuals having BMI>=40 considered affected increased body mass index;increased susceptibility to weight gain Obesity 1642925 15470360 13 19907040 45907040 3 - by peak only
1643288 human BW140_H Body weight QTL 140 (human) 2 30.9 1334899 D2S2179 1341152 D2S2244 1337443 D2S2250 Body weight genome screening and linkage analysis to identify a new lethal neonatal metabolic syndrome locus 1642888 9792866 recessive 2 218519882 219942672 1 - by flanking markers
1643290 human BW206_H Body weight QTL 206 (human) 10 1340909 D10S197 Body weight BMI Body mass index (BMI) measured as (weight in kg)/(height in meters)2; linkage to the qualitative trait assessed using dichotomized phenotypes with individuals having BMI>=27 considered affected increased body mass index;increased susceptibility to weight gain Obesity 1334490 14988268 10 13566984 39566984 3 - by peak only
1643291 human SADIPOQ3_H Serum adiponectin level QTL 3 (human) 2 1.82 1338989 D2S1334 Hormone level serum adiponectin level Serum adiponectin concentration was measured by radioimmunoassay 1642892 17495197 2 123173055 149173055 3 - by peak only
1643292 human SADIPOQ4_H Serum adiponectin level QTL 4 (human) 2 1.64 1338864 D2S1356 Hormone level serum adiponectin level Serum adiponectin concentration was measured by radioimmunoassay 1642892 17495197 2 30227143 56227143 3 - by peak only
1643293 human BW197_H Body weight QTL 197 (human) 4 1.71 0.002 1298110 D4S1644 Body weight BMI Body mass index (BMI) measured as (weight in kg)/(height in meters)2; linkage to the quantitative trait was assessed using untransformed values increased body mass index;increased susceptibility to weight gain Obesity 1334490 14988268 735821 UCP1 4 128971005 154971005 3 - by peak only
1643294 human BW194_H Body weight QTL 194 (human) 9 0.001 1337783 D9S910 Body weight BMI Body mass index (BMI) measured as (weight in kg)/(height in meters)2; linkage to the qualitative trait assessed using dichotomized phenotypes with individuals having BMI>=30 considered affected increased body mass index;increased susceptibility to weight gain Obesity 1334490 14988268
1643295 human BW196_H Body weight QTL 196 (human) 8 0.0083 1334926 D8S2324 Body weight BMI Body mass index (BMI) measured as (weight in kg)/(height in meters)2; linkage to the qualitative trait assessed using dichotomized phenotypes with individuals having BMI>=35 considered affected increased body mass index;increased susceptibility to weight gain Obesity 1334490 14988268 8 61416986 87416986 3 - by peak only
1643296 human BW208_H Body weight QTL 208 (human) 3 0.0178 1299926 D3S3045 Body weight BMI Body mass index (BMI) measured as (weight in kg)/(height in meters)2; linkage to the qualitative trait assessed using dichotomized phenotypes with individuals having BMI>=30 considered affected increased body mass index;increased susceptibility to weight gain Obesity 1642925 15470360 3 95472703 121472703 3 - by peak only
1643297 human BW204_H Body weight QTL 204 (human) 13 1.8 0.002 1339782 D13S779 Body morphometry waist circumference Waist circumference in centimeters was measured at the same time blood samples were taken for analysis abnormal adipose tissue distribution;abnormal lateral ganglionic eminence morphology;increased susceptibility to weight gain Obesity 1334490 14988268 736204 IRS2 13 87302049 113302049 3 - by peak only
1643298 human BW212_H Body weight QTL 212 (human) 13 2.67 2.0E-4 1341029 G09183 Body weight BMI Body mass index (BMI) measured as (weight in kg)/(height in meters)2; linkage to the quantitative trait was assessed using untransformed values increased body mass index;increased susceptibility to weight gain Obesity 1642925 15470360
1643299 human BW237_H Body weight QTL 237 (human) X 0.85 1337980 DXS6800 Body weight body mass index a three-stage genome-wide scan for linkage to obesity in Finnish sibpairs increased body mass index;obese Obesity 1642895 10999806 X 65567162 91567162 3 - by peak only
1643301 human BW247_H Body weight QTL 247 (human) 18 2.32 1341413 D18S64 Body weight body mass index a three-stage genome-wide scan for linkage to obesity in Finnish sibpairs increased body mass index;obese Obesity 1642895 10999806 18 42577141 68577141 3 - by peak only
1643302 human BW229_H Body weight QTL 229 (human) 9 0.93 1339170 D9S921 Body weight body mass index a three-stage genome-wide scan for linkage to obesity in Finnish sibpairs increased body mass index;obese Obesity 1642895 10999806 9 1 23499528 3 - by peak only
1643303 human BW242_H Body weight QTL 242 (human) X 2.17 1338280 DXS1001 Body weight body mass index a three-stage genome-wide scan for linkage to obesity in Finnish sibpairs increased body mass index;obese Obesity 1642895 10999806 X 106720798 132720798 3 - by peak only
1643304 human BW243_H Body weight QTL 243 (human) 18 1.62 1331553 D18S851 Body weight body mass index a three-stage genome-wide scan for linkage to obesity in Finnish sibpairs increased body mass index;obese Obesity 1642895 10999806 18 35361535 61361535 3 - by peak only
1643305 human BW241_H Body weight QTL 241 (human) X 2.73 1340945 DXS8067 Body weight body mass index a three-stage genome-wide scan for linkage to obesity in Finnish sibpairs increased body mass index;obese Obesity 1642895 10999806 X 106244683 132244683 3 - by peak only
1643306 human BW230_H Body weight QTL 230 (human) 9 1.18 1336259 D9S1118 Body weight body mass index a three-stage genome-wide scan for linkage to obesity in Finnish sibpairs increased body mass index;obese Obesity 1642895 10999806 9 18915421 44915421 3 - by peak only
1643307 human BW223_H Body weight QTL 223 (human) 1 1.44 1298271 D1S518 Body weight body mass index a three-stage genome-wide scan for linkage to obesity in Finnish sibpairs increased body mass index;obese Obesity 1642895 10999806 1 172817015 198817015 3 - by peak only
1643308 human BW235_H Body weight QTL 235 (human) 12 1.86 1341328 D12S395 Body weight body mass index a three-stage genome-wide scan for linkage to obesity in Finnish sibpairs obese;increased body mass index Obesity 1642895 10999806 12 105672967 131672967 3 - by peak only
1643309 human BW232_H Body weight QTL 232 (human) 10 1.25 1342103 D10S169 Body weight body mass index a three-stage genome-wide scan for linkage to obesity in Finnish sibpairs obese;increased body mass index Obesity 1642895 10999806 10 119411672 135374737 3 - by peak only
1643310 human BW236_H Body weight QTL 236 (human) 16 1.26 1339196 D16S3110 Body weight body mass index a three-stage genome-wide scan for linkage to obesity in Finnish sibpairs obese;increased body mass index Obesity 1642895 10999806 16 41557185 67557185 3 - by peak only
1643311 human BW228_H Body weight QTL 228 (human) 5 1.17 1331595 D5S1456 Body weight body mass index a three-stage genome-wide scan for linkage to obesity in Finnish sibpairs increased body mass index;obese Obesity 1642895 10999806 5 155965194 180857866 3 - by peak only
1643312 human BW246_H Body weight QTL 246 (human) 18 2.42 1340489 D18S1155 Body weight body mass index a three-stage genome-wide scan for linkage to obesity in Finnish sibpairs increased body mass index;obese Obesity 1642895 10999806 733058 MC4R 18 42214776 68214776 3 - by peak only
1643313 human BW234_H Body weight QTL 234 (human) 12 1.08 1299944 D12S2070 Body weight body mass index a three-stage genome-wide scan for linkage to obesity in Finnish sibpairs obese;increased body mass index Obesity 1642895 10999806 12 101567143 127567143 3 - by peak only
1643314 human BW226_H Body weight QTL 226 (human) 5 1.04 1298254 D5S1501 Body weight body mass index a three-stage genome-wide scan for linkage to obesity in Finnish sibpairs increased body mass index;obese Obesity 1642895 10999806 5 65504264 91504264 3 - by peak only
1643315 human BW227_H Body weight QTL 227 (human) 5 0.87 1298261 D5S1462 Body weight body mass index a three-stage genome-wide scan for linkage to obesity in Finnish sibpairs increased body mass index;obese Obesity 1642895 10999806 5 83406384 109406384 3 - by peak only
1643316 human BW239_H Body weight QTL 239 (human) X 3.14 1335143 DXS6804 Body weight body mass index a three-stage genome-wide scan for linkage to obesity in Finnish sibpairs increased body mass index;obese Obesity 1642895 10999806 736842 HTR2C X 98999455 124999455 3 - by peak only
1643317 human BW233_H Body weight QTL 233 (human) 11 0.86 1298202 D11S2002 Body weight body mass index a three-stage genome-wide scan for linkage to obesity in Finnish sibpairs obese;increased body mass index Obesity 1642895 10999806 11 66643169 92643169 3 - by peak only
1643318 human BW240_H Body weight QTL 240 (human) X 0.96 1336945 DXS8064 Body weight body mass index a three-stage genome-wide scan for linkage to obesity in Finnish sibpairs increased body mass index;obese Obesity 1642895 10999806 X 104157044 130157044 3 - by peak only
1643319 human BW238_H Body weight QTL 238 (human) X 1.2 1339976 DXS6799 Body weight body mass index a three-stage genome-wide scan for linkage to obesity in Finnish sibpairs increased body mass index;obese Obesity 1642895 10999806 X 84265699 110265699 3 - by peak only
1643320 human BW245_H Body weight QTL 245 (human) 18 0.92 1298292 D18S858 Body weight body mass index a three-stage genome-wide scan for linkage to obesity in Finnish sibpairs increased body mass index;obese Obesity 1642895 10999806 18 40048190 66048190 3 - by peak only
1643321 human BW231_H Body weight QTL 231 (human) 9 1.01 1339367 D9S158 Body weight body mass index a three-stage genome-wide scan for linkage to obesity in Finnish sibpairs increased body mass index;obese Obesity 1642895 10999806 9 125239066 140273252 3 - by peak only
1643322 human BW244_H Body weight QTL 244 (human) 18 1.97 1340561 D18S487 Body weight body mass index a three-stage genome-wide scan for linkage to obesity in Finnish sibpairs increased body mass index;obese Obesity 1642895 10999806 18 36991769 62991769 3 - by peak only
1643323 human BW225_H Body weight QTL 225 (human) 5 1.19 1298246 D5S1470 Body weight body mass index a three-stage genome-wide scan for linkage to obesity in Finnish sibpairs increased body mass index;obese Obesity 1642895 10999806 5 19528144 45528144 3 - by peak only
1643324 human BW224_H Body weight QTL 224 (human) 4 1.37 1338059 D4S2368 Body weight body mass index a three-stage genome-wide scan for linkage to obesity in Finnish sibpairs increased body mass index;obese Obesity 1642895 10999806 4 155953024 181953024 3 - by peak only
1643360 human BW339_H Body weight QTL 339 (human) 11 2.0 1298156 D11S2371 Body fat amount percent body fat Percent body fat (%fat) measured by bioelectric impedance; linkage to the quantitative trait was assessed using untransformed values increased percent body fat;increased susceptibility to weight gain Obesity 1642952 15647995 11 60182876 86182876 3 - by peak only
1643361 human BW307_H Body weight QTL 307 (human) 5 2.04 0.0015 1331595 D5S1456 Body weight BMI Body mass index was measured as (weight in kilograms)/(height in meters)2 increased body mass index Obesity 1643170 17115187 68511 PTTG1 5 155965194 180857866 3 - by peak only
1643363 human BW303_H Body weight QTL 303 (human) 10 1298123 D10S1646 1341235 D10S535 1298123 D10S1646 Body weight BMI Body mass index (BMI) measured as (weight in kg)/(height in meters)2; linkage to the quantitative trait was assessed using untransformed values increased body mass index;increased susceptibility to weight gain Obesity 738100 12478478 10 68292844 76010858 1 - by flanking markers
1643364 human BW338_H Body weight QTL 338 (human) 11 2.21 1337563 D11S1993 Body fat amount percent body fat Percent body fat (%fat) measured by bioelectric impedance; linkage to the quantitative trait was assessed using untransformed values increased percent body fat;increased susceptibility to weight gain Obesity 1642952 15647995 11 30566783 56566783 3 - by peak only
1643365 human BW318_H Body weight QTL 318 (human) 4 2.7 6.0E-4 1642896 D4S3243 Body fat amount Fat mass was measured by dual-energy X-ray absorptiometry (DEXA) abnormal lateral ganglionic eminence morphology Obesity 1643170 17115187
1643367 human BW323_H Body weight QTL 323 (human) 6 2.42 5.0E-4 68980 TBP Body fat amount Body fat mass in grams measured by dual-energy x-ray scanners abnormal lateral ganglionic eminence morphology;increased bone mineral density Obesity 1643174 17473065 736559 ESR1 6 157714634 170899992 3 - by peak only
1643369 human BW317_H Body weight QTL 317 (human) 18 2.22 0.0011 1299942 D18S843 Body fat amount Fat mass was measured by dual-energy X-ray absorptiometry (DEXA) abnormal lateral ganglionic eminence morphology Obesity 1643170 17115187 18 1 21603861 3 - by peak only
1643370 human BW334_H Body weight QTL 334 (human) 2 2.0 1338979 D2S2952 Body morphometry waist circumference Waist circumference in centimeters was measured at the same time blood samples were taken for analysis abnormal adipose tissue distribution;abnormal lateral ganglionic eminence morphology;increased susceptibility to weight gain Obesity 1642952 15647995 2 1 20995586 3 - by peak only
1643371 human BW329_H Body weight QTL 329 (human) 11 2.64 2.0E-4 1298156 D11S2371 Body fat amount Body fat mass in grams measured by dual-energy x-ray scanners abnormal lateral ganglionic eminence morphology Obesity 1643174 17473065 733835;737194;69170 UCP3;GAL;UCP2 11 60182876 86182876 3 - by peak only
1643372 human BW336_H Body weight QTL 336 (human) 3 2.2 1337094 D3S2403 Body fat amount percent body fat Percent body fat (%fat) measured by bioelectric impedance; linkage to the quantitative trait was assessed using untransformed values increased percent body fat;increased susceptibility to weight gain Obesity 1642952 15647995 3 147530 26147530 3 - by peak only
1643373 human BW341_H Body weight QTL 341 (human) 10 5.69 1340909 D10S197 Body weight BMI Body mass index (BMI) measured as (weight in kg)/(height in meters)2; linkage to the quantitative trait was assessed using untransformed values increased body mass index;increased susceptibility to weight gain Obesity 1642952 15647995 733945 GAD2 10 13566984 39566984 3 - by peak only
1643374 human BW337_H Body weight QTL 337 (human) 3 3.66 1299926 D3S3045 Body weight BMI Body mass index (BMI) measured as (weight in kg)/(height in meters)2; linkage to the quantitative trait was assessed using untransformed values increased body mass index;increased susceptibility to weight gain Obesity 1642952 15647995 3 95472703 121472703 3 - by peak only
1643375 human BW342_H Body weight QTL 342 (human) 10 2.65 1337452 D10S193 Body weight BMI Body mass index (BMI) measured as (weight in kg)/(height in meters)2; linkage to the quantitative trait was assessed using untransformed values increased body mass index;increased susceptibility to weight gain Obesity 1642952 15647995 733945 GAD2 10 17613528 43613528 3 - by peak only
1643376 human BW305_H Body weight QTL 305 (human) 20 1298199 D20S178 1298154 D20S149 1338093 D20S887 Body weight BMI Body mass index (BMI) measured as (weight in kg)/(height in meters)2; linkage to the qualitative trait assessed using dichotomized phenotypes with individuals having BMI>=27 considered affected increased body mass index;increased susceptibility to weight gain Obesity 738100 12478478 69199;736916;736208;1345990 ASIP;GNAS;CEBPB;MC3R 20 45985389 54947834 1 - by flanking markers
1643377 human BW325_H Body weight QTL 325 (human) 6 2.32 5.0E-4 1298151 D6S1959 Body fat amount Body fat mass in grams measured by dual-energy x-ray scanners abnormal lateral ganglionic eminence morphology Obesity 1643174 17473065 736289;736398;1344192 PPARD;HSPA1B;TNF
1643378 human BW315_H Body weight QTL 315 (human) 7 2.79 3.0E-4 1334938 GATA104 Body weight lean mass Lean body mass was measured by dual-energy X-ray absorptiometry (DEXA) increased lean body mass Obesity 1643170 17115187
1643380 human BW316_H Body weight QTL 316 (human) 1 2.62 2.0E-4 1334703 G27311 Body weight BMI Body mass index was measured as (weight in kilograms)/(height in meters)2 increased body mass index Obesity 1643170 17115187
1643381 human BW335_H Body weight QTL 335 (human) 2 2.45 1335056 D2S1400 Body weight BMI Body mass index (BMI) measured as (weight in kg)/(height in meters)2; linkage to the quantitative trait was assessed using untransformed values increased body mass index;increased susceptibility to weight gain Obesity 1642952 15647995 2 1 24524447 3 - by peak only
1643382 human BW310_H Body weight QTL 310 (human) 17 1.97 0.0018 1331576 D17S1294 Body fat amount Fat mass was measured by dual-energy X-ray absorptiometry (DEXA) abnormal lateral ganglionic eminence morphology Obesity 1643170 17115187 17 12406428 38406428 3 - by peak only
1643383 human BW312_H Body weight QTL 312 (human) 20 2.92 4.0E-4 1336686 G10052 1335158 D20S478 1335824 G10432 Body fat amount percent fat Measurements for calculation of percent fat mass were made by dual-energy X-ray absorptiometry (DEXA). PFM = (fat mass)/(fat mass + lean mass + bone mineral content) increased percent body fat Obesity 1643170 17115187 69199;736916;736208;1345990;1605726 ASIP;GNAS;CEBPB;MC3R;FOXA2 20 10665697 36665697 4 - by one flank marker only
1643385 human BW311_H Body weight QTL 311 (human) 20 3.31 1.0E-4 1336686 G10052 1335158 D20S478 1335824 G10432 Body fat amount Fat mass was measured by dual-energy X-ray absorptiometry (DEXA) abnormal lateral ganglionic eminence morphology Obesity 1643170 17115187 69199;736916;736208;1345990;1605726 ASIP;GNAS;CEBPB;MC3R;FOXA2 20 10665697 36665697 4 - by one flank marker only
1643386 human BW301_H Body weight QTL 301 (human) 10 1299888 D10S582 1298290 D10S208 Body weight BMI Body mass index (BMI) measured as (weight in kg)/(height in meters)2; linkage to the qualitative trait assessed using dichotomized phenotypes with individuals having BMI>=27 considered affected increased body mass index;increased susceptibility to weight gain Obesity 738100 12478478 10 24522666 31720285 1 - by flanking markers
1643387 human BW328_H Body weight QTL 328 (human) 13 3.23 1.0E-4 1342079 D13S787 Body fat amount Body fat mass in grams measured by dual-energy x-ray scanners abnormal lateral ganglionic eminence morphology Obesity 1643174 17473065 734042 ATP12A 13 10278863 36278863 3 - by peak only
1643388 human BW321_H Body weight QTL 321 (human) 7 2.59 3.0E-4 1331594 D7S820 Body fat amount Body fat mass in grams measured by dual-energy x-ray scanners abnormal lateral ganglionic eminence morphology Obesity 1643174 17473065 735310;69014;1320575;1349272 PRKAR2B;SERPINE1;PON2;PON1 7 70627440 96627440 3 - by peak only
1643389 human BW308_H Body weight QTL 308 (human) 8 2.06 0.0013 1299947 D8S1136 Body fat amount Fat mass was measured by dual-energy X-ray absorptiometry (DEXA) abnormal lateral ganglionic eminence morphology Obesity 1643170 17115187
1643390 human BW343_H Body weight QTL 343 (human) 10 2.72 1339314 D10S1781 Body weight BMI Body mass index (BMI) measured as (weight in kg)/(height in meters)2; linkage to the quantitative trait was assessed using untransformed values increased body mass index;increased susceptibility to weight gain Obesity 1642952 15647995 733945 GAD2 10 18856331 44856331 3 - by peak only
1643391 human BW322_H Body weight QTL 322 (human) 7 2.69 2.0E-4 1341033 G10289 Body fat amount Body fat mass in grams measured by dual-energy x-ray scanners abnormal lateral ganglionic eminence morphology Obesity 1643174 17473065 1352582 IL6
1643392 human BW304_H Body weight QTL 304 (human) 10 1339435 D10S1679 1339713 D10S1656 Body morphometry waist to hip ratio Waist-to-hip ratio (WHR) calculated by dividing the circumference of the waist (cm) by the circumference of the hips (cm) abnormal adipose tissue distribution;increased susceptibility to weight gain;abnormal lateral ganglionic eminence morphology Obesity 738100 12478478 10 100091919 126091919 4 - by one flank marker only
1643419 human BW274_H Body Weight QTL 274 (human) 11 2.19 8.0E-4 1298202 D11S2002 Body weight central obesity factor (Central-OBS) was determined by factor analysis which was performed on 10 risk factors using maximum likelihood method obese Obesity 1642885 16172425 11 66643169 92643169 3 - by peak only
1643420 human BW275_H Body Weight QTL 275 (human) 21 2.13 9.0E-4 1298202 D11S2002 Body weight central obesity factor (Central-OBS) was determined by factor analysis which was performed on 10 risk factors using maximum likelihood method obese Obesity 1642885 16172425 11 66643169 92643169 3 - by peak only
1643432 human SLIPL4_H Serum lipid level QTL 4 (human) 2 1.76 0.0022 Lipid level lipids and insulin factor (Lipids-INS) was determined by factor analysis which was performed on 10 risk factors using maximum likelihood method 1642885 16172425
1643434 human SLIPL20_H Serum lipid level QTL 20 (human) 19 2.2 0.12 Lipid level plasma triglyceride concentration in low density lipoproteins (LDL-TG) 1642914 16159608
1643436 human SLIPL10_H Serum lipid level QTL 10 (human) 3 1.83 0.002 1299921 D3S1764 Lipid level lipids and insulin factor (Lipids-INS) was determined by factor analysis which was performed on 10 risk factors using maximum likelihood method 1642885 16172425 3 127671173 153671173 3 - by peak only
1643437 human SLIPL1_H Serum lipid level QTL 1 (human) 11 2.66 2.3E-4 1299919 D11S912 Lipid level lipids and insulin factor (Lipids-INS) was determined by factor analysis which was performed on 10 risk factors using maximum likelihood method 1642885 16172425 11 115129353 134452384 3 - by peak only
1643438 human SLIPL15_H Serum lipid level QTL 15 (human) 14 3.2 0.03 1337546 D14S53 Lipid level plasma triglyceride concentration in low density lipoproteins (LDL-TG) 1642914 16159608
1643439 human BW101_H Body weight QTL 101 (human) 7 1.97 0.001 1299946 D7S1875 Body fat amount abdominal visceral difference between the abdominal total fat area (ATF) and abdominal visceral fat area (AVF) was determined as abdominal subcutaneous fat area (ASF) Obesity 1334499 11246882 69123;1343117 LEP;CAV2 7 127537916 153537916 4 - by one flank marker only
1643441 human SLIPL17_H Serum lipid level QTL 17 (human) 10 2.2 0.36 1341947 D10S2470 Lipid level plasma triglyceride concentration in high density lipoproteins (HDL-TG) 1642914 16159608
1643443 human SLIPL3_H Serum lipid level QTL 3 (human) 4 2.07 0.001 1331573 D4S1625 Lipid level lipids and insulin factor (Lipids-INS) was determined by factor analysis which was performed on 10 risk factors using maximum likelihood method 1642885 16172425 4 130720502 156720502 3 - by peak only
1643444 human SLIPL13_H Serum lipid level QTL 13 (human) 13 3.8 0.006 1341616 D13S1493 Lipid level plasma triglyceride concentration in high density lipoproteins (HDL-TG) 1642914 16159608 13 19907040 45907040 3 - by peak only
1643445 human SLIPL19_H Serum lipid level QTL 19 (human) 15 2.3 0.36 1341649 D15S122 Lipid level plasma triglyceride concentration in high density lipoproteins (HDL-TG) 1642914 16159608 15 10231213 36231213 3 - by peak only
1643446 human SLIPL16_H Serum lipid level QTL 16 (human) 10 2.9 0.06 1299918 D10S2325 Lipid level plasma triglyceride concentration in low density lipoproteins (LDL-TG) 1642914 16159608
1643447 human BW103_H Body weight QTL 103 (human) 9 2.14 8.0E-4 1338296 D9S257 Body fat amount abdominal visceral difference between the abdominal total fat area (ATF) and abdominal visceral fat area (AVF) was determined as abdominal subcutaneous fat area (ASF) Obesity 1334499 11246882 9 89480562 115480562 4 - by one flank marker only
1643448 human BW109_H Body weight QTL 109 (human) 17 1.53 0.004 1341644 D17S1290 Body fat amount abdominal visceral difference between the abdominal total fat area (ATF) and abdominal visceral fat area (AVF) was determined as abdominal subcutaneous fat area (ASF) Obesity 1334499 11246882 1348512 PYY 17 53686448 78774742 4 - by one flank marker only
1643449 human BW98_H Body weight QTL 98 (human) 1 2.31 6.0E-4 1338626 D1S534 Body fat amount abdominal visceral difference between the abdominal total fat area (ATF) and abdominal visceral fat area (AVF) was determined as abdominal subcutaneous fat area (ASF) Obesity 1334499 11246882 1317985;1318588;1347893 NHLH2;HSD3B2;HSD3B1 1 119479787 145479787 4 - by one flank marker only
1643450 human SLIPL5_H Serum lipid level QTL 5 (human) 4 1.97 0.0013 1642896 D4S3243 Lipid level lipids and insulin factor (Lipids-INS) was determined by factor analysis which was performed on 10 risk factors using maximum likelihood method 1642885 16172425
1643451 human SLIPL6_H Serum lipid level QTL 6 (human) 19 2.19 8.0E-4 1334592 D19S591 Lipid level lipids and insulin factor (Lipids-INS) was determined by factor analysis which was performed on 10 risk factors using maximum likelihood method 1642885 16172425
1643452 human BW104_H Body weight QTL 104 (human) 12 1.89 0.005 70506 IGF1 Body fat amount abdominal visceral difference between the abdominal total fat area (ATF) and abdominal visceral fat area (AVF) was determined as abdominal subcutaneous fat area (ASF) Obesity 1334499 11246882 70506 IGF1 12 101313806 127313806 4 - by one flank marker only
1643453 human BW99_H Body weight QTL 99 (human) 4 2.3 5.0E-4 1298180 D4S2397 Body fat amount abdominal visceral difference between the abdominal total fat area (ATF) and abdominal visceral fat area (AVF) was determined as abdominal subcutaneous fat area (ASF) Obesity 1334499 11246882 1342674 PPARGC1A 4 26866965 52866965 4 - by one flank marker only
1643454 human SLIPL9_H Serum lipid level QTL 9 (human) 3 1.98 0.001 1298245 D3S2406 Lipid level lipids and insulin factor (Lipids-INS) was determined by factor analysis which was performed on 10 risk factors using maximum likelihood method 1642885 16172425 3 60341229 86341229 3 - by peak only
1643455 human SLIPL11_H Serum lipid level QTL 11 (human) 4 1.98 0.001 Lipid level lipids and insulin factor (Lipids-INS) was determined by factor analysis which was performed on 10 risk factors using maximum likelihood method 1642885 16172425
1643456 human BW74_H Body weight QTL 74 (human) 12 1.7 0.029 1337475 D12S1704 1336691 D12S335 1298304 D12S398 Body weight body mass index obesity driven type 2 diabetes mellitus increased body mass index Diabetes Mellitus, Non-Insulin-Dependent;Obesity in Diabetes 1334497 14636289 619561 VDR 12 29112094 66415909 1 - by flanking markers
1643458 human BW75_H Body weight QTL 75 (human) 18 2.3 0.028 1335178 D18S1098 1336700 D18S1126 1299911 D18S471 Body weight Body mass index genome-wide scan for obesity driven type 2 diabetes mellitus increased body mass index Diabetes Mellitus, Non-Insulin-Dependent;Obesity in Diabetes 1334497 14636289 18 2859699 45610730 1 - by flanking markers
1643460 human SLIPL12_H Serum lipid level QTL 12 (human) 4 1.86 0.002 1298161 D4S2394 Lipid level lipids and insulin factor (Lipids-INS) was determined by factor analysis which was performed on 10 risk factors using maximum likelihood method 1642885 16172425 4 117517406 143517406 3 - by peak only
1643461 human BW105_H Body weight QTL 105 (human) 12 2.88 1.0E-4 1357235 D12S2078 Body fat amount abdominal visceral difference between the abdominal total fat area (ATF) and abdominal visceral fat area (AVF) was determined as abdominal subcutaneous fat area (ASF) Obesity 1334499 11246882 737153 HNF1A 12 126527093 132349534 4 - by one flank marker only
1643462 human BW108_H Body weight QTL 108 (human) 17 2.24 7.0E-4 1298272 D17S2180 Body fat amount abdominal visceral difference between the abdominal total fat area (ATF) and abdominal visceral fat area (AVF) was determined as abdominal subcutaneous fat area (ASF) Obesity 1334499 11246882 736216 HSD17B1 17 44028109 70028109 4 - by one flank marker only
1643463 human BW110_H Body weight QTL 110 (human) 17 2.21 7.0E-4 1298312 D17S1301 Body fat amount abdominal visceral difference between the abdominal total fat area (ATF) and abdominal visceral fat area (AVF) was determined as abdominal subcutaneous fat area (ASF) Obesity 1334499 11246882 1348512 PYY 17 70192530 78774742 4 - by one flank marker only
1643464 human BW106_H Body weight QTL 106 (human) 12 1.51 0.004 1298109 D12S1045 Body fat amount abdominal visceral difference between the abdominal total fat area (ATF) and abdominal visceral fat area (AVF) was determined as abdominal subcutaneous fat area (ASF) Obesity 1334499 11246882 12 128963691 132349534 4 - by one flank marker only
1643465 human SLIPL7_H Serum lipid level QTL 7 (human) 2 2.0 0.001 1339630 D2S1328 Lipid level lipids and insulin factor (Lipids-INS) was determined by factor analysis which was performed on 10 risk factors using maximum likelihood method 1642885 16172425 2 112903275 138903275 3 - by peak only
1643466 human SLIPL2_H Serum lipid level QTL 2 (human) 8 2.43 4.1E-4 1337367 D8S264 Lipid level lipids and insulin factor (Lipids-INS) was determined by factor analysis which was performed on 10 risk factors using maximum likelihood method 1642885 16172425 8 1 15117817 3 - by peak only
1643467 human BW100_H Body weight QTL 100 (human) 4 1.76 0.002 1331597 D4S2417 Body fat amount abdominal visceral difference between the abdominal total fat area (ATF) and abdominal visceral fat area (AVF) was determined as abdominal subcutaneous fat area (ASF) Obesity 1334499 11246882 1348310 NPY2R
1643468 human SLIPL18_H Serum lipid level QTL 18 (human) 12 2.6 0.02 1357235 D12S2078 Lipid level plasma triglyceride concentration in high density lipoproteins (HDL-TG) 1642914 16159608 12 113527222 132349534 3 - by peak only
1643469 human BW107_H Body weight QTL 107 (human) 13 1.92 0.002 1342302 D13S285 Body fat amount abdominal visceral the difference between the abdominal total fat area (ATF) and abdominal visceral fat area (AVF) was determined as abdominal subcutaneous fat area (ASF) Obesity 1334499 11246882 13 111843434 114142980 4 - by one flank marker only
1643471 human SLIPL14_H Serum lipid level QTL 14 (human) 13 2.2 0.14 1339582 D13S219 Lipid level plasma triglyceride concentration in low density lipoproteins (LDL-TG) 1642914 16159608 13 23056644 49056644 3 - by peak only
1643472 human SLIPL8_H Serum lipid level QTL 8 (human) 3 2.02 0.001 1298321 D3S2432 Lipid level lipids and insulin factor (Lipids-INS) was determined by factor analysis which was performed on 10 risk factors using maximum likelihood method 1642885 16172425 3 19140311 45140311 3 - by peak only
1643473 human BW102_H Body weight QTL 102 (human) 9 2.37 5.0E-4 1298167 D9S1122 Body fat amount abdominal visceral difference between the abdominal total fat area (ATF) and abdominal visceral fat area (AVF) was determined as abdominal subcutaneous fat area (ASF) Obesity 1334499 11246882 1344400 HSD17B3 9 78878447 104878447 4 - by one flank marker only
1643495 human BW291_H Body Weight QTL 291 (human) 6 2.13 1334582 D6S942 1336268 D6S1006 1335783 SE30 Body weight BMI BMI was calculated as weight (in kg) divided by the square of height (in meters) 1642951 15181885 6 1 12968327 4 - by one flank marker only
1643497 human BW258_H Body weight QTL 258 (human) 7 4.9 1.0E-5 1338834 D7S1804 Body weight body mass index BMI was calculated as weight (in kg) divided by the square of height (in meters) 1642909 11713718 69123 LEP 7 118930309 144930309 3 - by peak only
1643499 human BW294_H Body Weight QTL 294 (human) 13 1.04 1342079 D13S787 1340707 ATA5A09 Body weight BMI BMI was calculated as weight (in kg) divided by the square of height (in meters) 1642951 15181885 13 23278738 49278738 4 - by one flank marker only
1643500 human BW257_H Body weight QTL 257 (human) 7 3.2 7.0E-5 1338834 D7S1804 Body weight body mass index BMI was calculated as weight (in kg) divided by the square of height (in meters) 1642909 11713718 69123 LEP 7 118930309 144930309 3 - by peak only
1643501 human BW261_H Body weight QTL 261 (human) 2 1.5 0.00482 1338318 D2S1279 Body weight body mass index BMI was calculated as weight (in kg) divided by the square of height (in meters) 1642909 11713718 2 220659092 242951149 3 - by peak only
1643502 human BW265_H Body Weight QTL 265 (human) 6 1.6 0.00321 Body weight body mass index BMI was calculated as weight (in kg) divided by the square of height (in meters) 1642909 11713718 736559 ESR1
1643503 human BW290_H Body Weight QTL 290 (human) 11 2.1 1298267 D11S4464 Body weight BMI BMI was calculated as weight (in kg) divided by the square of height (in meters) Obesity 1642945 11723070 11 110131956 134452384 3 - by peak only
1643504 human BW283_H Body Weight QTL 283 (human) 2 1.71 0.0025 1299929 D2S1777 Body weight obesity insulin factor (Obesity-INS) was determined by factor analysis which was performed on 10 risk factors using maximum likelihood method obese Obesity 1642885 16172425 2 65374039 91374039 3 - by peak only
1643505 human BW286_H Body Weight QTL 286 (human) 10 1.7 0.0026 1339504 D10S548 1334902 D10S1791 1340909 D10S197 Body weight BMI BMI was calculated as weight (in kg) divided by the square of height (in meters) obese Obesity 1298038;1642885 10946912;16172425 1299953 ZEB1 10 18761298 37141826 1 - by flanking markers
1643506 human BW288_H Body Weight QTL 288 (human) 5 1.7 1298298 D5S2500 Body weight BMI BMI was calculated as weight (in kg) divided by the square of height (in meters) Obesity 1642945 11723070 5 45733025 71733025 3 - by peak only
1643507 human BW292_H Body Weight QTL 292 (human) 7 2.4 1299933 D7S3051 1335975 D7S1808 1357237 D7S1802 Body weight BMI BMI was calculated as weight (in kg) divided by the square of height (in meters) 1642951 15181885 730830 NPY 7 18251053 28004358 1 - by flanking markers
1643508 human BW262_H Body weight QTL 262 (human) 3 1.5 0.00414 1341808 D3S2305 Body weight body mass index BMI was calculated as weight (in kg) divided by the square of height (in meters) 1642909 11713718 730861;734231;737460;731284;1343622;1351472 SLC2A2;SST;APOD;HSD17B4;PPP1R2;ADIPOQ
1643509 human BW293_H Body Weight QTL 293 (human) 3 1.42 1298325 D3S2409 Body weight BMI BMI was calculated as weight (in kg) divided by the square of height (in meters) 1642951 15181885
1643510 human BW289_H Body Weight QTL 289 (human) 10 1.7 1298105 D10S189 Body weight BMI BMI was calculated as weight (in kg) divided by the square of height (in meters) Obesity 1642945 11723070 10 1 19762006 3 - by peak only
1643511 human BW256_H Body weight QTL 256 (human) 7 4.7 1.0E-5 1338834 D7S1804 Body weight body mass index BMI was calculated as weight (in kg) divided by the square of height (in meters) 1642909 11713718 69123 LEP 7 118930309 144930309 3 - by peak only
1643512 human BW266_H Body Weight QTL 266 (human) 14 1.5 0.00394 1299930 D14S617 Body weight body mass index BMI was calculated as weight (in kg) divided by the square of height (in meters) 1642909 11713718 14 78272613 104272613 3 - by peak only
1643513 human BW264_H Body Weight QTL 264 (human) 5 1.8 0.00202 1341886 D5S211 Body weight body mass index BMI was calculated as weight (in kg) divided by the square of height (in meters) 1642909 11713718 5 160181041 180857866 3 - by peak only
1643514 human BW260_H Body weight QTL 260 (human) 1 1.6 0.00328 1298129 D1S1679 Body weight body mass index BMI was calculated as weight (in kg) divided by the square of height (in meters) 1642909 11713718 736008;735774 ATP1A2;ATP1B1 1 147628616 173628616 3 - by peak only
1643515 human BW287_H Body Weight QTL 287 (human) 10 2.45 4.0E-4 1340909 D10S197 1339094 D10S1768 1299953 ZEB1 Body weight BMI BMI was calculated as weight (in kg) divided by the square of height (in meters) obese Obesity 1298038;1642885 10946912;16172425 1299953 ZEB1 10 26566899 36229686 1 - by flanking markers
1643516 human BW285_H Body Weight QTL 285 (human) 10 3.11 1341909 D10S537 Body weight birth weight and hip circumference 1642941 17486370 10 59065420 85065420 3 - by peak only
1643518 human BW267_H Body Weight QTL 267 (human) 15 1.6 0.00308 1341844 D15S184 Body weight body mass index BMI was calculated as weight (in kg) divided by the square of height (in meters) 1642909 11713718 4 161113296 187113296 3 - by peak only
1643519 human BW263_H Body Weight QTL 263 (human) 5 1.5 0.00394 1336959 D5S1505 Body weight body mass index BMI was calculated as weight (in kg) divided by the square of height (in meters) 1642909 11713718 5 106129673 132129673 3 - by peak only
1643520 human BW259_H Body weight QTL 259 (human) 13 3.2 6.0E-5 Body weight body mass index BMI was calculated as weight (in kg) divided by the square of height (in meters) 1642909 11713718 734107;1354034 HTR2A;ESD
1643521 human BW295_H Body Weight QTL 295 (human) 15 1.49 1335361 D15S165 Body weight BMI BMI was calculated as weight (in kg) divided by the square of height (in meters) 1642951 15181885 15 16048012 42048012 3 - by peak only
1643522 human BW296_H Body Weight QTL 296 (human) 21 1.19 1339550 D21S2055 1342054 D21S1411 Body weight BMI BMI was calculated as weight (in kg) divided by the square of height (in meters) 1642951 15181885 21 40113290 43034036 1 - by flanking markers
1643523 human BW284_H Body Weight QTL 284 (human) 15 1.95 0.0013 735789 ACTC1 Body weight obesity insulin factor (Obesity-INS) was determined by factor analysis which was performed on 10 risk factors using maximum likelihood method obese Obesity 1642885 16172425 15 19872438 45872438 3 - by peak only
1643535 human GLUCO24_H Glucose level QTL 24 (human) 7 0.003 1298140 D7S513 Glucose level non-insulin-dependent fasting plasma glucose (>7.8 mmol/l) was used for diagnosis of type 2 diabetes according to the 1985 World Health Organization criteria hyperglycemia Diabetes Mellitus, Non-Insulin-Dependent 1334498 12502515 7 1 24617972 3 - by peak only
1643537 human SADIPOQ11_H Serum adiponectin level QTL 11 (human) 8 1.6 1334607 D8S1771 1337365 D8S1784 Hormone level adiponectin level fasting serum adiponectin levels measured by radioimmunoassay (RIA) 1642929 16894363 8 25497152 106172524 1 - by flanking markers
1643539 human GLUCO18_H Glucose level QTL 18 (human) 4 0.79 0.028 1298248 D4S1647 Glucose level non-insulin-dependent fasting plasma glucose (>7.8 mmol/l) was used for diagnosis of type 2 diabetes according to the 1985 World Health Organization criteria hyperglycemia Diabetes Mellitus, Non-Insulin-Dependent 1334498 12502515 4 86654067 112654067 3 - by peak only
1643540 human GLUCO17_H Glucose level QTL 17 (human) 3 0.007 1298316 D3S3038 Glucose level non-insulin-dependent fasting plasma glucose (>7.8 mmol/l) was used for diagnosis of type 2 diabetes according to the 1985 World Health Organization criteria hyperglycemia Diabetes Mellitus, Non-Insulin-Dependent 1334498 12502515 3 8924608 34924608 3 - by peak only
1643541 human GLUCO7_H Glucose level QTL 7 (human) 1 2.6 1299917 D1S2127 Glucose level non-insulin-dependent fasting blood glucose >=140 mg/dl, or blood glucose 2 h after 75g oral glucose load >=200 mg/dl, or diabetes independently diagnosed in a clinical setting hyperglycemia Diabetes Mellitus, Non-Insulin-Dependent 1642945 11723070 1 170005144 196005144 3 - by peak only
1643543 human SADIPOQ14_H Serum adiponectin level QTL 14 (human) 10 2.5 1341057 D10S547 1340909 D10S197 Hormone level adiponectin level fasting serum adiponectin levels measured by radioimmunoassay (RIA) 1642929 16894363 10 10590527 26567069 1 - by flanking markers
1643544 human GLUCO27_H Glucose level QTL 27 (human) 8 0.62 0.046 1340315 D8S2323 1337826 D8S1119 Glucose level non-insulin-dependent fasting plasma glucose (>7.8 mmol/l) was used for diagnosis of type 2 diabetes according to the 1985 World Health Organization criteria hyperglycemia Diabetes Mellitus, Non-Insulin-Dependent 1334498 12502515 8 70235224 87241316 1 - by flanking markers
1643545 human GLUCO5_H Glucose level QTL 5 (human) 5 1.5 0.005 1336473 D5S426 Glucose level non-insulin-dependent fasting blood glucose >=140 mg/dl, or blood glucose 2 h after 75g oral glucose load >=200 mg/dl, or diabetes independently diagnosed in a clinical setting hyperglycemia Diabetes Mellitus, Non-Insulin-Dependent 1642945 11723070 5 21798808 47798808 3 - by peak only
1643546 human GLUCO33_H Glucose level QTL 33 (human) 21 0.042 1298173 D21S1440 Glucose level non-insulin-dependent fasting plasma glucose (>7.8 mmol/l) was used for diagnosis of type 2 diabetes according to the 1985 World Health Organization criteria hyperglycemia Diabetes Mellitus, Non-Insulin-Dependent 1334498 12502515 21 25063577 46944323 3 - by peak only
1643547 human GLUCO25_H Glucose level QTL 25 (human) 7 0.011 1335509 D7S2204 Glucose level non-insulin-dependent fasting plasma glucose (>7.8 mmol/l) was used for diagnosis of type 2 diabetes according to the 1985 World Health Organization criteria hyperglycemia Diabetes Mellitus, Non-Insulin-Dependent 1334498 12502515 7 64964972 90964972 3 - by peak only
1643548 human SADIPOQ10_H Serum adiponectin level QTL 10 (human) 11 4.2 1337255 D11S925 1299904 D11S968 Hormone level adiponectin level fasting serum adiponectin levels measured by radioimmunoassay (RIA) 1642929 16894363 732016;1312969;1322402;1345886;1348841;1602686 KCNJ1;TBRG1;TIRAP;CDON;ESAM;ASAM 11 120333478 134452384 2 - by one flank and peak markers
1643549 human GLUCO34_H Glucose level QTL 34 (human) 21 1.92 0.001 1342402 D21S266 1339309 D21S1446 Glucose level non-insulin-dependent fasting plasma glucose (>7.8 mmol/l) was used for diagnosis of type 2 diabetes according to the 1985 World Health Organization criteria hyperglycemia Diabetes Mellitus, Non-Insulin-Dependent 1334498 12502515 21 41606434 46862233 1 - by flanking markers
1643550 human GLUCO14_H Glucose level QTL 14 (human) 2 0.016 1298234 D2S1391 1339403 D2S2366 Glucose level non-insulin-dependent fasting plasma glucose (>7.8 mmol/l) was used for diagnosis of type 2 diabetes according to the 1985 World Health Organization criteria hyperglycemia Diabetes Mellitus, Non-Insulin-Dependent 1334498 12502515 2 158200585 184200585 4 - by one flank marker only
1643551 human GLUCO3_H Glucose level QTL 3 (human) 19 2.7 1338351 D19S884 1299977 D19S221 Glucose level fasting fasting serum glucose levels measured enzymatically with glucose oxidase 1642940 17925332 19 8056011 12574009 1 - by flanking markers
1643553 human ACTIV2_H Activity level QTL 2 (human) 18 2.2 4.0E-10 1335856 D18S474 1334652 D18S61 1341413 D18S64 Activity level percentage of awake time spent in moderate activity 1642672 17030971 733058 MC4R 18 46948821 65587255 1 - by flanking markers
1643555 human GLUCO20_H Glucose level QTL 20 (human) 5 0.04 1331600 D5S1471 Glucose level non-insulin-dependent fasting plasma glucose (>7.8 mmol/l) was used for diagnosis of type 2 diabetes according to the 1985 World Health Organization criteria hyperglycemia Diabetes Mellitus, Non-Insulin-Dependent 1334498 12502515 5 153809133 179809133 3 - by peak only
1643556 human GLUCO11_H Glucose level QTL 11 (human) 1 0.77 0.03 1336052 D1S1597 Glucose level non-insulin-dependent fasting plasma glucose (>7.8 mmol/l) was used for diagnosis of type 2 diabetes according to the 1985 World Health Organization criteria hyperglycemia Diabetes Mellitus, Non-Insulin-Dependent 1334498 12502515 1 656858 26656858 3 - by peak only
1643557 human SADIPOQ12_H Serum adiponectin level QTL 12 (human) 18 1.8 1334652 D18S61 1335010 D18S1161 Hormone level adiponectin level fasting serum adiponectin levels measured by radioimmunoassay (RIA) 1642929 16894363 18 65587099 70399514 1 - by flanking markers
1643558 human GLUCO15_H Glucose level QTL 15 (human) 2 0.99 0.016 1338107 D2S1353 1340813 D2S1776 Glucose level non-insulin-dependent fasting plasma glucose (>7.8 mmol/l) was used for diagnosis of type 2 diabetes according to the 1985 World Health Organization criteria hyperglycemia Diabetes Mellitus, Non-Insulin-Dependent 1334498 12502515 2 159267177 169353753 1 - by flanking markers
1643559 human GLUCO8_H Glucose level QTL 8 (human) 6 3.0 1298306 D6S1056 Glucose level non-insulin-dependent fasting blood glucose >=140 mg/dl, or blood glucose 2 h after 75g oral glucose load >=200 mg/dl, or diabetes independently diagnosed in a clinical setting hyperglycemia Diabetes Mellitus, Non-Insulin-Dependent 1642945 11723070 6 81154351 107154351 3 - by peak only
1643560 human SADIPOQ13_H Serum adiponectin level QTL 13 (human) 3 2.1 1342413 D3S1285 1337283 D3S1271 Hormone level adiponectin level fasting serum adiponectin levels measured by radioimmunoassay (RIA) 1642929 16894363 3 64914199 102217592 1 - by flanking markers
1643561 human GLUCO30_H Glucose level QTL 30 (human) 13 0.038 1342334 D13S770 Glucose level non-insulin-dependent fasting plasma glucose (>7.8 mmol/l) was used for diagnosis of type 2 diabetes according to the 1985 World Health Organization criteria hyperglycemia Diabetes Mellitus, Non-Insulin-Dependent 1334498 12502515 13 85429453 111429453 3 - by peak only
1643562 human GLUCO22_H Glucose level QTL 22 (human) 6 0.003 1298296 D6S1009 Glucose level non-insulin-dependent fasting plasma glucose (>7.8 mmol/l) was used for diagnosis of type 2 diabetes according to the 1985 World Health Organization criteria hyperglycemia Diabetes Mellitus, Non-Insulin-Dependent 1334498 12502515 6 124344004 150344004 3 - by peak only
1643563 human GLUCO26_H Glucose level QTL 26 (human) 8 0.73 0.033 1336791 D8S1099 1336611 D8S1130 Glucose level non-insulin-dependent fasting plasma glucose (>7.8 mmol/l) was used for diagnosis of type 2 diabetes according to the 1985 World Health Organization criteria hyperglycemia Diabetes Mellitus, Non-Insulin-Dependent 1334498 12502515 8 6163341 32163341 4 - by one flank marker only
1643564 human GLUCO6_H Glucose level QTL 6 (human) 14 1.6 0.005 1299930 D14S617 Glucose level non-insulin-dependent fasting blood glucose >=140 mg/dl, or blood glucose 2 h after 75g oral glucose load >=200 mg/dl, or diabetes independently diagnosed in a clinical setting hyperglycemia Diabetes Mellitus, Non-Insulin-Dependent 1642945 11723070 14 78272613 104272613 3 - by peak only
1643241 human BW129_H Body Weight QTL 129 (human) 5 0.93 0.019 1336959 D5S1505 1340849 D5S816 Body weight body mass index log-transformed BMI (lnBMI) 1334498 12502515 5 119129545 135329651 1 - by flanking markers
1643243 human BW132_H Body weight QTL 132 (human) 1 1.71 1298271 D1S518 1298252 D1S1660 Body weight genome-wide scan for linkage to birth weight in Mexican-Americans using the data from the San Antonio Family Birth Weight Study 1642884 16611675 735591;737360;737364;1312426 IL10;APOA2;PKLR;LMX1A 1 185816911 196878197 1 - by flanking markers
1643245 human BW137_H Body weight QTL 137 (human) 9 2.28 1335858 G10361 Body weight genome-wide scan for linkage to birth weight in Mexican-Americans using the data from the San Antonio Family Birth Weight Study 1642884 16611675 733926 VLDLR
1643246 human BW124_H Body Weight QTL 124 (human) 2 1.28 0.008 1338107 D2S1353 1340813 D2S1776 Body weight body mass index log-transformed BMI (lnBMI) 1334498 12502515 2 159267177 169353753 1 - by flanking markers
1643247 human BW130_H Body Weight QTL 130 (human) 7 1.28 0.008 1336977 D7S3056 Body weight body mass index log-transformed BMI (lnBMI) 1334498 12502515
1643248 human BW138_H Body weight QTL 138 (human) 19 1.47 1335579 D19S586 Body weight genome-wide scan for linkage to birth weight in Mexican-Americans using the data from the San Antonio Family Birth Weight Study 1642884 16611675 735594 LDLR 19 1 22665918 3 - by peak only
1643249 human BW135_H Body weight QTL 135 (human) 4 1.92 1331573 D4S1625 Body weight genome-wide scan for linkage to birth weight in Mexican-Americans using the data from the San Antonio Family Birth Weight Study 1642884 16611675 731586;732381;735821;1347163;1348310 NPY5R;CPE;UCP1;NPY1R;NPY2R 4 130720502 156720502 3 - by peak only
1643250 human BW134_H Body weight QTL 134 (human) 3 1.57 1298243 D3S1311 Body weight genome-wide scan for linkage to birth weight in Mexican-Americans using the data from the San Antonio Family Birth Weight Study 1642884 16611675 735893;1312550;1343622 MUC4;MUC20;PPP1R2 3 185502595 199501827 3 - by peak only
1643251 human BW139_H Body weight QTL 139 (human) 19 1.25 1331580 D19S589 1336474 D19S418 Body weight genome-wide scan for linkage to birth weight in Mexican-Americans using the data from the San Antonio Family Birth Weight Study 1642884 16611675 736043;736378;735472;1352001;1350993 APOC4;APOE;APOC1;APOC2;ATF5 19 58475270 60237940 1 - by flanking markers
1643252 human BW131_H Body Weight QTL 131 (human) 10 1.16 0.01 1338460 D10S1220 Body weight body mass index log-transformed BMI (lnBMI) 1334498 12502515 10 39348689 65348689 3 - by peak only
1643253 human BW133_H Body weight QTL 133 (human) 2 2.66 1340813 D2S1776 Body weight genome-wide scan for linkage to birth weight in Mexican-Americans using the data from the San Antonio Family Birth Weight Study 1642884 16611675 734123 ACVR1C 2 156353605 182353605 3 - by peak only
1643254 human BW125_H Body Weight QTL 125 (human) 2 1.45 0.005 1339308 D2S2944 Body weight body mass index log-transformed BMI (lnBMI) 1334498 12502515
1643255 human BW128_H Body Weight QTL 128 (human) 4 0.88 0.022 1331573 D4S1625 Body weight body mass index log-transformed BMI (lnBMI) 1334498 12502515 4 130720502 156720502 3 - by peak only
1643394 human BW309_H Body weight QTL 309 (human) 10 1.9 0.0019 1298189 D10S1423 Body fat amount Fat mass was measured by dual-energy X-ray absorptiometry (DEXA) abnormal lateral ganglionic eminence morphology Obesity 1643170 17115187 10 6478021 32478021 3 - by peak only
1643395 human BW326_H Body weight QTL 326 (human) 2 2.29 6.0E-4 1298234 D2S1391 Body fat amount Body fat mass in grams measured by dual-energy x-ray scanners abnormal lateral ganglionic eminence morphology Obesity 1643174 17473065 736334 MSTN
1643396 human BW306_H Body weight QTL 306 (human) 20 1298199 D20S178 1298154 D20S149 Body fat amount percent body fat Percent body fat (%fat) measured by bioelectric impedance; linkage to the quantitative trait was assessed using untransformed values increased percent body fat;increased susceptibility to weight gain Obesity 738100 12478478 69199;736916;736208;1345990 ASIP;GNAS;CEBPB;MC3R 20 45985389 54947834 1 - by flanking markers
1643397 human BW319_H Body weight QTL 319 (human) 4 2.43 8.0E-4 1642896 D4S3243 Body fat amount percent fat Measurements for calculation of percent fat mass were made by dual-energy X-ray absorptiometry (DEXA). PFM = (fat mass)/(fat mass + lean mass + bone mineral content) increased percent body fat Obesity 1643170 17115187
1643398 human BW302_H Body weight QTL 302 (human) 10 2.5 1298123 D10S1646 1341235 D10S535 1298123 D10S1646 Body morphometry waist circumference Waist circumference in centimeters was measured at the same time blood samples were taken for analysis abnormal adipose tissue distribution;increased susceptibility to weight gain;abnormal lateral ganglionic eminence morphology Obesity 738100 12478478 10 68292844 76010858 1 - by flanking markers
1643399 human BMD5_H Bone mineral density QTL 5 (human) 6 2.32 5.0E-4 1298151 D6S1959 Bone mineral density Bone mineral density in grams per sqare centimeter measured at the femoral neck, trochanter and intertrochanteric regions of the hip, at the L1-L4 region of the lumbar spine and at the wrist at the ultra distal region of the forearm by dual-energy x-ray scanners increased bone mineral density Obesity 1643174 17473065 1344192;1348975;1349444 TNF;RUNX2;HLA-A
1643401 human BMD1_H Bone mineral density QTL 1 (human) 7 2.59 3.0E-4 1331594 D7S820 Bone mineral density Bone mineral density in grams per sqare centimeter measured at the femoral neck, trochanter and intertrochanteric regions of the hip, at the L1-L4 region of the lumbar spine and at the wrist at the ultra distal region of the forearm by dual-energy x-ray scanners increased bone mineral density Obesity 1643174 17473065 731272;69014;1349272 CALCR;SERPINE1;PON1 7 70627440 96627440 3 - by peak only
1643402 human BMD2_H Bone mineral density QTL 2 (human) 7 2.69 2.0E-4 1341033 G10289 Bone mineral density Bone mineral density in grams per sqare centimeter measured at the femoral neck, trochanter and intertrochanteric regions of the hip, at the L1-L4 region of the lumbar spine and at the wrist at the ultra distal region of the forearm by dual-energy x-ray scanners increased bone mineral density Obesity 1643174 17473065 1352582;1605432 IL6;RAC1
1643403 human BMD8_H Bone mineral density QTL 8 (human) 13 3.23 1.0E-4 1342079 D13S787 Bone mineral density Bone mineral density in grams per sqare centimeter measured at the femoral neck, trochanter and intertrochanteric regions of the hip, at the L1-L4 region of the lumbar spine and at the wrist at the ultra distal region of the forearm by dual-energy x-ray scanners increased bone mineral density Obesity 1643174 17473065 732783 KL 13 10278863 36278863 3 - by peak only
1643404 human BMD3_H Bone mineral density QTL 3 (human) 6 2.42 5.0E-4 68980 TBP Bone mineral density Bone mineral density in grams per sqare centimeter measured at the femoral neck, trochanter and intertrochanteric regions of the hip, at the L1-L4 region of the lumbar spine and at the wrist at the ultra distal region of the forearm by dual-energy x-ray scanners increased bone mineral density;abnormal lateral ganglionic eminence morphology Obesity 1643174 17473065 736559 ESR1 6 157714634 170899992 3 - by peak only
1643405 human BMD9_H Bone mineral density QTL 9 (human) 11 2.64 2.0E-4 1298156 D11S2371 Bone mineral density Bone mineral density in grams per sqare centimeter measured at the femoral neck, trochanter and intertrochanteric regions of the hip, at the L1-L4 region of the lumbar spine and at the wrist at the ultra distal region of the forearm by dual-energy x-ray scanners increased bone mineral density Obesity 1643174 17473065 732196;737428;1319617 FOSL1;GAB2;LRP5 11 60182876 86182876 3 - by peak only
1643406 human BMD6_H Bone mineral density QTL 6 (human) 2 2.29 6.0E-4 1298234 D2S1391 Bone mineral density Bone mineral density in grams per sqare centimeter measured at the femoral neck, trochanter and intertrochanteric regions of the hip, at the L1-L4 region of the lumbar spine and at the wrist at the ultra distal region of the forearm by dual-energy x-ray scanners increased bone mineral density Obesity 1643174 17473065 732184;736334 STAT1;MSTN
1643408 human BW273_H Body Weight QTL 273 (human) 4 2.0 0.0012 1341198 D4S3248 Body weight obesity insulin factor (Obesity-INS) was determined by factor analysis which was performed on 10 risk factors using maximum likelihood method obese Obesity 1642885 16172425 4 46704213 72704213 3 - by peak only
1643409 human BW271_H Body Weight QTL 271 (human) 17 2.09 0.001 1298272 D17S2180 Body weight obesity insulin factor (Obesity-INS) was determined by factor analysis which was performed on 10 risk factors using maximum likelihood method obese Obesity 1642885 16172425 17 31028167 57028167 3 - by peak only
1643410 human BW281_H Body Weight QTL 281 (human) 11 2.03 0.001 1298333 D11S1985 Body weight obesity insulin factor (Obesity-INS) was determined by factor analysis which was performed on 10 risk factors using maximum likelihood method obese Obesity 1642885 16172425
1643411 human BW278_H Body Weight QTL 278 (human) 12 1.79 0.002 1341328 D12S395 Body weight obesity insulin factor (Obesity-INS) was determined by factor analysis which was performed on 10 risk factors using maximum likelihood method obese Obesity 1642885 16172425 12 105672967 131672967 3 - by peak only
1643412 human BW276_H Body Weight QTL 276 (human) 21 2.15 8.0E-4 1338108 D21S1432 Body weight obesity insulin factor (Obesity-INS) was determined by factor analysis which was performed on 10 risk factors using maximum likelihood method obese Obesity 1642885 16172425 21 3265382 29265382 3 - by peak only
1643413 human BW270_H Body Weight QTL 270 (human) 8 1.96 0.0013 1334904 D8S1106 Body weight obesity insulin factor (Obesity-INS) was determined by factor analysis which was performed on 10 risk factors using maximum likelihood method obese Obesity 1642885 16172425 8 1 25880399 3 - by peak only
1643414 human BW279_H Body Weight QTL 279 (human) 5 1.87 0.002 1341886 D5S211 Body weight central obesity factor (Central-OBS) was determined by factor analysis which was performed on 10 risk factors using maximum likelihood method obese Obesity 1642885 16172425 5 160181041 180857866 3 - by peak only
1643415 human BW272_H Body Weight QTL 272 (human) 3 1.8 0.002 1299972 D3S1304 Body weight obesity insulin factor (Obesity-INS) was determined by factor analysis which was performed on 10 risk factors using maximum likelihood method obese Obesity 1642885 16172425 3 1 19894439 3 - by peak only
1643416 human BW280_H Body Weight QTL 280 (human) 8 1.92 0.001 1337367 D8S264 Body weight central obesity factor (Central-OBS) was determined by factor analysis which was performed on 10 risk factors using maximum likelihood method obese Obesity 1642885 16172425 8 1 15117817 3 - by peak only
1643417 human BW277_H Body Weight QTL 277 (human) 21 1.98 0.001 Body weight obesity insulin factor (Obesity-INS) was determined by factor analysis which was performed on 10 risk factors using maximum likelihood method obese Obesity 1642885 16172425
1643418 human BW282_H Body Weight QTL 282 (human) 6 2.07 0.001 1335783 SE30 Body weight central obesity factor (Central-OBS) was determined by factor analysis which was performed on 10 risk factors using maximum likelihood method obese Obesity 1642885 16172425
1643583 human ACTIV1_H Activity level QTL 1 (human) 18 4.07 4.0E-14 1341022 D18S53 1334759 D18S68 1334562 D18S1102 Activity level percentage of awake time spent in sedentary activity 1642672 17030971 733058 MC4R 18 11482737 59688958 1 - by flanking markers
1643585 human SGHRL1_H Serum ghrelin level QTL 1 (human) 1 3.2 6.0E-5 1341819 D1S2667 1337874 D1S255 1341324 D1S199 Hormone level ghrelin level fasting serum ghrelin measured by radioimmunoassay (RIA) 1642936 17667848 732569;68533;1298224 MFN2;MTOR;TNFRSF1B 1 11409625 37422383 1 - by flanking markers
1643587 human SADIPOQ8_H Serum adiponectin level QTL 8 (human) 8 3.0 1334607 D8S1771 1337365 D8S1784 Hormone level adiponectin level fasting serum adiponectin levels measured by radioimmunoassay (RIA) 1642929 16894363 8 25497152 106172524 1 - by flanking markers
1643588 human GLUCO4_H Glucose level QTL 4 (human) 13 4.6 1338880 D13S159 1342302 D13S285 1340179 D13S173 Glucose level fasting fasting serum glucose levels measured enzymatically with glucose oxidase 1642940 17925332 736204 IRS2 13 97851595 111843529 1 - by flanking markers
1643565 human GLUCO28_H Glucose level QTL 28 (human) 9 1.4 0.006 1340005 D9S282 Glucose level non-insulin-dependent fasting plasma glucose (>7.8 mmol/l) was used for diagnosis of type 2 diabetes according to the 1985 World Health Organization criteria hyperglycemia Diabetes Mellitus, Non-Insulin-Dependent 1334498 12502515 9 112848784 138848784 3 - by peak only
1643566 human GLUCO16_H Glucose level QTL 16 (human) 2 0.61 0.047 1339325 D2S427 Glucose level non-insulin-dependent fasting plasma glucose (>7.8 mmol/l) was used for diagnosis of type 2 diabetes according to the 1985 World Health Organization criteria hyperglycemia Diabetes Mellitus, Non-Insulin-Dependent 1334498 12502515 2 218914630 242951149 3 - by peak only
1643567 human GLUCO29_H Glucose level QTL 29 (human) 11 0.71 0.035 1299919 D11S912 Glucose level non-insulin-dependent fasting plasma glucose (>7.8 mmol/l) was used for diagnosis of type 2 diabetes according to the 1985 World Health Organization criteria hyperglycemia Diabetes Mellitus, Non-Insulin-Dependent 1334498 12502515 11 115129353 134452384 3 - by peak only
1643568 human SADIPOQ9_H Serum adiponectin level QTL 9 (human) 18 2.6 1334652 D18S61 1335010 D18S1161 Hormone level adiponectin level fasting serum adiponectin levels measured by radioimmunoassay (RIA) 1642929 16894363 18 65587099 70399514 1 - by flanking markers
1643569 human GLUCO21_H Glucose level QTL 21 (human) 6 0.021 1298151 D6S1959 Glucose level non-insulin-dependent fasting plasma glucose (>7.8 mmol/l) was used for diagnosis of type 2 diabetes according to the 1985 World Health Organization criteria hyperglycemia Diabetes Mellitus, Non-Insulin-Dependent 1334498 12502515
1643570 human GLUCO13_H Glucose level QTL 13 (human) 2 0.019 1298195 D2S1788 Glucose level non-insulin-dependent fasting plasma glucose (>7.8 mmol/l) was used for diagnosis of type 2 diabetes according to the 1985 World Health Organization criteria hyperglycemia Diabetes Mellitus, Non-Insulin-Dependent 1334498 12502515 2 23113904 49113904 3 - by peak only
1643571 human GLUCO12_H Glucose level QTL 12 (human) 1 0.019 1336052 D1S1597 Glucose level non-insulin-dependent fasting plasma glucose (>7.8 mmol/l) was used for diagnosis of type 2 diabetes according to the 1985 World Health Organization criteria hyperglycemia Diabetes Mellitus, Non-Insulin-Dependent 1334498 12502515 1 656858 26656858 3 - by peak only
1643572 human GLUCO9_H Glucose level QTL 9 (human) 17 1.6 1299971 D17S784 Glucose level non-insulin-dependent fasting blood glucose >=140 mg/dl, or blood glucose 2 h after 75g oral glucose load >=200 mg/dl, or diabetes independently diagnosed in a clinical setting hyperglycemia Diabetes Mellitus, Non-Insulin-Dependent 1642945 11723070 17 62416927 78774742 3 - by peak only
1643573 human FOCO1_H Food consumption QTL 1 (human) 18 1.84 8.0E-10 1334759 D18S68 Consumption level multiple-pass 24-hour recall method of carbohydrate dietary intake 1642672 17030971 733058 MC4R 18 46688816 72688816 3 - by peak only
1643575 human GLUCO35_H Glucose level QTL 35 (human) 22 0.002 1339581 D22S420 Glucose level non-insulin-dependent fasting plasma glucose (>7.8 mmol/l) was used for diagnosis of type 2 diabetes according to the 1985 World Health Organization criteria hyperglycemia Diabetes Mellitus, Non-Insulin-Dependent 1334498 12502515 22 3239551 29239551 3 - by peak only
1643576 human GLUCO1_H Glucose level QTL 1 (human) 7 2.2 1339181 D7S657 Glucose level fasting fasting serum glucose levels measured enzymatically with glucose oxidase 1642940 17925332 7 79644265 105644265 3 - by peak only
1643577 human GLUCO31_H Glucose level QTL 31 (human) 17 0.67 0.04 1341260 D17S921 Glucose level non-insulin-dependent fasting plasma glucose (>7.8 mmol/l) was used for diagnosis of type 2 diabetes according to the 1985 World Health Organization criteria hyperglycemia Diabetes Mellitus, Non-Insulin-Dependent 1334498 12502515 17 1201518 27201518 3 - by peak only
1643578 human GLUCO32_H Glucose level QTL 32(human) 20 0.003 1334643 D20S107 Glucose level non-insulin-dependent fasting plasma glucose (>7.8 mmol/l) was used for diagnosis of type 2 diabetes according to the 1985 World Health Organization criteria hyperglycemia Diabetes Mellitus, Non-Insulin-Dependent 1334498 12502515 20 25316105 51316105 3 - by peak only
1643579 human GLUCO23_H Glucose level QTL 23 (human) 6 0.69 0.037 1298275 D6S2439 Glucose level non-insulin-dependent fasting plasma glucose (>7.8 mmol/l) was used for diagnosis of type 2 diabetes according to the 1985 World Health Organization criteria hyperglycemia Diabetes Mellitus, Non-Insulin-Dependent 1334498 12502515
1643580 human GLUCO2_H Glucose level QTL 2 (human) 10 2.6 1337530 D10S597 1338547 D10S1693 Glucose level fasting fasting serum glucose levels measured enzymatically with glucose oxidase 1642940 17925332 10 111220779 119435134 1 - by flanking markers
1643581 human GLUCO19_H Glucose level QTL 19 (human) 5 0.67 0.04 1357239 D5S1453 Glucose level non-insulin-dependent fasting plasma glucose (>7.8 mmol/l) was used for diagnosis of type 2 diabetes according to the 1985 World Health Organization criteria hyperglycemia Diabetes Mellitus, Non-Insulin-Dependent 1334498 12502515
1643582 human GLUCO10_H Glucose level QTL 10 (human) 5 1.7 1334984 D5S807 Glucose level non-insulin-dependent fasting blood glucose >=140 mg/dl, or blood glucose 2 h after 75g oral glucose load >=200 mg/dl, or diabetes independently diagnosed in a clinical setting hyperglycemia Diabetes Mellitus, Non-Insulin-Dependent 1642945 11723070 5 1 22261035 3 - by peak only
2289299 human BW375_H Body weight QTL 375 (human) 2 2.49 3.5E-4 1299945 D2S434 Body fat amount abdominal baseline abdominal visceral fat, whites(Caucasian in original HERITAGE Study description) increased body weight;abnormal lateral ganglionic eminence morphology Obesity 1354697 11872690 733473 IRS1 2 205284868 231284868 3 - by peak only
2289301 human BW387_H Body weight QTL 387 (human) 22 1.96 0.00132 1685619 Body fat amount abdominal baseline abdominal subcutaneous fat, whites (Caucasian in original HERITAGE Study description) abnormal lateral ganglionic eminence morphology;increased body weight Obesity 1354697 11872690
2289303 human BW394_H Body weight QTL 394 (human) 15 1.49 1335361 D15S165 Body weight BMI (weight in kg divided by height in meters, squared) based on self-reported weight and height increased body mass index Obesity 1642951 15181885 15 16048012 42048012 3 - by peak only
2289305 human BW395_H Body weight QTL 395 (human) 21 1.19 1339550 D21S2055 1342054 D21S1411 Body weight BMI (weight in kg divided by height in meters, squared) based on self-reported weight and height increased body mass index Obesity 1642951 15181885 21 40113290 43034036 1 - by flanking markers
2289306 human BW373_H Body weight QTL 373 (human) 2 1.97 0.00131 1338989 D2S1334 Body fat amount abdominal baseline abdominal visceral fat, whites (Caucasian in original HERITAGE Study description) increased body weight;abnormal lateral ganglionic eminence morphology Obesity 1354697 11872690 733473 IRS1 2 123173055 149173055 3 - by peak only
2289308 human BW392_H Body weight QTL 392 (human) 3 1.42 1298325 D3S2409 Body weight BMI (weight in kg divided by height in meters, squared) based on self-reported weight and height increased body mass index Obesity 1642951 15181885
2289309 human BW382_H Body weight QTL 382 (human) 5 1.87 0.00169 1298302 D5S1480 Body fat amount abdominal Baseline abdominal total fat, whites (Caucasian in original HERITAGE Study description) abnormal lateral ganglionic eminence morphology;increased body weight Obesity 1354697 11872690 5 131124026 157124026 3 - by peak only
2289311 human BW380_H Body weight QTL 380 (human) 5 2.06 0.00104 1341217 D5S658 Body fat amount abdominal baseline abdominal subcutaneous fat, whites (Caucasian in original HERITAGE Study description) increased body weight;abnormal lateral ganglionic eminence morphology Obesity 1354697 11872690 5 127353236 153353236 3 - by peak only
2289312 human BW391_H Body weight QTL 391 (human) 7 2.4 1299933 D7S3051 1335975 D7S1808 1357237 D7S1802 Body weight BMI (weight in kg divided by height in meters, squared) based on self-reported weight and height increased body mass index Obesity 1642951 15181885 730830 NPY 7 18251053 28004358 1 - by flanking markers
2289313 human BW388_H Body weight QTL 388 (human) 11 1.57 0.00356 70070 sur Body fat amount abdominal baseline abdominal subcutaneous fat, blacks abnormal lateral ganglionic eminence morphology;increased body weight Obesity 1354697 11872690
2289315 human BW374_H Body weight QTL 374 (human) 2 2.33 5.3E-4 1298132 D2S1399 Body fat amount abdominal baseline abdominal visceral fat, whites (Caucasian in original HERITAGE Study description) increased body weight;abnormal lateral ganglionic eminence morphology Obesity 1354697 11872690 733473 IRS1 2 134926654 160926654 3 - by peak only
2289316 human BW389_H Body weight QTL 389 (human) 4 1.34 0.00655 1299895 D4S2951 Body fat amount abdominal baseline abdominal subcutaneous fat, blacks abnormal lateral ganglionic eminence morphology;increased body weight Obesity 1354697 11872690 4 170397220 191273063 3 - by peak only
2289317 human BW379_H Body weight QTL 379 (human) 4 2.34 5.2E-4 1340836 D4S2431 Body fat amount abdominal baseline abdominal subcutaneous fat, blacks increased body weight;abnormal lateral ganglionic eminence morphology Obesity 1354697 11872690 732381 CPE 4 162057363 188057363 3 - by peak only
2289318 human BW377_H Body weight QTL 377 (human) 3 2.16 8.0E-4 1298277 D3S2387 Body fat amount abdominal baseline abdominal subcutaneous fat, blacks increased body weight;abnormal lateral ganglionic eminence morphology Obesity 1354697 11872690 3 1 14011366 3 - by peak only
2289319 human BW381_H Body weight QTL 381 (human) 5 1.84 0.00179 1341217 D5S658 Body fat amount abdominal Baseline abdominal total fat, whites (Caucasian in original HERITAGE Study description) abnormal lateral ganglionic eminence morphology;increased body weight Obesity 1354697 11872690 5 127353236 153353236 3 - by peak only
2289320 human BW390_H Body weight QTL 390 (human) 6 2.13 1335783 SE30 Body weight BMI (weight in kg divided by height in meters, squared) based on self-reported weight and height, which were highly correlated (0.92-0.93) with measured values increased body mass index Obesity 1642951 15181885
2289322 human BW372_H Body weight QTL 372 (human) 2 1.88 0.00164 1357238 D2S441 Body fat amount abdominal baseline abdominal subcutaneous fat, whites (Caucasian in original HERITAGE Study description) increased body weight;abnormal lateral ganglionic eminence morphology Obesity 1354697 11872690 2 55092581 81092581 3 - by peak only
2289323 human BW386_H Body weight QTL 386 (human) 14 2.38 4.7E-4 1337101 D14S588 Body fat amount abdominal baseline abdominal subcutaneous fat, blacks. abnormal lateral ganglionic eminence morphology;increased body weight Obesity 1354697 11872690 14 56290098 82290098 3 - by peak only
2301805 human PRSTS432_H Prostate tumor susceptibility QTL 432 (human) 8 0.005 1658291 D8S1135 Prostate tumor susceptibility Prostate cancer confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2301543 12244320 1347158 MSR1 8 3109992 29109992 3 - by peak only
2301806 human PRSTS437_H Prostate tumor susceptibility QTL 437 (human) 20 0.13 1340191 D20S186 Prostate tumor susceptibility Prostate cancer confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2301543;2301544 12244320;11409871 20 1 24471866 3 - by peak only
2301807 human PRSTS433_H Prostate tumor susceptibility QTL 433 (human) 20 0.11 1341027 D20S195 Prostate tumor susceptibility Prostate cancer confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2301544;2301543 11409871;12244320 20 18289479 44289479 3 - by peak only
2301808 human PRSTS435_H Prostate tumor susceptibility QTL 435 (human) 20 0.037 1335497 D20S889 Prostate tumor susceptibility Prostate cancer confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2301543;2301544 12244320;11409871 20 1 16895114 3 - by peak only
2301809 human PRSTS436_H Prostate tumor susceptibility QTL 436 (human) 20 0.15 1335293 D20S117 Prostate tumor susceptibility Prostate cancer confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2301543;2301544 12244320;11409871 20 1 13603206 3 - by peak only
2301810 human PRSTS434_H Prostate tumor susceptibility QTL 434 (human) 20 0.029 1340191 D20S186 Prostate tumor susceptibility Prostate cancer confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2301543;2301544 12244320;11409871 20 1 24471866 3 - by peak only
2299922 human PRSTS343_H Prostate tumor susceptibility QTL 343 (human) X 2.03 0.002 1340800 DXS984 1703132 DXS297 2121897 DXS6751 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2299892 9771711 X 139459424 145811809 1 - by flanking markers
2299923 human PRSTS341_H Prostate tumor susceptibility QTL 341 (human) X 2.34 0.001 1340800 DXS984 1337159 DXS8011 1340760 DXS8091 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2299892 9771711 X 139459424 154913754 2 - by one flank and peak markers
2299924 human PRSTS342_H Prostate tumor susceptibility QTL 342 (human) X 1.03 0.029 1340800 DXS984 1730812 DXS1108 1339855 DXS8069 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2299892 9771711 X 139459424 154515206 1 - by flanking markers
2299925 human PRSTS344_H Prostate tumor susceptibility QTL 344 (human) X 3.85 2.0E-5 1340800 DXS984 1336189 DXS1193 1703132 DXS297 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2299892 9771711 X 139459424 148188160 1 - by flanking markers
2299926 human PRSTS340_H Prostate tumor susceptibility QTL 340 (human) x 4.6 6.0E-5 1337237 DXS1200 1703132 DXS297 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2299892 9771711 X 145553035 145811809 1 - by flanking markers
2299927 human PRSTS345_H Prostate tumor susceptibility QTL 345 (human) X 2.46 1703132 DXS297 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2299892 9771711 X 132811713 154913754 3 - by peak only
2301799 human PRSTS429_H Prostate tumor susceptibility QTL 429 (human) 1 1.45 0.01 1335830 D1S514 Prostate tumor susceptibility Prostate cancer confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2301348 11379880 1 107070354 133070354 3 - by peak only
2301800 human PRSTS427_H Prostate tumor susceptibility QTL 427 (human) 1 2.76 4.0E-4 1337647 D1S413 Prostate tumor susceptibility Prostate cancer confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2301348 11379880 1346643 RNASEL 1 183887150 209887150 3 - by peak only
2301801 human PRSTS426_H Prostate tumor susceptibility QTL 426 (human) 1 6.0E-4 1337647 D1S413 Prostate tumor susceptibility Prostate cancer confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2301348 11379880 1346643 RNASEL 1 183887150 209887150 3 - by peak only
2301802 human PRSTS428_H Prostate tumor susceptibility QTL 428 (human) 1 3.05 2.0E-4 1337647 D1S413 1335951 D1S249 Prostate tumor susceptibility Prostate cancer confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2301348 11379880 1346643 RNASEL 1 196887027 203982277 1 - by flanking markers
2301803 human PRSTS431_H Prostate tumor susceptibility QTL 431 (human) 1 1.71 0.005 1335951 D1S249 Prostate tumor susceptibility Prostate cancer confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2301348 11379880 1 190982189 216982189 3 - by peak only
2301804 human PRSTS430_H Prostate tumor susceptibility QTL 430 (human) 1 2.93 2.0E-4 1341913 D1S1677 Prostate tumor susceptibility Prostate cancer confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2301348 11379880 1 148826426 174826426 3 - by peak only
2292945 human PRSTS170_H Prostate tumor susceptibility QTL 170 (human) 12 3.6 0.0015 Prostate tumor susceptibility Diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2292644 16328469
2292946 human PRSTS174_H Prostate tumor susceptibility QTL 174 (human) 20 3.16 8.0E-4 Prostate tumor susceptibility Diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2292644 16328469
2292947 human PRSTS130_H Prostate tumor susceptibility QTL 130 (human) 15 2.68 1337014 D15S128 Prostate tumor susceptibility Diagnosis confirmed by medical records or independent reports from 2 family members abnormal sciatic nerve Prostatic Neoplasms 2292069 15316059 15 9681992 35681992 3 - by peak only
2292948 human PRSTS109_H Prostate tumor susceptibility QTL 109 (human) 17 2.99 1340733 D17S1820 Prostate tumor susceptibility Diagnosis confirmed by medical records or independent reports from 2 family members abnormal sciatic nerve Prostatic Neoplasms 2292472;2292401 17120048;15988677 17 34139989 60139989 3 - by peak only
2292949 human PRSTS151_H Prostate tumor susceptibility QTL 151 (human) 16 5.13 5.5E-5 1336553 D16S503 Prostate tumor susceptibility Diagnosis confirmed by medical records, or independent reports from at least two family members abnormal sciatic nerve Prostatic Neoplasms 2292644 16328469 16 49156417 75156417 3 - by peak only
2292950 human PRSTS143_H Prostate tumor susceptibility QTL 143 (human) 13 6.12 1.5E-5 1337854 D13S1241 Prostate tumor susceptibility Diagnosis confirmed by medical records, or independent reports from at least two family members abnormal sciatic nerve Prostatic Neoplasms 2292644 16328469 13 83348448 109348448 3 - by peak only
2292951 human PRSTS141_H Prostate tumor susceptibility QTL 141 (human) 8 4.2E-9 Prostate tumor susceptibility Diagnosed with prostate cancer abnormal sciatic nerve Prostatic Neoplasms 2292606 16945910 731438 MYC
2292952 human PRSTS193_H Prostate tumor susceptibility QTL 193 (human) 17 4.51 0.0045 1334736 D17S787 Prostate tumor susceptibility Diagnosis confirmed by medical records or independent reports from at least two family members abnormal sciatic nerve Prostatic Neoplasms 2292644 16328469 17 37637158 63637158 3 - by peak only
2292953 human PRSTS184_H Prostate tumor susceptibility QTL 184 (human) 17 5.82 0.0053 1334736 D17S787 Prostate tumor susceptibility Diagnosis confirmed by medical records or independent reports from at least two family members abnormal sciatic nerve Prostatic Neoplasms 2292644 16328469 17 37637158 63637158 3 - by peak only
2292954 human PRSTS167_H Prostate tumor susceptibility QTL 167 (human) 13 5.69 2.0E-4 Prostate tumor susceptibility Diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2292644 16328469
2292955 human PRSTS145_H Prostate tumor susceptibility QTL 145 (human) 21 5.15 1.9E-5 1342402 D21S266 Prostate tumor susceptibility Diagnosis confirmed by medical records, or independent reports from at least two family members abnormal sciatic nerve Prostatic Neoplasms 2292644 16328469 21 28606510 46944323 3 - by peak only
2292956 human PRSTS159_H Prostate tumor susceptibility QTL 159 (human) 16 4.21 6.0E-4 Prostate tumor susceptibility Diagnosis confirmed by medical records, or independent reports from at least two family members abnormal sciatic nerve Prostatic Neoplasms 2292644 16328469
2292957 human PRSTS185_H Prostate tumor susceptibility QTL 185 (human) 4 5.82 0.0053 1331564 D4S403 Prostate tumor susceptibility Diagnosis confirmed by medical records or independent reports from at least two family members abnormal sciatic nerve Prostatic Neoplasms 2292644 16328469 4 360154 26360154 3 - by peak only
2292958 human PRSTS181_H Prostate tumor susceptibility QTL 181 (human) 2 6.18 0.0065 1338927 D2S391 Prostate tumor susceptibility Diagnosis confirmed by medical records or independent reports from at least two family members abnormal sciatic nerve Prostatic Neoplasms 2292644 16328469 2 33265079 59265079 3 - by peak only
2292959 human PRSTS124_H Prostate tumor susceptibility QTL 124 (human) 2 2.31 1298257 D2S117 Prostate tumor susceptibility Diagnosis confirmed by medical records or independent reports from 2 family members abnormal sciatic nerve Prostatic Neoplasms 2292069 15316059 2 182327142 208327142 3 - by peak only
2292960 human PRSTS137_H Prostate tumor susceptibility QTL 137 (human) 8 1.5E-4 Prostate tumor susceptibility Diagnosed with prostate cancer abnormal sciatic nerve Prostatic Neoplasms 2292606 16945910 731438 MYC
2292961 human PRSTS192_H Prostate tumor susceptibility QTL 192 (human) 11 4.51 0.0045 1298172 D11S901 Prostate tumor susceptibility Diagnosis confirmed by medical records or independent reports from at least two family members abnormal sciatic nerve Prostatic Neoplasms 2292644 16328469 11 68522518 94522518 3 - by peak only
2292962 human PRSTS161_H Prostate tumor susceptibility QTL 161 (human) 7 4.6 0.002 Prostate tumor susceptibility Diagnosis confirmed by medical records, or independent reports from at least two family members abnormal sciatic nerve Prostatic Neoplasms 2292644 16328469
2292963 human PRSTS178_H Prostate tumor susceptibility QTL 178 (human) 17 6.18 0.0033 1334736 D17S787 Prostate tumor susceptibility Diagnosis confirmed by medical records or independent reports from at least two family members abnormal sciatic nerve Prostatic Neoplasms 2292644 16328469 17 37637158 63637158 3 - by peak only
2292964 human PRSTS150_H Prostate tumor susceptibility QTL 150 (human) 20 5.13 5.5E-5 1335293 D20S117 Prostate tumor susceptibility Diagnosis confirmed by medical records, or independent reports from at least two family members abnormal sciatic nerve Prostatic Neoplasms 2292644 16328469 20 1 13603206 3 - by peak only
2292965 human PRSTS154_H Prostate tumor susceptibility QTL 154 (human) 11 2.27 0.06 Prostate tumor susceptibility Diagnosis confirmed by medical records, or independent reports from at least two family members abnormal sciatic nerve Prostatic Neoplasms 2292644 16328469
2292966 human PRSTS114_H Prostate tumor susceptibility QTL 114 (human) 17 3.85 1340733 D17S1820 Prostate tumor susceptibility Diagnosis confirmed by medical records or independent reports from 2 family members abnormal sciatic nerve Prostatic Neoplasms 2292472;2292401 17120048;15988677 17 34139989 60139989 3 - by peak only
2292967 human PRSTS164_H Prostate tumor susceptibility QTL 164 (human) 5 3.15 0.009 Prostate tumor susceptibility Diagnosis confirmed by medical records, or independent reports from at least two family members abnormal sciatic nerve Prostatic Neoplasms 2292644 16328469
2292970 human PRSTS134_H Prostate tumor susceptibility QTL 134 (human) 4 2.24 1336802 D4S1615 Prostate tumor susceptibility Diagnosis confirmed by medical records or independent reports from 2 family members abnormal sciatic nerve Prostatic Neoplasms 2292069 15316059 4 115429293 141429293 3 - by peak only
2292971 human PRSTS148_H Prostate tumor susceptibility QTL 148 (human) 8 5.66 8.3E-5 1336716 D8S514 Prostate tumor susceptibility Diagnosis confirmed by medical records, or independent reports from at least two family members abnormal sciatic nerve Prostatic Neoplasms 2292644 16328469 8 110811524 136811524 3 - by peak only
2292972 human PRSTS190_H Prostate tumor susceptibility QTL 190 (human) 4 4.13 0.0018 1337851 D4S426 Prostate tumor susceptibility Diagnosis confirmed by medical records or independent reports from at least two family members abnormal sciatic nerve Prostatic Neoplasms 2292644 16328469 4 176344813 191273063 3 - by peak only
2292973 human PRSTS189_H Prostate tumor susceptibility QTL 189 (human) 11 6.06 0.0029 1298172 D11S901 Prostate tumor susceptibility Diagnosis confirmed by medical records or independent reports from at least two family members abnormal sciatic nerve Prostatic Neoplasms 2292644 16328469 11 68522518 94522518 3 - by peak only
2292974 human PRSTS126_H Prostate tumor susceptibility QTL 126 (human) X 2.19 1337455 DXS1227 Prostate tumor susceptibility Diagnosis confirmed by medical records or independent reports from 2 family members abnormal sciatic nerve Prostatic Neoplasms 2292069 15316059 X 127630167 153630167 3 - by peak only
2292975 human PRSTS112_H Prostate tumor susceptibility QTL 112 (human) 17 2.55 1340733 D17S1820 Prostate tumor susceptibility Diagnosis confirmed by medical records or independent reports from 2 family members abnormal sciatic nerve Prostatic Neoplasms 2292472;2292401 17120048;15988677 17 34139989 60139989 3 - by peak only
2292976 human PRSTS162_H Prostate tumor susceptibility QTL 162 (human) 20 3.06 0.01 Prostate tumor susceptibility Diagnosis confirmed by medical records, or independent reports from at least two family members abnormal sciatic nerve Prostatic Neoplasms 2292644 16328469
2292977 human PRSTS107_H Prostate tumor susceptibility QTL 107 (human) 17 1.2 Prostate tumor susceptibility Diagnosis confirmed by medical records or independent reports from 2 family members abnormal sciatic nerve Prostatic Neoplasms 2292472;2292401 17120048;15988677
2292978 human PRSTS152_H Prostate tumor susceptibility QTL 152 (human) 5 5.94 1.0E-4 1336473 D5S426 Prostate tumor susceptibility Diagnosis confirmed by medical records, or independent reports from at least two family members abnormal sciatic nerve Prostatic Neoplasms 2292644 16328469 5 21798808 47798808 3 - by peak only
2292979 human PRSTS186_H Prostate tumor susceptibility QTL 186 (human) 17 5.75 0.0079 1334736 D17S787 Prostate tumor susceptibility Diagnosis confirmed by medical records or independent reports from at least two family members abnormal sciatic nerve Prostatic Neoplasms 2292644 16328469 17 37637158 63637158 3 - by peak only
2292980 human PRSTS115_H Prostate tumor susceptibility QTL 115 (human) 17 1.7 1340733 D17S1820 Prostate tumor susceptibility Diagnosis confirmed by medical records or independent reports from 2 family members abnormal sciatic nerve Prostatic Neoplasms 2292472;2292401 17120048;15988677 17 34139989 60139989 3 - by peak only
2292981 human PRSTS168_H Prostate tumor susceptibility QTL 168 (human) 22 3.43 1.0E-4 Prostate tumor susceptibility Diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2292644 16328469
2292982 human PRSTS144_H Prostate tumor susceptibility QTL 144 (human) 22 5.15 1.9E-5 1299924 D22S274 Prostate tumor susceptibility Diagnosis confirmed by medical records, or independent reports from at least two family members abnormal sciatic nerve Prostatic Neoplasms 2292644 16328469 22 30647918 49691432 3 - by peak only
2292983 human PRSTS127_H Prostate tumor susceptibility QTL 127 (human) 6 2.15 1341107 D6S287 Prostate tumor susceptibility Diagnosis confirmed by medical records or independent reports from 2 family members abnormal sciatic nerve Prostatic Neoplasms 2292069 15316059 6 106595555 132595555 3 - by peak only
2292984 human PRSTS165_H Prostate tumor susceptibility QTL 165 (human) 16 3.15 0.009 Prostate tumor susceptibility Diagnosis confirmed by medical records, or independent reports from at least two family members abnormal sciatic nerve Prostatic Neoplasms 2292644 16328469
2292985 human PRSTS156_H Prostate tumor susceptibility QTL 156 (human) 22 2.39 0.03 Prostate tumor susceptibility Diagnosis confirmed by medical records, or independent reports from at least two family members abnormal sciatic nerve Prostatic Neoplasms 2292644 16328469
2292986 human PRSTS183_H Prostate tumor susceptibility QTL 183 (human) 2 5.44 0.0026 1341679 D2S151 Prostate tumor susceptibility Diagnosis confirmed by medical records or independent reports from at least two family members abnormal sciatic nerve Prostatic Neoplasms 2292644 16328469 2 134503137 160503137 3 - by peak only
2292987 human PRSTS116_H Prostate tumor susceptibility QTL 116 (human) 17 5.49 1340733 D17S1820 Prostate tumor susceptibility Diagnosis confirmed by medical records or independent reports from 2 family members abnormal sciatic nerve Prostatic Neoplasms 2292472;2292401 17120048;15988677 17 34139989 60139989 3 - by peak only
2292988 human PRSTS122_H Prostate tumor susceptibility QTL 122 (human) 1 4.74 1340774 D1S407 Prostate tumor susceptibility Affected with prostate cancer abnormal sciatic nerve Prostatic Neoplasms 2292707 10053012
2292989 human PRSTS138_H Prostate tumor susceptibility QTL 138 (human) 8 3.4E-4 Prostate tumor susceptibility Diagnosed with prostate cancer abnormal sciatic nerve Prostatic Neoplasms 2292606 16945910 731438 MYC
2292990 human PRSTS147_H Prostate tumor susceptibility QTL 147 (human) 16 5.69 2.2E-5 1335604 D16S404 Prostate tumor susceptibility Diagnosis confirmed by medical records, or independent reports from at least two family members abnormal sciatic nerve Prostatic Neoplasms 2292644 16328469 16 1 22625957 3 - by peak only
2292991 human PRSTS133_H Prostate tumor susceptibility QTL 133 (human) 17 2.56 0.01 1334736 D17S787 Prostate tumor susceptibility Diagnosis confirmed by medical records or independent reports from 2 family members abnormal sciatic nerve Prostatic Neoplasms 2292069 15316059 69132 BRCA1 17 37637158 63637158 3 - by peak only
2292992 human PRSTS123_H Prostate tumor susceptibility QTL 123 (human) 17 2.32 0.03 1335855 D17S1868 1341417 D17S944 1334736 D17S787 Prostate tumor susceptibility Diagnosis confirmed by medical records or independent reports from 2 family members abnormal sciatic nerve Prostatic Neoplasms 2292069 15316059 69132 BRCA1 17 44539852 58790253 1 - by flanking markers
2292993 human PRSTS120_H Prostate tumor susceptibility QTL 120 (human) 1 3.65 1340774 D1S407 Prostate tumor susceptibility Affected with prostate cancer abnormal sciatic nerve Prostatic Neoplasms 2292707 10053012
2292994 human PRSTS146_H Prostate tumor susceptibility QTL 146 (human) 12 5.69 2.2E-5 1338105 D12S79 Prostate tumor susceptibility Diagnosis confirmed by medical records, or independent reports from at least two family members abnormal sciatic nerve Prostatic Neoplasms 2292644 16328469 12 101544922 127544922 3 - by peak only
2292995 human PRSTS176_H Prostate tumor susceptibility QTL 176 (human) 5 3.57 0.02 Prostate tumor susceptibility Diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2292644 16328469
2292996 human PRSTS108_H Prostate tumor susceptibility QTL 108 (human) 17 2.52 1340733 D17S1820 Prostate tumor susceptibility Diagnosis confirmed by medical records or independent reports from 2 family members abnormal sciatic nerve Prostatic Neoplasms 2292472;2292401 17120048;15988677 17 34139989 60139989 3 - by peak only
2292997 human PRSTS113_H Prostate tumor susceptibility QTL 113 (human) 17 3.24 1340733 D17S1820 Prostate tumor susceptibility Diagnosis confirmed by medical records or independent reports from 2 family members abnormal sciatic nerve Prostatic Neoplasms 2292472;2292401 17120048;15988677 17 34139989 60139989 3 - by peak only
2292998 human PRSTS153_H Prostate tumor susceptibility QTL 153 (human) 16 5.94 1.0E-4 1339571 D16S3103 Prostate tumor susceptibility Diagnosis confirmed by medical records, or independent reports from at least two family members abnormal sciatic nerve Prostatic Neoplasms 2292644 16328469 16 4381168 30381168 3 - by peak only
2292999 human PRSTS179_H Prostate tumor susceptibility QTL 179 (human) 17 6.18 0.0033 1334736 D17S787 Prostate tumor susceptibility Diagnosis confirmed by medical records or independent reports from at least two family members abnormal sciatic nerve Prostatic Neoplasms 2292644 16328469 17 37637158 63637158 3 - by peak only
2293000 human PRSTS117_H Prostate tumor susceptibility QTL 117 (human) 1 2.75 1336060 D1S218 Prostate tumor susceptibility Prostate cancer verified by medical records abnormal sciatic nerve Prostatic Neoplasms 2292628 8910276 734274;1315384;1342955;1352263 NTRK1;LAMC2;SKI;ABL2 1 159769894 185769894 3 - by peak only
2293001 human PRSTS160_H Prostate tumor susceptibility QTL 160 (human) 8 4.6 0.002 Prostate tumor susceptibility Diagnosis confirmed by medical records, or independent reports from at least two family members abnormal sciatic nerve Prostatic Neoplasms 2292644 16328469
2293002 human PRSTS171_H Prostate tumor susceptibility QTL 171 (human) 16 3.6 0.0015 Prostate tumor susceptibility Diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2292644 16328469
2293003 human PRSTS175_H Prostate tumor susceptibility QTL 175 (human) 16 3.16 8.0E-4 Prostate tumor susceptibility Diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2292644 16328469
2293004 human PRSTS125_H Prostate tumor susceptibility QTL 125 (human) 15 2.21 1337014 D15S128 Prostate tumor susceptibility Diagnosis confirmed by medical records or independent reports from 2 family members abnormal sciatic nerve Prostatic Neoplasms 2292069 15316059 15 9681992 35681992 3 - by peak only
2293005 human PRSTS135_H Prostate tumor susceptibility QTL 135 (human) 8 8.39 Prostate tumor susceptibility early onset Age at diagnosis less than 72 years abnormal sciatic nerve Prostatic Neoplasms 2292606 16945910 731438 MYC
2293007 human PRSTS169_H Prostate tumor susceptibility QTL 169 (human) 21 3.43 1.0E-4 Prostate tumor susceptibility Diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2292644 16328469
2293008 human PRSTS188_H Prostate tumor susceptibility QTL 188 (human) 17 6.06 0.0029 1334736 D17S787 Prostate tumor susceptibility Diagnosis confirmed by medical records or independent reports from at least two family members abnormal sciatic nerve Prostatic Neoplasms 2292644 16328469 17 37637158 63637158 3 - by peak only
2293009 human PRSTS194_H Prostate tumor susceptibility QTL 194 (human) 11 1.57 1298330 D11S987 Prostate tumor susceptibility Diagnosis confirmed by medical records or independent reports from at least two family members abnormal sciatic nerve Prostatic Neoplasms 2292644 16328469
2293010 human PRSTS111_H Prostate tumor susceptibility QTL 111 (human) 17 3.99 1340733 D17S1820 Prostate tumor susceptibility Diagnosis confirmed by medical records or independent reports from 2 family members abnormal sciatic nerve Prostatic Neoplasms 2292472;2292401 17120048;15988677 17 34139989 60139989 3 - by peak only
2289499 human BW445_H Body weight QTL 445 (human) 1 2.26 1339881 D1S1728 Body morphometry waist to hip ratio largest diameter between tenth rib and top of pelvis divided by largest diameter around buttocks increased body weight;increased body size Obesity 1643326 15534617
2289501 human BW444_H Body weight QTL 444 (human) 17 2.83 1341644 D17S1290 Body weight BMI weight (kg) divided by height in meters, squared increased body mass index Obesity 1643326 15534617 737129;736216;69010;1348512 PPY;HSD17B1;GCGR;PYY 17 40686541 66686541 3 - by peak only
2289503 human BW443_H Body weight QTL 443 (human) 3 3.7 1298277 D3S2387 Body weight BMI weight (kg) divided by height in meters, squared increased body mass index Obesity 1643326 15534617 69168;730950 PPARG;GHRL 3 1 14011366 3 - by peak only
2289599 human BW479_H Body weight QTL 479 (human) 20 1.0 1342225 D20S189 Body fat amount none dual energy X-ray absorptometry technique abnormal lateral ganglionic eminence morphology Obesity 1643357 16391564 20 1 24121953 3 - by peak only
2289601 human BW472_H Body weight QTL 472 (human) 10 1.2 1298105 D10S189 Body morphometry waist to hip ratio waist (smallest circumferance between tenth rib and iliac crest): hip (largest circumferance around buttocks) abnormal lateral ganglionic eminence morphology;abnormal body size Obesity 1643357 16391564 10 1 19762006 3 - by peak only
2289603 human BW478_H Body weight QTL 478 (human) 14 1.2 1334796 D14S261 Body fat amount abdominal intraabdominal fat, with some subcutaneous; dual energy X-ray absorptometry technique, assessed between top of 2nd and bottom of 4th lumbar vertebrae abnormal lateral ganglionic eminence morphology Obesity 1643357 16391564 14 6910386 32910386 3 - by peak only
2289604 human BW477_H Body weight QTL 477 (human) 14 2.1 1334796 D14S261 Body weight lean mass dual energy X-ray technique increased body weight;increased lean body mass Obesity 1643357 16391564 14 6910386 32910386 3 - by peak only
2300297 human PRSTS323_H Prostate tumor susceptibility QTL 323 (human) 10 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293520 14601030
2300298 human PRSTS326_H Prostate tumor susceptibility QTL 326 (human) X Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293520 14601030
2300299 human PRSTS322_H Prostate tumor susceptibility QTL 322 (human) 9 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293520 14601030
2300300 human PRSTS324_H Prostate tumor susceptibility QTL 324 (human) 22 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293520 14601030
2300301 human PRSTS317_H Prostate tumor susceptibility QTL 317 (human) 6 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293520 14601030
2300302 human PRSTS320_H Prostate tumor susceptibility QTL 320 (human) 6 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293520 14601030
2300303 human PRSTS327_H Prostate tumor susceptibility QTL 327 (human) X Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293520 14601030
2300304 human PRSTS318_H Prostate tumor susceptibility QTL 318 (human) X Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293520 14601030
2300305 human PRSTS321_H Prostate tumor susceptibility QTL 321 (human) 6 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293520 14601030
2300306 human PRSTS319_H Prostate tumor susceptibility QTL 319 (human) 2 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293520 14601030
2300307 human PRSTS325_H Prostate tumor susceptibility QTL 325 (human) X Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293520 14601030
2314547 human GLUCO51_H Glucose level QTL 51 (human) 10 1.0 1340909 D10S197 Glucose level Exercise induced change in Glucose effectiveness (SG) glucose homeostasis traits 2313873 15868134 10 13566984 39566984 3 - by peak only
2314549 human GLUCO54_H Glucose level QTL 54 (human) 13 1.0 1341425 D13S788 Glucose level Disposition index(DI) by glucose tolerance test, product of acute insulin response (AIRGlucose) and insulin sensitivity index (SI) glucose homeostasis traits 2313873 15868134 13 37790761 63790761 3 - by peak only
2314551 human GLUCO52_H Glucose level QTL 52 (human) 10 1.4 1341947 D10S2470 Glucose level Exercise induced change in Glucose effectiveness (SG) glucose homeostasis traits 2313873 15868134
2314552 human GLUCO56_H Glucose level QTL 56 (human) 19 3.1 1335633 D19S254 Glucose level Exercise induced change in Glucose effectiveness (SG) glucose homeostasis traits 2313873 15868134 19 49358819 63811651 3 - by peak only
2314553 human INSUL3_H Insulin level QTL 3 (human) 16 2.8 4.8E-4 1341614 D16S2622 Insulin level fasting Fasting insulin decreased circulating insulin level;glucose homeostasis traits 2313848 11880950 16 1 16649765 3 - by peak only
2314555 human GLUCO53_H Glucose level QTL 53 (human) 12 1.3 1339529 D12S1604 Glucose level Exercise induced change in Glucose effectiveness (SG) glucose homeostasis traits 2313873 15868134 12 39014370 65014370 3 - by peak only
2314556 human GLUCO45_H Glucose level QTL 45 (human) 10 1.1 1336158 D10S191 Glucose level Exercise induced change in Disposition Index(DI) which is the product of acute insulin response (AIRGlucose) and insulin sensitivity index (SI) glucose homeostasis traits 2313873 15868134 10 1599737 27599737 3 - by peak only
2314558 human GLUCO46_H Glucose level QTL 46 (human) 12 1.1 1357235 D12S2078 Glucose level Exercise induced change in Disposition Index(DI) which is the product of acute insulin response (AIRGlucose) and insulin sensitivity index (SI) glucose homeostasis traits 2313873 15868134 12 113527222 132349534 3 - by peak only
2292912 human PRSTS173_H Prostate tumor susceptibility QTL 173 (human) 7 2.15 0.07 Prostate tumor susceptibility Diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2292644 16328469
2292914 human PRSTS129_H Prostate tumor susceptibility QTL 129 (human) X 2.12 1337455 DXS1227 Prostate tumor susceptibility Diagnosis confirmed by medical records or independent reports from 2 family members abnormal sciatic nerve Prostatic Neoplasms 2292069 15316059 X 127630167 153630167 3 - by peak only
2292916 human PRSTS172_H Prostate tumor susceptibility QTL 172 (human) 8 2.15 0.07 Prostate tumor susceptibility Diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2292644 16328469
2292917 human PRSTS128_H Prostate tumor susceptibility QTL 128 (human) 17 2.2 1341417 D17S944 Prostate tumor susceptibility Diagnosis confirmed by medical records or independent reports from 2 family members abnormal sciatic nerve Prostatic Neoplasms 2292069 15316059 69132 BRCA1 17 45790145 71790145 3 - by peak only
2292918 human PRSTS142_H Prostate tumor susceptibility QTL 142 (human) 11 6.12 1.5E-5 1298330 D11S987 Prostate tumor susceptibility Diagnosis confirmed by medical records, or independent reports from at least two family members abnormal sciatic nerve Prostatic Neoplasms 2292644 16328469
2292920 human PRSTS119_H Prostate tumor susceptibility QTL 119 (human) 1 2.13 0.02 1336052 D1S1597 Prostate tumor susceptibility Affected with prostate cancer abnormal sciatic nerve Prostatic Neoplasms 2292707 10053012 1 656858 26656858 3 - by peak only
2292922 human PRSTS136_H Prostate tumor susceptibility QTL 136 (human) 8 5.4 Prostate tumor susceptibility early onset Peak LOD score for this location occurs when considering patients diagnosed at 71 or less years of age; abnormal sciatic nerve Prostatic Neoplasms 2292606 16945910 731438 MYC
2292924 human PRSTS157_H Prostate tumor susceptibility QTL 157 (human) 21 2.39 0.03 Prostate tumor susceptibility Diagnosis confirmed by medical records, or independent reports from at least two family members abnormal sciatic nerve Prostatic Neoplasms 2292644 16328469
2292925 human PRSTS110_H Prostate tumor susceptibility QTL 110 (human) 17 3.15 1340733 D17S1820 Prostate tumor susceptibility Diagnosis confirmed by medical records or independent reports from 2 family members abnormal sciatic nerve Prostatic Neoplasms 2292472;2292401 17120048;15988677 17 34139989 60139989 3 - by peak only
2292926 human PRSTS121_H Prostate tumor susceptibility QTL 121 (human) 1 3.22 1336132 D1S507 Prostate tumor susceptibility Affected with prostate cancer abnormal sciatic nerve Prostatic Neoplasms 2292707 10053012 1 1901462 27901462 3 - by peak only
2292927 human PRSTS191_H Prostate tumor susceptibility QTL 191 (human) 17 4.13 0.0018 1334736 D17S787 Prostate tumor susceptibility Diagnosis confirmed by medical records or independent reports from at least two family members abnormal sciatic nerve Prostatic Neoplasms 2292644 16328469 17 37637158 63637158 3 - by peak only
2292929 human PRSTS132_H Prostate tumor susceptibility QTL 132 (human) 8 1.72 1334607 D8S1771 Prostate tumor susceptibility Diagnosis confirmed by medical records or independent reports from 2 family members abnormal sciatic nerve Prostatic Neoplasms 2292069 15316059 8 12497264 38497264 3 - by peak only
2292930 human PRSTS131_H Prostate tumor susceptibility QTL 131 (human) 2 1.86 1298257 D2S117 Prostate tumor susceptibility Diagnosis confirmed by medical records or independent reports from 2 family members abnormal sciatic nerve Prostatic Neoplasms 2292069 15316059 2 182327142 208327142 3 - by peak only
2292931 human PRSTS155_H Prostate tumor susceptibility QTL 155 (human) 13 2.27 0.06 Prostate tumor susceptibility Diagnosis confirmed by medical records, or independent reports from at least two family members abnormal sciatic nerve Prostatic Neoplasms 2292644 16328469
2292932 human PRSTS163_H Prostate tumor susceptibility QTL 163 (human) 16 3.06 0.01 Prostate tumor susceptibility Diagnosis confirmed by medical records, or independent reports from at least two family members abnormal sciatic nerve Prostatic Neoplasms 2292644 16328469
2292933 human PRSTS182_H Prostate tumor susceptibility QTL 182 (human) 17 5.44 0.0026 1334736 D17S787 Prostate tumor susceptibility Diagnosis confirmed by medical records or independent reports from at least two family members abnormal sciatic nerve Prostatic Neoplasms 2292644 16328469 17 37637158 63637158 3 - by peak only
2292934 human PRSTS166_H Prostate tumor susceptibility QTL 166 (human) 11 5.69 2.0E-4 Prostate tumor susceptibility Diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2292644 16328469
2292935 human PRSTS187_H Prostate tumor susceptibility QTL 187 (human) 8 5.75 0.0079 1334607 D8S1771 Prostate tumor susceptibility Diagnosis confirmed by medical records or independent reports from at least two family members abnormal sciatic nerve Prostatic Neoplasms 2292644 16328469 8 12497264 38497264 3 - by peak only
2292936 human PRSTS118_H Prostate tumor susceptibility QTL 118 (human) 1 5.43 1340333 D1S422 Prostate tumor susceptibility Prostate cancer verified by medical records abnormal sciatic nerve Prostatic Neoplasms 2292628 8910276 734274;1315384;1342955;1352263 NTRK1;LAMC2;SKI;ABL2 1 176645553 202645553 3 - by peak only
2292938 human PRSTS149_H Prostate tumor susceptibility QTL 149 (human) 7 5.66 8.3E-5 1299970 D7S669 Prostate tumor susceptibility Diagnosis confirmed by medical records, or independent reports from at least two family members abnormal sciatic nerve Prostatic Neoplasms 2292644 16328469 7 64710512 90710512 3 - by peak only
2292939 human PRSTS140_H Prostate tumor susceptibility QTL 140 (human) 8 0.022 Prostate tumor susceptibility Diagnosed with prostate cancer abnormal sciatic nerve Prostatic Neoplasms 2292606 16945910 731438 MYC
2292940 human PRSTS177_H Prostate tumor susceptibility QTL 177 (human) 16 3.57 0.02 Prostate tumor susceptibility Diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2292644 16328469
2292941 human PRSTS139_H Prostate tumor susceptibility QTL 139 (human) 8 0.0014 Prostate tumor susceptibility Diagnosed with prostate cancer abnormal sciatic nerve Prostatic Neoplasms 2292606 16945910 731438 MYC
2292942 human PRSTS195_H Prostate tumor susceptibility QTL 195 (human) 11 1.28 1298330 D11S987 Prostate tumor susceptibility Diagnosis confirmed by medical records or independent reports from at least two family members abnormal sciatic nerve Prostatic Neoplasms 2292644 16328469
2292943 human PRSTS158_H Prostate tumor susceptibility QTL 158 (human) 12 4.21 6.0E-4 Prostate tumor susceptibility Diagnosis confirmed by medical records, or independent reports from at least two family members abnormal sciatic nerve Prostatic Neoplasms 2292644 16328469
2292944 human PRSTS180_H Prostate tumor susceptibility QTL 180 (human) 17 6.18 0.0065 1334736 D17S787 Prostate tumor susceptibility Diagnosis confirmed by medical records or independent reports from at least two family members abnormal sciatic nerve Prostatic Neoplasms 2292644 16328469 17 37637158 63637158 3 - by peak only
2314559 human INSUL2_H Insulin level QTL 2 (human) 1 1.0 0.039 1338577 D1S2644 Insulin level fasting Fasting insulin decreased circulating insulin level;glucose homeostasis traits 2313848 11880950 1 5899200 31899200 3 - by peak only
2314560 human GLUCO48_H Glucose level QTL 48 (human) 1 1.7 1335946 D1S2682 Glucose level Exercise induced change in Glucose effectiveness (SG) glucose homeostasis traits 2313873 15868134 1 233196984 247249719 3 - by peak only
2314561 human GLUCO47_H Glucose level QTL 47 (human) 1 1.1 1337417 D1S476 Glucose level Exercise induced change in Glucose effectiveness (SG) glucose homeostasis traits 2313873 15868134 1 45011640 71011640 3 - by peak only
2314562 human GLUCO57_H Glucose level QTL 57 (human) 20 1.1 1339243 D20S481 Glucose level Training induced change in Insulin sensitivity (SI) by glucose tolerance test glucose homeostasis traits 2313873 15868134 20 30201813 56201813 3 - by peak only
2314564 human GLUCO44_H Glucose level QTL 44 (human) 7 1.4 1298320 D7S821 Glucose level Exercise induced change in Disposition Index(DI) which is the product of acute insulin response (AIRGlucose) and insulin sensitivity index (SI) glucose homeostasis traits 2313873 15868134 7 82895575 108895575 3 - by peak only
2314565 human GLUCO50_H Glucose level QTL 50 (human) 6 1.0 1298133 D6S2239 Glucose level Disposition index(DI) by glucose tolerance test, product of acute insulin response (AIRGlucose) and insulin sensitivity index (SI) glucose homeostasis traits 2313873 15868134
2314566 human INSUL8_H Insulin level QTL 8 (human) 18 1.1 1336696 D18S535 Insulin level Acute insulin response to glucose (AIRGlucose)(insulin secretion) response to exercise training glucose homeostasis traits 2313873 15868134 18 23402859 49402859 3 - by peak only
2314568 human GLUCO38_H Glucose level QTL 38 (human) 9 1.9 0.00156 1336757 D9S1817 Glucose level Glucose effectiveness(SG) by glucose tolerance test glucose homeostasis traits 2313853 12601641 9 20849756 46849756 3 - by peak only
2314570 human INSUL12_H Insulin level QTL 12 (human) 2 2.62 0.031075 1298104 D2S1790 Insulin level insulin resistance HOMA-IR, calculated as fasting insulin multiplied by fasting glucose, divided by 22.5 glucose homeostasis traits 2313904 15734873 2 71928947 97928947 3 - by peak only
2314572 human GLUCO40_H Glucose level QTL 40 (human) 13 2.08 9.8E-4 1335651 D13S892 Glucose level Disposition index(DI) by glucose tolerance test, product of acute insulin response (AIRGlucose) and insulin sensitivity index (SI) glucose homeostasis traits 2313853 12601641 13 83749941 109749941 3 - by peak only
2314573 human GLUCO60_H Glucose level QTL 60 (human) 19 3.33 0.016545 1331580 D19S589 Glucose level fasting Fasting glucose (at least 8 hour fast) glucose homeostasis traits 2313904 15734873 19 45475329 63811651 3 - by peak only
2314575 human INSUL11_H Insulin level QTL 11 (human) 7 2.26 0.057268 1299920 D7S3070 Insulin level fasting Fasting insulin (at least 8 hour fast) glucose homeostasis traits 2313904 15734873 7 138198143 158821424 3 - by peak only
2314577 human GLUCO59_H Glucose level QTL 59 (human) 7 2.31 0.068 1299920 D7S3070 Glucose level fasting Fasting glucose (at least 8 hour fast) glucose homeostasis traits 2313904 15734873 7 138198143 158821424 3 - by peak only
2314578 human INSUL7_H Insulin level QTL 7 (human) 15 1.0 1336799 D15S117 Insulin level Acute insulin response to glucose (AIRGlucose)(insulin secretion) response to exercise training glucose homeostasis traits 2313873 15868134 15 43267017 69267017 3 - by peak only
2314579 human GLUCO58_H Glucose level QTL 58 (human) 22 1.1 1341006 D22S421 Glucose level Insulin sensitivity (SI) by glucose tolerance test pre- and post-training glucose homeostasis traits 2313873 15868134 22 11282272 37282272 3 - by peak only
2314581 human INSUL5_H Insulin level QTL 5 (human) 4 1.79 0.00204 1331597 D4S2417 Insulin level insulin secretion Acute insulin response to glucose (AIRGlucose) was computed as the incremental integrated area under the insulin curve for the first 10 minutes of the intravenous glucose tolerance test glucose homeostasis traits 2313853 12601641
2314583 human GLUCO43_H Glucose level QTL 43 (human) 6 1.2 1336249 D6S1660 1298134 D6S1017 1336009 D6S299 Glucose level Exercise induced change in Disposition Index(DI) which is the product of acute insulin response (AIRGlucose) and insulin sensitivity index (SI) glucose homeostasis traits 2313873 15868134 6 23421875 41785332 1 - by flanking markers
2314584 human INSUL10_H Insulin level QTL 10 (human) 4 2.48 0.057268 1642896 D4S3243 Insulin level fasting Fasting insulin (at least 8 hour fast) glucose homeostasis traits 2313904 15734873
2314585 human INSUL9_H Insulin level QTL 9 (human) 2 2.35 0.057268 1299929 D2S1777 Insulin level fasting Fasting insulin (at least 8 hour fast) glucose homeostasis traits 2313904 15734873 2 65374039 91374039 3 - by peak only
2314586 human GLUCO41_H Glucose level QTL 41 (human) 1 1.2 1342100 D1S1622 Glucose level Exercise induced change in Disposition Index(DI) which is the product of acute insulin response (AIRGlucose) and insulin sensitivity index (SI) glucose homeostasis traits 2313873 15868134 1 17083670 43083670 3 - by peak only
2314587 human GLUCO37_H Glucose level QTL 37 (human) 8 2.23 6.8E-4 1298326 D8S277 Glucose level insulin sensitivity Insulin sensitivity (SI) by glucose tolerance test glucose homeostasis traits 2313853 12601641 8 1 19504205 3 - by peak only
2314589 human INSUL6_H Insulin level QTL 6 (human) 10 1.78 0.00212 2173121 D10S1435 Insulin level insulin secretion (AIRGlucose) was computed as the incremental integrated area under the insulin curve for the first 10 minutes of the intravenous glucose tolerance test glucose homeostasis traits 2313853 12601641 10 1 15233400 3 - by peak only
2314591 human INSUL4_H Insulin level QTL 4 (human) 19 3.8 3.8E-5 1334592 D19S591 Insulin level fasting Fasting insulin decreased circulating insulin level;glucose homeostasis traits 2313848 11880950
2314592 human GLUCO42_H Glucose level QTL 42 (human) 3 1.2 1338430 D3S1279 Glucose level Exercise induced change in Disposition Index(DI) which is the product of acute insulin response (AIRGlucose) and insulin sensitivity index (SI) glucose homeostasis traits 2313873 15868134 3 139508089 165508089 3 - by peak only
2314593 human GLUCO36_H Glucose level QTL 36 (human) 1 1.89 0.0016 1337995 D1S2703 Glucose level insulin sensitivity Insulin sensitivity (SI) by glucose tolerance test glucose homeostasis traits 2313853 12601641 1 198156185 224156185 3 - by peak only
2314594 human INSUL13_H Insulin level QTL 13 (human) 7 3.21 0.022266 1299920 D7S3070 Insulin level insulin resistance HOMA-IR, calculated as fasting insulin multiplied by fasting glucose, divided by 22.5 glucose homeostasis traits 2313904 15734873 7 138198143 158821424 3 - by peak only
2314595 human GLUCO49_H Glucose level QTL 49 (human) 2 1.5 1337629 D2S2374 Glucose level Exercise induced change in Glucose effectiveness (SG) glucose homeostasis traits 2313873 15868134 2 22563486 48563486 3 - by peak only
2314596 human GLUCO55_H Glucose level QTL 55 (human) 15 1.0 2113862 IGF1R Glucose level Exercise induced change in Glucose effectiveness (SG) glucose homeostasis traits 2313873 15868134 15 42367071 68367071 3 - by peak only
2314597 human GLUCO39_H Glucose level QTL 39 (human) 10 1.8 0.002 1338521 D10S1230 Glucose level insulin sensitivity Insulin sensitivity(SI) by glucose tolerance test glucose homeostasis traits 2313853 12601641 10 109732744 135374737 3 - by peak only
2314763 human GLUCO104_H Glucose level QTL 104 (human) 12 1339759 D12S1691 1341685 D12S375 1338208 D12S1684 Glucose level non-insulin dependent Diabetes or impaired glucose tolerance (WHO criteria), fasting serum glucose exceeded 7 mmol/l, or HbA1c greater than 7.0%, or use of insulin or hypoglycaemic agents glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 2314153 10535461 12 55792133 67231192 1 - by flanking markers
2314765 human GLUCO100_H Glucose level QTL 100 (human) 8 3.1 0.003 1298285 D8S1110 Glucose level non-insulin dependent Diagnosed with diabetes mellitus (WHO criteria), likely Type 1 diabetics excluded glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 2313993 15561964 732290;737467 FGFR1;ADRB3 8 40343661 66343661 3 - by peak only
2314767 human GLUCO102_H Glucose level QTL 102 (human) 17 3.0 1299913 D17S947 Glucose level non-insulin dependent Participants who reported using hypoglycaemic medications and/or whose fasting glucose exceeded 7 mmol/l, excluding those diagnosed at less than 30 years of age glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 2314150 16906437 17 1 25747231 3 - by peak only
2314769 human GLUCO98_H Glucose level QTL 98 (human) 17 2.7 1331576 D17S1294 Glucose level non-insulin dependent Diagnosed with diabetes mellitus (WHO criteria), likely Type 1 diabetics excluded glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 2313993 15561964 17 12406428 38406428 3 - by peak only
2314770 human GLUCO105_H Glucose level QTL 105 (human) 12 0.002 1339759 D12S1691 1341685 D12S375 1338208 D12S1684 Glucose level non-insulin dependent Diabetes or impaired glucose tolerance (WHO criteria), fasting serum glucose exceeded 7 mmol/l, or HbA1c greater than 7.0%, or use of insulin or hypoglycaemic agents glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 2314153 10535461 12 55792133 67231192 1 - by flanking markers
2314771 human GLUCO108_H Glucose level QTL 108 (human) 8 1.77 1298096 D8S549 Glucose level non-insulin dependent Diagnosed with type 2 diabetes, or fasting plasma glucose of 7 mmol/l or more, no history of ketosis, normal or unaffected subjects with fasting plasma glucose of 6 mmol/l or less glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 2314160 11742441 70836 LPL 8 2694056 28694056 3 - by peak only
2314773 human GLUCO107_H Glucose level QTL 107 (human) 3 1.8 1298243 D3S1311 Glucose level non-insulin dependent Diagnosed with type 2 diabetes, or fasting plasma glucose of 7 mmol/l or more, no history of ketosis, normal or unaffected subjects with fasting plasma glucose of 6 mmol/l or less glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 2314160 11742441 1343622 PPP1R2 3 185502595 199501827 3 - by peak only
2314774 human GLUCO103_H Glucose level QTL 103 (human) 17 2.2 1331576 D17S1294 Glucose level non-insulin dependent Participants who reported using hypoglycaemic medications and/or whose fasting glucose exceeded 7 mmol/l, excluding those diagnosed at less than 30 years of age glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 2314150 16906437 17 12406428 38406428 3 - by peak only
2314775 human GLUCO99_H Glucose level QTL 99 (human) 17 3.0 0.003 1331576 D17S1294 Glucose level non-insulin dependent Diagnosed with diabetes mellitus (WHO criteria), likely Type 1 diabetics excluded glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 2313993 15561964 17 12406428 38406428 3 - by peak only
2314776 human GLUCO101_H Glucose level QTL 101 (human) 8 2.5 1298285 D8S1110 Glucose level non-insulin dependent Diagnosed with diabetes mellitus (WHO criteria), likely Type 1 diabetics excluded glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 2313993 15561964 732290;737467 FGFR1;ADRB3 8 40343661 66343661 3 - by peak only
2314777 human GLUCO106_H Glucose level QTL 106 (human) 2 3.9 1336069 D2S2330 1338140 D2S2345 Glucose level non-insulin dependent Diagnosed with type 2 diabetes, or fasting plasma glucose of 7 mmol/l or more, no history of ketosis, normal or unaffected subjects with fasting plasma glucose of 6 mmol/l or less glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 2314160 11742441 732013;733789;737186;1344189 GRB14;KCNJ3;GPD2;G6PC2 2 166405834 168428817 1 - by flanking markers
2314778 human GLUCO97_H Glucose level QTL 97 (human) 22 3.4 0.001 1340346 D22S689 Glucose level non-insulin dependent Diagnosed with diabetes mellitus (WHO criteria), likely Type 1 diabetics excluded glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 2313993 15561964 735333;736774;1343358;1348736 GALR3;LIF;APOL4;APOL1 22 14186571 40186571 3 - by peak only
2289624 human BW483_H Body weight QTL 483 (human) 2 3.3 1334875 D2S2739 Body fat amount percent fat bioelectric impedance analysis was used to estimate fat mass; percent fat is fat mass divided by body mass increased percent body fat Obesity 1643407 15611782 2 36475831 62475831 3 - by peak only
2289625 human BW481_H Body weight QTL 481 (human) 1 1.56 1336087 D1S1589 1298271 D1S518 Body weight BMI weight (kg) divided by height in meters, squared increased body mass index Obesity 1643407 15611782 736008;735774 ATP1A2;ATP1B1 1 172527725 185817119 1 - by flanking markers
2289626 human BW484_H Body weight QTL 484 (human) 4 2.39 1298248 D4S1647 1338978 D4S2623 Body fat amount percent fat bioelectric impedance analysis was used to estimate fat mass; percent fat is fat mass divided by body mass increased percent body fat Obesity 1643407 15611782 4 99653996 111109439 1 - by flanking markers
2289627 human BW482_H Body weight QTL 482 (human) 2 2.56 1334875 D2S2739 1357238 D2S441 Body fat amount none bioelectric impedance analysis was used to estimate fat mass abnormal lateral ganglionic eminence morphology Obesity 1643407 15611782 2 49475690 68092661 1 - by flanking markers
2289628 human BW500_H Body weight QTL 500 (human) 12 3.8 1341328 D12S395 1357235 D12S2078 Body fat amount percent fat estimated from bioelectrical impedance abnormal percent body fat;obese Obesity 1643421 15809668 731908;735633 ACACB;SCARB1 12 118672849 126527352 1 - by flanking markers
2289630 human BW501_H Body weight QTL 501 (human) 12 2.4 1341328 D12S395 1357235 D12S2078 Body fat amount percent fat estimated from bioelectrical impedance abnormal percent body fat;obese Obesity 1643421 15809668 731908;735633 ACACB;SCARB1 12 118672849 126527352 1 - by flanking markers
2289631 human BW503_H Body weight QTL 503 (human) 15 3.0 1337510 D15S655 Body fat amount percent fat estimated from bioelectrical impedance abnormal percent body fat;obese Obesity 1643421 15809668 733482 PLIN 15 72777192 98777192 3 - by peak only
2289632 human BW502_H Body weight QTL 502 (human) 12 1.5 1341328 D12S395 1357235 D12S2078 Body fat amount percent fat estimated from bioelectrical impedance abnormal percent body fat;obese Obesity 1643421 15809668 731908;735633 ACACB;SCARB1 12 118672849 126527352 1 - by flanking markers
2289633 human BW506_H Body weight QTL 506 (human) 3 2.8 1298169 D3S2427 Body weight BMI weight in kg divided by square of height in meters obese;increased body mass index Obesity 1643421 15809668 1351472 ADIPOQ 3 164267613 190267613 3 - by peak only
2289635 human BW505_H Body weight QTL 505 (human) 15 1.8 1337510 D15S655 Body fat amount percent fat estimated from bioelectrical impedance abnormal percent body fat;obese Obesity 1643421 15809668 733482 PLIN 15 72777192 98777192 3 - by peak only
2289636 human BW504_H Body weight QTL 504 (human) 15 1.1 1337510 D15S655 Body fat amount percent fat estimated from bioelectrical impedance abnormal percent body fat;obese Obesity 1643421 15809668 733482 PLIN 15 72777192 98777192 3 - by peak only
2289640 human BW510_H Body weight QTL 510 (human) 18 2.6 1298292 D18S858 Body weight BMI bivariate LOD; weight in kg divided by square of height in meters, along with systolic blood pressure change in response to a supine to standing posture change increased body mass index;decreased systemic arterial systolic blood pressure Obesity 1298212 14967843 733058 MC4R 18 40048190 66048190 3 - by peak only
2289642 human BW507_H Body weight QTL 507 (human) 2 2.91 1335090 D2S165 Body weight BMI weight (kg) divided by square of height (meters) obese;increased body mass index Obesity 1643431 16731856 1352097 POMC 2 15457029 41457029 3 - by peak only
2289644 human BW509_H Body weight QTL 509 (Human) 13 3.2 1341616 D13S1493 Body weight BMI bivariate LOD; weight in kg divided by square of height in meters, along with systolic blood pressure change in response to a supine to standing posture change increased body mass index;decreased systemic arterial systolic blood pressure Obesity 1298212 14967843 736367 PDX1 13 19907040 45907040 3 - by peak only
2289645 human BW511_H Body Weight QTL 511 (human) 13 2.4 1341616 D13S1493 Body weight BMI weight in kg divided by square of height in meters. increased body mass index Obesity 1298212 14967843 736367 PDX1 13 19907040 45907040 3 - by peak only
2289647 human INSUL1_H Insulin level QTL 1 (human) 2 3.0 1335090 D2S165 Insulin level fasting units of microunit/milliliter abnormal circulating insulin level Diabetes Mellitus;Obesity 1643431 16731856 1352097 POMC additive 2 15457029 41457029 3 - by peak only
2289649 human BW508_H Body weight QTL 508 (human) 2 3.43 1335090 D2S165 Body fat amount none log fasting insulin plus body fat estimated from bioelectric impedance measurement, adjusted for population obese;abnormal percent body fat Obesity 1643431 16731856 1352097 POMC 2 15457029 41457029 3 - by peak only
2289564 human BW489_H Body weight QTL 489 (human) 4 2.6 1337288 D4S1535 Body weight BMI Weight in kilograms divided by the square of height in meters increased body mass index Obesity 1643430 17636092 4 172472997 191273063 3 - by peak only
2289566 human BW490_H Body weight QTL 490 (human) 4 1.52 1337288 D4S1535 Body weight none Weight in kilograms divided by the square of height in meters increased body weight Obesity 1643430 17636092 4 172472997 191273063 3 - by peak only
2289408 human BW324_H Body weight QTL 324 (human) 6 3.15 1.0E-4 1353193 BMP6 Body fat amount Body fat mass in grams measured by dual-energy x-ray scanners abnormal lateral ganglionic eminence morphology Obesity 1643174 17473065 1607074 PECI 6 1 20749367 3 - by peak only
2289409 human BW320_H Body weight QTL 320 (human) 5 3.5 2.0E-4 1323642 CPEB4 Body weight lean mass Lean body mass was measured by dual-energy X-ray absorptiometry (DEXA) increased lean body mass Obesity 1643170 17115187 68511 PTTG1 5 160284356 180857866 3 - by peak only
2289410 human BW327_H Body weight QTL 327 (human) 15 3.32 1.0E-4 1606398 FMN1 Body fat amount Body fat mass in grams measured by dual-energy x-ray scanners abnormal lateral ganglionic eminence morphology Obesity 1643174 17473065 15 18000507 44000507 3 - by peak only
2289411 human BW193_H Body weight QTL 193 (human) 13 0.0236 2162974 D13S894 Body weight BMI Body mass index (BMI) measured as (weight in kg)/(height in meters)2; linkage to the qualitative trait assessed using dichotomized phenotypes with individuals having BMI>=27 considered affected increased body mass index Obesity 1334490 14988268 734107 HTR2A 13 24636607 50636607 3 - by peak only
2289412 human BW408_H Body weight QTL 408 (human) 8 1.54 1334535 D8S272 Body fat amount percent fat fat mass measured by DXA divided by body weight measured by DXA increased percent body fat Obesity 738102 11923910 8 124804652 146274826 3 - by peak only
2289414 human BW405_H Body weight QTL 405 (human) 8 1.95 0.014 1298096 D8S549 Body fat amount none fat mass measured by DXA abnormal lateral ganglionic eminence morphology Obesity 738102 11923910 8 2694056 28694056 3 - by peak only
2289416 human BW158_H Body weight QTL 158 (human) 10 0.0248 1645904 D10S670 Body weight BMI Body mass index (BMI) measured as kg/m2 increased body mass index Obesity 1642891 9915959 10 99381863 125381863 3 - by peak only
2289417 human BW411_H Body weight QTL 411 (human) 7 1.52 1340238 D7S613 1340763 D7S517 Body weight lean mass lean mass measured by DXA increased lean body mass Obesity 738102;738106 11923910;14764808 7 1 73210124 2 - by one flank and peak markers
2289419 human BW402_H Body weight QTL 402 (human) 2 1.91 1298118 D2S347 Body fat amount percent fat fat mass measured by DXA divided by body weight measured by DXA increased percent body fat Obesity 738102 11923910 2 110966452 136966452 3 - by peak only
2289420 human BW314_H Body weight QTL 314 (human) 15 2.72 3.0E-4 1606398 FMN1 Body weight lean mass Lean body mass was measured by dual-energy X-ray absorptiometry (DEXA) increased lean body mass Obesity 1643170 17115187 15 18000507 44000507 3 - by peak only
2289421 human BW399_H Body weight QTL 399 (human) 4 2.29 1298205 D4S391 1298176 D4S1534 1298203 D4S1592 Body weight BMI weight(kg) divided by height(m)2 increased body weight;increased body mass index Obesity 738102;738106 11923910;14764808 4 27221423 86527489 1 - by flanking markers
2289440 human BW416_H Body weight QTL 416 (human) 4 1.58 1298203 D4S1592 Body weight BMI weight(kg) divided by height (m)2 increased body mass index Obesity 738106 14764808 4 44376666 70376666 3 - by peak only
2289442 human BW407_H Body weight QTL 407 (human) 5 1.59 1299941 D5S407 Body weight lean mass lean mass measured by DXA increased lean body mass Obesity 738102 11923910 5 43030583 69030583 3 - by peak only
2289443 human BW413_H Body weight QTL 413 (human) 1 2.32 1298152 D1S214 1298138 D1S468 Body weight BMI weight(kg) divided by height (m)2 increased body mass index Obesity 738106 14764808 735832;732873;1298224 LEPR;NR0B2;TNFRSF1B 1 265020 6884796 2 - by one flank and peak markers
2289568 human BW493_H Body weight QTL 493 (human) 5 2.59 1336473 D5S426 Body weight BMI Weight in kilograms divided by square of height in meters increased body mass index Obesity 1643430 17636092 5 21798808 47798808 3 - by peak only
2289570 human BW494_H Body weight QTL 494 (human) 5 2.73 1336473 D5S426 Body weight Weight in kilograms increased body weight Obesity 1643430 17636092 5 21798808 47798808 3 - by peak only
2289572 human BW495_H Body weight QTL 495 (human) 7 2.23 1337752 D7S2423 Body weight Weight in kilograms increased body weight Obesity 1643430 17636092 7 144290683 158821424 3 - by peak only
2289573 human BW491_H Body weight QTL 491 (human) 4 5.08 1337288 D4S1535 Body weight BMI Weight in kilograms divided by square of height in meters increased body mass index Obesity 1643430 17636092 4 172472997 191273063 3 - by peak only
2289574 human BW499_H Body weight QTL 499 (human) 17 1.96 1337721 D17S798 Body weight BMI Weight in kilograms divided by square of height in meters increased body mass index Obesity 1643430 17636092 17 15314195 41314195 3 - by peak only
2289575 human BW492_H Body weight QTL 492 (human) 4 5.17 1337288 D4S1535 Body weight Weight in kilograms increased body weight Obesity 1643430 17636092 4 172472997 191273063 3 - by peak only
2289576 human BW498_H Body weight QTL 498 (human) 10 1.61 1340810 D10S1651 Body weight BMI Weight in kilograms divided by square of height in meters increased body mass index Obesity 1643430 17636092 10 119582646 135374737 3 - by peak only
2289577 human BW497_H Body weight QTL 497 (human) 10 2.46 1340810 D10S1651 Body weight BMI Weight in kilograms divided by square of height in meters increased body mass index Obesity 1643430 17636092 10 119582646 135374737 3 - by peak only
2289578 human BW496_H Body weight QTL 496 (human) 8 2.14 1340395 D8S260 Body weight none Weight in kilograms increased body weight Obesity 1643430 17636092 8 48984464 74984464 3 - by peak only
2302737 human MAMTS24_H Mammary tumor susceptibility QTL 24 (human) 17 0.049 1337228 D16S422 Mammary tumor susceptibility Probability of case versus control allele frequency difference mammary adenocarcinoma Breast Neoplasms 2302072 15668479 16 68469029 88827254 3 - by peak only
2302739 human MAMTS10_H Mammary tumor susceptibility QTL 10 (human) 2 0.039 1335148 D2S1384 Mammary tumor susceptibility Probability of case versus control allele frequency difference mammary adenocarcinoma Breast Neoplasms 2302072 15668479 2 191935442 217935442 3 - by peak only
2302740 human MAMTS40_H Mammary tumor susceptibility QTL 40 (human) 3 0.068 1341099 D3S3053 1342408 D3S3725 Mammary tumor susceptibility Probability of haplotype frequency difference for cases versus controls mammary adenocarcinoma Breast Neoplasms 2302072 15668479 3 173233565 173292556 1 - by flanking markers
2302742 human MAMTS14_H Mammary tumor susceptibility QTL 14 (human) 3 0.004 1341099 D3S3053 Mammary tumor susceptibility Probability of case versus control allele frequency difference mammary adenocarcinoma Breast Neoplasms 2302072 15668479 3 160233676 186233676 3 - by peak only
2302743 human MAMTS22_H Mammary tumor susceptibility QTL 22 (human) 14 0.003 1338763 D14S749 Mammary tumor susceptibility Probability of case versus control allele frequency difference mammary adenocarcinoma Breast Neoplasms 2302072 15668479 14 80449597 106368585 3 - by peak only
2302744 human MAMTS26_H Mammary tumor susceptibility QTL 26 (human) 19 0.025 1298198 D19S178 Mammary tumor susceptibility Probability of case versus control allele frequency difference mammary adenocarcinoma Breast Neoplasms 2302072 15668479 19 36097564 62097564 3 - by peak only
2302745 human MAMTS27_H Mammary tumor susceptibility QTL 27 (human) 19 0.034 1298198 D19S178 Mammary tumor susceptibility Probability of case versus control allele frequency difference mammary adenocarcinoma Breast Neoplasms 2302072 15668479 19 36097564 62097564 3 - by peak only
2302746 human MAMTS29_H Mammary tumor susceptibility QTL 29 (human) 20 0.041 1338093 D20S887 Mammary tumor susceptibility Probability of case versus control allele frequency difference mammary adenocarcinoma Breast Neoplasms 2302072 15668479 20 34106786 60106786 3 - by peak only
2302747 human MAMTS32_H Mammary tumor susceptibility QTL 32 (human) 22 0.022 1339133 D22S445 Mammary tumor susceptibility Probability of case versus control allele frequency difference mammary adenocarcinoma Breast Neoplasms 2302072 15668479
2302748 human MAMTS34_H Mammary tumor susceptibility QTL 34 (human) 3 0.012 1336912 D3S3630 1339957 D3S3050 Mammary tumor susceptibility Probability of case versus control haplotype frequency difference mammary adenocarcinoma Breast Neoplasms 2302072 15668479 3 2675554 3271750 1 - by flanking markers
2302750 human MAMTS28_H Mammary tumor susceptibility QTL 28 (human) 20 0.054 1298198 D19S178 Mammary tumor susceptibility Probability of case versus control allele frequency difference mammary adenocarcinoma Breast Neoplasms 2302072 15668479 19 36097564 62097564 3 - by peak only
2302751 human MAMTS37_H Mammary tumor susceptibility QTL 37 (human) 22 0.058 1336843 D22S1177 1339133 D22S445 Mammary tumor susceptibility Probability of case versus control haplotype frequency difference mammary adenocarcinoma Breast Neoplasms 2302072 15668479
2315438 human INSUL41_H Insulin level QTL 41 (human) 10 6.2 1.0E-4 1335493 D10S1713 Insulin level Homeostasis model assessment of beta cell function(%B) from HOMA2 model, using fasting insulin and fasting glucose measurements glucose homeostasis traits 2315075 18174525 735947;1353901 IL2RA;AKR1C2 10 1 18318694 3 - by peak only
2315440 human INSUL43_H Insulin level QTL 43 (human) 18 3.1 0.007 1338314 D18S464 Insulin level Homeostasis model assessment of beta cell function(%B) from HOMA2 model, using fasting insulin and fasting glucose measurements glucose homeostasis traits 2315075 18174525 1316264 LAMA1 18 1 22951484 3 - by peak only
2315441 human INSUL42_H Insulin level QTL 42 (human) 17 3.2 0.0012 1299973 D17S785 Insulin level Homeostasis model assessment of beta cell function(%B) from HOMA2 model, using fasting insulin and fasting glucose measurements glucose homeostasis traits 2315075 18174525 69010 GCGR 17 58943066 78774742 3 - by peak only
2315442 human GLUCO141_H Glucose level QTL 141 (human) 22 3.2 0.0016 1335607 D22S1167 Glucose level Homeostasis model assessment of insulin resistance from HOMA2 model, using fasting insulin and fasting glucose measurements glucose homeostasis traits 2315075 18174525 1352787 XBP1 22 12361815 38361815 3 - by peak only
2315444 human GLUCO140_H Glucose level QTL 140 (human) 17 2.38 0.0087 1299973 D17S785 Glucose level Homeostasis model assessment of insulin resistance from HOMA2 model, using fasting insulin and fasting glucose measurements glucose homeostasis traits 2315075 18174525 69010 GCGR 17 58943066 78774742 3 - by peak only
2289379 human BW419_H Body weight QTL 419 (human) 2 3.57 2.0E-5 1341472 D2S139 1334924 D2S2264 1336804 D2S2216 Body morphometry length at birth increased body weight Obesity 1643151 16849411 2 79617104 101786292 1 - by flanking markers
2289381 human BW417_H Body weight QTL 417 (human) 7 3.1 8.0E-5 1341880 D7S2513 1338400 D7S661 1341880 D7S2513 Body weight weight at birth increased body weight Obesity 1643151 16849411 7 141053887 143233188 1 - by flanking markers
2289383 human BW418_H Body weight QTL 418 (human) 2 2.69 2.0E-4 1338062 D2S2328 1340580 D2S2227 1337364 D2S2259 Body morphometry length at birth increased body weight Obesity 1643151 16849411 2 40532317 47123414 1 - by flanking markers
2289384 human BW420_H Body weight QTL 420 (human) 9 1.51 0.004 1334553 D9S285 1334851 D9S161 Body weight BMI ponderal index; birth weight divided by birth length cubed increased body weight Obesity 1643151 16849411
2292678 human MYI17_H Myocardial infarction susceptibility QTL 17 (human) 1 1331563 G15725 Myocardial infarction susceptibility early-onset genome-wide scan for susceptibility genes for myocardial infarction in families with familial premature coronary artery disease and myocardial infarction cardiomyopathy Myocardial Ischemia 1554326 14732905
2292709 human PRSTS2_H Prostate tumor susceptibility QTL 2 (human) 8 1337130 D8S1774 1335263 D8S557 1340371 D8S1732 Prostate tumor susceptibility Prostate cancer occurence Prostatic Neoplasms 2290528 17654497 731438;1602783;1606136 MYC;TMEM75;FAM84B 8 127491666 133159666 1 - by flanking markers
2292711 human PRSTS1_H Prostate tumor susceptibility QTL 1 (Human) 22 1341539 D22S281 1340618 D22S683 Prostate tumor susceptibility Prostate tumor presence confirmed by medical record or death certificate abnormal sciatic nerve Prostatic Neoplasms 2290503;2292401 17478474;15988677 22 32666709 34844050 1 - by flanking markers
2289163 human SADIPOQ2_H Serum adiponectin level QTL 2 (human) 4 2.12 1668850 D4S2632 Hormone level serum adiponectin level Serum adiponectin concentration was measured by radioimmunoassay 1642892 17495197 4 22380599 48380599 3 - by peak only
2289164 human BW111_H Body weight QTL 111 (human) 6 0.002 2106181 D6S2791 Body fat amount percent fat percent body fat measured by hydrostatic weighing increased body mass index;increased percent body fat Obesity 1642910 7615786 1344192 TNF 6 18648430 44648430 3 - by peak only
2289166 human SLEP5_H Serum leptin level QTL 5 (human) 2 1.26 0.008 1298195 D2S1788 Hormone level serum leptin level serum leptin assay increased circulating leptin level Obesity 1642927 10078570 69123;1352097 LEP;POMC 2 23113904 49113904 3 - by peak only
2289168 human BW126_H Body Weight QTL 126 (human) 3 0.95 0.018 1341099 D3S3053 1642898 D3S1754 Body weight BMI BMI normalized by expression as z-score after correction for age and sex increased body weight;increased body mass index Obesity 1642944;1334498 11151766;12502515 3 173233565 199233565 4 - by one flank marker only
2289169 human BW268_H Body Weight QTL 268 (human) 18 3.44 3.0E-5 1299942 D18S843 1336696 D18S535 1342398 D18S877 Body weight obesity insulin factor (Obesity-INS) was determined by factor analysis which was performed on 10 risk factors using maximum likelihood method obese Obesity 1642885 16172425 18 8603770 36402932 1 - by flanking markers
2289170 human BW113_H Body weight QTL 113 (human) 6 0.018 1298131 D6S291 Body fat amount percent fat percent body fat measured by hydrostatic weighing technique increased percent body fat;increased body mass index Obesity 1642910 7615786
2289172 human SLEP6_H Serum leptin level QTL 6 (human) 2 2.68 1335090 D2S165 1298195 D2S1788 1342357 D2S367 Hormone level leptin serum leptin level (ng/ml) measurements increased circulating leptin level Obesity 1298035 9806554 1352097 POMC 2 28456983 36113999 1 - by flanking markers
2289174 human SADIPOQ7_H Serum adiponectin level QTL 7 (human) 11 4.2 1337255 D11S925 1730449 D11S956 1299904 D11S968 Hormone level adiponectin level fasting serum adiponectin levels measured by radioimmunoassay (RIA) 1642929 16894363 732016;1312969;1322402;1345886;1348841;1602686 KCNJ1;TBRG1;TIRAP;CDON;ESAM;ASAM 11 58253071 120333478 1 - by flanking markers
2289175 human BW112_H Body weight QTL 112 (human) 6 0.048 1338813 D6S273 Body fat amount percent fat percent body fat measured by hydrostatic technique increased percent body fat;increased body mass index Obesity 1642910 7615786 6 18791864 44791864 3 - by peak only
2289177 human SLEP7_H Serum leptin level QTL 7 (human) 5 2.93 1336473 D5S426 Hormone level leptin serum leptin level (ng/ml) increased circulating leptin level Obesity 1298035 9806554 5 21798808 47798808 3 - by peak only
2289179 human BW269_H Body Weight QTL 269 (human) 18 2.4 4.4E-4 1342398 D18S877 1336503 D18S1357 1331553 D18S851 Body weight obesity insulin factor (Obesity-INS) was determined by factor analysis which was performed on 10 risk factors using maximum likelihood method obese Obesity 1642885 16172425 18 24979188 56970972 1 - by flanking markers
2289256 human BW95_H Body weight QTL 95 (human) 3 1.61 0.0032 1335788 D3S3608 Body fat amount percent fat bioelectroimpedance method increased percent body fat Obesity 1642890;1643034 11238509;14627748 69168 PPARG 3 679335 26679335 3 - by peak only
2289259 human BW97_H Body weight QTL 97 (human) 16 1.68 0.0027 1340882 D16S510 Body weight BMI weight(kg) dividied by square of height(m) increased percent body fat Obesity 1642890;1643034 11238509;14627748
2289261 human BW96_H Body weight QTL 96 (human) 14 1.8 0.002 1341855 D14S276 Body morphometry waist circumference minimum waist girth at the natural indentation, or midway between top of pelvis and lowest rib. increased percent body fat Obesity 1642890;1643034 11238509;14627748 14 41752813 67752813 3 - by peak only
2289263 human BW92_H Body weight QTL 92 (human) 17 0.1 3.16 1334736 D17S787 1337867 D17S1352 1341417 D17S944 Body weight BMI BMI more than 35 kg/m2 increased body mass index Obesity 1643034;1642950 14627748;15220211 17 50637083 69509710 1 - by flanking markers
2289264 human BW93_H Body weight QTL 93 (human) 4 2.55 0.266 1339514 D4S406 Body weight BMI BMI more than 35 kg/m2 increased body mass index Obesity 1643034;1642950 14627748;15220211 4 98938014 124938014 3 - by peak only
2289325 human BW86_H Body weight QTL 86 (human) 1 1.5 1337261 D1S1678 1342325 D1S2141 Body weight BMI weight(kg) divided by height (m2) increased body mass index Obesity 1643034 14627748 732800;731611 CAPN2;CAPN9 1 201798348 213262150 1 - by flanking markers
2289327 human BW383_H Body weight QTL 383 (human) 7 2.53 3.2E-4 1299920 D7S3070 Body fat amount abdominal post-training (response) abdominal total fat, blacks. abnormal lateral ganglionic eminence morphology;increased body weight Obesity 1354697 11872690 735618 NOS3 7 138198143 158821424 3 - by peak only
2289329 human BW393_H Body weight QTL 393 (human) 13 1.04 1342079 D13S787 1340707 ATA5A09 Body weight BMI (weight in kg divided by height in meters, squared) based on self-reported weight and height increased body mass index Obesity 1642951 15181885 13 23278738 49278738 4 - by one flank marker only
2293358 human PRSTS265_H Prostate tumor susceptibility QTL 265 (human) 13 1337276 D13S271 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293192 15536476 13 71278860 97278860 3 - by peak only
2293360 human PRSTS221_H Prostate tumor susceptibility QTL 221 (human) 14 1.68 1337101 D14S588 Prostate tumor susceptibility Diagnosis before age 61, confirmed by medical record abnormal sciatic nerve Prostatic Neoplasms 2293133 10820127 14 56290098 82290098 3 - by peak only
2293362 human PRSTS280_H Prostate tumor susceptibility QTL 280 (human) 17 1335999 D17S969 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293192 15536476 1342597 ELAC2 17 1 24785756 3 - by peak only
2293363 human PRSTS197_H Prostate tumor susceptibility QTL 197 (human) 1 2.25 1336648 D1S252 Prostate tumor susceptibility Affected status confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293051 14601028 1 104358348 130358348 3 - by peak only
2293364 human PRSTS266_H Prostate tumor susceptibility QTL 266 (human) 15 1334823 D15S231 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293192 15536476 15 18038054 44038054 3 - by peak only
2293365 human PRSTS245_H Prostate tumor susceptibility QTL 245 (human) 1 1340336 D1S438 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293192 15536476 1 50589345 76589345 3 - by peak only
2293366 human PRSTS233_H Prostate tumor susceptibility QTL 233 (human) 16 1.22 1298279 D16S748 Prostate tumor susceptibility Diagnosis at before age 66, confirmed by medical record abnormal sciatic nerve Prostatic Neoplasms 2293133 10820127 16 1 25047040 3 - by peak only
2293368 human PRSTS218_H Prostate tumor susceptibility QTL 218 (human) 12 1.05 1298109 D12S1045 Prostate tumor susceptibility Diagnosis confirmed by medical record abnormal sciatic nerve Prostatic Neoplasms 2293133 10820127 12 115963729 132349534 3 - by peak only
2293370 human PRSTS203_H Prostate tumor susceptibility QTL 203 (human) 7 1.68 1339905 D7S486 Prostate tumor susceptibility Affected status confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293051 14601028 7 102682068 128682068 3 - by peak only
2293371 human PRSTS271_H Prostate tumor susceptibility QTL 271 (human) 8 1342360 D8S543 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293192 15536476 8 57175673 83175673 3 - by peak only
2293372 human PRSTS238_H Prostate tumor susceptibility QTL 238 (human) 4 0.03 1334904 D8S1106 Prostate tumor susceptibility Diagnosis before age 66, confirmed by medical record abnormal sciatic nerve Prostatic Neoplasms 2293133 10820127 8 1 25880399 3 - by peak only
2293374 human PRSTS278_H Prostate tumor susceptibility QTL 278 (human) 1 1335710 D1S304 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293192 15536476 1343740 PCAP 1 226355387 247249719 3 - by peak only
2293375 human PRSTS237_H Prostate tumor susceptibility QTL 237 (human) 8 0.026 1334904 D8S1106 Prostate tumor susceptibility Diagnosis at age 66 or later, confirmed by medical record abnormal sciatic nerve Prostatic Neoplasms 2293133 10820127 8 1 25880399 3 - by peak only
2293377 human PRSTS236_H Prostate tumor susceptibility QTL 236 (human) 2 1.58 1298104 D2S1790 Prostate tumor susceptibility Diagnosis before age 61, confirmed by medical record abnormal sciatic nerve Prostatic Neoplasms 2293133 10820127 2 71928947 97928947 3 - by peak only
2293378 human PRSTS214_H Prostate tumor susceptibility QTL 214 (human) 1 0.003 1342100 D1S1622 1340396 D1S3721 Prostate tumor susceptibility Gleason scores from concordant sibships abnormal sciatic nerve Prostatic Neoplasms 2293118;2293051 10825281;14601028 1 30083541 41499293 1 - by flanking markers
2293380 human PRSTS219_H Prostate tumor susceptibility QTL 219 (human) 14 1.74 1337101 D14S588 Prostate tumor susceptibility Diagnosis confirmed by medical record abnormal sciatic nerve Prostatic Neoplasms 2293133 10820127 14 56290098 82290098 3 - by peak only
2293381 human PRSTS255_H Prostate tumor susceptibility QTL 255 (human) 5 1341981 D5S2030 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293192 15536476 5 164740034 180857866 3 - by peak only
2293382 human PRSTS267_H Prostate tumor susceptibility QTL 267 (human) 15 1334823 D15S231 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293192 15536476 15 18038054 44038054 3 - by peak only
2293383 human PRSTS256_H Prostate tumor susceptibility QTL 256 (human) 5 1341981 D5S2030 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293192 15536476 5 164740034 180857866 3 - by peak only
2293384 human PRSTS259_H Prostate tumor susceptibility QTL 259 (human) 6 1336670 D6S503 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293192 15536476 6 154932822 170899992 3 - by peak only
2293385 human PRSTS241_H Prostate tumor susceptibility QTL 241 (human) 3 0.073 1336813 D3S1744 1340780 D3S1763 Prostate tumor susceptibility Diagnosis confirmed by medical record abnormal sciatic nerve Prostatic Neoplasms 2293133 10820127 3 142722661 168722661 4 - by one flank marker only
2293386 human PRSTS226_H Prostate tumor susceptibility QTL 226 (human) 10 1.28 1335446 D10S1222 Prostate tumor susceptibility Diagnosis before age 66, confirmed by medical record abnormal sciatic nerve Prostatic Neoplasms 2293133 10820127 10 116150850 135374737 3 - by peak only
2293387 human PRSTS275_H Prostate tumor susceptibility QTL 275 (human) 11 1298102 D11S908 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293192 15536476 11 101792629 127792629 3 - by peak only
2293388 human PRSTS222_H Prostate tumor susceptibility QTL 222 (human) 11 3.02 1338746 ATA34E08 Prostate tumor susceptibility Diagnosis after age 65, confirmed by medical record abnormal sciatic nerve Prostatic Neoplasms 2293133 10820127
2293390 human PRSTS200_H Prostate tumor susceptibility QTL 200 (human) 3 2.44 1299975 D3S1297 Prostate tumor susceptibility Affected status confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293051 14601028 3 1 15013567 3 - by peak only
2293391 human PRSTS242_H Prostate tumor susceptibility QTL 242 (human) 3 0.048 1336813 D3S1744 1340780 D3S1763 Prostate tumor susceptibility Diagnosis at age 66 or later confirmed by medical record abnormal sciatic nerve Prostatic Neoplasms 2293133 10820127 3 142722661 168722661 4 - by one flank marker only
2293393 human PRSTS281_H Prostate tumor susceptibility QTL 281 (human) 8 1335091 D8S1827 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293192 15536476 1347158 MSR1 8 1862807 27862807 3 - by peak only
2293394 human PRSTS231_H Prostate tumor susceptibility QTL 231 (human) 1 1.46 1334926 D8S2324 Prostate tumor susceptibility Diagnosis before age 66, confirmed by medical record abnormal sciatic nerve Prostatic Neoplasms 2293133 10820127 8 61416986 87416986 3 - by peak only
2293395 human PRSTS199_H Prostate tumor susceptibility QTL 199 (human) 2 3.1 1341679 D2S151 Prostate tumor susceptibility Affected status confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293051 14601028 2 134503137 160503137 3 - by peak only
2293396 human PRSTS213_H Prostate tumor susceptibility QTL 213 (human) 19 4.0E-4 1298168 D19S433 Prostate tumor susceptibility Gleason scores from concordant sibships abnormal sciatic nerve Prostatic Neoplasms 2293118;2293051 10825281;14601028 19 22108969 48108969 3 - by peak only
2293397 human PRSTS250_H Prostate tumor susceptibility QTL 250 (human) 5 1299951 D5S428 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293192 15536476 5 72446574 98446574 3 - by peak only
2293398 human PRSTS246_H Prostate tumor susceptibility QTL 246 (human) 1 1336394 D1S189 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293192 15536476 1 103495436 129495436 3 - by peak only
2293399 human PRSTS257_H Prostate tumor susceptibility QTL 257 (human) 5 1331599 D5S2040 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293192 15536476 5 152001672 178001672 3 - by peak only
2293400 human PRSTS224_H Prostate tumor susceptibility QTL 224 (human) 9 1.62 1357243 D9S925 Prostate tumor susceptibility Diagnosis after age 65, confirmed by medical record abnormal sciatic nerve Prostatic Neoplasms 2293133 10820127
2293401 human PRSTS216_H Prostate tumor susceptibility QTL 216 (human) 12 1.76 1298109 D12S1045 Prostate tumor susceptibility Diagnosis confirmed by medical record for 333 of 340 affected men abnormal sciatic nerve Prostatic Neoplasms 2293133 10820127 12 115963729 132349534 3 - by peak only
2293403 human PRSTS252_H Prostate tumor susceptibility QTL 252 (human) 5 1331599 D5S2040 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293192 15536476 5 152001672 178001672 3 - by peak only
2293404 human PRSTS239_H Prostate tumor susceptibility QTL 239 (human) 2 0.032 1298132 D2S1399 Prostate tumor susceptibility Diagnosis before age 66, confirmed by medical record abnormal sciatic nerve Prostatic Neoplasms 2293133 10820127 2 134926654 160926654 3 - by peak only
2293405 human PRSTS268_H Prostate tumor susceptibility QTL 268 (human) 15 1334823 D15S231 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293192 15536476 15 18038054 44038054 3 - by peak only
2293406 human PRSTS196_H Prostate tumor susceptibility QTL 196 (human) 1 2.61 1340435 D1S2713 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293051 14601028 1 31286196 57286196 3 - by peak only
2293407 human PRSTS277_H Prostate tumor susceptibility QTL 277 (human) 1 1336060 D1S218 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293192 15536476 1346643;1353721 RNASEL;HPC1 1 159769894 185769894 3 - by peak only
2293408 human PRSTS258_H Prostate tumor susceptibility QTL 258 (human) 6 1341981 D5S2030 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293192 15536476 5 164740034 180857866 3 - by peak only
2293409 human PRSTS254_H Prostate tumor susceptibility QTL 254 (human) 5 1331599 D5S2040 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293192 15536476 5 152001672 178001672 3 - by peak only
2293410 human PRSTS264_H Prostate tumor susceptibility QTL 264 (human) 12 1342093 D12S351 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293192 15536476 12 77429552 103429552 3 - by peak only
2293411 human PRSTS234_H Prostate tumor susceptibility QTL 234 (human) 15 1.04 1340735 D15S652 Prostate tumor susceptibility Diagnosis confirmed by medical record abnormal sciatic nerve Prostatic Neoplasms 2293133 10820127 15 77318513 100338915 3 - by peak only
2293412 human PRSTS228_H Prostate tumor susceptibility QTL 228 (human) 8 2.17 1334926 D8S2324 Prostate tumor susceptibility Diagnosis confirmed by medical record abnormal sciatic nerve Prostatic Neoplasms 2293133 10820127 8 61416986 87416986 3 - by peak only
2293413 human PRSTS210_H Prostate tumor susceptibility QTL 210 (human) X 1.84 1337455 DXS1227 Prostate tumor susceptibility Affected status confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293051 14601028 1345191 HPCX X 127630167 153630167 3 - by peak only
2293414 human PRSTS202_H Prostate tumor susceptibility QTL 202 (human) 6 1.61 1341107 D6S287 Prostate tumor susceptibility Affected status confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293051 14601028 6 106595555 132595555 3 - by peak only
2293415 human PRSTS232_H Prostate tumor susceptibility QTL 232 (human) 16 1.58 1298279 D16S748 Prostate tumor susceptibility Diagnosis confirmed by medical record abnormal sciatic nerve Prostatic Neoplasms 2293133 10820127 16 1 25047040 3 - by peak only
2293416 human PRSTS282_H Prostate tumor susceptibility QTL 282 (human) 17 1335999 D17S969 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293192 15536476 1342597 ELAC2 17 1 24785756 3 - by peak only
2293417 human PRSTS209_H Prostate tumor susceptibility QTL 209 (human) x 1.88 1341091 DXS8055 Prostate tumor susceptibility Affected status confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293051 14601028 X 101561279 127561279 3 - by peak only
2293418 human PRSTS248_H Prostate tumor susceptibility QTL 248 (human) 1 1336394 D1S189 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293192 15536476 1 103495436 129495436 3 - by peak only
2293419 human PRSTS253_H Prostate tumor susceptibility QTL 253 (human) 5 1331599 D5S2040 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293192 15536476 5 152001672 178001672 3 - by peak only
2293420 human PRSTS217_H Prostate tumor susceptibility QTL 217 (human) 12 1.89 1298109 D12S1045 Prostate tumor susceptibility Diagnosis confirmed by medical record abnormal sciatic nerve Prostatic Neoplasms 2293133 10820127 12 115963729 132349534 3 - by peak only
2293421 human PRSTS244_H Prostate tumor susceptibility QTL 244 (human) 1 1340336 D1S438 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293192 15536476 1 50589345 76589345 3 - by peak only
2293422 human PRSTS249_H Prostate tumor susceptibility QTL 249 (human) 5 1299951 D5S428 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293192 15536476 5 72446574 98446574 3 - by peak only
2293423 human PRSTS274_H Prostate tumor susceptibility QTL 274 (human) 9 1336906 D9S1777 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293192 15536476 9 57377595 83377595 3 - by peak only
2293424 human PRSTS272_H Prostate tumor susceptibility QTL 272 (human) 8 1338047 D8S273 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293192 15536476 8 75980633 101980633 3 - by peak only
2293425 human PRSTS279_H Prostate tumor susceptibility QTL 279 (human) 8 1335091 D8S1827 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293192 15536476 1347158 MSR1 8 1862807 27862807 3 - by peak only
2293426 human PRSTS215_H Prostate tumor susceptibility QTL 215 (human) 9 0.008 1341701 D9S930 Prostate tumor susceptibility Gleason scores from concordant sibships abnormal sciatic nerve Prostatic Neoplasms 2293118;2293051 10825281;14601028 9 101276177 127276177 3 - by peak only
2293427 human PRSTS230_H Prostate tumor susceptibility QTL 230 (human) 1 1.99 1334926 D8S2324 Prostate tumor susceptibility Diagnosis confirmed by medical record abnormal sciatic nerve Prostatic Neoplasms 2293133 10820127 8 61416986 87416986 3 - by peak only
2293428 human PRSTS227_H Prostate tumor susceptibility QTL 227 (human) 10 1.17 1335446 D10S1222 Prostate tumor susceptibility Diagnosis after age 65, confirmed by medical record abnormal sciatic nerve Prostatic Neoplasms 2293133 10820127 10 116150850 135374737 3 - by peak only
2293429 human PRSTS212_H Prostate tumor susceptibility QTL 212 (human) 7 7.0E-4 1338834 D7S1804 Prostate tumor susceptibility Gleason scores from concordant sibships abnormal sciatic nerve Prostatic Neoplasms 2293118;2293051 10825281;14601028 7 105930452 131930452 4 - by one flank marker only
2293430 human PRSTS243_H Prostate tumor susceptibility QTL 243 (human) 1 0.077 1336052 D1S1597 Prostate tumor susceptibility Diagnosis confirmed by medical record abnormal sciatic nerve Prostatic Neoplasms 2293133 10820127 1 656858 26656858 3 - by peak only
2293431 human PRSTS207_H Prostate tumor susceptibility QTL 207 (human) 18 3.77 1335805 D18S452 Prostate tumor susceptibility Affected status confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293051 14601028
2293432 human PRSTS269_H Prostate tumor susceptibility QTL 269 (human) 19 1341825 D19S565 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293192 15536476 19 1 15518316 3 - by peak only
2293433 human PRSTS223_H Prostate tumor susceptibility QTL 223 (human) 9 1.6 1357243 D9S925 Prostate tumor susceptibility Diagnosis before age 61, confirmed by medical record abnormal sciatic nerve Prostatic Neoplasms 2293133 10820127
2293434 human PRSTS208_H Prostate tumor susceptibility QTL 208 (human) 20 1.02 1335497 D20S889 Prostate tumor susceptibility Affected status confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293051 14601028 20 1 16895114 3 - by peak only
2293435 human PRSTS205_H Prostate tumor susceptibility QTL 205 (human) 9 2.17 1336577 D9S1826 Prostate tumor susceptibility Affected status confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293051 14601028 9 124588212 140273252 3 - by peak only
2293436 human PRSTS263_H Prostate tumor susceptibility QTL 263 (human) 8 1335091 D8S1827 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293192 15536476 8 1862807 27862807 3 - by peak only
2293437 human PRSTS220_H Prostate tumor susceptibility QTL 220 (human) 14 1.03 1337101 D14S588 Prostate tumor susceptibility Diagnosis before age 66, confirmed by medical record abnormal sciatic nerve Prostatic Neoplasms 2293133 10820127 14 56290098 82290098 3 - by peak only
2293438 human PRSTS247_H Prostate tumor susceptibility QTL 247 (human) 1 1336394 D1S189 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293192 15536476 1 103495436 129495436 3 - by peak only
2293439 human PRSTS225_H Prostate tumor susceptibility QTL 225 (human) 10 2.46 1335446 D10S1222 Prostate tumor susceptibility Diagnosis confirmed by medical record abnormal sciatic nerve Prostatic Neoplasms 2293133 10820127 10 116150850 135374737 3 - by peak only
2293440 human PRSTS240_H Prostate tumor susceptibility QTL 240 (human) 1 0.016 1298138 D1S468 1331547 D1S3669 1298303 D1S1612 Prostate tumor susceptibility Diagnosis before age 61, confirmed by medical record abnormal sciatic nerve Prostatic Neoplasms 2293133 10820127 1 3574817 17656435 1 - by flanking markers
2293441 human PRSTS273_H Prostate tumor susceptibility QTL 273 (human) 9 1341653 D9S1858 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293192 15536476 9 1 13687150 3 - by peak only
2293442 human PRSTS198_H Prostate tumor susceptibility QTL 198 (human) 1 3.48 1337647 D1S413 Prostate tumor susceptibility Affected status confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293051 14601028 1353721 HPC1 1 183887150 209887150 3 - by peak only
2293443 human PRSTS201_H Prostate tumor susceptibility QTL 201 (human) 4 3.76 1336802 D4S1615 Prostate tumor susceptibility Affected status confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293051 14601028 4 115429293 141429293 3 - by peak only
2293444 human PRSTS276_H Prostate tumor susceptibility QTL 276 (human) 11 1340830 D11S2367 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293192 15536476 11 118043375 134452384 3 - by peak only
2293445 human PRSTS206_H Prostate tumor susceptibility QTL 206 (human) 10 3.0 1335224 D10S249 Prostate tumor susceptibility Affected status confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293051 14601028 10 1 13270956 3 - by peak only
2293446 human PRSTS261_H Prostate tumor susceptibility QTL 261 (human) 8 1335091 D8S1827 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293192 15536476 8 1862807 27862807 3 - by peak only
2293447 human PRSTS229_H Prostate tumor susceptibility QTL 229 (human) 8 2.05 1334926 D8S2324 Prostate tumor susceptibility Diagnosis at age 66 or later, confirmed by medical record abnormal sciatic nerve Prostatic Neoplasms 2293133 10820127 8 61416986 87416986 3 - by peak only
2293448 human PRSTS211_H Prostate tumor susceptibility QTL 211 (human) 5 2.0E-4 1298302 D5S1480 1331610 D5S820 Prostate tumor susceptibility Gleason scores from concordant sibships abnormal sciatic nerve Prostatic Neoplasms 2293118;2293051 10825281;14601028 1348842 CTNNA1 5 144123911 156055188 1 - by flanking markers
2293449 human PRSTS270_H Prostate tumor susceptibility QTL 270 (human) 19 1341825 D19S565 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293192 15536476 19 1 15518316 3 - by peak only
2293450 human PRSTS260_H Prostate tumor susceptibility QTL 260 (human) 6 1336670 D6S503 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293192 15536476 6 154932822 170899992 3 - by peak only
2293451 human PRSTS204_H Prostate tumor susceptibility QTL 204 (human) 8 1.87 1335686 D8S555 Prostate tumor susceptibility Affected status confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293051 14601028 1347158 MSR1 8 101456936 127456936 3 - by peak only
2293452 human PRSTS251_H Prostate tumor susceptibility QTL 251 (human) 5 1299951 D5S428 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293192 15536476 5 72446574 98446574 3 - by peak only
2293453 human PRSTS262_H Prostate tumor susceptibility QTL 262 (human) 8 1335091 D8S1827 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293192 15536476 8 1862807 27862807 3 - by peak only
2293454 human PRSTS235_H Prostate tumor susceptibility QTL 235 (human) 15 0.025 1340735 D15S652 Prostate tumor susceptibility Diagnosis at age 66 or later confirmed by medical record abnormal sciatic nerve Prostatic Neoplasms 2293133 10820127 15 77318513 100338915 3 - by peak only
2314708 human GLUCO65_H Glucose level QTL 65 (human) 2 2.03 0.058 1299945 D2S434 Glucose level insulin sensitivity Insulin sensitivity calculated from fasting insulin and fasting glucose levels, using HOMA2 program glucose homeostasis traits 2313933 16443794 2 205284868 231284868 3 - by peak only
2314710 human GLUCO61_H Glucose level QTL 61 (human) 17 1.74 0.576 1299971 D17S784 Glucose level insulin sensitivity Insulin sensitivity calculated from fasting insulin and fasting glucose levels, using HOMA2 program glucose homeostasis traits 2313933 16443794 17 62416927 78774742 3 - by peak only
2314711 human GLUCO67_H Glucose level QTL 67(human) 7 3.01 0.018 1342229 D7S3046 Glucose level insulin sensitivity Insulin sensitivity calculated from fasting insulin and fasting glucose levels, using HOMA2 program glucose homeostasis traits 2313933 16443794 7 55190426 81190426 3 - by peak only
2314712 human GLUCO64_H Glucose level QTL 64 (human) 12 1.76 0.165 1655602 D12S1301 Glucose level insulin sensitivity Insulin sensitivity calculated from fasting insulin and fasting glucose levels, using HOMA2 program glucose homeostasis traits 2313933 16443794 12 29348962 55348962 3 - by peak only
2314713 human INSUL15_H Insulin level QTL 15 (human) 8 1.9 0.188 1298265 D8S1179 Insulin level Beta cell function calculated from fasting insulin and fasting glucose levels, using HOMA2 program glucose homeostasis traits 2313933 16443794 8 112976351 138976351 3 - by peak only
2314715 human GLUCO62_H Glucose level QTL 62 (human) 6 2.81 0.059 1341899 D6S1277 Glucose level insulin sensitivity Insulin sensitivity calculated from fasting insulin and fasting glucose levels, using HOMA2 program glucose homeostasis traits 2313933 16443794 6 151217880 170899992 3 - by peak only
2314716 human INSUL17_H Insulin level QTL 17 (human) 8 2.29 0.106 1334904 D8S1106 Insulin level Beta cell function calculated from fasting insulin and fasting glucose levels, using HOMA2 program glucose homeostasis traits 2313933 16443794 8 1 25880399 3 - by peak only
2314717 human GLUCO69_H Glucose level QTL 69 (human) 12 2.86 0.018 1655602 D12S1301 Glucose level insulin sensitivity Insulin sensitivity calculated from fasting insulin and fasting glucose levels, using HOMA2 program glucose homeostasis traits 2313933 16443794 12 29348962 55348962 3 - by peak only
2314718 human GLUCO66_H Glucose level QTL 66 (human) 6 2.99 0.018 1341899 D6S1277 Glucose level insulin sensitivity Insulin sensitivity calculated from fasting insulin and fasting glucose levels, using HOMA2 program glucose homeostasis traits 2313933 16443794 6 151217880 170899992 3 - by peak only
2314719 human INSUL20_H Insulin level QTL 20 (human) 8 4.2 0.002 1298265 D8S1179 Insulin level Beta cell function calculated from fasting insulin and fasting glucose levels, using HOMA2 program glucose homeostasis traits 2313933 16443794 8 112976351 138976351 3 - by peak only
2314720 human INSUL18_H Insulin level QTL 18(human) 12 2.0 0.106 1299944 D12S2070 Insulin level Beta cell function calculated from fasting insulin and fasting glucose levels, using HOMA2 program glucose homeostasis traits 2313933 16443794 12 101567143 127567143 3 - by peak only
2314721 human INSUL19_H Insulin level QTL 19 (human) 13 1.93 0.106 1342079 D13S787 Insulin level Beta cell function calculated from fasting insulin and fasting glucose levels, using HOMA2 program glucose homeostasis traits 2313933 16443794 13 10278863 36278863 3 - by peak only
2314722 human INSUL16_H Insulin level QTL 16 (human) 7 1.77 0.127 1335509 D7S2204 Insulin level Beta cell function calculated from fasting insulin and fasting glucose levels, using HOMA2 program glucose homeostasis traits 2313933 16443794 7 64964972 90964972 3 - by peak only
2314723 human INSUL14_H Insulin level QTL 14 (human) 2 2.1 0.188 2183445 D2S1799 Insulin level Beta cell function calculated from fasting insulin and fasting glucose levels, using HOMA2 program glucose homeostasis traits 2313933 16443794 2 131590759 157590759 3 - by peak only
2314724 human GLUCO68_H Glucose level QTL 68 (human) 9 2.32 0.04 1341701 D9S930 Glucose level insulin sensitivity Insulin sensitivity calculated from fasting insulin and fasting glucose levels, using HOMA2 program glucose homeostasis traits 2313933 16443794 9 101276177 127276177 3 - by peak only
2314725 human GLUCO63_H Glucose level QTL 63 (human) 7 2.11 0.165 1342229 D7S3046 Glucose level insulin sensitivity Insulin sensitivity calculated from fasting insulin and fasting glucose levels, using HOMA2 program glucose homeostasis traits 2313933 16443794 7 55190426 81190426 3 - by peak only
2314779 human GLUCO115_H Glucose level QTL 115 (human) 13 1.86 1342302 D13S285 Glucose level Blood samples collected after fasting were analyzed for plasma glucose and insulin, and trait was QUICKI = 1/[log fasting insulin(mU/ml)+ log fasting glucose(mg/dl)] glucose homeostasis traits 2314192 15111508 13 98843481 114142980 3 - by peak only
2314781 human GLUCO109_H Glucose level QTL 109 (human) 8 3.09 1336611 D8S1130 1334904 D8S1106 Glucose level Blood samples collected after fasting and 2 hours after 75 g oral glucose load were analyzed for plasma glucose and insulin, and trait was insulin response to glucose, calculated as [2hr insulin - fasting insulin(mU/ml)]/[2 hr glucose - fasting glucose(mmol/l)] glucose homeostasis traits 2314192 15111508 70836;1347158 LPL;MSR1 8 1 12880475 4 - by one flank marker only
2314783 human GLUCO114_H Glucose level QTL 114 (human) 13 1.35 1342302 D13S285 Glucose level Blood samples collected after fasting were analyzed for plasma glucose and insulin, and trait was HOMA-IR, calculated as fasting insulin(mU/ml) x fasting glucose(mmol/l)/22.5 glucose homeostasis traits 2314192 15111508 13 98843481 114142980 3 - by peak only
2314785 human GLUCO110_H Glucose level QTL 110 (human) 9 2.19 1337019 D9S301 Glucose level fasting Blood sample collected after an overnight fast and analyzed for plasma glucose(mmol/l)] glucose homeostasis traits 2314192 15111508 9 59992657 85992657 3 - by peak only
2314787 human GLUCO113_H Glucose level QTL 113 (human) 13 2.98 1342079 D13S787 1339818 D13S252 Glucose level Blood samples collected after fasting and 2 hours after 75 g oral glucose load were analyzed for plasma glucose and insulin, and trait was corrected insulin response(CIR), calculated as [2hr insulin/[2hr glucose x (2hr glucose - 70mg/dl)] glucose homeostasis traits 2314192 15111508 736367 PDX1 13 23278738 27376424 1 - by flanking markers
2314789 human GLUCO111_H Glucose level QTL 111 (human) 12 1.9 1341822 D12S1090 Glucose level Blood samples collected after fasting and 2 hours after 75 g oral glucose load were analyzed for plasma glucose and insulin, and trait was insulin response to glucose(IRG), calculated as [2hr insulin - fasting insulin(mU/ml)]/[2 hr glucose - fasting glucose(mmol/l)] glucose homeostasis traits 2314192 15111508
2314791 human BW512_H Body weight QTL 512 (human) 8 2.68 1334904 D8S1106 Body fat amount abdominal Average skin fold measurement (mm) 3 cm lateral to and 1 cm inferior to umbilicus 2314192 15111508 70836;1347158 LPL;MSR1 8 1 25880399 3 - by peak only
2314793 human GLUCO112_H Glucose level QTL 112 (human) 12 2.24 1341328 D12S395 1298109 D12S1045 Glucose level Blood samples collected after fasting and 2 hours after 75 g oral glucose load were analyzed for plasma glucose and insulin, and trait was corrected insulin response(CIR), calculated as [2hr insulin/[2hr glucose x (2hr glucose - 70mg/dl)] glucose homeostasis traits 2314192 15111508 12 118672849 128963767 1 - by flanking markers
2314794 human INSUL21_H Insulin level QTL 21 (human) 18 1.87 1298292 D18S858 Insulin level 2 hour post glucose challenge Plasma insulin level (mU/ml) 2 hours after a 75 g oral glucose load glucose homeostasis traits 2314192 15111508 18 40048190 66048190 3 - by peak only
2315054 human GLUCO132_H Glucose level QTL 132 (human) 2 1.97 1335653 D2S2987 Glucose level Diagnosed as type 2 diabetic, 1999 WHO criteria, excluding late onset autoimmunity diabetics, and maturity-onset diabetes of the youth or mitochondrial associated diabetics 2315019 12652528 732443 CAPN10 2 229502125 242951149 3 - by peak only
2315056 human GLUCO134_H Glucose level QTL 134 (human) 2 2.18 1339912 D2S336 Glucose level Diagnosed as type 2 diabetic or glucose intolerant, 1999 WHO criteria, excluding late onset autoimmunity diabetics, and maturity-onset diabetes of the youth or mitochondrial associated diabetics glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 2315040 10331426 2 222441887 242951149 3 - by peak only
2289330 human BW384_H Body weight QTL 384 (human) 7 2.34 5.1E-4 3186 Nos3 Body fat amount abdominal post-training (response) abdominal total fat, blacks. abnormal lateral ganglionic eminence morphology;increased body weight Obesity 1354697 11872690 735618 NOS3
2289331 human BW385_H Body weight QTL 385 (human) 7 1.74 0.0023 1299922 D7S559 Body fat amount abdominal baseline abdominal subcutaneous fat, blacks. abnormal lateral ganglionic eminence morphology;increased body weight Obesity 1354697 11872690 7 143165923 158821424 3 - by peak only
2289332 human BW376_H Body weight QTL 376 (human) 2 1.87 0.00168 733473 IRS1 Body fat amount abdominal baseline abdominal visceral fat, whites(Caucasian in original HERITAGE Study description) increased body weight;abnormal lateral ganglionic eminence morphology Obesity 1354697 11872690 733473 IRS1 2 214340450 240340450 3 - by peak only
2289333 human BW378_H Body weight QTL 378 (human) 3 2.45 3.9E-4 1298243 D3S1311 Body fat amount abdominal baseline abdominal subcutaneous fat, blacks increased body weight;abnormal lateral ganglionic eminence morphology Obesity 1354697 11872690 3 185502595 199501827 3 - by peak only
2289334 human BW87_H Body weight QTL 87 (human) 11 2.3 1337711 D11S1887 1341181 D11S940 Body weight BMI weight(kg) divided by height (m2) increased body mass index Obesity 1643034 14627748 11 86068752 100978652 1 - by flanking markers
2289423 human BW404_H Body weight QTL 404 (human) 6 2.02 1298145 D6S281 Body fat amount none fat mass measured by DXA abnormal lateral ganglionic eminence morphology Obesity 738102 11923910 6 156739933 170899992 3 - by peak only
2289426 human BW213_H Body weight QTL 213 (human) 13 2.78 2.0E-4 1315628 MBNL2 Body weight BMI Body mass index (BMI) measured as (weight in kg)/(height in meters)2; linkage to the quantitative trait was assessed using untransformed values increased body mass index Obesity 1642925 15470360 13 83758475 109758475 3 - by peak only
2289427 human BW166_H Body weight QTL 166 (human) 20 0.0126 1334800 D20S857 Body weight BMI Body mass index (BMI) measured as kg/m2 increased body mass index Obesity 1642891 9915959 20 36541785 62435964 3 - by peak only
2289428 human BW313_H Body weight QTL 313 (human) 22 2.09 0.0015 1603682 CYTSA Body weight BMI Body mass index was measured as (weight in kilograms)/(height in meters)2 increased body mass index Obesity 1643170 17115187 22 10070043 36070043 3 - by peak only
2289429 human BW177_H Body weight QTL 177 (human) 20 3.17 6.7E-5 1334800 D20S857 Body weight BMI Body mass index (BMI) measured as kg/m2; linkage to the discrete trait assessed using dichotomized phenotypes with individuals having BMI>=30 considered "affected" and those having lower BMI considered "unaffected" increased body mass index Obesity 1642891 9915959 69199;736916;736208;69093;1345990;1347922 ASIP;GNAS;CEBPB;HNF4A;MC3R;PCK1 20 36541785 62435964 3 - by peak only
2289430 human BMD7_H Bone mineral density QTL 7 (human) 15 3.32 1.0E-4 1606398 FMN1 Bone mineral density Bone mineral density in grams per sqare centimeter measured at the femoral neck, trochanter and intertrochanteric regions of the hip, at the L1-L4 region of the lumbar spine and at the wrist at the ultra distal region of the forearm by dual-energy x-ray scanners increased bone mineral density Obesity 1643174 17473065 15 18000507 44000507 3 - by peak only
2289431 human BW178_H Body weight QTL 178 (human) 20 3.17 6.7E-5 1334800 D20S857 Body fat amount percent fat Percent body fat (%fat) measured by bioelectric impedance; linkage to the discrete trait assessed using dichotomized phenotypes with individuals having %fat>=40 considered "affected" and those having lower %fat considered "unaffected" increased body weight;increased percent body fat Obesity 1642891 9915959 69199;736916;736208;69093;1345990;1347922 ASIP;GNAS;CEBPB;HNF4A;MC3R;PCK1 20 36541785 62435964 3 - by peak only
2289433 human BW340_H Body weight QTL 340 (human) 13 3.11 1315628 MBNL2 Body morphometry waist circumference Waist circumference in centimeters was measured at the same time blood samples were taken for analysis abnormal adipose tissue distribution;abnormal lateral ganglionic eminence morphology;increased susceptibility to weight gain Obesity 1642952 15647995 13 83758475 109758475 3 - by peak only
2289437 human BW401_H Body weight QTL 401 (human) 2 1.95 1299966 D2S206 Body fat amount percent fat fat mass measured by DXA divided by body weight measured by DXA increased percent body fat Obesity 738102 11923910 2 220416145 242951149 3 - by peak only
2289438 human BW403_H Body weight QTL 403 (human) 2 2.03 1298118 D2S347 Body fat amount none fat mass measured by DXA abnormal lateral ganglionic eminence morphology Obesity 738102 11923910 2 110966452 136966452 3 - by peak only
2289439 human BW400_H Body weight QTL 400 (human) 6 1.77 0.0021 1298145 D6S281 Body weight BMI weight(kg) divided by height(m)2 increased body weight;increased body mass index Obesity 738102;738106 11923910;14764808 6 156739933 170899992 3 - by peak only
2289458 human BW215_H Body weight QTL 215 (human) 14 1.47 1338458 D14S275 1341752 D14S70 Body weight BMI weight(kg) divided by height(m) squared increased body mass index Obesity 1643159 17621312 14 25766625 33529158 1 - by flanking markers
2289460 human BW216_H Body weight QTL 216 (human) 16 1.57 1336553 D16S503 Body weight BMI weight(kg) divided by height(m) squared increased body mass index Obesity 1643159 17621312 16 49156417 75156417 3 - by peak only
2289461 human BW222_H Body morphometry QTL 222 (human) 6 1.55 1339217 D6S262 Body morphometry waist circumference minimum waist girth at the natural indentation, or midway between top of pelvis and lowest rib. increased body size Obesity 1643159 17621312 6 118772431 144772431 3 - by peak only
2289462 human SADIPOQ15_H Serum adiponectin level QTL 15 (human) 13 2.41 1334556 D13S158 Hormone level adiponectin level serum adiponectin measured with radioimmunoassay kit from Linco, Inc, St Charles, MI, USA increased adiponectin level Obesity 1643159 17621312 13 89774451 114142980 3 - by peak only
2289464 human SLEP13_H Serum leptin level QTL 13 (Human) 1 1.97 1335412 D1S2800 1336704 D1S2785 Hormone level leptin radioimmunoassay kit from ALPCO increased circulating leptin level Obesity 1643159 17621312 1 232525001 238943570 1 - by flanking markers
2289466 human SLEP14_H Serum leptin level QTL 14 (human) 5 2.08 1299941 D5S407 Hormone level leptin radioimmunoassay kit from ALPCO increased circulating leptin level Obesity 1643159 17621312 736062 ISL1 5 43030583 69030583 3 - by peak only
2289467 human BW221_H Body weight QTL 221 (human) 2 1.92 1298185 D2S286 1298201 D2S2333 Body morphometry waist circumference minimum waist girth at the natural indentation, or midway between top of pelvis and lowest rib. increased body size Obesity 1643159 17621312 2 75195641 85341937 1 - by flanking markers
2289468 human BW219_H Body weight QTL 219 (human) 14 1.63 1338458 D14S275 1341752 D14S70 Body fat amount percent fat estimated from bioelectrical impedance and equations from other studies in Samoans increased percent body fat Obesity 1643159 17621312 14 25766625 33529158 1 - by flanking markers
2289470 human SLEP15_H Serum leptin level QTL 15 (human) 6 3.83 1339217 D6S262 Hormone level leptin radioimmunoassay kit from ALPCO increased circulating leptin level Obesity 1643159 17621312 1351327 ENPP1 6 118772431 144772431 3 - by peak only
2289471 human BW218_H Body weight QTL 218 (human) 12 1.96 1338986 D12S86 1299909 D12S324 Body fat amount percent fat estimated from bioelectrical impedance and equations from other studies in Samoans increased percent body fat Obesity 1643159 17621312 12 99191356 125191356 4 - by one flank marker only
2289472 human SLEP19_H Serum leptin level QTL 19 (human) 19 2.05 1336308 D19S209 1336340 D19S216 Hormone level leptin radioimmunoassay kit from ALPCO increased circulating leptin level Obesity 1643159 17621312 19 3265332 4900636 1 - by flanking markers
2289473 human SLEP17_H Serum leptin level QTL 17 (human) 13 1.77 1334923 D13S153 1341348 D13S156 Hormone level leptin radioimmunoassay kit from ALPCO increased circulating leptin level Obesity 1643159 17621312 13 47788774 73555775 1 - by flanking markers
2289474 human BW220_H Body weight QTL 220 (human) 16 2.24 1337425 D16S415 1336553 D16S503 Body fat amount percent fat estimated from bioelectrical impedance and equations from other studies in Samoans increased percent body fat Obesity 1643159 17621312 16 52228236 62156530 1 - by flanking markers
2289475 human SLEP20_H Serum leptin level QTL 20 (human) 14 2.01 1338458 D14S275 Hormone level leptin adjusted by percent body fat increased circulating leptin level Obesity 1643159 17621312 14 12766678 38766678 3 - by peak only
2289477 human BW217_H Body weight QTL 217 (human) 8 1.82 1298096 D8S549 1339561 D8S258 Body fat amount percent fat estimated from bioelectrical impedance and equations from other studies in Samoans increased percent body fat Obesity 1643159 17621312 8 15693972 20411650 1 - by flanking markers
2289478 human SLEP18_H Serum leptin level QTL 18 (human) 16 2.98 1336553 D16S503 Hormone level leptin radioimmunoassay kit from ALPCO increased circulating leptin level Obesity 1643159 17621312 736333 AGRP 16 49156417 75156417 3 - by peak only
2289504 human BW450_H Body weight QTL 450 (Human) 12 3.4 1298293 D12S1052 1335722 D12S1064 Body morphometry waist to hip ratio largest diameter between tenth rib and top of pelvis divided by largest diameter around buttocks increased body weight;increased body size Obesity 1643326 15534617 12 73895728 89347604 1 - by flanking markers
2289505 human BW447_H Body weight QTL 447 (human) 11 2.94 1335740 D11S2006 1298156 D11S2371 Body morphometry waist to hip ratio largest diameter between tenth rib and top of pelvis divided by largest diameter around buttocks increased body weight;increased body size Obesity 1643326 15534617 733835;69170 UCP3;UCP2 11 59478464 73182973 1 - by flanking markers
2289506 human BW446_H Body weight QTL 446 (human) 8 2.4 1334527 D8S502 Body morphometry waist to hip ratio largest diameter between tenth rib and top of pelvis divided by largest diameter around buttocks increased body weight;increased body size Obesity 1643326 15534617 8 124539420 146274826 3 - by peak only
2289507 human BW448_H Body weight QTL 448 (human) 12 3.31 1336494 D12S297 1341824 D12S1291 Body morphometry waist to hip ratio largest diameter between tenth rib and top of pelvis divided by largest diameter around buttocks increased body weight;increased body size Obesity 1643326 15534617 619561 VDR 12 50899321 66220652 1 - by flanking markers
2289508 human BW452_H Body weight QTL 452 (human) 11 2.36 1335740 D11S2006 1298156 D11S2371 Body fat amount abdominal Visceral abdominal tissue, measured in square cm from CT images(1 cm thick slice at L4/L5); bowel fat was subtracted increased body size;increased body weight Obesity 1643326 15534617 733835;69170 UCP3;UCP2 11 59478464 73182973 1 - by flanking markers
2289510 human BW451_H Body weight QTL 451 (human) 12 2.89 1331611 PAH 1299944 D12S2070 Body morphometry waist to hip ratio largest diameter between tenth rib and top of pelvis divided by largest diameter around buttocks increased body weight;increased body size Obesity 1643326 15534617 735633 SCARB1 12 88567195 114567195 4 - by one flank marker only
2289511 human BW453_H Body weight QTL 453 (human) 17 2.15 1341644 D17S1290 Body fat amount abdominal visceral abdominal tissue, measured in square cm from CT images(1 cm thick slice at L4/L5). Bowel fat was subtracted increased body size;increased body weight Obesity 1643326 15534617 737129;736216;69010;1348512 PPY;HSD17B1;GCGR;PYY 17 40686541 66686541 3 - by peak only
2289513 human BW449_H Body weight QTL 449 (human) 12 3.23 1298293 D12S1052 Body morphometry waist to hip ratio largest diameter between tenth rib and top of pelvis divided by largest diameter around buttocks increased body weight;increased body size Obesity 1643326 15534617 70506 IGF1 12 60895805 86895805 3 - by peak only
2289514 human BW456_H Body weight QTL 456 (human) 5 2.2 1331610 D5S820 1331595 D5S1456 Body fat amount subcutaneous subcutaneous abdominal tissue, measured in square cm from CT images(1 cm thick slice at L4/L5) increased body size;increased body weight Obesity 1643326 15534617 733595;732227 ADRB2;NR3C1 5 156054978 168965291 1 - by flanking markers
2289516 human BW442_H Body weight QTL 442 (human) 1 2.14 Body weight BMI weight (kg) divided by height in meters, squared increased body mass index Obesity 1643326 15534617 1298224;1343939 TNFRSF1B;PGD
2289517 human BW455_H Body weight QTL 455 (human) 5 2.27 1331610 D5S820 1331595 D5S1456 Body fat amount subcutaneous subcutaneous abdominal tissue, measured in square cm from CT images(1 cm thick slice at L4/L5) increased body size;increased body weight Obesity 1643326 15534617 733595;732227 ADRB2;NR3C1 5 156054978 168965291 1 - by flanking markers
2289518 human BW454_H Body weight QTL 454 (human) 3 3.19 1298277 D3S2387 Body fat amount subcutaneous subcutaneous abdominal tissue, measured in square cm from CT images(1 cm thick slice at L4/L5) increased body size;increased body weight Obesity 1643326 15534617 69168;730950 PPARG;GHRL 3 1 14011366 3 - by peak only
2289519 human BW459_H Body weight QTL 459 (human) 17 1.86 1298314 D17S1308 Body fat amount subcutaneous subcutaneous abdominal tissue, measured in square cm from CT images(1 cm thick slice at L4/L5) increased body size;increased body weight Obesity 1643326 15534617 17 1 13570067 3 - by peak only
2289520 human BW458_H Body weight QTL 458 (human) 8 2.03 1298285 D8S1110 1339606 D8S1113 Body fat amount subcutaneous subcutaneous abdominal tissue, measured in square cm from CT images(1 cm thick slice at L4/L5) increased body size;increased body weight Obesity 1643326 15534617 737467 ADRB3 8 53343525 59871002 1 - by flanking markers
2289521 human BW457_H Body weight QTL 457 (human) 6 2.02 1298306 D6S1056 1298206 D6S1021 Body fat amount subcutaneous subcutaneous abdominal tissue, measured in square cm from CT images(1 cm thick slice at L4/L5) increased body size;increased body weight Obesity 1643326 15534617 6 94154229 104780753 1 - by flanking markers
2289522 human BW437_H Body weight QTL 437 (human) 20 1.5 1337428 D20S486 1299965 D20S119 1340050 D20S438 Body weight BMI greatest lifetime BMI (kg per meter squared) increased body mass index Obesity 1643195;1643163;1643162 16899800;14975103;11702208 dominant 20 24583134 43082585 1 - by flanking markers
2289524 human BW435_H Body weight QTL 435 (human) 1 1.38 1334695 D1S2697 1341324 D1S199 Body weight BMI units given as kg/meter-squared increased body mass index Obesity 1643160 16731858 1 16292128 19829731 1 - by flanking markers
2289526 human BW438_H Body weight QTL 438 (human) 20 2.2 1335976 D20S471 1340125 D20S896 1334650 D20S101 Body weight BMI weight in kg divided by height in meters, squared 1643162;1643325 11702208;16537441 recessive 20 19779543 34162034 1 - by flanking markers
2289527 human BW436_H Body weight QTL 436 (human) 10 3.74 0.0186 1298290 D10S208 1341859 D10S196 Body weight BMI units given as kg/meter-squared increased body mass index Obesity 1643160 16731858 731662;733945;1352070 PPYR1;GAD2;UCN3 10 31720106 51812385 1 - by flanking markers
2289585 human BW468_H Body weight QTL 468 (human) 6 1.3 1334598 D6S1719 Body morphometry waist to hip ratio waist (smallest circumferance between tenth rib and iliac crest): hip (largest circumferance around buttocks) ratio increased body weight;abnormal body size Obesity 1643357 16391564 6 152989781 170899992 3 - by peak only
2289587 human BW467_H Body weight QTL 467 (human) 6 2.4 1335212 D6S426 1339217 D6S262 1337496 D6S257 Body fat amount percent fat dual energy X-ray technique increased percent body fat Obesity 1643357 16391564 6 40750185 131772514 1 - by flanking markers
2289589 human BW465_H Body weight QTL 465 (human) 2 2.4 1342134 D2S2308 1338037 D2S338 1341606 D2S2344 Body weight lean mass dual energy X-ray technique increased body weight;increased lean body mass Obesity 1643357 16391564 2 227001301 236900439 1 - by flanking markers
2289591 human BW464_H Body weight QTL 464 (human) 2 1.2 1336436 D2S337 Body morphometry waist to hip ratio waist (narrowest circumference between tenth rib and iliac crest) to hip (largest circumfence around buttocks) ratio abnormal lateral ganglionic eminence morphology;abnormal body size Obesity 1643357 16391564 2 48523555 74523555 3 - by peak only
2289593 human BW469_H Body weight QTL 469 (human) 8 1.6 1340103 D8S505 Body morphometry waist to hip ratio waist (smallest circumferance between tenth rib and iliac crest): hip (largest circumferance around buttocks) ratio increased body weight;abnormal body size Obesity 1643357 16391564 8 21570583 47570583 3 - by peak only
2289594 human BW463_H Body weight QTL 463 (human) 1 2.1 1341324 D1S199 Body fat amount abdominal intraabdominal fat, with some subcutaneous; dual energy X-ray absorptometry technique, assessed between top of 2nd and bottom of 4th lumbar vertebrae abnormal lateral ganglionic eminence morphology;increased body weight Obesity 1643357 16391564 1 6829668 32829668 3 - by peak only
2289596 human BW466_H Body weight QTL 466 (human) 3 1.2 1342413 D3S1285 Body weight lean mass dual energy X-ray technique increased body weight;increased lean body mass Obesity 1643357 16391564 3 51914316 77914316 3 - by peak only
2289597 human BW470_H Body weight QTL 470 (human) 8 1.3 1338783 D8S601 Body weight BMI weight in kg divided by height in meters squared increased body mass index Obesity 1643357 16391564
2289605 human BW474_H Body weight QTL 474 (human) 11 1.4 1337255 D11S925 Body fat amount abdominal intraabdominal fat, with some subcutaneous; dual energy X-ray absorptometry technique, assessed between top of 2nd and bottom of 4th lumbar vertebrae abnormal lateral ganglionic eminence morphology Obesity 1643357 16391564 11 107333578 133333578 3 - by peak only
2289606 human BW476_H Body weight QTL 476 (human) 12 2.9 1338105 D12S79 1335506 D12S1723 1342274 D12S1612 Body fat amount abdominal intraabdominal fat, with some subcutaneous; dual energy X-ray absorptometry technique, assessed between top of 2nd and bottom of 4th lumbar vertebrae abnormal lateral ganglionic eminence morphology Obesity 1643357 16391564 735909;732285 PLA2G1B;P2RX4
2289607 human BW475_H Body weight QTL 475 (human) 12 1.6 1338499 D12S352 Body morphometry waist to hip ratio waist (smallest circumferance between tenth rib and iliac crest): hip (largest circumferance around buttocks) abnormal lateral ganglionic eminence morphology;abnormal body size Obesity 1643357 16391564 12 1 13531739 3 - by peak only
2289608 human BW471_H Body weight QTL 471 (human) 8 1.6 1338223 D8S285 Body morphometry waist circumferance weight in kg divided by height in meters squared abnormal lateral ganglionic eminence morphology;abnormal body size Obesity 1643357 16391564 8 44229684 70229684 3 - by peak only
2289610 human BW480_H Body weight QTL 480 (human) 22 1.4 1338422 D22S1151 Body weight lean mass dual energy X-ray absorptometry technique increased body weight;increased lean body mass Obesity 1643357 16391564 22 28870899 49691432 3 - by peak only
2289612 human BW473_H Body weight QTL 473 (Human) 10 1.9 1336025 D10S1779 Body weight lean mass dual energy X-ray technique increased body weight;increased lean body mass Obesity 1643357 16391564 10 1 21252019 3 - by peak only
2289615 human BW406_H Body weight QTL 406 (human) 12 1.79 1337215 D12S83 Body weight lean mass lean mass measured by DXA. increased body weight;increased lean body mass Obesity 738102;738106 11923910;14764808 12 46175697 72175697 3 - by peak only
2289618 human BW487_H Body weight QTL 487 (human) 17 1.44 1298312 D17S1301 Body weight BMI weight (kg) divided by height in meters, squared increased body mass index Obesity 1643407 15611782 17 57192606 78774742 3 - by peak only
2289619 human BW486_H Body weight QTL 486 (human) 10 1.01 1338820 D10S1237 Body weight BMI weight (kg) divided by height in meters, squared increased body mass index Obesity 1643407 15611782 10 103110181 129110181 3 - by peak only
2289620 human BW488_H Body weight QTL 488 (human) 20 1.51 1338506 D20S851 Body fat amount none bioelectric impedance analysis was used to estimate fat mass abnormal lateral ganglionic eminence morphology Obesity 1643407 15611782 20 1 21810009 3 - by peak only
2289622 human BW485_H Body weight QTL 485 (human) 5 2.56 1340416 D5S1725 Body fat amount percent fat bioelectric impedance analysis was used to estimate fat mass; percent fat is fat mass divided by body mass increased percent body fat Obesity 1643407 15611782 5 76202450 102202450 3 - by peak only
2289613 human BW396_H Body weight QTL 396 (human) 1 2.75 1298138 D1S468 Body weight BMI weight(kg) divided by height(m)2 increased body mass index Obesity 738102;738106 11923910;14764808 732873;1298224;1343939 NR0B2;TNFRSF1B;PGD 1 1 16574908 3 - by peak only
2289614 human BW398_H Body weight QTL 398 (human) 2 2.56 1340718 D2S160 Body weight BMI weight(kg) divided by height(m)2 increased body weight;increased body mass index Obesity 738102;738106 11923910;14764808 2 99715066 125715066 3 - by peak only
2289580 human BW461_H Body weight QTL 461 (human) 17 2.44 1298312 D17S1301 1337536 D17S801 Body weight BMI weight in kg divided by height in meters, squared increased body mass index Obesity 1643328 16520807 732473;733781 GRB2;GALR2 17 70192530 72018533 1 - by flanking markers
2289581 human BW460_H Body weight QTL 460 (human) 17 3.05 1298312 D17S1301 1337536 D17S801 Body fat amount abdominal visceral abdominal tissue, measured in square cm from CT images (1 cm thick slice at L4/L5); bowel fat was subtracted abnormal lateral ganglionic eminence morphology Obesity 1643328 16520807 732473;733781 GRB2;GALR2 17 70192530 72018533 1 - by flanking markers
2289583 human BW462_H Body weight QTL 462 (human) 17 1.92 1298312 D17S1301 1337536 D17S801 Body morphometry waist circumference minimum, between tenth rib and the iliac crest (cm) abnormal body size Obesity 1643328 16520807 732473;733781 GRB2;GALR2 17 70192530 72018533 1 - by flanking markers
2289226 human SLEP8_H Serum leptin level QTL 8 (human) 2 2.03 0.021 1339777 D2S2221 1335090 D2S165 1340804 D2S2337 Hormone level leptin serum leptin level (ng/ml) increased circulating leptin level Obesity 1298035;1642944 9806554;11151766 1352097 POMC 2 23077407 28457075 1 - by flanking markers
2315058 human GLUCO133_H Glucose level QTL 133 (human) 1 4.295 0.02 2161733 D1S2384 2149301 APOA2 Glucose level Diagnosed as type 2 diabetic or glucose intolerant, 1999 WHO criteria, excluding late onset autoimmunity diabetics, and maturity-onset diabetes of the youth or mitochondrial associated diabetics glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 2315040 10331426 737360;737364;1312426 APOA2;PKLR;LMX1A 1 157949091 159459538 1 - by flanking markers
2315059 human GLUCO138_H Glucose level QTL 138 (human) 11 1.155 1337255 D11S925 1299919 D11S912 Glucose level Diagnosed as type 2 diabetic or glucose intolerant, 1999 WHO criteria, excluding late onset autoimmunity diabetics, and maturity-onset diabetes of the youth or mitochondrial associated diabetics glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 2315040 10331426 11 120333478 128129403 1 - by flanking markers
2315060 human GLUCO129_H Glucose level QTL 129 (human) 11 1.47 0.0046 1298235 D11S1998 1341818 D11S1304 1299919 D11S912 Glucose level Diagnosed as diabetic, 1999 WHO criteria, fasting glucose levels more than 126 mg/dl and/or 2-hr glucose levels more than 200 mg/dl, or using insulin or oral antidiabetic agents, and with a history of diabetes 2315019 12652528 11 117202970 132091609 1 - by flanking markers
2315062 human GLUCO130_H Glucose level QTL 130 (human) 11 2.32 5.0E-4 1298235 D11S1998 1341818 D11S1304 1299919 D11S912 Glucose level Age(truncated) at diagnosis as type 2 diabetic, 1999 WHO criteria, fasting glucose levels more than 126 mg/dl and/or 2-hr glucose levels more than 200 mg/dl, or using insulin or oral antidiabetic agents, and with a history of diabetes 2315019 12652528 11 117202970 132091609 1 - by flanking markers
2315064 human GLUCO136_H Glucose level QTL 136 (human) 8 1.348 1338138 D8S136 Glucose level Diagnosed as type 2 diabetic or glucose intolerant, 1999 WHO criteria, excluding late onset autoimmunity diabetics, and maturity-onset diabetes of the youth or mitochondrial associated diabetics glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 2315040 10331426 8 9489374 35489374 3 - by peak only
2315065 human GLUCO139_H Glucose level QTL 139 (human) 18 2.361 1340121 D18S59 Glucose level Diagnosed as type 2 diabetic or glucose intolerant, 1999 WHO criteria, excluding late onset autoimmunity diabetics, and maturity-onset diabetes of the youth or mitochondrial associated diabetics glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 2315040 10331426 18 1 13636538 3 - by peak only
2315066 human GLUCO131_H Glucose level QTL 131 (human) 2 3.19 5.8E-4 1335653 D2S2987 Glucose level Diagnosed as type 2 diabetic, or with impaired glucose tolerance, 1999 WHO criteria, excluding late onset autoimmunity diabetics, and maturity-onset diabetes of the youth or mitochondrial associated diabetics 2315019 12652528 732443 CAPN10 2 229502125 242951149 3 - by peak only
2315068 human GLUCO137_H Glucose level QTL 137 (human) 8 1.365 1340253 D8S87 1342354 D8S532 Glucose level Diagnosed as type 2 diabetic or glucose intolerant, 1999 WHO criteria, excluding late onset autoimmunity diabetics, and maturity-onset diabetes of the youth or mitochondrial associated diabetics glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 2315040 10331426 8 14907821 40907821 4 - by one flank marker only
2315069 human GLUCO135_H Glucose level QTL 135 (human) 2 1.386 1298257 D2S117 Glucose level Diagnosed as type 2 diabetic or glucose intolerant, 1999 WHO criteria, excluding late onset autoimmunity diabetics, and maturity-onset diabetes of the youth or mitochondrial associated diabetics glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 2315040 10331426 2 182327142 208327142 3 - by peak only
2315762 human GLUCO151_H Glucose level QTL 151 (human) 2 1.26 0.0079 1298283 D2S396 Glucose level Diagnosed with diabetes, or with hyperglycemia per World Health Organization[1985] guidelines between 35 and 70 years of age glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 2315708 11484155 2 217392009 242951149 3 - by peak only
2315764 human GLUCO153_H Glucose level QTL 153 (human) 5 1.46 0.0048 1338437 D5S436 Glucose level Diagnosed with diabetes, or with hyperglycemia per World Health Organization[1985] guidelines between 35 and 70 years of age glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 2315708 11484155 5 132184279 158184279 3 - by peak only
2315765 human GLUCO149_H Glucose level QTL 149 (human) 1 1.98 0.0013 1338728 D1S196 1336060 D1S218 Glucose level Diagnosed with diabetes, or with hyperglycemia per World Health Organization[1985] guidelines between 35 and 70 years of age glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 2315708 11484155 732790;736633;737360;733408;1343442 LMNA;CRP;APOA2;RXRG;KCNJ9 1 165870924 172770032 1 - by flanking markers
2315766 human GLUCO142_H Glucose level QTL 142 (human) 1 2.14 0.00156 1335516 D1S2836 Glucose level Previously diagnosed with diabetes, or with fasting glucose more than 7 mmol/l or 2 hour post glucose tolerance glucose measurement of 11.1 mmol/l glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 1559422 11734540 1 231936869 247249719 3 - by peak only
2315768 human GLUCO148_H Glucose level QTL 148 (human) 19 2.2 0.002 1338183 D19S414 Glucose level Previously diagnosed with diabetes, or with fasting glucose more than 7 mmol/l or 2 hour post glucose tolerance glucose measurement of 11.1 mmol/l glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 1559422 11734540 19 23606692 49606692 3 - by peak only
2315769 human GLUCO147_H Glucose level QTL 147 (human) 16 1.96 0.006 1337425 D16S415 Glucose level Previously diagnosed with diabetes, or with fasting glucose more than 7 mmol/l or 2 hour post glucose tolerance glucose measurement of 11.1 mmol/l glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 1559422 11734540 16 39228348 65228348 3 - by peak only
2315770 human GLUCO150_H Glucose level QTL 150 (human) 1 3.63 2.2E-5 1335516 D1S2836 Glucose level Diagnosed with diabetes, or with hyperglycemia per World Health Organization[1985] guidelines between 35 and 70 years of age glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 2315708 11484155 1 231936869 247249719 3 - by peak only
2315771 human GLUCO144_H Glucose level QTL 144 (human) 8 1.73 0.00421 1337365 D8S1784 Glucose level Previously diagnosed with diabetes, or with fasting glucose more than 7 mmol/l or 2 hour post glucose tolerance glucose measurement of 11.1 mmol/l glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 1559422 11734540 1314398 ZFPM2 8 93172444 119172444 3 - by peak only
2315772 human GLUCO146_H Glucose level QTL 146 (human) 2 3.03 0.002 1340298 D2S125 Glucose level Previously diagnosed with diabetes, or with fasting glucose more than 7 mmol/l or 2 hour post glucose tolerance glucose measurement of 11.1 mmol/l glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 1559422 11734540 732443 CAPN10 2 227816846 242951149 3 - by peak only
2315773 human GLUCO152_H Glucose level QTL 152 (human) 5 1.35 0.0064 1335487 D5S647 Glucose level Diagnosed with diabetes, or with hyperglycemia per World Health Organization[1985] guidelines between 35 and 70 years of age glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 2315708 11484155 5 53283203 79283203 3 - by peak only
2315774 human GLUCO143_H Glucose level QTL 143 (human) 3 2.06 0.0019 1340665 D3S1292 Glucose level Previously diagnosed with diabetes, or with fasting glucose more than 7 mmol/l or 2 hour post glucose tolerance glucose measurement of 11.1 mmol/l glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 1559422 11734540 3 120113133 146113133 3 - by peak only
2315775 human GLUCO145_H Glucose level QTL 145 (human) 16 1.15 0.01796 1298187 D16S407 Glucose level Previously diagnosed with diabetes, or with fasting glucose more than 7 mmol/l or 2 hour post glucose tolerance glucose measurement of 11.1 mmol/l glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 1559422 11734540 735798;736501;1347441 ACSM3;SSTR5;SOCS1 16 1 23184956 3 - by peak only
2315776 human GLUCO162_H Glucose level QTL 162 (human) 17 3.74 1.7E-5 1341260 D17S921 Glucose level Diagnosed with diabetes, or with hyperglycemia per World Health Organization[1985] guidelines between 35 and 70 years of age glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 2315708 11484155 17 1201518 27201518 3 - by peak only
2315777 human GLUCO161_H Glucose level QTL 161 (human) 12 1.7 0.0026 1342093 D12S351 Glucose level Diagnosed with diabetes, or with hyperglycemia per World Health Organization[1985] guidelines between 35 and 70 years of age glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 2315708 11484155 12 77429552 103429552 3 - by peak only
2315778 human GLUCO160_H Glucose level QTL 160 (human) 11 1.65 0.003 1340365 D11S904 Glucose level Diagnosed with diabetes, or with hyperglycemia per World Health Organization[1985] guidelines between 35 and 70 years of age glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 2315708 11484155 11 13637273 39637273 3 - by peak only
2315779 human GLUCO155_H Glucose level QTL 155 (human) 7 2.26 6.3E-4 1336288 D7S493 Glucose level Diagnosed with diabetes, or with hyperglycemia per World Health Organization[1985] guidelines between 35 and 70 years of age glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 2315708 11484155 7 8771771 34771771 3 - by peak only
2315780 human GLUCO154_H Glucose level QTL 154 (human) 6 1.97 0.0013 1339217 D6S262 Glucose level Diagnosed with diabetes, or with hyperglycemia per World Health Organization[1985] guidelines between 35 and 70 years of age glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 2315708 11484155 6 118772431 144772431 3 - by peak only
2315781 human GLUCO158_H Glucose level QTL 158 (human) 8 1.41 0.0054 1341759 D8S284 1334535 D8S272 Glucose level Diagnosed with diabetes, or with hyperglycemia per World Health Organization[1985] guidelines between 35 and 70 years of age glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 2315708 11484155 8 131580880 137804711 1 - by flanking markers
2315782 human GLUCO156_H Glucose level QTL 156 (human) 8 1.22 0.0087 1338216 D8S520 Glucose level Diagnosed with diabetes, or with hyperglycemia per World Health Organization[1985] guidelines between 35 and 70 years of age glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 2315708 11484155 8 1 23593878 3 - by peak only
2315783 human GLUCO157_H Glucose level QTL 157 (human) 8 2.55 3.1E-4 1298096 D8S549 1339561 D8S258 Glucose level Diagnosed with diabetes, or with hyperglycemia per World Health Organization[1985] guidelines between 35 and 70 years of age glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 2315708 11484155 8 15693972 20411650 1 - by flanking markers
2315784 human GLUCO164_H Glucose level QTL 164 (human) 2 1.77 0.0022 1335620 D2S312 1334801 D2S220 Glucose level Plasma glucose 120 minutes after 75 g oral glucose challenge glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 1642893 12540634 2 15144745 20949668 1 - by flanking markers
2315786 human GLUCO163_H Glucose level QTL 163 (human) 1 1.44 0.0115 1342315 D1S209 1341145 D1S216 Glucose level Subjects between 35 and 65 years of age, diagnosed with diabetes, or with fasting glucose greater than or equal to 7 mmol/l or 2 hour oral glucose tolerance test value equal to or greater than 11.1 mmol/l, normoglycemia defined as fasting glucose less than 6.1 mmol/l and 2 hour value less than 7.8 mmol/l, impaired glucose homeostasis values between normal and diabetic glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 1642893 12540634 1 61744824 77428177 1 - by flanking markers
2315788 human GLUCO159_H Glucose level QTL 159 (human) 10 1.99 0.0012 1340411 D10S1765 Glucose level Diagnosed with diabetes, or with hyperglycemia per World Health Organization[1985] guidelines between 35 and 70 years of age glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 2315708 11484155 10 76591610 102591610 3 - by peak only
2315790 human GLUCO169_H Glucose level QTL 169 (human) 7 1.45 0.0049 1299970 D7S669 1339181 D7S657 Glucose level Plasma glucose 60 minutes after administration of 75 g oral glucose challenge glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 1642893 12540634 7 77710454 92644390 1 - by flanking markers
2315792 human GLUCO171_H Glucose level QTL 171 (human) 14 1.75 0.0023 1336177 D14S80 1341752 D14S70 Glucose level Plasma glucose 120 minutes after administration of 75 g oral glucose challenge glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 1642893 12540634 1318730;1344819;1348020;1353259;1353495;1353545 IRF9;IL25;LTB4R;TRA@;GZMB;TRD@ 14 26794265 33529158 1 - by flanking markers
2315794 human GLUCO172_H Glucose level QTL 172 (human) 15 1.3 0.0072 1340676 D15S130 1336426 D15S1014 Glucose level Plasma glucose 120 minutes after administration of 75 g oral glucose challenge glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 1642893 12540634 15 92512236 95803789 1 - by flanking markers
2315795 human GLUCO170_H Glucose level QTL 170 (human) 8 1.27 0.0078 1341759 D8S284 1334535 D8S272 Glucose level Plasma glucose 180 minutes after administration of 75 g oral glucose challenge glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 1642893 12540634 8 131580880 137804711 1 - by flanking markers
2315797 human GLUCO175_H Glucose level QTL 175 (human) 18 3.07 8.5E-5 1340121 D18S59 1335805 D18S452 Glucose level HbA1c level glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 1642893 12540634 18 636461 26636461 4 - by one flank marker only
2315799 human GLUCO168_H Glucose level QTL 168 (human) 4 1.28 0.0141 1342110 D4S1575 1336674 D4S424 Glucose level Diagnosed with type 2 diabetes or impaired glucose homeostasis glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 1642893 12540634 4 135009884 142417432 1 - by flanking markers
2315801 human GLUCO173_H Glucose level QTL 173 (human) 16 1.48 0.0045 1340691 D16S520 Glucose level Plasma glucose 180 minutes after administration of 75 g oral glucose challenge glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 1642893 12540634 16 72073740 88827254 3 - by peak only
2315802 human GLUCO165_H Glucose level QTL 165 (human) 2 1.59 0.0034 1298118 D2S347 1337735 D2S368 Glucose level Plasma glucose 120 minutes after 75 g oral glucose challenge glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 1642893 12540634 2 123966318 134893694 1 - by flanking markers
2315803 human GLUCO167_H Glucose level QTL 167 (human) 4 1.23 0.0087 1335649 D4S419 1298205 D4S391 Glucose level HbA1c level glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 1642893 12540634 4 1221589 27221589 4 - by one flank marker only
2315804 human GLUCO166_H Glucose level QTL 166 (human) 2 1.87 0.0017 1299966 D2S206 1338037 D2S338 Glucose level HbA1c level glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 1642893 12540634 2 233416070 236900439 1 - by flanking markers
2315805 human GLUCO174_H Glucose level QTL 174 (human) 17 1.48 0.0081 1298171 D17S949 1341087 D17S802 Glucose level Diagnosed with diabetes or impaired glucose homeostasis glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 1642893 12540634
2315893 human GLUCO189_H Glucose level QTL 189 (human) 11 2.25 1337563 D11S1993 Glucose level Diagnosed as diabetic by fasting glucose level of 7 mmol/l or more, or 2 hour glucose of 11.1 mmol/l or more after oral glucose challenge, which are WHO standards of 1999 2315859 16123354 11 30566783 56566783 3 - by peak only
2315895 human GLUCO188_H Glucose level QTL 188 (human) 4 1.43 1298248 D4S1647 Glucose level Diagnosed as diabetic by fasting glucose level of 7 mmol/l or more, or 2 hour glucose of 11.1 mmol/l or more after oral glucose challenge, which are WHO standards of 1999 2315859 16123354 4 86654067 112654067 3 - by peak only
2315896 human GLUCO190_H Glucose level QTL 190 (human) 15 1.47 1340590 D15S659 Glucose level Diagnosed as diabetic by fasting glucose level of 7 mmol/l or more, or 2 hour glucose of 11.1 mmol/l or more after oral glucose challenge, which are WHO standards of 1999 2315859 16123354 15 31161391 57161391 3 - by peak only
2315897 human GLUCO187_H Glucose level QTL 187 (human) 3 1.9 1339283 D3S1296 1339832 D3S3633 1298245 D3S2406 Glucose level Diagnosed as diabetic by fasting glucose level of 7 mmol/l or more, or 2 hour glucose of 11.1 mmol/l or more after oral glucose challenge, which are WHO standards of 1999 2315859 16123354 1312779;1318576;1320598 SUCLG2;FOXP1;GBE1 3 69846156 82085987 1 - by flanking markers
2315898 human GLUCO191_H Glucose level QTL 191 (human) 9 1.83 1357243 D9S925 Glucose level Martingale residual for age of onset of diabetes, incorporates age at entry into study as well as age of onset or age at end of study 2315859 16123354
2292765 human PRSTS74_H Prostate tumor susceptibility QTL 74 (human) 22 1.87 Prostate tumor susceptibility Affected status confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2292015 14601029
2292767 human PRSTS102_H Prostate tumor susceptibility QTL 102 (human) 20 Prostate tumor susceptibility Clinically aggressive prostate cancer; affected individuals had one of the following; regional or distant stage based on pathology or clinical stage, Gleason score at diagnosis 7 or higher, pretreatment PSA of 20 or more ng/ml, or prostate cancer listed as primary cause of death on death certificate abnormal sciatic nerve Prostatic Neoplasms 2292444 16508751
2292769 human PRSTS16_H Prostate tumor susceptibility QTL 16 (human) 6 2.74 Prostate tumor susceptibility Aggressive prostate cancer with at least one of the following criteria: 1) regional or distal stage; 2) Gleason grade at diagnosis of 7 or more (poorly differentiated grade if no Gleason grade was available); 3) pre-treatment PSA at diagnosis of 20 ng/ml or more; 4) death from metastatic cancer before age 65 (if deceased) abnormal sciatic nerve Prostatic Neoplasms 2291841 16932970
2289188 human BW349_H Body weight QTL 349 (human) 3 0.0015 1298321 D3S2432 Body fat amount percent fat hydrostatic weighing technique increased body weight;increased percent body fat Obesity 1642923 8981960 3 19140311 45140311 3 - by peak only
2289190 human SLEP11_H Serum leptin level QTL 11 (human) 14 2.47 4.0E-4 1338522 D14S280 Hormone level leptin whole genome scans conducted in F2 progeny from intercrossing female OLETF, which has significantly higher leptin levels than lean controls, with male F344; serum leptin and triglyceride levels were measured via ELISA kits increased body mass index;increased circulating leptin level Obesity 1642890;1643034 11238509;14627748 10 116109062 135374737 3 - by peak only
2289191 human BW366_H Body weight QTL 366 (human) 18 0.0057 1342398 D18S877 Body fat amount percent fat hydrostatic weighing technique increased body weight;increased percent body fat Obesity 1642923 8981960 18 11979245 37979245 3 - by peak only
2289192 human BW359_H Body weight QTL 359 (human) 13 0.0344 1336644 D13S889 Body fat amount percent fat hydrostatic weighing technique increased body weight;increased percent body fat Obesity 1642923 8981960
2289193 human BW348_H Body weight QTL 348 (human) 3 0.0259 1341733 D3S1280 Body fat amount percent fat hydrostatic weighing technique increased body weight;increased percent body fat Obesity 1642923 8981960 3 140591036 166591036 3 - by peak only
2289194 human BW353_H Body weight QTL 353 (human) 6 0.012 2106181 D6S2791 Body fat amount percent fat hydrostatic weighing technique increased body weight;increased percent body fat Obesity 1642923 8981960 6 18648430 44648430 3 - by peak only
2289195 human SLEP12_H Serum leptin level QTL 12 (human) 16 1.72 0.0024 1298187 D16S407 Hormone level leptin whole genome scans conducted in F2 progeny from intercrossing female OLETF, which has significantly higher leptin levels than lean controls, with male F344; serum leptin and triglyceride levels were measured via ELISA kits increased body mass index;increased circulating leptin level Obesity 1642890;1643034 11238509;14627748 16 1 23184956 3 - by peak only
2289196 human BW371_H Body weight QTL371 (human) 11 2.7 1299908 D11S2000 Body fat amount percent fat underwater weighing technique increased body weight;increased percent body fat Obesity 1642923 8981960 11 92064058 118064058 3 - by peak only
2289198 human BW369_H Body weight QTL 369 (human) 21 0.0303 1340966 D21S112 Body fat amount percent fat hydrostatic weighing technique increased body weight;increased percent body fat Obesity 1642923 8981960 21 33152674 46944323 3 - by peak only
2289199 human BW351_H Body weight QTL 351 (human) 4 0.0154 1298309 D4S3253 Body fat amount percent fat hydrostatic weighing technique increased body weight;increased percent body fat Obesity 1642923 8981960 4 54152317 80152317 3 - by peak only
2289200 human BW356_H Body weight QTL 356 (human) 11 0.0163 1298156 D11S2371 Body fat amount percent fat hydrostatic weighing technique increased body weight;increased percent body fat Obesity 1642923 8981960 11 60182876 86182876 3 - by peak only
2289201 human BW345_H Body weight QTL 345 (human) 1 0.0148 1341913 D1S1677 Body fat amount percent fat hydrostatic weighing technique increased body weight;increased percent body fat Obesity 1642923 8981960 1 148826426 174826426 3 - by peak only
2289202 human BW350_H Body weight QTL 350 (human) 4 0.0146 1298180 D4S2397 Body fat amount percent fat hydrostatic weighing technique increased body weight;increased percent body fat Obesity 1642923 8981960 4 13867033 39867033 3 - by peak only
2289203 human BW364_H Body weight QTL 364 (human) 17 0.0463 1299971 D17S784 Body fat amount percent fat hydrostatic weighing technique increased body weight;increased percent body fat Obesity 1642923 8981960 17 62416927 78774742 3 - by peak only
2289204 human BW362_H Body weight QTL 362 (human) 16 0.0221 1729430 D16S266 Body fat amount percent fat hydrostatic weighing technique increased body weight;increased percent body fat Obesity 1642923 8981960 16 62240968 88240968 3 - by peak only
2289205 human BW370_H Body weight QTL 370 (human) 3 1.9 1298321 D3S2432 Body fat amount percent fat hydrostatic weighing technique increased body weight;increased percent body fat Obesity 1642923 8981960 3 19140311 45140311 3 - by peak only
2289206 human BW355_H Body weight QTL 355 (human) 11 9.0E-4 1674883 D11S2366 Body fat amount percent fat hydrostatic weighing technique increased body weight;increased percent body fat Obesity 1642923 8981960 11 94022927 120022927 3 - by peak only
2289207 human SLEP10_H Serum leptin level QTL 10 (human) 10 2.73 2.0E-4 1341283 D10S220 Hormone level leptin whole genome scans conducted in F2 progeny from intercrossing female OLETF, which has significantly higher leptin levels than lean controls, with male F344; serum leptin and triglyceride levels were measured via ELISA kits increased body mass index;increased circulating leptin level Obesity 1642890;1643034 11238509;14627748 10 39017509 65017509 3 - by peak only
2289208 human BW365_H Body weight QTL 365 (human) 18 0.0075 1298119 D18S844 Body fat amount percent fat hydrostatic weighing technique increased body weight;increased percent body fat Obesity 1642923 8981960 18 59483761 76117153 3 - by peak only
2289209 human BW347_H Body weight QTL 347 (human) 2 0.0123 1340264 D2S172 Body fat amount percent fat hydrostatic weighing technique increased body weight;increased percent body fat Obesity 1642923 8981960 2 217880949 242951149 3 - by peak only
2289210 human BW354_H Body weight QTL 354 (human) 8 0.0246 1298238 D8S261 Body fat amount percent fat hydrostatic weighing technique increased body weight;increased percent body fat Obesity 1642923 8981960 8 4870547 30870547 3 - by peak only
2289211 human BW360_H Body weight QTL 360 (human) 14 0.0131 1298288 D14S1280 Body fat amount percent fat hydrostatic weighing technique increased body weight;increased percent body fat Obesity 1642923 8981960 14 12725778 38725778 3 - by peak only
2289212 human BW357_H Body weight QTL 357 (human) 11 0.0365 1339037 D11S988 Body fat amount percent fat hydrostatic weighing technique increased body weight;increased percent body fat Obesity 1642923 8981960 11 1 17496486 3 - by peak only
2289213 human BW346_H Body weight QTL 346 (human) 2 0.003 1336092 D2S1394 Body fat amount percent fat hydrostatic weighing technique increased body weight;increased percent body fat Obesity 1642923 8981960 2 59992782 85992782 3 - by peak only
2289214 human BW358_H Body weight QTL 358 (human) 13 0.0473 1334606 D13S232 Body fat amount percent fat hydrostatic weighing technique increased body weight;increased percent body fat Obesity 1642923 8981960 13 9697923 35697923 3 - by peak only
2289215 human BW344_H Body weight QTL 344 (human) 1 0.0499 1338999 D1S1646 Body fat amount percent fat hydrostatic weighing technique increased body weight;increased percent body fat Obesity 1642923 8981960 1 1 20065101 3 - by peak only
2289216 human BW367_H Body weight QTL 367 (human) 19 0.0469 1339033 D19S1036 Body fat amount percent fat hydrostatic weighing technique increased body weight;increased percent body fat Obesity 1642923 8981960 19 10444765 36444765 3 - by peak only
2289217 human BW361_H Body weight QTL 361 (human) 15 0.0077 1336135 D15S207 Body fat amount percent fat hydrostatic weighing technique increased body weight;increased percent body fat Obesity 1642923 8981960 15 81011875 100338915 3 - by peak only
2289218 human BW368_H Body weight QTL 368 (human) 20 0.0185 1335995 D20S103 Body fat amount percent fat hydrostatic weighing technique increased body weight;increased percent body fat Obesity 1642923 8981960 20 1 13507306 3 - by peak only
2289219 human BW363_H Body weight QTL 363 (human) 17 0.023 1298232 D17S579 Body fat amount percent fat hydrostatic weighing technique increased body weight;increased percent body fat Obesity 1642923 8981960 17 27162609 53162609 3 - by peak only
2289220 human BW352_H Body weight QTL 352 (human) 5 0.0241 1339269 D5S1716 Body fat amount percent fat hydrostatic weighing technique increased body weight;increased percent body fat Obesity 1642923 8981960 5 70580955 96580955 3 - by peak only
2289221 human BW73_H Body weight QTL 73 (human) 10 4.85 1339504 D10S548 1298290 D10S208 1340909 D10S197 Body weight BMI qualitative trait analysis; BMI > 27 is obese increased body mass index Obesity 1298035 9806554 10 18761298 31720285 1 - by flanking markers
2289223 human SLEP9_H Serum leptin level QTL 9 (human) 7 1.77 0.0022 1336097 D7S636 Hormone level leptin whole genome scans conducted in F2 progeny from intercrossing female OLETF, which has significantly higher leptin levels than lean controls, with male F344; serum leptin and triglyceride levels were measured via ELISA kits increased body mass index;increased circulating leptin level Obesity 1642890;1643034 11238509;14627748 69123 LEP 7 137330429 158821424 3 - by peak only
2289436 human BW397_H Body weight QTL 397 (human) 2 4.04 1298127 D2S142 1298201 D2S2333 1298118 D2S347 Body weight BMI weight(kg) divided by height(m)2 increased body mass index;increased body weight Obesity 738102;738106 11923910;14764808 2 85341937 155991476 1 - by flanking markers
2289448 human BW410_H Body weight QTL 410 (human) 17 1.64 1342347 D17S1852 1341260 D17S921 1298144 D17S799 Body weight lean mass lean mass measured by DXA increased lean body mass Obesity 738106;738102 14764808;11923910 17 10456232 14201607 1 - by flanking markers
2289449 human BW409_H Body weight QTL 409 (human) 20 1.64 0.003 1299965 D20S119 1335922 D20S196 1298199 D20S178 Body fat amount none fat mass measured by DXA abnormal lateral ganglionic eminence morphology Obesity 738102 11923910 20 43082465 48995328 1 - by flanking markers
2289451 human BW299_H Body weight QTL 299 (human) 1 2.24 1338626 D1S534 Body weight body mass index BMI calculated as weight(kg) divided by height(m) squared increased body mass index Obesity 1334491 12582223 732790 LMNA 1 106479888 132479888 3 - by peak only
2289453 human BW297_H Body weight QTL 297 (human) 7 3.83 1357237 D7S1802 1335908 D7S1818 1298114 D7S817 Body weight body mass index BMI calculated as weight(kg) divided by height(m) squared increased body mass index Obesity 1334491 12582223 730830 NPY 7 20671829 49359606 1 - by flanking markers
2289454 human BW298_H Body weight QTL 298 (human) 11 3.35 1298202 D11S2002 1298267 D11S4464 1299908 D11S2000 Body weight body mass index BMI calculated as weight(kg) divided by height(m) squared increased body mass index Obesity 1334491 12582223 737553;736796 APOA4;DRD2 11 79643051 123132075 1 - by flanking markers
2289455 human BW300_H Body weight QTL 300 (human) 8 2.34 1335303 G10585 Body weight body mass index BMI calculated as weight (kg) divided by height(m) squared increased body mass index Obesity 1334491 12582223 70836 LPL 8 296910 26296910 3 - by peak only
2289480 human SLEP16_H Serum leptin level QTL 16 (human) 12 2.06 1338986 D12S86 Hormone level leptin radioimmunoassay kit from ALPCO increased circulating leptin level Obesity 1643159 17621312 737153 HNF1A
2289481 human BW252_H Body weight QTL 252 (human) 12 2.04 1340578 D12S310 Body morphometry waist circumference adjusted by percent body fat increased body size Obesity 1643159 17621312 12 5864933 31864933 3 - by peak only
2289483 human BW251_H Body weight QTL 251 (human) 3 2.1 1335890 D3S1262 1342246 D3S1580 Body morphometry waist circumference minimum waist girth at the natural indentation, or midway between top of pelvis and lowest rib. increased body size Obesity 1643159 17621312 3 187706173 190025819 1 - by flanking markers
2289484 human BW249_H Body weight QTL 249 (human) 16 1.95 1341872 D16S515 1298258 D16S516 Body morphometry waist circumference minimum waist girth at the natural indentation, or midway between top of pelvis and lowest rib. increased body size Obesity 1643159 17621312 16 75074570 88827254 4 - by one flank marker only
2289485 human BW250_H Body weight QTL 250 (human) 1 2.36 1337838 D1S238 Body morphometry waist circumference minimum waist girth at the natural indentation, or midway between top of pelvis and lowest rib. increased body size Obesity 1643159 17621312 1 173412963 199412963 3 - by peak only
2289486 human BW248_H Body weight QTL 248 (human) 12 1.86 1338499 D12S352 Body weight body mass index a three-stage genome-wide scan for linkage to obesity in Finnish sibpairs increased body size Obesity 1642895;1643159 10999806;17621312 12 1 13531739 3 - by peak only
2289397 human BW94_H Body weight QTL 94 (human) 6 0.297 2.49 1298111 D6S462 Body weight BMI BMI more than 35 kg/m2 1642950 15220211 6 77985454 103985454 3 - by peak only
2289528 human BW424_H Body weight QTL 424 (human) 18 2.3 1299942 D18S843 Body weight BMI weight(kg) / height(m)2 measured in 1971 increased body mass index Obesity 1643195;1643163 16899800;14975103 18 1 21603861 3 - by peak only
2289530 human BW423_H Body weight QTL 423 (human) 10 2.1 1335624 D10S1208 Body weight BMI weight(kg)/height(m)2 measured in 1971 increased body mass index Obesity 1643195;1643163 16899800;14975103
2289532 human BW422_H Body weight QTL 422 (human) 6 2.9 1338844 D6S2436 Body weight BMI weight(kg)/height(m)2 measured in 1971 increased body mass index Obesity 1643195;1643163 16899800;14975103
2289533 human BW421_H Body weight QTL 421 (human) 16 3.0 1298329 D16S403 1334914 D16S769 Body weight BMI weight(kg)/height(m)2 measured in 1971 increased body mass index Obesity 1643195;1643163 16899800;14975103 16 22945152 26066530 1 - by flanking markers
2289534 human BW253_H Body weight QTL 253 (human) 2 2.54 0.001 1331557 D2S2968 1339843 D2S2585 Body fat amount percent fat DXA used to estimate fat mass and lean mass in trunk; parameter was trunk fat divided by (trunk fat + trunk lean) times 100 percent abnormal percent body fat Obesity 1643195 16899800 2 237743204 242575229 1 - by flanking markers
2289536 human BW254_H Body weight QTL 254 (human) 2 3.12 0.002 1331557 D2S2968 1339843 D2S2585 Body morphometry body surface area (BSA) BSA= 0.20247 * [(height in meters)0.725] * [(weight in kilograms) 0.425] (Dubois formula) abnormal body size Obesity 1643195 16899800 2 237743204 242575229 1 - by flanking markers
2289538 human BW255_H Body weight QTL 255 (human) 2 2.45 0.004 1331557 D2S2968 1339843 D2S2585 Body weight BMI weight(kg) divided by height(m)2 increased body mass index Obesity 1643195 16899800 2 237743204 242575229 1 - by flanking markers
2289540 human BW425_H Body weight QTL 425 (human) 1 1298138 D1S468 Body weight BMI weight(kg) divided by height(m) squared increased body mass index Obesity 738101 11957135 codominant 1 1 16574908 3 - by peak only
2289541 human BW433_H Body weight QTL 433 (human) X 1340778 DXS1059 Body weight BMI weight(kg) divided by height(m) squared increased body mass index Obesity 738101 11957135 dominant X 98212725 124212725 3 - by peak only
2289542 human BW432_H Body weight QTL 432 (human) X 1337387 DXS8099 Body weight BMI weight(kg) divided by height(m) squared increased body mass index Obesity 738101 11957135 dominant X 11329182 37329182 3 - by peak only
2289543 human BW434_H Body weight QTL 434 (human) 4 1298098 D4S3350 Body weight BMI weight(kg) divided by height(m) squared increased body mass index Obesity 738101 11957135 4 20857080 46857080 3 - by peak only
2289544 human BW427_H Body weight QTL 427 (human) 4 1336411 D4S2289 Body weight BMI weight(kg) divided by height(m) squared increased body mass index Obesity 738101 11957135 dominant
2289545 human BW428_H Body weight QTL 428 (human) 4 Body weight BMI weight(kg) divided by height(m) squared increased body mass index Obesity 738101 11957135 codominant
2289546 human BW426_H Body weight QTL 426 (human) 4 1298204 D4S2639 Body weight BMI weight(kg) divided by height(m) squared increased body mass index Obesity 738101 11957135 codominant 4 5454441 31454441 3 - by peak only
2289547 human BW431_H Body weight QTL 431 (human) 20 1340440 D20S465 Body weight BMI weight(kg) divided by height(m) squared increased body mass index Obesity 738101 11957135 dominant 20 25230365 51230365 3 - by peak only
2289548 human BW430_H Body weight QTL 430 (human) 11 1298323 D11S934 Body weight BMI weight(kg) divided by height(m) squared increased body mass index Obesity 738101 11957135 codominant 11 112585636 134452384 3 - by peak only
2289549 human BW429_H Body weight QTL 429 (human) 8 1298313 D8S282 Body weight BMI weight(kg) divided by height(m) squared increased body mass index Obesity 738101 11957135 dominant 8 8459252 34459252 3 - by peak only
2289561 human BW440_H Body weight QTL 440 (human) 15 2.61 4.0E-4 1335361 D15S165 1340590 D15S659 1335583 D15S1012 Body morphometry height height in meters increased body height 1643327 16138910 731577;736253;1313085;1346462;1606587 FBN1;HDC;MEIS2;GREM1;CYP19A1 15 29047915 44161483 1 - by flanking markers
2289563 human BW441_H Body weight QTL 441 (human) 4 2.66 5.0E-4 1298248 D4S1647 1298122 D4S408 1338059 D4S2368 Body weight BMI weight (kg) divided by height in meters, squared increased body mass index 1643327 16138910 731586;735842;732381;735821;1319511;1347163;1348310 NPY5R;FABP2;CPE;UCP1;BBS7;NPY1R;NPY2R 4 99653996 185388311 1 - by flanking markers
2289434 human BW156_H Body weight QTL 156 (human) 10 0.0166 1851034 D10S1211 Body weight BMI Body mass index (BMI) measured as kg/m2 increased body mass index Obesity 1642891 9915959 10 53394298 79394298 3 - by peak only
2289435 human BMD4_H Bone mineral density QTL 4 (human) 6 3.15 1.0E-4 1353193 BMP6 Bone mineral density Bone mineral density in grams per sqare centimeter measured at the femoral neck, trochanter and intertrochanteric regions of the hip, at the L1-L4 region of the lumbar spine and at the wrist at the ultra distal region of the forearm by dual-energy x-ray scanners increased bone mineral density Obesity 1643174 17473065 1353193 BMP6 6 1 20749367 3 - by peak only
2289444 human BW414_H Body weight QTL 414 (human) 2 3.42 1298184 D2S112 1298118 D2S347 Body weight BMI weight(kg) divided by height (m)2 increased body mass index Obesity 738106 14764808 2 115007599 132925305 2 - by one flank and peak markers
2289445 human BW415_H Body weight QTL 415 (human) 6 1.24 1298174 D6S1697 Body fat amount none fat mass measured with DXA abnormal lateral ganglionic eminence morphology Obesity 738106 14764808 732660;736559;1354229 IGF2R;ESR1;ACAT2 6 154764421 170899992 3 - by peak only
2289550 human SLEP21_H Serum leptin level QTL 21 (human) 5 1341886 D5S211 Hormone level leptin plasma leptin level abnormal lipid level Obesity 1643325 16537441 5 160181041 180857866 3 - by peak only
2289553 human BP95_H Blood pressure QTL 95 (human) 20 1341151 D20S604 Blood pressure systolic systolic blood pressure increased systemic arterial systolic blood pressure Obesity 1643325 16537441 20 1 25532381 3 - by peak only
2289555 human SLIPL23_H Lipid level QTL 23 (human) 2 1335056 D2S1400 1334898 D2S1360 Lipid level apolipoprotein level ApoB abnormal lipid level Obesity 1643325 16537441 2 11524390 17355576 1 - by flanking markers
2289557 human SLIPL22_H Serum lipid level QTL 22 (human) 19 1341439 D19S250 Lipid level cholesterol level cholesterol level abnormal lipid level Obesity 1643325 16537441 19 9549597 35549597 4 - by one flank marker only
2289559 human BW439_H Body weight QTL 439 (human) 10 1335681 D10S187 Body morphometry hip circumference increased body size Obesity 1643325 16537441 10 105643136 131643136 3 - by peak only
2292771 human PRSTS33_H Prostate tumor susceptibility QTL 33 (human) 11 1298156 D11S2371 Prostate tumor susceptibility early onset Diagnosed with prostate cancer before age 69 abnormal sciatic nerve Prostatic Neoplasms 2291884 16037989 11 60182876 86182876 3 - by peak only
2292773 human PRSTS54_H Prostate tumor susceptibility QTL 54 (human) 15 1.49 Prostate tumor susceptibility Affected status confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2292015 14601029
2292774 human PRSTS104_H Prostate tumor susceptibility QTL 104 (human) 15 4.76 1299967 D15S1002 Prostate tumor susceptibility Clinically aggressive prostate cancer; affected individuals had one of the following; regional or distant stage based on pathology or clinical stage, Gleason score at diagnosis 7 or higher, pretreatment PSA of 20 or more ng/ml, or prostate cancer listed as primary cause of death on death certificate abnormal sciatic nerve Prostatic Neoplasms 2292444 16508751 15 12523382 38523382 3 - by peak only
2292775 human PRSTS86_H Prostate tumor susceptibility QTL 86 (human) 1 2.62 1342283 D1S2818 Prostate tumor susceptibility Affected status confirmed by medical records or death certificate abnormal sciatic nerve Prostatic Neoplasms 2292401 15988677 1 167605725 193605725 3 - by peak only
2292777 human PRSTS59_H Prostate tumor susceptibility QTL 59 (human) 20 1.24 Prostate tumor susceptibility Affected status confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2292015 14601029
2292778 human PRSTS76_H Prostate tumor susceptibility QTL 76 (human) 3 1.16 Prostate tumor susceptibility Affected status confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2292015 14601029
2292779 human PRSTS98_H Prostate tumor susceptibility QTL 98 (human) 3 1.21 Prostate tumor susceptibility Clinically aggressive prostate cancer; affected individuals had one of the following; regional or distant stage based on pathology or clinical stage, Gleason score at diagnosis 7 or higher, pretreatment PSA of 20 or more ng/ml, or prostate cancer listed as primary cause of death on death certificate abnormal sciatic nerve Prostatic Neoplasms 2292444 16508751
2292780 human PRSTS79_H Prostate tumor susceptibility QTL 79 (human) 21 1.11 Prostate tumor susceptibility Affected status confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2292015 14601029
2292781 human PRSTS11_H Prostate tumor susceptibility QTL 11 (human) 14 Prostate tumor susceptibility Aggressive prostate cancer with at least one of the following criteria: 1) regional or distal stage; 2) poorly differentiated or undifferentiated grade; 3) death due to metastatic cancer (per death certificate) abnormal sciatic nerve Prostatic Neoplasms 2290529 17299800
2292783 human MYI29_H Myocardial infarction susceptibility QTL 29 (human) 11 1666288 D11S2365 Myocardial infarction susceptibility early-onset Premature coronary artery disease and myocardial infarction cardiomyopathy Myocardial Ischemia 1554326 14732905 11 42962491 68962491 3 - by peak only
2292785 human PRSTS3_H Prostate tumor susceptibility QTL 3 (human) 14 1336053 D14S1434 1336903 D14S1426 Prostate tumor susceptibility Aggressive prostate cancer with at least one of the following criteria: 1) regional or distal stage; 2) poorly differentiated or undifferentiated grade; 3) death due to metastatic cancer (per death certificate) abnormal sciatic nerve Prostatic Neoplasms 2290529 17299800 14 94378110 105000676 2 - by one flank and peak markers
2292786 human PRSTS7_H Prostate tumor susceptibility QTL 7 (human) 6 1298134 D6S1017 Prostate tumor susceptibility late onset Age at diagnosis greater than or equal to 70 years abnormal sciatic nerve Prostatic Neoplasms 2290529 17299800 6 28785253 54785253 3 - by peak only
2292788 human PRSTS71_H Prostate tumor susceptibility QTL 71 (human) 17 3.27 5.0E-5 Prostate tumor susceptibility Affected status confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2292015 14601029
2292789 human PRSTS55_H Prostate tumor susceptibility QTL 55 (human) 17 2.12 Prostate tumor susceptibility Affected status confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2292015 14601029
2292790 human PRSTS38_H Prostate tumor susceptibility QTL 38 (human) 20 7.9E-4 1299965 D20S119 Prostate tumor susceptibility Affected status confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2291963 10820130 20 30082525 56082525 3 - by peak only
2292791 human PRSTS37_H Prostate tumor susceptibility QTL 37 (human) 20 0.002 1338093 D20S887 Prostate tumor susceptibility Affected status confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2291963 10820130 20 34106786 60106786 3 - by peak only
2292792 human PRSTS89_H Prostate tumor susceptibility QTL 89 (human) 16 1.88 1335387 D16S764 Prostate tumor susceptibility Affected status confirmed by medical records or death certificate abnormal sciatic nerve Prostatic Neoplasms 2292401 15988677 16 3554365 29554365 3 - by peak only
2292793 human PRSTS24_H Prostate tumor susceptibility QTL 24 (human) 1 1339881 D1S1728 Prostate tumor susceptibility late onset Diagnosed with prostate cancer after age 69 abnormal sciatic nerve Prostatic Neoplasms 2291884 16037989
2292795 human PRSTS63_H Prostate tumor susceptibility QTL 63 (human) 17 1.28 Prostate tumor susceptibility Affected status confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2292015 14601029
2292796 human PRSTS106_H Prostate tumor susceptibility QTL 106 (human) 15 2.15 Prostate tumor susceptibility Clinically aggressive prostate cancer; affected individuals had one of the following; regional or distant stage based on pathology or clinical stage, Gleason score at diagnosis 7 or higher, pretreatment PSA of 20 or more ng/ml, or prostate cancer listed as primary cause of death on death certificate abnormal sciatic nerve Prostatic Neoplasms 2292444 16508751
2292797 human PRSTS53_H Prostate tumor susceptibility QTL 53 (human) 12 1.0 Prostate tumor susceptibility Affected status confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2292015 14601029
2292798 human PRSTS50_H Prostate tumor susceptibility QTL 50 (human) 5 1.32 Prostate tumor susceptibility Affected status confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2292015 14601029
2292799 human PRSTS105_H Prostate tumor susceptibility QTL 105 (human) 15 2.43 Prostate tumor susceptibility Clinically aggressive prostate cancer; affected individuals had one of the following; regional or distant stage based on pathology or clinical stage, Gleason score at diagnosis 7 or higher, pretreatment PSA of 20 or more ng/ml, or prostate cancer listed as primary cause of death on death certificate abnormal sciatic nerve Prostatic Neoplasms 2292444 16508751
2292800 human PRSTS10_H Prostate tumor susceptibility QTL 10 (human) 1 1.45 1337874 D1S255 Prostate tumor susceptibility Aggressive prostate cancer with at least one of the following criteria: 1) regional or distal stage; 2) poorly differentiated or undifferentiated grade; 3) death due to metastatic cancer (per death certificate) abnormal sciatic nerve Prostatic Neoplasms 2290529 17299800 1605126 EPHB2 1 24422343 50422343 3 - by peak only
2292801 human MYI35_H Myocardial infarction susceptibility QTL 35 (human) 20 1357241 D20S482 Myocardial infarction susceptibility early-onset Premature coronary artery disease and myocardial infarction cardiomyopathy Myocardial Ischemia 1554326 14732905 20 1 17454357 3 - by peak only
2292802 human PRSTS73_H Prostate tumor susceptibility QTL 73 (human) 21 1.14 Prostate tumor susceptibility Affected status confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2292015 14601029
2292803 human PRSTS95_H Prostate tumor susceptibility QTL 95 (human) X 1337582 DXS7132 Prostate tumor susceptibility Affected status confirmed by medical records or death certificate abnormal sciatic nerve Prostatic Neoplasms 2292401 15988677 X 51572204 77572204 3 - by peak only
2292804 human PRSTS87_H Prostate tumor susceptibility QTL 87 (human) 8 1342360 D8S543 Prostate tumor susceptibility Affected status confirmed by medical records or death certificate abnormal sciatic nerve Prostatic Neoplasms 2292401 15988677 8 57175673 83175673 3 - by peak only
2292805 human PRSTS22_H Prostate tumor susceptibility QTL 22 (human) 2 Prostate tumor susceptibility Aggressive prostate cancer with at least one of the following criteria: 1) regional or distal stage; 2) Gleason grade at diagnosis of 7 or more (poorly differentiated grade if no Gleason grade was available); 3) pre-treatment PSA at diagnosis of 20 ng/ml or more; 4) death from metastatic cancer before age 65 (if deceased) abnormal sciatic nerve Prostatic Neoplasms 2291841 16932970
2292806 human MYI27_H Myocardial infarction susceptibility QTL 27 (human) 10 Myocardial infarction susceptibility early-onset Premature coronary artery disease and myocardial infarction cardiomyopathy Myocardial Ischemia 1554326 14732905
2292807 human PRSTS19_H Prostate tumor susceptibility QTL 19 (human) 20 Prostate tumor susceptibility Aggressive prostate cancer with at least one of the following criteria: 1) regional or distal stage; 2) Gleason grade at diagnosis of 7 or more (poorly differentiated grade if no Gleason grade was available); 3) pre-treatment PSA at diagnosis of 20 ng/ml or more; 4) death from metastatic cancer before age 65 (if deceased) abnormal sciatic nerve Prostatic Neoplasms 2291841 16932970
2292808 human PRSTS6_H Prostate tumor susceptibility QTL 6 (human) 8 1357236 D8S1132 Prostate tumor susceptibility early onset Age at diagnosis less than 70 years abnormal sciatic nerve Prostatic Neoplasms 2290529 17299800 8 94398122 120398122 3 - by peak only
2292810 human PRSTS4_H Prostate tumor susceptibility QTL 4 (human) 9 1339755 D9S1786 Prostate tumor susceptibility Aggressive prostate cancer with at least one of the following criteria: 1) regional or distal stage; 2) poorly differentiated or undifferentiated grade; 3) death due to metastatic cancer (per death certificate) abnormal sciatic nerve Prostatic Neoplasms 2290529 17299800 9 85079932 111079932 3 - by peak only
2292811 human PRSTS78_H Prostate tumor susceptibility QTL 78 (human) 17 2.31 Prostate tumor susceptibility Affected status confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2292015 14601029
2292812 human PRSTS100_H Prostate tumor susceptibility QTL 100 (human) 15 3.49 0.005 1299967 D15S1002 Prostate tumor susceptibility Clinically aggressive prostate cancer; affected individuals had one of the following; regional or distant stage based on pathology or clinical stage, Gleason score at diagnosis 7 or higher, pretreatment PSA of 20 or more ng/ml, or prostate cancer listed as primary cause of death on death certificate abnormal sciatic nerve Prostatic Neoplasms 2292444 16508751 15 12523382 38523382 3 - by peak only
2292813 human PRSTS61_H Prostate tumor susceptibility QTL 61 (human) 3 1.4 Prostate tumor susceptibility Affected status confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2292015 14601029
2292814 human MYI36_H Myocardial infarction susceptibility QTL 36 (human) 20 1357241 D20S482 Myocardial infarction susceptibility early-onset Premature coronary artery disease and myocardial infarction cardiomyopathy Myocardial Ischemia 1554326 14732905 20 1 17454357 3 - by peak only
2292815 human PRSTS64_H Prostate tumor susceptibility QTL 64 (human) 4 1.88 Prostate tumor susceptibility Affected status confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2292015 14601029
2292816 human PRSTS60_H Prostate tumor susceptibility QTL 60 (human) 22 2.35 5.0E-4 Prostate tumor susceptibility Affected status confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2292015 14601029
2292817 human MAMTS101_H Mammary tumor susceptibility QTL 101 (human) 5 2.9 1337476 D5S419 1336473 D5S426 Mammary tumor susceptibility mammary density Mammary density adjusted for age, BMI, menopausal status, hormone therapy, lifetime alcohol consumption, oral contraceptive use, education, number of live births, age at first birth, and pack-years smoking 2290472 17804758 1343875 CDH12 5 26694298 34798909 1 - by flanking markers
2292819 human MYI37_H Myocardial infarction susceptibility QTL 37 (human) 21 1339309 D21S1446 Myocardial infarction susceptibility early-onset Premature coronary artery disease and myocardial infarction cardiomyopathy Myocardial Ischemia 1554326 14732905 21 33862123 46944323 3 - by peak only
2292820 human PRSTS58_H Prostate tumor susceptibility QTL 58 (human) 11 1.19 Prostate tumor susceptibility Affected status confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2292015 14601029
2292821 human PRSTS46_H Prostate tumor susceptibility QTL 46 (human) 7 1.48 Prostate tumor susceptibility Affected status confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2292015 14601029
2292822 human MYI28_H Myocardial infarction susceptibility QTL 28 (human) 10 1338111 G10336 Myocardial infarction susceptibility early-onset Premature coronary artery disease and myocardial infarction cardiomyopathy Myocardial Ischemia 1554326 14732905
2292823 human PRSTS88_H Prostate tumor susceptibility QTL 88 (human) 13 1673722 D13S1807 Prostate tumor susceptibility Affected status confirmed by medical records or death certificate abnormal sciatic nerve Prostatic Neoplasms 2292401 15988677 13 41004194 67004194 3 - by peak only
2292824 human PRSTS5_H Prostate tumor susceptibility QTL 5 (human) 6 732286 F13A1 Prostate tumor susceptibility Aggressive prostate cancer with at least one of the following criteria: 1) regional or distal stage; 2) poorly differentiated or undifferentiated grade; 3) death due to metastatic cancer (per death certificate) abnormal sciatic nerve Prostatic Neoplasms 2290529 17299800 6 1 19177609 3 - by peak only
2292825 human MYI22_H Myocardial infarction susceptibility QTL 22 (human) 5 1337940 D5S2505 Myocardial infarction susceptibility early-onset Premature coronary artery disease and myocardial infarction cardiomyopathy Myocardial Ischemia 1554326 14732905 5 1 18870255 3 - by peak only
2292826 human PRSTS12_H Prostate tumor susceptibility QTL 12 (human) 6 3.0 Prostate tumor susceptibility Aggressive prostate cancer with at least one of the following criteria: 1) regional or distal stage; 2) Gleason grade at diagnosis of 7 or more (poorly differentiated grade if no Gleason grade was available); 3) pre-treatment PSA at diagnosis of 20 ng/ml or more; 4) death from metastatic cancer before age 65 (if deceased) abnormal sciatic nerve Prostatic Neoplasms 2291841 16932970
2292827 human PRSTS75_H Prostate tumor susceptibility QTL 75 (human) 1 1.18 Prostate tumor susceptibility Affected status confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2292015 14601029
2292828 human PRSTS14_H Prostate tumor susceptibility QTL 14 (human) 20 Prostate tumor susceptibility Aggressive prostate cancer with at least one of the following criteria: 1) regional or distal stage; 2) Gleason grade at diagnosis of 7 or more (poorly differentiated grade if no Gleason grade was available); 3) pre-treatment PSA at diagnosis of 20 ng/ml or more; 4) death from metastatic cancer before age 65 (if deceased) abnormal sciatic nerve Prostatic Neoplasms 2291841 16932970
2292829 human PRSTS69_H Prostate tumor susceptibility QTL 69 (human) 7 1.31 Prostate tumor susceptibility Affected status confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2292015 14601029
2292830 human PRSTS99_H Prostate tumor susceptibility QTL 99 (human) 6 2.09 0.15 1337699 D6S289 Prostate tumor susceptibility Clinically aggressive prostate cancer; affected individuals had one of the following; regional or distant stage based on pathology or clinical stage, Gleason score at diagnosis 7 or higher, pretreatment PSA of 20 or more ng/ml, or prostate cancer listed as primary cause of death on death certificate abnormal sciatic nerve Prostatic Neoplasms 2292444 16508751 6 2390123 28390123 3 - by peak only
2292831 human PRSTS80_H Prostate tumor susceptibility QTL 80 (human) 22 1.09 Prostate tumor susceptibility Affected status confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2292015 14601029
2292832 human PRSTS8_H Prostate tumor susceptibility QTL 8 (human) 3 1298282 D3S3023 Prostate tumor susceptibility early onset Age at diagnosis less than 70 years abnormal sciatic nerve Prostatic Neoplasms 2290529 17299800 3 109374882 135374882 3 - by peak only
2292833 human MYI25_H Myocardial infarction susceptibility QTL 25 (human) 5 1336959 D5S1505 Myocardial infarction susceptibility early-onset Premature coronary artery disease and myocardial infarction cardiomyopathy Myocardial Ischemia 1554326 14732905 5 106129673 132129673 3 - by peak only
2292834 human PRSTS26_H Prostate tumor susceptibility QTL 26 (human) 2 1339325 D2S427 Prostate tumor susceptibility early onset Diagnosed with prostate cancer before age 69 abnormal sciatic nerve Prostatic Neoplasms 2291884 16037989 2 218914630 242951149 3 - by peak only
2292835 human PRSTS30_H Prostate tumor susceptibility QTL 30 (human) 6 1298275 D6S2439 Prostate tumor susceptibility late onset Diagnosed with prostate cancer after age 69 abnormal sciatic nerve Prostatic Neoplasms 2291884 16037989
2292836 human MYI33_H Myocardial infarction susceptibility QTL 33 (human) 11 1298267 D11S4464 Myocardial infarction susceptibility early-onset Premature coronary artery disease and myocardial infarction cardiomyopathy Myocardial Ischemia 1554326 14732905 11 110131956 134452384 3 - by peak only
2292837 human PRSTS17_H Prostate tumor susceptibility QTL 17 (human) 7 Prostate tumor susceptibility Aggressive prostate cancer with at least one of the following criteria: 1) regional or distal stage; 2) Gleason grade at diagnosis of 7 or more (poorly differentiated grade if no Gleason grade was available); 3) pre-treatment PSA at diagnosis of 20 ng/ml or more; 4) death from metastatic cancer before age 65 (if deceased) abnormal sciatic nerve Prostatic Neoplasms 2291841 16932970
2292838 human PRSTS9_H Prostate tumor susceptibility QTL 9 (human) 10 1342004 D10S1412 Prostate tumor susceptibility Aggressive prostate cancer with at least one of the following criteria: 1) regional or distal stage; 2) poorly differentiated or undifferentiated grade; 3) death due to metastatic cancer (per death certificate) abnormal sciatic nerve Prostatic Neoplasms 2290529 17299800
2292839 human PRSTS21_H Prostate tumor susceptibility QTL 21 (human) 1 Prostate tumor susceptibility Aggressive prostate cancer with at least one of the following criteria: 1) regional or distal stage; 2) Gleason grade at diagnosis of 7 or more (poorly differentiated grade if no Gleason grade was available); 3) pre-treatment PSA at diagnosis of 20 ng/ml or more; 4) death from metastatic cancer before age 65 (if deceased) abnormal sciatic nerve Prostatic Neoplasms 2291841 16932970
2292840 human PRSTS91_H Prostate tumor susceptibility QTL 91 (human) 22 1339568 D22S283 Prostate tumor susceptibility Affected status confirmed by medical records or death certificate abnormal sciatic nerve Prostatic Neoplasms 2292401;2290503 15988677;17478474 22 22080904 48080904 3 - by peak only
2292841 human PRSTS83_H Prostate tumor susceptibility QTL 83 (human) 15 1338263 D15S817 Prostate tumor susceptibility Affected status confirmed by medical records or death certificate abnormal sciatic nerve Prostatic Neoplasms 2292401 15988677
2292842 human MYI34_H Myocardial infarction susceptibility QTL 34 (human) 16 1338725 D16S753 Myocardial infarction susceptibility early-onset Premature coronary artery disease and myocardial infarction cardiomyopathy Myocardial Ischemia 1554326 14732905 16 18181139 44181139 3 - by peak only
2292843 human PRSTS27_H Prostate tumor susceptibility QTL 27 (human) 3 1298169 D3S2427 Prostate tumor susceptibility early onset Diagnosed with prostate cancer before age 69 abnormal sciatic nerve Prostatic Neoplasms 2291884 16037989 3 164267613 190267613 3 - by peak only
2292844 human PRSTS85_H Prostate tumor susceptibility QTL 85 (human) 22 1339568 D22S283 Prostate tumor susceptibility Affected status confirmed by medical records or death certificate abnormal sciatic nerve Prostatic Neoplasms 2292401;2290503 15988677;17478474 22 22080904 48080904 3 - by peak only
2292845 human PRSTS41_H Prostate tumor susceptibility QTL 41 (human) 20 1.0E-4 1336023 D20S893 Prostate tumor susceptibility Affected status confirmed by medical records; no male to male transmission in this population, less than 5 affected individuals per pedigree, and age at diagnosis 66 or more years abnormal sciatic nerve Prostatic Neoplasms 2291963 10820130
2292847 human PRSTS13_H Prostate tumor susceptibility QTL 13 (human) 11 Prostate tumor susceptibility Aggressive prostate cancer with at least one of the following criteria: 1) regional or distal stage; 2) Gleason grade at diagnosis of 7 or more (poorly differentiated grade if no Gleason grade was available); 3) pre-treatment PSA at diagnosis of 20 ng/ml or more; 4) death from metastatic cancer before age 65 (if deceased) abnormal sciatic nerve Prostatic Neoplasms 2291841 16932970
2292848 human MYI23_H Myocardial infarction susceptibility QTL 23 (human) 5 1337940 D5S2505 Myocardial infarction susceptibility early-onset Premature coronary artery disease and myocardial infarction cardiomyopathy Myocardial Ischemia 1554326 14732905 5 1 18870255 3 - by peak only
2292849 human MYI31_H Myocardial infarction susceptibility QTL 31 (human) 11 1298202 D11S2002 Myocardial infarction susceptibility early-onset Premature coronary artery disease and myocardial infarction cardiomyopathy Myocardial Ischemia 1554326 14732905 11 66643169 92643169 3 - by peak only
2292850 human MYI18_H Myocardial infarction susceptibility QTL 18 (human) 3 1643947 G10448 Myocardial infarction susceptibility early-onset Premature coronary artery disease and myocardial infarction cardiomyopathy Myocardial Ischemia 1554326 14732905 3 1 17288192 3 - by peak only
2292851 human PRSTS31_H Prostate tumor susceptibility QTL 31 (human) 8 1331581 D8S1108 Prostate tumor susceptibility early onset Diagnosed with prostate cancer before age 69 abnormal sciatic nerve Prostatic Neoplasms 2291884 16037989 8 123360965 146274826 3 - by peak only
2292852 human PRSTS28_H Prostate tumor susceptibility QTL 28 (human) 5 1298299 D5S1457 Prostate tumor susceptibility Diagnosed with prostate cancer abnormal sciatic nerve Prostatic Neoplasms 2291884 16037989 5 28069671 54069671 3 - by peak only
2292854 human PRSTS62_H Prostate tumor susceptibility QTL 62 (human) 4 1.21 Prostate tumor susceptibility Affected status confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2292015 14601029
2292855 human MYI30_H Myocardial infarction susceptibility QTL 30 (human) 11 1298202 D11S2002 Myocardial infarction susceptibility early-onset Premature coronary artery disease and myocardial infarction cardiomyopathy Myocardial Ischemia 1554326 14732905 11 66643169 92643169 3 - by peak only
2292856 human MYI32_H Myocardial infarction susceptibility QTL 32 (human) 11 1298267 D11S4464 Myocardial infarction susceptibility early-onset Premature coronary artery disease and myocardial infarction cardiomyopathy Myocardial Ischemia 1554326 14732905 11 110131956 134452384 3 - by peak only
2292857 human PRSTS40_H Prostate tumor susceptibility QTL 40 (human) 20 7.0E-5 1338093 D20S887 Prostate tumor susceptibility Affected status confirmed by medical records; no male to male transmission in this population abnormal sciatic nerve Prostatic Neoplasms 2291963 10820130 20 34106786 60106786 3 - by peak only
2292859 human PRSTS25_H Prostate tumor susceptibility QTL 25 (human) 2 1334898 D2S1360 Prostate tumor susceptibility early onset Diagnosed with prostate cancer before age 69 abnormal sciatic nerve Prostatic Neoplasms 2291884 16037989 2 4355507 30355507 3 - by peak only
2292860 human PRSTS32_H Prostate tumor susceptibility QTL 32 (human) 9 1336259 D9S1118 Prostate tumor susceptibility Diagnosed with prostate cancer abnormal sciatic nerve Prostatic Neoplasms 2291884 16037989 9 18915421 44915421 3 - by peak only
2292861 human PRSTS48_H Prostate tumor susceptibility QTL 48 (human) 15 1.13 Prostate tumor susceptibility Affected status confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2292015 14601029
2292862 human PRSTS70_H Prostate tumor susceptibility QTL 70 (human) 15 1.47 Prostate tumor susceptibility Affected status confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2292015 14601029
2292863 human PRSTS23_H Prostate tumor susceptibility QTL 23 (human) 1 1337874 D1S255 Prostate tumor susceptibility late onset Diagnosed with prostate cancer after age 69 abnormal sciatic nerve Prostatic Neoplasms 2291884 16037989 1 24422343 50422343 3 - by peak only
2292864 human PRSTS43_H Prostate tumor susceptibility QTL 43 (human) 20 0.62 0.05 1335925 D20S173 Prostate tumor susceptibility Affected status confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2291984 11179028 20 45311492 62435964 3 - by peak only
2292865 human PRSTS56_H Prostate tumor susceptibility QTL 56 (human) 2 1.64 Prostate tumor susceptibility Affected status confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2292015 14601029
2292866 human PRSTS93_H Prostate tumor susceptibility QTL 93 (human) 5 1331595 D5S1456 Prostate tumor susceptibility Affected status confirmed by medical records or death certificate abnormal sciatic nerve Prostatic Neoplasms 2292401 15988677 5 155965194 180857866 3 - by peak only
2292867 human PRSTS92_H Prostate tumor susceptibility QTL 92 (human) 3 1298321 D3S2432 Prostate tumor susceptibility Affected status confirmed by medical records or death certificate abnormal sciatic nerve Prostatic Neoplasms 2292401 15988677 3 19140311 45140311 3 - by peak only
2292868 human MYI19_H Myocardial infarction susceptibility QTL 19 (human) 4 1337519 D4S3360 Myocardial infarction susceptibility early-onset Premature coronary artery disease and myocardial infarction cardiomyopathy Myocardial Ischemia 1554326 14732905 4 1 13105992 3 - by peak only
2292869 human PRSTS29_H Prostate tumor susceptibility QTL 29 (human) 5 1337509 D5S1503 Prostate tumor susceptibility early onset Diagnosed with prostate cancer before age 69 abnormal sciatic nerve Prostatic Neoplasms 2291884 16037989 5 85199613 111199613 3 - by peak only
2292870 human PRSTS52_H Prostate tumor susceptibility QTL 52 (human) 9 1.27 Prostate tumor susceptibility Affected status confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2292015 14601029
2292871 human PRSTS67_H Prostate tumor susceptibility QTL 67 (human) 15 1.31 Prostate tumor susceptibility Affected status confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2292015 14601029
2292872 human PRSTS18_H Prostate tumor susceptibility QTL 18 (human) 11 Prostate tumor susceptibility Aggressive prostate cancer with at least one of the following criteria: 1) regional or distal stage; 2) Gleason grade at diagnosis of 7 or more (poorly differentiated grade if no Gleason grade was available); 3) pre-treatment PSA at diagnosis of 20 ng/ml or more; 4) death from metastatic cancer before age 65 (if deceased) abnormal sciatic nerve Prostatic Neoplasms 2291841 16932970
2292873 human PRSTS65_H Prostate tumor susceptibility QTL 65 (human) 5 1.31 Prostate tumor susceptibility Affected status confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2292015 14601029
2292874 human PRSTS82_H Prostate tumor susceptibility QTL 82 (human) 8 1338307 D8S1048 Prostate tumor susceptibility Affected status confirmed by medical records or death certificate abnormal sciatic nerve Prostatic Neoplasms 2292401 15988677 8 13867829 39867829 3 - by peak only
2292875 human PRSTS68_H Prostate tumor susceptibility QTL 68 (human) 6 1.04 Prostate tumor susceptibility Affected status confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2292015 14601029
2292876 human PRSTS42_H Prostate tumor susceptibility QTL 42 (human) 20 0.86 0.023 1336023 D20S893 1341566 D20S120 Prostate tumor susceptibility Affected status confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2291984 11179028 20 26439123 52439123 4 - by one flank marker only
2292877 human PRSTS44_H Prostate tumor susceptibility QTL 44 (human) 4 1.06 Prostate tumor susceptibility Affected status confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2292015 14601029
2292878 human PRSTS72_H Prostate tumor susceptibility QTL 72 (human) 20 1.28 Prostate tumor susceptibility Affected status confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2292015 14601029
2292879 human PRSTS15_H Prostate tumor susceptibility QTL 15 (human) 5 2.24 Prostate tumor susceptibility Aggressive prostate cancer with at least one of the following criteria: 1) regional or distal stage; 2) Gleason grade at diagnosis of 7 or more (poorly differentiated grade if no Gleason grade was available); 3) pre-treatment PSA at diagnosis of 20 ng/ml or more; 4) death from metastatic cancer before age 65 (if deceased) abnormal sciatic nerve Prostatic Neoplasms 2291841 16932970
2292880 human PRSTS81_H Prostate tumor susceptibility QTL 81 (human) 5 2.28 1644455 D5S2858 Prostate tumor susceptibility Affected status confirmed by medical records or death certificate abnormal sciatic nerve Prostatic Neoplasms 2292401 15988677 5 50956909 76956909 3 - by peak only
2292881 human PRSTS20_H Prostate tumor susceptibility QTL 20 (human) 21 Prostate tumor susceptibility Aggressive prostate cancer with at least one of the following criteria: 1) regional or distal stage; 2) Gleason grade at diagnosis of 7 or more (poorly differentiated grade if no Gleason grade was available); 3) pre-treatment PSA at diagnosis of 20 ng/ml or more; 4) death from metastatic cancer before age 65 (if deceased) abnormal sciatic nerve Prostatic Neoplasms 2291841 16932970
2292882 human PRSTS94_H Prostate tumor susceptibility QTL 94 (human) 11 1339770 D11S898 Prostate tumor susceptibility Affected status confirmed by medical records or death certificate abnormal sciatic nerve Prostatic Neoplasms 2292401 15988677 11 87561751 113561751 3 - by peak only
2292883 human PRSTS47_H Prostate tumor susceptibility QTL 47 (human) 9 1.29 Prostate tumor susceptibility Affected status confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2292015 14601029
2292884 human PRSTS36_H Prostate tumor susceptibility QTL 36 (human) 22 1298301 D22S685 Prostate tumor susceptibility early onsset Diagnosed with prostate cancer before age 69 abnormal sciatic nerve Prostatic Neoplasms 2291884 16037989 22 19925686 45925686 3 - by peak only
2292886 human MYI20_H Myocardial infarction susceptibility QTL 20 (human) 4 1341136 D4S1629 Myocardial infarction susceptibility early-onset Premature coronary artery disease and myocardial infarction cardiomyopathy Myocardial Ischemia 1554326 14732905 4 145556329 171556329 3 - by peak only
2292887 human PRSTS90_H Prostate tumor susceptibility QTL 90 (human) 17 1340733 D17S1820 Prostate tumor susceptibility Affected status confirmed by medical records or death certificate abnormal sciatic nerve Prostatic Neoplasms 2292401;2292472 15988677;17120048 17 34139989 60139989 3 - by peak only
2292888 human MYI24_H Myocardial infarction susceptibility QTL 24 (human) 5 1298254 D5S1501 Myocardial infarction susceptibility early-onset Premature coronary artery disease and myocardial infarction cardiomyopathy Myocardial Ischemia 1554326 14732905 5 65504264 91504264 3 - by peak only
2292889 human PRSTS35_H Prostate tumor susceptibility QTL 35 (human) 20 1335158 D20S478 Prostate tumor susceptibility Diagnosed with prostate cancer abnormal sciatic nerve Prostatic Neoplasms 2291884 16037989 20 23665569 49665569 3 - by peak only
2292890 human PRSTS84_H Prostate tumor susceptibility QTL 84 (human) 17 1340733 D17S1820 Prostate tumor susceptibility Affected status confirmed by medical records or death certificate abnormal sciatic nerve Prostatic Neoplasms 2292401;2292472 15988677;17120048 17 34139989 60139989 3 - by peak only
2292891 human PRSTS45_H Prostate tumor susceptibility QTL 45 (human) 5 1.19 Prostate tumor susceptibility Affected status confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2292015 14601029
2292892 human PRSTS51_H Prostate tumor susceptibility QTL 51 (human) 7 1.07 Prostate tumor susceptibility Affected status confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2292015 14601029
2292893 human PRSTS49_H Prostate tumor susceptibility QTL 49 (human) 17 2.36 5.0E-4 Prostate tumor susceptibility Affected status confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2292015 14601029
2292894 human MYI26_H Myocardial infarction susceptibility QTL 26 (human) 5 1336959 D5S1505 Myocardial infarction susceptibility early-onset Premature coronary artery disease and myocardial infarction cardiomyopathy Myocardial Ischemia 1554326 14732905 5 106129673 132129673 3 - by peak only
2292895 human PRSTS96_H Prostate tumor susceptibility QTL 96 (human) 1 Prostate tumor susceptibility Clinically aggressive prostate cancer; affected individuals had one of the following; regional or distant stage based on pathology or clinical stage, Gleason score at diagnosis 7 or higher, pretreatment PSA of 20 or more ng/ml, or prostate cancer listed as primary cause of death on death certificate abnormal sciatic nerve Prostatic Neoplasms 2292444 16508751
2292896 human PRSTS57_H Prostate tumor susceptibility QTL 57 (human) 8 1.02 Prostate tumor susceptibility Affected status confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2292015 14601029
2292897 human PRSTS103_H Prostate tumor susceptibility QTL 103 (human) 15 4.05 1299967 D15S1002 Prostate tumor susceptibility Clinically aggressive prostate cancer; affected individuals had one of the following; regional or distant stage based on pathology or clinical stage, Gleason score at diagnosis 7 or higher, pretreatment PSA of 20 or more ng/ml, or prostate cancer listed as primary cause of death on death certificate abnormal sciatic nerve Prostatic Neoplasms 2292444 16508751 15 12523382 38523382 3 - by peak only
2292898 human PRSTS77_H Prostate tumor susceptibility QTL 77 (human) 5 1.41 Prostate tumor susceptibility Affected status confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2292015 14601029
2292899 human PRSTS34_H Prostate tumor susceptibility QTL 34 (human) 19 1299939 D19S245 Prostate tumor susceptibility late onset Diagnosed with prostate cancer after age 69 abnormal sciatic nerve Prostatic Neoplasms 2291884 16037989 19 25790099 51790099 3 - by peak only
2292900 human PRSTS101_H Prostate tumor susceptibility QTL 101 (human) 18 1.03 Prostate tumor susceptibility Clinically aggressive prostate cancer; affected individuals had one of the following; regional or distant stage based on pathology or clinical stage, Gleason score at diagnosis 7 or higher, pretreatment PSA of 20 or more ng/ml, or prostate cancer listed as primary cause of death on death certificate abnormal sciatic nerve Prostatic Neoplasms 2292444 16508751
2292901 human MYI21_H Myocardial infarction susceptibility QTL 21 (human) 4 1341136 D4S1629 Myocardial infarction susceptibility early-onset Premature coronary artery disease and myocardial infarction cardiomyopathy Myocardial Ischemia 1554326 14732905 4 145556329 171556329 3 - by peak only
2292902 human PRSTS66_H Prostate tumor susceptibility QTL 66 (human) 6 1.59 Prostate tumor susceptibility Affected status confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2292015 14601029
2292903 human PRSTS39_H Prostate tumor susceptibility QTL 39 (human) 20 6.0E-4 1336023 D20S893 Prostate tumor susceptibility Late onset Affected status confirmed by medical records at 66 or more years of age Prostatic Neoplasms 2291963 10820130
2292905 human PRSTS97_H Prostate tumor susceptibility QTL 97 (human) 2 Prostate tumor susceptibility Clinically aggressive prostate cancer; affected individuals had one of the following; regional or distant stage based on pathology or clinical stage, Gleason score at diagnosis 7 or higher, pretreatment PSA of 20 or more ng/ml, or prostate cancer listed as primary cause of death on death certificate abnormal sciatic nerve Prostatic Neoplasms 2292444 16508751
2299878 human PRSTS315_H Prostate tumor susceptibility QTL 315 (human) 1 0.08 1336704 D1S2785 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293501 10677314 1343740 PCAP 1 225943481 247249719 3 - by peak only
2299879 human PRSTS314_H Prostate tumor susceptibility QTL 314 (human) 1 0.13 1337223 D1S452 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293501 10677314 1353721 HPC1 1 155790383 181790383 3 - by peak only
2299880 human PRSTS313_H Prostate tumor susceptibility QTL 313 (human) 1 0.01 1337223 D1S452 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293501 10677314 1353721 HPC1 1 155790383 181790383 3 - by peak only
2299881 human PRSTS316_H Prostate tumor susceptibility QTL 316 (human) 1 0.1 1336704 D1S2785 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293501 10677314 1343740 PCAP 1 225943481 247249719 3 - by peak only
2299882 human PRSTS312_H Prostate tumor susceptibility QTL 312 (human) 1 0.03 1335036 D1S212 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293501 10677314 1353721 HPC1 1 163349281 189349281 3 - by peak only
2300001 human PRSTS346_H Prostate tumor susceptibility QTL 346 (human) 1 0.0026 1336704 D1S2785 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2300000 11313747 1 225943481 247249719 3 - by peak only
2300229 human PRSTS357_H Prostate tumor susceptibility QTL 357 (human) 6 0.011 1298275 D6S2439 Prostate tumor susceptibility The majority of cases presented with clinically detected disease, others found with PSA screening abnormal sciatic nerve Prostatic Neoplasms 2300192 14601023
2300231 human PRSTS350_H Prostate tumor susceptibility QTL 350 (human) 15 0.0014 1338409 D15S131 Prostate tumor susceptibility Gleason score used as a quantitative trait abnormal sciatic nerve Prostatic Neoplasms 2300096 12563560 15 55971033 81971033 3 - by peak only
2300233 human PRSTS359_H Prostate tumor susceptibility QTL 359 (human) 18 0.013 1342398 D18S877 Prostate tumor susceptibility The majority of cases presented with clinically detected disease, others found with PSA screening abnormal sciatic nerve Prostatic Neoplasms 2300192 14601023 18 11979245 37979245 3 - by peak only
2300234 human PRSTS353_H Prostate tumor susceptibility QTL 353 (human) 2 0.021 1298132 D2S1399 Prostate tumor susceptibility The majority of cases presented with clinically detected disease, others found with PSA screening abnormal sciatic nerve Prostatic Neoplasms 2300192 14601023 2 134926654 160926654 3 - by peak only
2300235 human PRSTS358_H Prostate tumor susceptibility QTL 358 (human) 11 0.018 1298156 D11S2371 Prostate tumor susceptibility The majority of cases presented with clinically detected disease, others found with PSA screening abnormal sciatic nerve Prostatic Neoplasms 2300192 14601023 11 60182876 86182876 3 - by peak only
2300236 human PRSTS354_H Prostate tumor susceptibility QTL 354 (human) 3 0.016 1340780 D3S1763 Prostate tumor susceptibility The majority of cases presented with clinically detected disease, others found with PSA screening abnormal sciatic nerve Prostatic Neoplasms 2300192 14601023 3 155722527 181722527 3 - by peak only
2300237 human PRSTS360_H Prostate tumor susceptibility QTL 360 (human) 18 0.011 1357242 D18S1364 Prostate tumor susceptibility The majority of cases presented with clinically detected disease, others found with PSA screening abnormal sciatic nerve Prostatic Neoplasms 2300192 14601023 18 48551224 74551224 3 - by peak only
2300238 human PRSTS348_H Prostate tumor susceptibility QTL 348 (human) X 0.009 1340800 DXS984 Prostate tumor susceptibility early onset Diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2300075 11992616 X 126459507 152459507 3 - by peak only
2300240 human PRSTS349_H Prostate tumor susceptibility QTL 349 (human) 19 1.0E-4 1337083 D19S902 Prostate tumor susceptibility Gleason score used as a quantitative trait abnormal sciatic nerve Prostatic Neoplasms 2300096 12563560 19 40023976 63811651 3 - by peak only
2300241 human PRSTS356_H Prostate tumor susceptibility QTL 356 (human) 5 0.019 1357239 D5S1453 Prostate tumor susceptibility The majority of cases presented with clinically detected disease, others found with PSA screening abnormal sciatic nerve Prostatic Neoplasms 2300192 14601023
2300242 human PRSTS351_H Prostate tumor susceptibility QTL 351 (human) 4 1.2E-4 1331564 D4S403 Prostate tumor susceptibility Gleason score used as a quantitative trait abnormal sciatic nerve Prostatic Neoplasms 2300096 12563560 4 360154 26360154 3 - by peak only
2300243 human PRSTS352_H Prostate tumor susceptibility QTL 352 (human) 4 1.6 1339365 D4S430 Prostate tumor susceptibility Prostate cancer verified by medical records abnormal sciatic nerve Prostatic Neoplasms 2292628;2300096 8910276;12563560 4 110827186 136827186 3 - by peak only
2300244 human PRSTS347_H Prostate tumor susceptibility QTL 347 (human) 10 0.014 1342127 D10S222 Prostate tumor susceptibility Diagnosis confirmed by medical records or from 2 other independent sources abnormal sciatic nerve Prostatic Neoplasms 2300004 11668516 10 92308292 118308292 3 - by peak only
2300246 human PRSTS355_H Prostate tumor susceptibility QTL 355 (human) 4 0.015 1338059 D4S2368 Prostate tumor susceptibility The majority of cases presented with clinically detected disease, others found with PSA screening abnormal sciatic nerve Prostatic Neoplasms 2300192 14601023 4 155953024 181953024 3 - by peak only
2301894 human PRSTS418_H Prostate tumor susceptibility QTL 418 (human) 1 3.31E-8 1335036 D1S212 Prostate tumor susceptibility Prostate cancer confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2301206 10712209 1346643 RNASEL 1 163349281 189349281 3 - by peak only
2289232 human BW89_H Body weight QTL 89 (human) 19 3.21 0.091 1331586 D19S246 1340463 D19S210 1336474 D19S418 Body weight BMI BMI > 35 kg/m2 increased body mass index Obesity 1643034;1642950 14627748;15220211 1321519;1320086;1352469 TULP2;GYS1;NR1H2 19 55647457 61711519 1 - by flanking markers
2289234 human BW142_H Body weight QTL 142 (human) 6 3.13 7.0E-5 1298111 D6S462 1338883 D6S441 Body weight BMI BMI > 95th percentile in standard tables of a French reference population increased body mass index Obesity 1642946 14988267 1320567;1351327;1347761 SIM1;ENPP1;MCHR2 6 90985312 153856159 1 - by flanking markers
2289236 human BW91_H Body weight QTL 91 (human) 10 2.47 0.291 1331549 D10S1753 1338103 D10S186 1336726 D10S1267 Body weight BMI BMI > 27 kg/m2 increased body mass index Obesity 1643034;1642950 14627748;15220211 10 92402953 128681114 1 - by flanking markers
2289238 human BW148_H Body weight QTL 148 (human) 19 2.13 9.0E-4 1299977 D19S221 1338183 D19S414 Body weight BMI Age of adiposity rebound (AAR) increased body mass index Obesity 1642946 14988267 19 12573944 36606773 1 - by flanking markers
2289240 human BW147_H Body weight QTL 147 (human) 16 2.54 3.0E-4 1337425 D16S415 1340691 D16S520 Body weight BMI Age of adiposity rebound (AAR) increased body mass index Obesity 1642946 14988267 16 52228236 85073835 1 - by flanking markers
2289241 human SLIPL21_H Serum lipid level QTL 21 (human) 1 3.39 0.014402 1338626 D1S534 1298129 D1S1679 1339714 D1S1595 Lipid level lipoprotein level lipoprotein-associated phopholipase A2 increased circulating phospholipid level Obesity 1642928 17160904 1 119479787 160628693 1 - by flanking markers
2289243 human BW143_H Body weight QTL143 (human) 2 2.73 2.0E-4 1298184 D2S112 1298283 D2S396 Body weight BMI BMI greater than 99 percentile increased body mass index Obesity 1642946 14988267 2 132925170 230392178 1 - by flanking markers
2289245 human BW144_H Body weight QTL 144 (human) 2 2.08 0.001 1298184 D2S112 1298283 D2S396 Body weight BMI BMI > 97th percentile in standard tables of a French reference population. increased body mass index Obesity 1642946 14988267 2 132925170 230392178 1 - by flanking markers
2289247 human BW146_H Body weight QTL 146 (human) 15 2.53 3.0E-4 1337014 D15S128 1341623 D15S153 Body weight BMI Age of adiposity rebound increased body mass index Obesity 1642946 14988267 15 22681893 64347234 1 - by flanking markers
2289249 human BW90_H Body weight QTL 90 (human) 5 2.68 0.212 1336355 D5S641 1336441 D5S2027 1335243 D5S1463 Body weight BMI BMI > 27 kg/m2 increased body mass index Obesity 1643034;1642950 14627748;15220211 734345 PCSK1 5 82038693 98445525 2 - by one flank and peak markers
2289250 human BW145_H Body weight QTL 145 (human) 17 2.25 7.0E-4 1339405 D17S849 1298144 D17S799 Body weight BMI BMI greater than 95 percentile increased body mass index Obesity 1642946 14988267 17 379301 13111885 1 - by flanking markers
2289252 human BW141_H Body weight QTL 141 (human) 6 4.06 2.0E-5 1341107 D6S287 Body weight BMI BMI > 97th percentile in standard tables of a French reference population increased body mass index Obesity 1642946 14988267 1320567;1351327;1347761 SIM1;ENPP1;MCHR2 6 106595555 132595555 3 - by peak only
2299934 human PRSTS333_H Prostate tumor susceptibility QTL 333 (human) 1 0.001 1336704 D1S2785 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2298952 9585607 1345118;1351964;1354427 PARP1;RAB4A;LGALS8 1 225943481 247249719 3 - by peak only
2299935 human PRSTS334_H Prostate tumor susceptibility QTL 334 (human) 1 3.3 0.001 1336704 D1S2785 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2298952 9585607 1345118;1351964;1354427 PARP1;RAB4A;LGALS8 1 225943481 247249719 3 - by peak only
2314813 human INSUL28_H Insulin level QTL 28 (human) 18 2.18 0.0094 1331566 D18S976 Insulin level Plasma C-peptide, radioimmunoassay, using commercially available (Linco)antibody glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 2312444 17548123 732730 ADCYAP1 18 1 18239033 3 - by peak only
2314815 human INSUL26_H Insulin level QTL 26 (human) 15 2.41 0.0068 1340590 D15S659 Insulin level Plasma C-peptide, radioimmunoassay, using commercially available (Linco)antibody glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 2312444 17548123 15 31161391 57161391 3 - by peak only
2314816 human INSUL29_H Insulin level QTL 29 (human) 20 3.01 6.0E-5 1341151 D20S604 1339271 D20S470 Insulin level fasting Plasma insulin measured by enzymatic assay (Access System, Beckman Coulter) at 8 AM after 8-10 hour fast glucose homeostasis traits 2314471 15793262 20 12532311 17320770 1 - by flanking markers
2314818 human GLUCO125_H Glucose level QTL 125 (human) 2 4.1 1.0E-4 1341363 D2S140 1340298 D2S125 Glucose level Diagnosed with type 2 diabetes, National Diabetes Data Group(NDDG) standards, 1995 glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 2314486 8640221 2 240245403 241388289 2 - by one flank and peak markers
2314820 human GLUCO124_H Glucose level QTL 124 (human) 20 2.27 2.0E-4 2156941 D20S477 1339243 D20S481 Glucose level fasting Fasting glucose, measured with Elan Diagnostics analyzer after overnight(8-10 hour) fast glucose homeostasis traits 2314471 15793262 20 22360084 43201932 1 - by flanking markers
2314822 human GLUCO126_H Glucose level QTL 126 (human) 15 4.0 4.0E-4 2457 Cyp19a1 Glucose level Homeostasis model assessment of insulin sensitivity, calculated from fasting insulin and fasting glucose (HOMA%S) glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 2314906;1298533 11283790;9988276 1351327 ENPP1
2314823 human GLUCO122_H Glucose level QTL 122 (human) 20 2.94 1.3E-4 1341151 D20S604 1339271 D20S470 Glucose level HOMA-IR (insulin resistance index) calculated from fasting insulin and fasting glucose glucose homeostasis traits 2314471 15793262 20 12532311 17320770 1 - by flanking markers
2314825 human INSUL24_H Insulin level QTL 24 (human) 9 1.58 0.027 1341701 D9S930 Insulin level Plasma C-peptide, radioimmunoassay, using commercially available (Linco)antibody glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 2312444 17548123 9 101276177 127276177 3 - by peak only
2314826 human INSUL27_H Insulin level QTL 27 (human) 15 1.28 0.0403 1340735 D15S652 Insulin level Plasma C-peptide, radioimmunoassay, using commercially available (Linco)antibody glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 2312444 17548123 15 77318513 100338915 3 - by peak only
2314827 human INSUL22_H Insulin level QTL 22 (human) 3 1.08 0.0532 1340974 D3S2418 Insulin level Plasma C-peptide, radioimmunoassay, using commercially available (Linco)antibody glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 2312444 17548123 3 180799751 199501827 3 - by peak only
2314828 human GLUCO123_H Glucose level QTL 123 (human) 20 1.31 0.0059 1341151 D20S604 1339271 D20S470 Glucose level HOMA-beta (beta cell function index) calculated from fasting insulin and fasting glucose glucose homeostasis traits 2314471 15793262 20 12532311 17320770 1 - by flanking markers
2314830 human INSUL25_H Insulin level QTL 25 (human) 10 4.04 4.0E-4 1298280 D10S2327 Insulin level Plasma C-peptide, radioimmunoassay, using commercially available (Linco)antibody glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 2312444 17548123 732801;69119;1319302 IDE;PTEN;PPP1R3C 10 67382154 93382154 3 - by peak only
2314831 human INSUL23_H Insulin level QTL 23 (human) 4 3.48 0.0013 1668850 D4S2632 Insulin level Plasma C-peptide, radioimmunoassay, using commercially available (Linco)antibody glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 2312444 17548123 1342674 PPARGC1A 4 22380599 48380599 3 - by peak only
2301140 human PRSTS374_H Prostate tumor susceptibility QTL 374 (human) 5 2.34 1335487 D5S647 Prostate tumor susceptibility Confirmed prostate cancer patients abnormal sciatic nerve Prostatic Neoplasms 2300407;2300371 14601025;14601024 5 53283203 79283203 3 - by peak only
2301142 human PRSTS401_H Prostate tumor susceptibility QTL 401 (human) X 1.53 1341002 DXS9895 Prostate tumor susceptibility Self reported prostate cancer cases, with most (810/859) confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2301025;2300371 14601027;14601024 X 1 20387180 3 - by peak only
2301144 human PRSTS389_H Prostate tumor susceptibility QTL 389 (human) 6 1.66 1341899 D6S1277 Prostate tumor susceptibility Self reported prostate cancer cases, with most (810/859) confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms;Ovarian Neoplasms 2301025;2300371 14601027;14601024 6 151217880 170899992 3 - by peak only
2301145 human PRSTS371_H Prostate tumor susceptibility QTL 371 (human) 19 2.91 1.0E-4 1338183 D19S414 1336308 D19S209 Prostate tumor susceptibility Confirmed prostate cancer patients abnormal sciatic nerve Prostatic Neoplasms 2300407;2300371 14601025;14601024 19 1 36606773 2 - by one flank and peak markers
2301146 human PRSTS372_H Prostate tumor susceptibility QTL 372 (human) 5 2.24 7.0E-4 1299941 D5S407 Prostate tumor susceptibility Confirmed prostate cancer patients abnormal sciatic nerve Prostatic Neoplasms 2300407;2300371 14601025;14601024 5 43030583 69030583 3 - by peak only
2301147 human PRSTS369_H Prostate tumor susceptibility QTL 369 (human) 11 1298172 D11S901 Prostate tumor susceptibility Confirmed prostate cancer patients from Finnish families abnormal sciatic nerve Prostatic Neoplasms 2300371 14601024 11 68522518 94522518 3 - by peak only
2301149 human PRSTS383_H Prostate tumor susceptibility QTL 383 (human) 14 1.43 1336903 D14S1426 Prostate tumor susceptibility Self reported prostate cancer cases, with most (810/859) confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2301025;2300371 14601027;14601024 14 86689393 106368585 3 - by peak only
2301150 human PRSTS400_H Prostate tumor susceptibility QTL 400 (human) 16 1.59 1298258 D16S516 Prostate tumor susceptibility Self reported prostate cancer cases, with most (810/859) confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2301025;2300371 14601027;14601024
2301151 human PRSTS363_H Prostate tumor susceptibility QTL 363 (human) 9 1.93 0.0333 1339902 D9S1690 Prostate tumor susceptibility Confirmed prostate cancer patients from Finnish families abnormal sciatic nerve Prostatic Neoplasms 2300371 14601024 9 90140105 116140105 3 - by peak only
2301152 human PRSTS373_H Prostate tumor susceptibility QTL 373 (human) 19 2.94 1336308 D19S209 Prostate tumor susceptibility Confirmed prostate cancer patients abnormal sciatic nerve Prostatic Neoplasms 2300407;2300371 14601025;14601024 19 1 16265463 3 - by peak only
2301153 human PRSTS390_H Prostate tumor susceptibility QTL 390 (human) 7 1.96 1335509 D7S2204 Prostate tumor susceptibility Self reported prostate cancer cases, with most (810/859) confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms;Ovarian Neoplasms 2301025;2300371 14601027;14601024 7 64964972 90964972 3 - by peak only
2301154 human PRSTS364_H Prostate tumor susceptibility QTL 364 (human) 11 1298172 D11S901 Prostate tumor susceptibility Confirmed prostate cancer patients from Finnish families abnormal sciatic nerve Prostatic Neoplasms 2300371 14601024 11 68522518 94522518 3 - by peak only
2301155 human PRSTS402_H Prostate tumor susceptibility QTL 402 (human) 12 1.0 1341487 D12S1042 Prostate tumor susceptibility Self reported prostate cancer cases, with most (810/859) confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2301025;2300371 14601027;14601024 12 14538701 40538701 3 - by peak only
2301156 human PRSTS393_H Prostate tumor susceptibility QTL 393 (human) 17 2.28 1299928 D17S2196 Prostate tumor susceptibility Self reported prostate cancer cases, with most (810/859) confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms;Ovarian Neoplasms 2301025;2300371 14601027;14601024 17 4205275 30205275 3 - by peak only
2301157 human PRSTS362_H Prostate tumor susceptibility QTL 362 (human) 8 1.64 0.06 1341759 D8S284 Prostate tumor susceptibility Confirmed prostate cancer patients from Finnish families abnormal sciatic nerve Prostatic Neoplasms 2300371 14601024 8 118581014 144581014 3 - by peak only
2301158 human PRSTS396_H Prostate tumor susceptibility QTL 396 (human) 10 1339722 D10S1432 Prostate tumor susceptibility Self reported prostate cancer cases, with most (810/859) confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2301025;2300371 14601027;14601024 10 61329488 87329488 3 - by peak only
2301159 human PRSTS386_H Prostate tumor susceptibility QTL 386 (human) 1 1.55 1336087 D1S1589 Prostate tumor susceptibility Self reported prostate cancer cases, with most (810/859) confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms;Brain Neoplasms 2301025;2300371 14601027;14601024 1 159527826 185527826 3 - by peak only
2301160 human PRSTS397_H Prostate tumor susceptibility QTL 397 (human) 13 1342302 D13S285 Prostate tumor susceptibility Self reported prostate cancer cases, with most (810/859) confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2301025;2300371 14601027;14601024 13 98843481 114142980 3 - by peak only
2301161 human PRSTS391_H Prostate tumor susceptibility QTL 391 (human) 7 1.67 1335392 D7S1826 Prostate tumor susceptibility Self reported prostate cancer cases, with most (810/859) confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms;Ovarian Neoplasms 2301025;2300371 14601027;14601024
2301162 human PRSTS392_H Prostate tumor susceptibility QTL 392 (human) 8 1.84 1334926 D8S2324 Prostate tumor susceptibility Self reported prostate cancer cases, with most (810/859) confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms;Ovarian Neoplasms 2301025;2300371 14601027;14601024 8 61416986 87416986 3 - by peak only
2301163 human PRSTS377_H Prostate tumor susceptibility QTL 377 (human) 19 1.59 1336308 D19S209 Prostate tumor susceptibility Confirmed prostate cancer patients abnormal sciatic nerve Prostatic Neoplasms 2300407;2300371 14601025;14601024 19 1 16265463 3 - by peak only
2301164 human PRSTS387_H Prostate tumor susceptibility QTL 387 (human) 15 1.75 1336087 D1S1589 Prostate tumor susceptibility Self reported prostate cancer cases, with most (810/859) confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms;Brain Neoplasms 2301025;2300371 14601027;14601024 1 159527826 185527826 3 - by peak only
2301165 human PRSTS379_H Prostate tumor susceptibility QTL 379 (human) 6 1337397 D6S1281 Prostate tumor susceptibility Self reported prostate cancer cases, with most (810/859) confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2301025;2300371 14601027;14601024 1345296 HFE 6 12405100 38405100 3 - by peak only
2301166 human PRSTS398_H Prostate tumor susceptibility QTL 398 (human) 22 2.21 1298301 D22S685 Prostate tumor susceptibility Self reported prostate cancer cases, with most (810/859) confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2301025;2300371 14601027;14601024 22 19925686 45925686 3 - by peak only
2301167 human PRSTS381_H Prostate tumor susceptibility QTL 381 (human) 8 1334926 D8S2324 Prostate tumor susceptibility Self reported prostate cancer cases, with most (810/859) confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2301025;2300371 14601027;14601024 8 61416986 87416986 3 - by peak only
2301168 human PRSTS378_H Prostate tumor susceptibility QTL 378 (human) 19 1.09 1336308 D19S209 Prostate tumor susceptibility Confirmed prostate cancer patients abnormal sciatic nerve Prostatic Neoplasms 2300407;2300371 14601025;14601024 19 1 16265463 3 - by peak only
2301169 human PRSTS382_H Prostate tumor susceptibility QTL 382 (human) 14 1.2 1336875 D14S592 Prostate tumor susceptibility Self reported prostate cancer cases, with most (810/859) confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2301025;2300371 14601027;14601024 14 47466722 73466722 3 - by peak only
2301170 human PRSTS375_H Prostate tumor susceptibility QTL 375 (human) 19 1.87 1336308 D19S209 Prostate tumor susceptibility Confirmed prostate cancer patients abnormal sciatic nerve Prostatic Neoplasms 2300407;2300371 14601025;14601024 19 1 16265463 3 - by peak only
2301171 human PRSTS384_H Prostate tumor susceptibility QTL 384 (human) 16 1.25 1298287 D16S3396 Prostate tumor susceptibility Self reported prostate cancer cases, with most (810/859) confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2301025;2300371 14601027;14601024 16 36749928 62749928 3 - by peak only
2301172 human PRSTS388_H Prostate tumor susceptibility QTL 388 (human) 1 1.69 1342100 D1S1622 Prostate tumor susceptibility Self reported prostate cancer cases, with most (810/859) confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms;Ovarian Neoplasms 2301025;2300371 14601027;14601024 1 17083670 43083670 3 - by peak only
2301173 human PRSTS367_H Prostate tumor susceptibility QTL 367 (human) 8 2.25 0.02 1341759 D8S284 Prostate tumor susceptibility Confirmed prostate cancer patients from Finnish families abnormal sciatic nerve Prostatic Neoplasms 2300371 14601024 8 118581014 144581014 3 - by peak only
2301174 human PRSTS394_H Prostate tumor susceptibility QTL 394 (human) 2 2.63 1298234 D2S1391 Prostate tumor susceptibility Self reported prostate cancer cases, with most (810/859) confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2301025;2300371 14601027;14601024
2301175 human PRSTS361_H Prostate tumor susceptibility QTL 361 (human) 3 2.46 1299975 D3S1297 Prostate tumor susceptibility Confirmed prostate cancer patients from Finnish families abnormal sciatic nerve Prostatic Neoplasms 2300371 14601024 3 1 15013567 3 - by peak only
2301176 human PRSTS395_H Prostate tumor susceptibility QTL 395 (human) 8 2.01 1337826 D8S1119 Prostate tumor susceptibility Self reported prostate cancer cases, with most (810/859) confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2301025;2300371 14601027;14601024 8 74241226 100241226 3 - by peak only
2301177 human PRSTS370_H Prostate tumor susceptibility QTL 370 (human) 12 1.89 0.04 1342304 D12S326 Prostate tumor susceptibility Confirmed prostate cancer patients from Finnish families abnormal sciatic nerve Prostatic Neoplasms 2300371 14601024 12 63498097 89498097 3 - by peak only
2301178 human PRSTS365_H Prostate tumor susceptibility QTL 365 (human) 12 1.99 0.02998 1342093 D12S351 Prostate tumor susceptibility Confirmed prostate cancer patients from Finnish families abnormal sciatic nerve Prostatic Neoplasms 2300371 14601024 12 90429472 116429472 4 - by one flank marker only
2301179 human PRSTS368_H Prostate tumor susceptibility QTL 368 (human) 9 1.32 0.1 1342068 D9S290 Prostate tumor susceptibility Confirmed prostate cancer patients from Finnish families abnormal sciatic nerve Prostatic Neoplasms 2300371 14601024 9 117567367 140273252 3 - by peak only
2301180 human PRSTS376_H Prostate tumor susceptibility QTL 376 (human) 5 2.17 1335306 D5S424 Prostate tumor susceptibility lesions with ACI-type nuclei animals were sacrificed at 30 months of age and male sex orgains and bladder were resected. The vetral prostate was fixed, removed from bse of bladder neck and weighed. Hyperplastic and tumorous lesions were classified by structure and atypical nuclei. abnormal sciatic nerve Prostatic Neoplasms 2300407;2300371 14601025;14601024 5 63193743 89193743 3 - by peak only
2301181 human PRSTS385_H Prostate tumor susceptibility QTL 385 (human) 10 1.51 1341944 D10S1213 Prostate tumor susceptibility Self reported prostate cancer cases, with most (810/859) confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2301025;2300371 14601027;14601024 10 112396682 135374737 3 - by peak only
2301182 human PRSTS399_H Prostate tumor susceptibility QTL 399 (human) 8 1.64 1337826 D8S1119 Prostate tumor susceptibility Self reported prostate cancer cases, with most (810/859) confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2301025;2300371 14601027;14601024 8 74241226 100241226 3 - by peak only
2301183 human PRSTS380_H Prostate tumor susceptibility QTL 380 (human) 7 1298266 D7S2212 Prostate tumor susceptibility Self reported prostate cancer cases, with most (810/859) confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2301025;2300371 14601027;14601024 7 69634822 95634822 3 - by peak only
2301184 human PRSTS366_H Prostate tumor susceptibility QTL 366 (human) 3 2.57 1299975 D3S1297 Prostate tumor susceptibility Confirmed prostate cancer patients from Finnish families abnormal sciatic nerve Prostatic Neoplasms 2300371 14601024 3 1 15013567 3 - by peak only
2314796 human GLUCO121_H Glucose level QTL 121 (human) 1 1340203 D1S1158 Glucose level Non-insulin dependent diagnosed with type 2 diabetes before age 65, or impaired glucose tolerance (oral glucose tolerance test) glucose homeostasis traits 2314358 14747303 733408;1312426 RXRG;LMX1A 1 151862765 177862765 3 - by peak only
2314798 human GLUCO117_H Glucose level QTL 117 (human) 1 1342069 D1S2771 1338548 D1S2675 1335027 D1S484 Glucose level Non-insulin dependent diagnosed with type 2 diabetes before age 65, or impaired glucose tolerance (oral glucose tolerance test) glucose homeostasis traits 2314358 14747303 736633;737360;731912;1314452;1343442 CRP;APOA2;KCNJ10;PEA15;KCNJ9 1 158862166 160476778 1 - by flanking markers
2314799 human GLUCO116_H Glucose level QTL 116 (human) 13 4.6 1334556 D13S158 1340179 D13S173 Glucose level fasting Fasting serum glucose, 12 hour overnight fast at metabolic research unit glucose homeostasis traits 1642940 17925332 736204 IRS2 13 102774399 106605119 1 - by flanking markers
2314801 human GLUCO120_H Glucose level QTL 120 (human) 1 2149301 APOA2 Glucose level Non-insulin dependent diagnosed with type 2 diabetes before age 65, or impaired glucose tolerance (oral glucose tolerance test) glucose homeostasis traits 2314358 14747303 736633;737360;731912;1314452;1343442 CRP;APOA2;KCNJ10;PEA15;KCNJ9 1 146459467 172459467 3 - by peak only
2314802 human GLUCO118_H Glucose level QTL 118 (human) 1 1341562 D1S400 1334882 D1S2799 1340203 D1S1158 Glucose level Non-insulin dependent diagnosed with type 2 diabetes before age 65, or impaired glucose tolerance (oral glucose tolerance test) glucose homeostasis traits 2314358 14747303 733408;1312426 RXRG;LMX1A 1 162743430 166359504 1 - by flanking markers
2314803 human GLUCO119_H Glucose level QTL 119 (human) 1 1336648 D1S252 1338828 D1S305 Glucose level Non-insulin dependent diagnosed with type 2 diabetes before age 65, or impaired glucose tolerance (oral glucose tolerance test) glucose homeostasis traits 2314358 14747303 736525;736594;737364;1317896 IL6R;ENSA;PKLR;RORC 1 117358295 152548738 1 - by flanking markers
2300112 human PRSTS335_H Prostate tumor susceptibility QTL 335 (human) 5 1644455 D5S2858 Prostate tumor susceptibility Prostate cancer verified by medical records abnormal sciatic nerve Prostatic Neoplasms 2299086 11404817 5 50956909 76956909 3 - by peak only
2300113 human PRSTS337_H Prostate tumor susceptibility QTL 337 (human) 19 1339612 D19S894 Prostate tumor susceptibility Prostate cancer verified by medical records abnormal sciatic nerve Prostatic Neoplasms 2299086 11404817 19 1 17343514 3 - by peak only
2300114 human PRSTS338_H Prostate tumor susceptibility QTL 338 (human) X 1338044 D3S2390 Prostate tumor susceptibility Prostate cancer verified by medical records abnormal sciatic nerve Prostatic Neoplasms 2299086 11404817 X 127062044 153062044 3 - by peak only
2300115 human PRSTS336_H Prostate tumor susceptibility QTL 336 (human) 12 1299937 D12S372 Prostate tumor susceptibility Prostate cancer verified by medical records abnormal sciatic nerve Prostatic Neoplasms 2299086 11404817 12 1 16457710 3 - by peak only
2302752 human MAMTS35_H Mammary tumor susceptibility QTL 35 (human) 11 0.046 1338308 D11S1986 1336030 D11S1347 Mammary tumor susceptibility Probability of case versus control haplotype frequency difference mammary adenocarcinoma Breast Neoplasms 2302072 15668479 11 110728815 111637492 1 - by flanking markers
2302753 human MAMTS17_H Mammary tumor susceptibility QTL 17 (human) 8 0.045 1341834 D8S592 Mammary tumor susceptibility Probability of case versus control allele frequency difference mammary adenocarcinoma Breast Neoplasms 2302072 15668479 8 105525408 131525408 3 - by peak only
2302754 human MAMTS30_H Mammary tumor susceptibility QTL 30 (human) 22 0.013 1340423 D22S426 Mammary tumor susceptibility Probability of case versus control allele frequency difference mammary adenocarcinoma Breast Neoplasms 2302072 15668479 22 22353305 48353305 3 - by peak only
2302755 human MAMTS15_H Mammary tumor susceptibility QTL 15 (human) 4 0.029 1298161 D4S2394 Mammary tumor susceptibility Probability of case versus control allele frequency difference mammary adenocarcinoma Breast Neoplasms 2302072 15668479 4 117517406 143517406 3 - by peak only
2302756 human MAMTS6_H Mammary tumor susceptibility QTL 6 (human) 22 0.041 1336843 D22S1177 2896 Il2rb Mammary tumor susceptibility Haplotype of rs25095 and rs733655 mammary adenocarcinoma Breast Neoplasms 2301994 16533768 1316154 TMPRSS6
2302758 human MAMTS5_H Mammary tumor susceptibility QTL 5 (human) 22 3.0E-4 1652588 D22S1197 2896 Il2rb Mammary tumor susceptibility Genotype frequencies of rs733655 mammary adenocarcinoma Breast Neoplasms 2301994 16533768 1316154 TMPRSS6 22 38749278 49691432 4 - by one flank marker only
2302760 human MAMTS31_H Mammary tumor susceptibility QTL 31 (human) 22 0.018 1336843 D22S1177 Mammary tumor susceptibility Probability of case versus control allele frequency difference mammary adenocarcinoma Breast Neoplasms 2302072 15668479
2302761 human MAMTS20_H Mammary tumor susceptibility QTL 20 (human) 11 0.023 1338308 D11S1986 Mammary tumor susceptibility Probability of case versus control allele frequency difference mammary adenocarcinoma Breast Neoplasms 2302072 15668479 11 97728932 123728932 3 - by peak only
2302762 human MAMTS7_H Mammary tumor susceptibility QTL 7 (human) 1 0.014 1341601 D1S3462 Mammary tumor susceptibility Probability of case versus control allele frequency difference mammary adenocarcinoma Breast Neoplasms 2302072 15668479 1 217017269 243017269 3 - by peak only
2302763 human MAMTS1_H Mammary tumor susceptibility QTL 1 (human) 9 3.96 1.0E-5 1334911 D9S1843 1341248 D9S1812 1337281 D9S167 Mammary tumor susceptibility Non-BRCA1/2 breast cancer mammary adenocarcinoma Breast Neoplasms 2301950 18663745 9 81728962 88513698 1 - by flanking markers
2302765 human MAMTS4_H Mammary tumor susceptibility QTL 4 (human) 22 0.044 1336843 D22S1177 2896 Il2rb Mammary tumor susceptibility Genotype frequencies of rs733655 mammary adenocarcinoma Breast Neoplasms 2301994 16533768 1316154 TMPRSS6
2302766 human MAMTS38_H Mammary tumor susceptibility QTL 38 (human) 2 0.077 1299938 D2S436 1298137 D2S410 Mammary tumor susceptibility Probability of case versus control haplotype frequency difference mammary adenocarcinoma Breast Neoplasms 2302072 15668479 2 106609665 115957555 1 - by flanking markers
2302767 human MAMTS19_H Mammary tumor susceptibility QTL 19 (human) 10 0.041 1298280 D10S2327 Mammary tumor susceptibility Probability of case versus control allele frequency difference mammary adenocarcinoma Breast Neoplasms 2302072 15668479 10 67382154 93382154 3 - by peak only
2302768 human MAMTS25_H Mammary tumor susceptibility QTL 25 (human) 17 0.01 1335200 D17S809 Mammary tumor susceptibility Probability of case versus control allele frequency difference mammary adenocarcinoma Breast Neoplasms 2302072 15668479 17 34272851 60272851 3 - by peak only
2302769 human MAMTS33_H Mammary tumor susceptibility QTL 33 (human) 22 0.046 1342048 D22S1142 Mammary tumor susceptibility Probability of case versus control allele frequency difference mammary adenocarcinoma Breast Neoplasms 2302072 15668479 22 21604019 47604019 3 - by peak only
2302770 human MAMTS23_H Mammary tumor susceptibility QTL 23 (human) 16 0.012 1337228 D16S422 Mammary tumor susceptibility Probability of case versus control allele frequency difference mammary adenocarcinoma Breast Neoplasms 2302072 15668479 16 68469029 88827254 3 - by peak only
2302771 human MAMTS2_H Mammary tumor susceptibility QTL 2 (human) 8 2.41 1298233 D8S137 1298260 D8S131 Mammary tumor susceptibility Non-BRCA1/2 breast cancer mammary adenocarcinoma Breast Neoplasms 735011 9038382
2302772 human MAMTS8_H Mammary tumor susceptibility QTL 8 (human) 1 0.038 1336357 D1S179 Mammary tumor susceptibility Probability of case versus control allele frequency difference mammary adenocarcinoma Breast Neoplasms 2302072 15668479 1 219726347 245726347 3 - by peak only
2302773 human MAMTS18_H Mammary tumor susceptibility QTL 18 (human) 9 0.039 1357243 D9S925 Mammary tumor susceptibility Probability of case versus control allele frequency difference mammary adenocarcinoma Breast Neoplasms 2302072 15668479
2302774 human MAMTS13_H Mammary tumor susceptibility QTL 13 (human) 3 0.034 1339957 D3S3050 Mammary tumor susceptibility Probability of case versus control allele frequency difference mammary adenocarcinoma Breast Neoplasms 2302072 15668479 3 1 16271633 3 - by peak only
2302775 human MAMTS36_H Mammary tumor susceptibility QTL 36 (human) 22 0.055 1336843 D22S1177 1340423 D22S426 Mammary tumor susceptibility Probability of case versus control haplotype frequency difference mammary adenocarcinoma Breast Neoplasms 2302072 15668479 22 9353364 35353364 4 - by one flank marker only
2302776 human MAMTS12_H Mammary tumor susceptibility QTL 12 (human) 2 0.046 1338037 D2S338 Mammary tumor susceptibility Probability of case versus control allele frequency difference mammary adenocarcinoma Breast Neoplasms 2302072 15668479 2 223900295 242951149 3 - by peak only
2302777 human MAMTS9_H Mammary tumor susceptibility QTL 9 (human) 2 0.013 1298137 D2S410 Mammary tumor susceptibility Probability of case versus control allele frequency difference mammary adenocarcinoma Breast Neoplasms 2302072 15668479 2 102957477 128957477 3 - by peak only
2302778 human MAMTS21_H Mammary tumor susceptibility QTL 21 (human) 13 0.057 1338308 D11S1986 Mammary tumor susceptibility Probability of case versus control allele frequency difference mammary adenocarcinoma Breast Neoplasms 2302072 15668479 11 97728932 123728932 3 - by peak only
2302779 human MAMTS39_H Mammary tumor susceptibility QTL 39 (human) 2 0.095 1298137 D2S410 1340659 D2S363 Mammary tumor susceptibility Probability of case versus control haplotype frequency difference mammary adenocarcinoma Breast Neoplasms 2302072 15668479 2 115957399 117112306 1 - by flanking markers
2302780 human MAMTS3_H Mammary tumor susceptibility QTL 3 (human) 8 2.51 621458 Nefl 1336029 D8S259 Mammary tumor susceptibility Non-BRCA1/2 breast cancer mammary adenocarcinoma Breast Neoplasms 2301977 7898921 8 7181361 33181361 4 - by one flank marker only
2302781 human MAMTS16_H Mammary tumor susceptibility QTL 16 (human) 7 0.033 1335908 D7S1818 Mammary tumor susceptibility Probability of case versus control allele frequency difference mammary adenocarcinoma Breast Neoplasms 2302072 15668479 7 36359513 62359513 3 - by peak only
2302782 human MAMTS11_H Mammary tumor susceptibility QTL 11 (human) 2 0.016 1299945 D2S434 Mammary tumor susceptibility Probability of case versus control allele frequency difference mammary adenocarcinoma Breast Neoplasms 2302072 15668479 2 205284868 231284868 3 - by peak only
2314972 human INSUL36_H Insulin level QTL 36 (human) 20 1.9 1299965 D20S119 Insulin level Fasting specific insulin, not including insulin precursors glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 2314906 11283790 20 30082525 56082525 3 - by peak only
2314975 human SLEP22_H Serum leptin level QTL 22(human) 6 2.2 1298296 D6S1009 1335480 D6S403 Hormone level leptin Leptin levels measured by a commercial radioimmunoassay (Linco Research) Diabetes Mellitus, Non-Insulin-Dependent 2314906 11283790 1351327 ENPP1 6 137343885 139755180 1 - by flanking markers
2314977 human BW515_H Body weight QTL 515 (human) 6 1.6 1340330 D6S264 1336670 D6S503 Body fat amount Sum of eight skin fold measurements(mm), intended to be an index of body fat amount Diabetes Mellitus, Non-Insulin-Dependent 2314906 11283790 732660;1354229 IGF2R;ACAT2 6 166629240 167932947 1 - by flanking markers
2314979 human INSUL39_H Insulin level QTL 39 (human) 6 1.4 1298296 D6S1009 1335480 D6S403 Insulin level Homeostasis model assessment of beta cell function, calculated from fasting insulin and fasting glucose (HOMA%B) glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 2314906 11283790 1351327 ENPP1 6 137343885 139755180 1 - by flanking markers
2314981 human SLIPL24_H Serum lipid level QTL 24(human) 6 1.3 1340330 D6S264 Lipid level triglyceride level Triglycerides levels by enzymatic procedures Diabetes Mellitus, Non-Insulin-Dependent 2314906 11283790 732660;1354229 IGF2R;ACAT2 6 153629300 170899992 3 - by peak only
2314983 human BW514_H Body weight QTL 514 (human) 6 1.6 1298296 D6S1009 1335480 D6S403 Body fat amount Sum of eight skin fold measurements(mm), intended to be an index of body fat amount Diabetes Mellitus, Non-Insulin-Dependent 2314906 11283790 1351327 ENPP1 6 137343885 139755180 1 - by flanking markers
2314984 human INSUL35_H Insulin level QTL 35 (human) 18 1.7 1336696 D18S535 Insulin level Fasting specific insulin, not including insulin precursors glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 2314906 11283790 18 23402859 49402859 3 - by peak only
2314985 human INSUL32_H Insulin level QTL 32 (human) 2 2.7 1337936 D2S141 Insulin level Fasting specific insulin, not including insulin precursors glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 2314906 11283790 733789;737186 KCNJ3;GPD2 2 143542857 169542857 3 - by peak only
2314986 human INSUL33_H Insulin level QTL 33 (human) 11 1.9 1339636 D11S1984 1339037 D11S988 Insulin level Fasting specific insulin, not including insulin precursors glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 2314906 11283790 736606 HBB 11 1523386 4496546 1 - by flanking markers
2314987 human SLEP23_H Serum leptin level QTL 23(human) 6 2.8 1340330 D6S264 Hormone level leptin Leptin levels measured by a commercial radioimmunoassay (Linco Research) Diabetes Mellitus, Non-Insulin-Dependent 2314906 11283790 732660;1354229 IGF2R;ACAT2 6 153629300 170899992 3 - by peak only
2314988 human INSUL38_H Insulin level QTL 38 (human) 6 1.1 1340330 D6S264 Insulin level Fasting serum immunoreactive insulin, standard radioimmunoassay(Diagnostic Products) which also detects insulin precursors glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 2314906 11283790 732660;1354229 IGF2R;ACAT2 6 153629300 170899992 3 - by peak only
2314990 human INSUL37_H Insulin level QTL 37 (human) 6 1.9 1298296 D6S1009 1335480 D6S403 Insulin level Fasting serum immunoreactive insulin, standard radioimmunoassay(Diagnostic Products) which also detects insulin precursors glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 2314906 11283790 1351327 ENPP1 6 137343885 139755180 1 - by flanking markers
2314991 human INSUL34_H Insulin level QTL 34 (human) 11 1.8 1298267 D11S4464 1299919 D11S912 1298323 D11S934 Insulin level Fasting specific insulin, not including insulin precursors glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 2314906 11283790 11 123131837 128129403 1 - by flanking markers
2314992 human BW513_H Body weight QTL 513 (human) 6 1.5 1298296 D6S1009 1335480 D6S403 Body weight BMI Body mass index (kg/M2) Diabetes Mellitus, Non-Insulin-Dependent 2314906 11283790 1351327 ENPP1 6 137343885 139755180 1 - by flanking markers
2314994 human INSUL40_H Insulin level QTL 40 (human) 6 1.7 1340330 D6S264 Insulin level Homeostasis model assessment of beta cell function, calculated from fasting insulin and fasting glucose (HOMA%B) glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 2314906 11283790 732660;1354229 IGF2R;ACAT2 6 153629300 170899992 3 - by peak only
2314995 human GLUCO127_H Glucose level QTL 127 (human) 6 2.7 1340330 D6S264 Glucose level Homeostasis model assessment of insulin sensitivity, calculated from fasting insulin and fasting glucose (HOMA%S) glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 2314906 11283790 732660;1354229 IGF2R;ACAT2 6 153629300 170899992 3 - by peak only
2314996 human INSUL31_H Insulin level QTL 31 (human) 6 2.2 1340330 D6S264 Insulin level Fasting specific insulin, not including insulin precursors glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 2314906 11283790 732660;1354229 IGF2R;ACAT2 6 153629300 170899992 3 - by peak only
2314997 human INSUL30_H Insulin level QTL 30 (human) 6 4.1 1298296 D6S1009 1341334 D6S1003 1335480 D6S403 Insulin level Fasting specific insulin, not including insulin precursors glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 2314906 11283790 1351327 ENPP1 6 137343885 144636295 1 - by flanking markers
2301719 human PRSTS419_H Prostate tumor susceptibility QTL 419 (human) 17 4.53 0.004 1660535 D17S1289 Prostate tumor susceptibility Prostate cancer confirmed by medical records in 97 percent of cases abnormal sciatic nerve Prostatic Neoplasms 2301306 11175785 1342597 ELAC2 17 1 23800181 3 - by peak only
2301721 human PRSTS403_H Prostate tumor susceptibility QTL 403 (human) 11 1.86 2301228 AAT268 Prostate tumor susceptibility Self reported prostate cancer cases, with most (810/859) confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2301025 14601027
2301722 human PRSTS438_H Prostate tumor susceptibility QTL 438 (human) 8 1.58 2301226 TTCA004 Prostate tumor susceptibility Self reported prostate cancer cases, with most (810/859) confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2301025 14601027
2301723 human PRSTS439_H Prostate tumor susceptibility QTL 439 (human) 8 1.45 2301226 TTCA004 Prostate tumor susceptibility Self reported prostate cancer cases, with most (810/859) confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2301025 14601027
2301724 human PRSTS404_H Prostate tumor susceptibility QTL 404 (human) 11 1.61 2301228 AAT268 Prostate tumor susceptibility Self reported prostate cancer cases, with most (810/859) confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2301025 14601027
2301830 human PRSTS413_H Prostate tumor susceptibility QTL 413 (human) 1 3.38E-7 1335036 D1S212 Prostate tumor susceptibility Prostate cancer confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2301206 10712209 1 163349281 189349281 3 - by peak only
2301831 human PRSTS415_H Prostate tumor susceptibility QTL 415 (human) 1 4.67E-5 1335036 D1S212 Prostate tumor susceptibility Prostate cancer confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2301206 10712209 1 163349281 189349281 3 - by peak only
2301832 human PRSTS416_H Prostate tumor susceptibility QTL 416 (human) 1 0.001 1335036 D1S212 Prostate tumor susceptibility Prostate cancer confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2301206 10712209 1 163349281 189349281 3 - by peak only
2301833 human PRSTS412_H Prostate tumor susceptibility QTL 412 (human) 1 8.59E-6 1335036 D1S212 Prostate tumor susceptibility Prostate cancer confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2301206 10712209 1 163349281 189349281 3 - by peak only
2301834 human PRSTS414_H Prostate tumor susceptibility QTL 414 (human) 1 9.22E-7 1335036 D1S212 Prostate tumor susceptibility Prostate cancer confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2301206 10712209 1 163349281 189349281 3 - by peak only
2301835 human PRSTS417_H Prostate tumor susceptibility QTL 417 (human) 1 0.001 1335036 D1S212 1729626 D1S158 Prostate tumor susceptibility Prostate cancer confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2292628;2301206 8910276;10712209 1346643 RNASEL 1 176349221 188466199 2 - by one flank and peak markers
2299955 human PRSTS328_H Prostate tumor susceptibility QTL 328 (human) 2 2.48 4.0E-4 1299945 D2S434 1331561 D2S1363 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2298844 11309685 2 218284736 226738038 1 - by flanking markers
2299956 human PRSTS331_H Prostate tumor susceptibility QTL 331 (human) 16 1.7 0.0026 1298279 D16S748 1335387 D16S764 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2298844 11309685 16 12046946 16554418 1 - by flanking markers
2299957 human PRSTS332_H Prostate tumor susceptibility QTL 332 (human) 16 1.07 0.0132 1298327 D16S2624 1298258 D16S516 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2298844 11309685 16 70292632 88827254 4 - by one flank marker only
2299958 human PRSTS330_H Prostate tumor susceptibility QTL 330 (human) 15 1.02 0.0151 1336236 ACTC 1335361 D15S165 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2298844 11309685 15 3048110 29048110 4 - by one flank marker only
2299959 human PRSTS329_H Prostate tumor susceptibility QTL 329 (human) 12 1.55 0.0038 1299937 D12S372 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2298844 11309685 12 1 16457710 3 - by peak only
2314732 human GLUCO96_H Glucose level QTL 96 (human) 18 0.003 1335076 D18S1140 1337839 D18S1132 1340842 D18S1105 Glucose level non-insulin dependent Diagnosed with Type 2 diabetes mellitus glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 2313943 14633863 18 615321 4609908 1 - by flanking markers
2314734 human GLUCO83_H Glucose level QTL 83 (human) 11 0.8 0.041 1337255 D11S925 Glucose level non-insulin dependent Diagnosed with Type 2 diabetes mellitus glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 2313943 14633863 11 107333578 133333578 3 - by peak only
2314735 human GLUCO74_H Glucose level QTL 74 (human) 3 1.2 0.005 1336837 D3S3681 Glucose level non-insulin dependent Diagnosed with Type 2 diabetes mellitus glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 2313943 14633863 3 66894530 92894530 3 - by peak only
2314736 human GLUCO71_H Glucose level QTL 71 (human) 2 1.6 0.01 1341945 D2S323 Glucose level non-insulin dependent Diagnosed with Type 2 diabetes mellitus glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 2313943 14633863 2 1 15085427 3 - by peak only
2314737 human GLUCO88_H Glucose level QTL 88 (human) 17 0.62 0.01 1337755 D17S927 Glucose level non-insulin dependent Diagnosed with Type 2 diabetes mellitus glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 2313943 14633863
2314738 human GLUCO84_H Glucose level QTL 84 (human) 11 0.89 0.005 1335662 D11S4126 Glucose level non-insulin dependent Diagnosed with Type 2 diabetes mellitus glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 2313943 14633863 11 118110959 134452384 3 - by peak only
2314739 human GLUCO86_H Glucose level QTL 86 (human) 15 0.8 0.01 1335583 D15S1012 Glucose level non-insulin dependent Diagnosed with Type 2 diabetes mellitus glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 2313943 14633863 15 23794921 49794921 3 - by peak only
2314740 human GLUCO81_H Glucose level QTL 81 (human) 9 1.0 0.005 1342121 D9S1682 Glucose level non-insulin dependent Diagnosed with Type 2 diabetes mellitus glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 2313943 14633863 9 111033106 137033106 3 - by peak only
2314741 human GLUCO78_H Glucose level QTL 78 (human) 4 0.66 0.01 1337156 D4S413 Glucose level non-insulin dependent Diagnosed with Type 2 diabetes mellitus glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 2313943 14633863 4 145572792 171572792 3 - by peak only
2314742 human GLUCO94_H Glucose level QTL 94 (human) 21 0.83 0.005 1340047 D21S1252 Glucose level non-insulin dependent Diagnosed with Type 2 diabetes mellitus glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 2313943 14633863 21 23748811 46944323 3 - by peak only
2314743 human GLUCO70_H Glucose level QTL 70 (human) 1 1.5 0.015 1335024 D1S2846 Glucose level non-insulin dependent Diagnosed with Type 2 diabetes mellitus glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 2313943 14633863 1 48372547 74372547 3 - by peak only
2314744 human GLUCO92_H Glucose level QTL 92 (human) 19 0.86 0.005 1338836 D19S865 Glucose level non-insulin dependent Diagnosed with Type 2 diabetes mellitus glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 2313943 14633863 19 1 22039483 3 - by peak only
2314745 human GLUCO85_H Glucose level QTL 85 (human) 14 1.6 0.005 1299943 D14S283 Glucose level non-insulin dependent Diagnosed with Type 2 diabetes mellitus glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 2313943 14633863 14 8757439 34757439 3 - by peak only
2314746 human GLUCO80_H Glucose level QTL 80 (human) 8 0.78 0.005 1335435 D8S552 Glucose level non-insulin dependent Diagnosed with Type 2 diabetes mellitus glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 2313943 14633863 8 1 25786608 3 - by peak only
2314747 human GLUCO72_H Glucose level QTL 72 (human) 3 1.3 0.011 1341790 D3S1270 Glucose level non-insulin dependent Diagnosed with Type 2 diabetes mellitus glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 2313943 14633863 3 1 14423372 3 - by peak only
2314748 human GLUCO93_H Glucose level QTL 93 (human) 20 0.59 0.015 1339278 D20S898 Glucose level non-insulin dependent Diagnosed with Type 2 diabetes mellitus glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 2313943 14633863 20 2224302 28224302 3 - by peak only
2314749 human GLUCO90_H Glucose level QTL 90 (human) 18 1.1 0.01 1334759 D18S68 Glucose level non-insulin dependent Diagnosed with Type 2 diabetes mellitus glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 2313943 14633863 18 46688816 72688816 3 - by peak only
2314750 human GLUCO87_H Glucose level QTL 87 (human) 17 0.66 0.021 1341260 D17S921 Glucose level non-insulin dependent Diagnosed with Type 2 diabetes mellitus glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 2313943 14633863 17 1201518 27201518 3 - by peak only
2314751 human GLUCO91_H Glucose level QTL 91 (human) 18 0.94 0.005 1335010 D18S1161 Glucose level non-insulin dependent Diagnosed with Type 2 diabetes mellitus glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 2313943 14633863 18 57399465 76117153 3 - by peak only
2314752 human GLUCO73_H Glucose level QTL 73 (human) 3 0.97 0.005 1336392 D3S3521 Glucose level non-insulin dependent Diagnosed with Type 2 diabetes mellitus glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 2313943 14633863 3 25844840 51844840 3 - by peak only
2314753 human GLUCO82_H Glucose level QTL 82 (human) 10 1.1 0.01 1342195 D10S212 Glucose level non-insulin dependent Diagnosed with Type 2 diabetes mellitus glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 2313943 14633863 10 121299685 135374737 3 - by peak only
2314754 human GLUCO95_H Glucose level QTL 95 (human) 18 0.005 1335076 D18S1140 1337839 D18S1132 1340842 D18S1105 Glucose level non-insulin dependent Diagnosed with Type 2 diabetes mellitus glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 2313943 14633863 18 615321 4609908 1 - by flanking markers
2314755 human GLUCO89_H Glucose level QTL 89 (human) 18 2.3 0.005 1335914 D18S63 Glucose level non-insulin dependent Diagnosed with Type 2 diabetes mellitus glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 2313943 14633863 18 1 16428648 3 - by peak only
2314756 human GLUCO75_H Glucose level QTL 75 (human) 4 0.82 0.01 1335649 D4S419 Glucose level non-insulin dependent Diagnosed with Type 2 diabetes mellitus glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 2313943 14633863
2314757 human GLUCO79_H Glucose level QTL 79 (human) 6 1.3 0.005 1340212 D6S1659 Glucose level non-insulin dependent Diagnosed with Type 2 diabetes mellitus glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 2313943 14633863 6 62166202 88166202 3 - by peak only
2314758 human GLUCO76_H Glucose level QTL 76 (human) 4 0.6 0.032 1334593 D4S428 Glucose level non-insulin dependent Diagnosed with Type 2 diabetes mellitus glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 2313943 14633863 4 42329330 68329330 3 - by peak only
2314759 human GLUCO77_H Glucose level QTL 77 (human) 4 0.77 0.005 1298147 D4S398 Glucose level non-insulin dependent Diagnosed with Type 2 diabetes mellitus glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 2313943 14633863 4 48929628 74929628 3 - by peak only
2301749 human PRSTS424_H Prostate tumor susceptibility QTL 424 (human) 8 1.31 1339985 D8S542 Prostate tumor susceptibility Prostate cancer confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2301317 11443539 68616;732527;736900;1344668 DLC1;NAT2;LZTS1;NAT1 8 1 23195039 3 - by peak only
2301750 human PRSTS421_H Prostate tumor susceptibility QTL 421 (human) 8 2.64 5.0E-4 1339018 D8S503 Prostate tumor susceptibility Prostate cancer confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2301317 11443539 68616;732527;736900;1344668 DLC1;NAT2;LZTS1;NAT1 8 1 22270678 3 - by peak only
2301751 human PRSTS420_H Prostate tumor susceptibility QTL 420 (human) 8 0.004 1336611 D8S1130 Prostate tumor susceptibility Prostate cancer confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2301317 11443539 68616;732527;736900;1344668 DLC1;NAT2;LZTS1;NAT1
2301752 human PRSTS425_H Prostate tumor susceptibility QTL 425 (human) 8 1.39 1336611 D8S1130 Prostate tumor susceptibility Prostate cancer confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2301317 11443539 68616;732527;736900;1344668 DLC1;NAT2;LZTS1;NAT1
2301753 human PRSTS422_H Prostate tumor susceptibility QTL 422 (human) 8 1.41 0.01 1339018 D8S503 Prostate tumor susceptibility Prostate cancer confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2301317 11443539 68616;732527;736900;1344668 DLC1;NAT2;LZTS1;NAT1 8 1 22270678 3 - by peak only
2301754 human PRSTS423_H Prostate tumor susceptibility QTL 423 (human) 8 1.31 0.01 1339018 D8S503 Prostate tumor susceptibility Prostate cancer confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2301317 11443539 68616;732527;736900;1344668 DLC1;NAT2;LZTS1;NAT1 8 1 22270678 3 - by peak only
2315001 human GLUCO128_H Glucose level QTL 128 (human) 6 3.5 1298296 D6S1009 1341334 D6S1003 1335480 D6S403 Glucose level Homeostasis model assessment of insulin sensitivity, calculated from fasting insulin and fasting glucose (HOMA%S) glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 2314906 11283790 1351327 ENPP1 6 137343885 144636295 1 - by flanking markers
2315812 human GLUCO182_H Glucose level QTL 182 (human) 8 2.48 1334535 D8S272 Glucose level Diagnosed with diabetes, or with hyperglycemia per World Health Organization[1985] guidelines between 35 and 55 years of age glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 738113 12829657 8 124804652 146274826 3 - by peak only
2315814 human GLUCO180_H Glucose level QTL 180 (human) 7 2.55 0.07 1336288 D7S493 Glucose level Diagnosed with diabetes, or with hyperglycemia per World Health Organization[1985] guidelines between 35 and 39 years of age glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 738113 12829657 7 8771771 34771771 3 - by peak only
2315816 human GLUCO177_H Glucose level QTL 177 (human) 1 2.38 1336060 D1S218 Glucose level Diagnosed with diabetes, or with hyperglycemia per World Health Organization[1985] guidelines between 35 and 55 years of age glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 738113 12829657 732790;736633;737360;733408;1343442 LMNA;CRP;APOA2;RXRG;KCNJ9 1 159769894 185769894 3 - by peak only
2315817 human GLUCO186_H Glucose level QTL 186 (human) 22 2.51 1339581 D22S420 Glucose level Diagnosed with diabetes, or with hyperglycemia per World Health Organization[1985] guidelines between 35 and 45 years of age glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 738113 12829657 22 3239551 29239551 3 - by peak only
2315819 human GLUCO178_H Glucose level QTL 178 (human) 5 1.28 1335487 D5S647 Glucose level Diagnosed with diabetes, or with hyperglycemia per World Health Organization[1985] guidelines between 35 and 55 years of age glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 738113 12829657 5 53283203 79283203 3 - by peak only
2315820 human GLUCO179_H Glucose level QTL 179 (human) 5 2.13 1337935 D5S410 Glucose level Diagnosed with diabetes, or with hyperglycemia per World Health Organization[1985] guidelines between 35 and 45 years of age glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 738113 12829657 5 139755268 165755268 3 - by peak only
2315821 human GLUCO181_H Glucose level QTL 181 (human) 8 1.68 1339561 D8S258 Glucose level Diagnosed with diabetes, or with hyperglycemia per World Health Organization[1985] guidelines between 35 and 55 years of age glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 738113 12829657 8 7411562 33411562 3 - by peak only
2315822 human GLUCO185_H Glucose level QTL 185 (human) 21 1.67 1342402 D21S266 Glucose level Diagnosed with diabetes, or with hyperglycemia per World Health Organization[1985] guidelines between 35 and 55 years of age glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 738113 12829657 21 28606510 46944323 3 - by peak only
2315823 human GLUCO184_H Glucose level QTL 184 (human) 8 1.44 1337824 D8S275 Glucose level Diagnosed with diabetes, or with hyperglycemia per World Health Organization[1985] guidelines between 35 and 55 years of age glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 738113 12829657 8 69564028 95564028 3 - by peak only
2315824 human GLUCO176_H Glucose level QTL 176 (human) 19 1.37 0.006 1299974 D19S226 1298168 D19S433 Glucose level Plasma glucose 120 minutes after oral administration of 75 g of glucose glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 1642893 12540634 19 14494406 35109072 1 - by flanking markers
2315826 human GLUCO183_H Glucose level QTL 183 (human) 10 3.07 1340411 D10S1765 Glucose level Diagnosed with diabetes, or with hyperglycemia per World Health Organization[1985] guidelines between 35 and 55 years of age glucose homeostasis traits Diabetes Mellitus, Non-Insulin-Dependent 738113 12829657 10 76591610 102591610 3 - by peak only
2293457 human PRSTS308_H Prostate tumor susceptibility QTL 308 (human) 21 0.013 1298173 D21S1440 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293207 10712208 21 25063577 46944323 3 - by peak only
2293458 human PRSTS291_H Prostate tumor susceptibility QTL 291 (human) 2 0.012 1339308 D2S2944 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293207 10712208
2293459 human PRSTS286_H Prostate tumor susceptibility QTL 286 (human) 16 1339571 D16S3103 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293207 10712208 16 4381168 30381168 3 - by peak only
2293460 human PRSTS302_H Prostate tumor susceptibility QTL 302 (human) 4 0.002 1338978 D4S2623 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293207 10712208 4 98109297 124109297 3 - by peak only
2293461 human PRSTS298_H Prostate tumor susceptibility QTL 298 (human) 18 0.031 2141465 D18S1369 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293207 10712208 18 18387970 44387970 3 - by peak only
2293462 human PRSTS307_H Prostate tumor susceptibility QTL 307 (human) 15 0.043 1298311 D15S657 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293207 10712208 15 81506023 100338915 3 - by peak only
2293463 human PRSTS293_H Prostate tumor susceptibility QTL 293 (human) 2 0.012 1339325 D2S427 1331557 D2S2968 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293207 10712208 2 231914508 237743384 1 - by flanking markers
2293464 human PRSTS303_H Prostate tumor susceptibility QTL 303 (human) 11 0.015 1298253 D11S1392 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293207 10712208 11 21596755 47596755 3 - by peak only
2293465 human PRSTS285_H Prostate tumor susceptibility QTL 285 (human) 15 1339016 D15S1010 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293207 10712208 15 17877754 43877754 3 - by peak only
2293466 human PRSTS305_H Prostate tumor susceptibility QTL 305 (human) 12 0.024 1341328 D12S395 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293207 10712208 12 105672967 131672967 3 - by peak only
2293467 human PRSTS304_H Prostate tumor susceptibility QTL 304 (human) 12 0.032 1340602 D12S1685 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293207 10712208 12 1 16862066 3 - by peak only
2293468 human PRSTS292_H Prostate tumor susceptibility QTL 292 (human) 2 0.013 1337160 D2S2228 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293207 10712208 2 211405159 237405159 3 - by peak only
2293469 human PRSTS297_H Prostate tumor susceptibility QTL 297 (human) 15 0.029 1341232 D15S1048 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293207 10712208 15 14656815 40656815 3 - by peak only
2293470 human PRSTS294_H Prostate tumor susceptibility QTL 294 (human) 3 0.016 1337809 D3S2459 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293207 10712208 3 90658068 116658068 3 - by peak only
2293471 human PRSTS300_H Prostate tumor susceptibility QTL 300 (human) 1 0.02 1298297 D1S547 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293207 10712208 1 226822702 247249719 3 - by peak only
2293472 human PRSTS296_H Prostate tumor susceptibility QTL 296 (human) 15 0.027 1299967 D15S1002 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293207 10712208 15 12523382 38523382 3 - by peak only
2293473 human PRSTS295_H Prostate tumor susceptibility QTL 295 (human) 8 0.009 1854687 RH28094 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293207 10712208 8 86259025 112259025 3 - by peak only
2293474 human PRSTS289_H Prostate tumor susceptibility QTL 289 (human) 1 0.003 1341913 D1S1677 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293207 10712208 1 148826426 174826426 3 - by peak only
2293475 human PRSTS290_H Prostate tumor susceptibility QTL 290 (human) 1 0.018 1342325 D1S2141 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293207 10712208 1 200262036 226262036 3 - by peak only
2293476 human PRSTS309_H Prostate tumor susceptibility QTL 309 (human) 1 1342100 D1S1622 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records 2293207 10712208 1 17083670 43083670 3 - by peak only
2293477 human PRSTS310_H Prostate tumor susceptibility QTL 310 (human) 1 0.009 1336465 D1S3728 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records 2293207 10712208
2293478 human PRSTS301_H Prostate tumor susceptibility QTL 301 (human) 2 0.002 1337160 D2S2228 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293207 10712208 2 211405159 237405159 3 - by peak only
2293479 human PRSTS287_H Prostate tumor susceptibility QTL 287 (human) 16 1336413 D16S3096 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293207 10712208 16 64602504 88827254 3 - by peak only
2293480 human PRSTS284_H Prostate tumor susceptibility QTL 284 (human) 12 1340602 D12S1685 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293207 10712208 12 1 16862066 3 - by peak only
2293481 human PRSTS311_H Prostate tumor susceptibility QTL 311 (human) 21 0.002 1339550 D21S2055 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records 2293207 10712208 21 27113385 46944323 3 - by peak only
2293482 human PRSTS306_H Prostate tumor susceptibility QTL 306 (human) 15 0.001 1339016 D15S1010 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293207 10712208 15 17877754 43877754 3 - by peak only
2293483 human PRSTS283_H Prostate tumor susceptibility QTL 283 (human) 2 1337160 D2S2228 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293207 10712208 2 211405159 237405159 3 - by peak only
2293484 human PRSTS299_H Prostate tumor susceptibility QTL 299 (human) 18 0.018 1337762 D18S363 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293207 10712208 18 33537273 59537273 3 - by peak only
2293485 human PRSTS288_H Prostate tumor susceptibility QTL 288 (human) 1 0.031 1331565 D1S1653 Prostate tumor susceptibility Prostate cancer diagnosis confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2293207 10712208 1 143199451 169199451 3 - by peak only
2301820 human PRSTS409_H Prostate tumor susceptibility QTL 409 (human) 1 0.001 1335036 D1S212 Prostate tumor susceptibility Prostate cancer confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2301206 10712209 1 163349281 189349281 3 - by peak only
2301821 human PRSTS406_H Prostate tumor susceptibility QTL 406 (human) 1 6.0E-4 1335036 D1S212 Prostate tumor susceptibility Prostate cancer confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2301206 10712209 1 163349281 189349281 3 - by peak only
2301822 human PRSTS411_H Prostate tumor susceptibility QTL 411 (human) 1 0.002 1335036 D1S212 Prostate tumor susceptibility Prostate cancer confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2301206 10712209 1 163349281 189349281 3 - by peak only
2301823 human PRSTS408_H Prostate tumor susceptibility QTL 408 (human) 1 0.02 1335036 D1S212 Prostate tumor susceptibility Prostate cancer confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2301206 10712209 1 163349281 189349281 3 - by peak only
2301824 human PRSTS407_H Prostate tumor susceptibility QTL 407 (human) 1 0.01 1335036 D1S212 Prostate tumor susceptibility Prostate cancer confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2301206 10712209 1 163349281 189349281 3 - by peak only
2301825 human PRSTS405_H Prostate tumor susceptibility QTL 405 (human) 1 0.01 1335036 D1S212 Prostate tumor susceptibility Prostate cancer confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2301206 10712209 1 163349281 189349281 3 - by peak only
2301826 human PRSTS410_H Prostate tumor susceptibility QTL 410 (human) 1 1729626 D1S158 Prostate tumor susceptibility Prostate cancer confirmed by medical records abnormal sciatic nerve Prostatic Neoplasms 2301206 10712209 1 169407710 195407710 3 - by peak only
2301895 human PRSTS339_H Prostate tumor susceptiblity QTL 339 (human) 5 1.0 1299941 D5S407 Prostate tumor susceptibility Prostrate cancer verified by medical records abnormal sciatic nerve Prostatic Neoplasms 2299086 11404817 5 43030583 69030583 3 - by peak only
2303074 human MAMTS46_H Mammary tumor susceptibility QTL 46 (human) 13 11.65 1336559 D13S260 Mammary tumor susceptibility Early-onset breast cancer not linked to BRCA1 mammary adenocarcinoma Breast Neoplasms 2302969 8091231 736254 BRCA2 13 18334915 44334915 3 - by peak only
2303076 human MAMTS43_H Mammary tumor susceptibility QTL 43 (human) 22 1.15 1331587 D22S278 1339568 D22S283 Mammary tumor susceptibility Diagnosed with breast cancer mammary adenocarcinoma Breast Neoplasms 2302791 16575876 22 34736599 35081014 1 - by flanking markers
2303078 human MAMTS42_H Mammary tumor susceptibility QTL 42 (human) 4 1.8 1298331 D4S392 Mammary tumor susceptibility Diagnosed with breast cancer mammary adenocarcinoma Breast Neoplasms 2302791 16575876 4 57558031 83558031 3 - by peak only
2303079 human MAMTS45_H Mammary tumor susceptibility QTL 45 (human) 17 5.98 2106449 BRCA1_4046 2190495 BRCA1 Mammary tumor susceptibility Diagnosed with breast cancer before age 46 mammary adenocarcinoma Breast Neoplasms 2302861 2270482 69132 BRCA1 17 38449842 38544890 2 - by one flank and peak markers
2303081 human MAMTS49_H Mammary tumor susceptibility QTL 49 (human) 21 1.72 1338360 D21S1256 1339009 D21S1914 Mammary tumor susceptibility Females diagnosed with mammary cancer, who did not test positive for BRCA1 or BRCA2 mammary adenocarcinoma Breast Neoplasms 2303050 16551851 21 18244636 24544482 1 - by flanking markers
2303083 human MAMTS47_H Mammary tumor susceptibility QTL 47 (human) 22 1.2 1339118 D22S1150 1335217 D22S928 Mammary tumor susceptibility Female breast cancer, non-BRCA1 and non-BRCA2 mammary adenocarcinoma Breast Neoplasms 1599601 11967536 732861 CHEK2 22 27831409 43854274 1 - by flanking markers
2303085 human MAMTS48_H Mammary tumor susceptibility QTL 48 (human) 13 1340040 D13S1296 1340557 D13S1308 Mammary tumor susceptibility Females diagnosed with mammary cancer, who did not test positive for BRCA1 or BRCA2 mammary adenocarcinoma Breast Neoplasms 2302993 10944226 1314916;1606339 PCDH9;DACH1 13 69554310 70109753 1 - by flanking markers
2303086 human MAMTS44_H Mammary tumor susceptibility QTL 44 (human) 2 3.2 1338182 D2S384 1337032 D2S2262 Mammary tumor susceptibility Diagnosed with breast cancer mammary adenocarcinoma Breast Neoplasms 2302792 14560309 1321618;1349068 ITGAV;PMS1 2 181211071 190991007 1 - by flanking markers
2303087 human MAMTS41_H Mammary tumor susceptibility QTL 41 (human) 2 1.2 1334560 D2S2211 Mammary tumor susceptibility Diagnosed with breast cancer mammary adenocarcinoma Breast Neoplasms 2302791 16575876 2 1 20388957 3 - by peak only
2316031 human GLUCO215_H Glucose level QTL 215 (human) 11 0.07 1338334 D11S935 Glucose level Diagnosed as diabetic per the World Health Organization's 1985 guidelines abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 2315992 11916952 11 22979936 48979936 3 - by peak only
2316033 human GLUCO218_H Glucose level QTL 218 (human) 14 9.0E-4 1338458 D14S275 Glucose level Diagnosed as diabetic per the World Health Organization's 1985 guidelines abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 2315992 11916952 14 12766678 38766678 3 - by peak only
2316034 human GLUCO220_H Glucose level QTL 220 (human) 20 0.00102 1299965 D20S119 Glucose level Diagnosed as diabetic per the World Health Organization's 1985 guidelines abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 2315992 11916952 20 30082525 56082525 3 - by peak only
2316035 human GLUCO214_H Glucose level QTL 214 (human) 6 0.046 1337699 D6S289 Glucose level Diagnosed as diabetic per the World Health Organization's 1985 guidelines abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 2315992 11916952 6 2390123 28390123 3 - by peak only
2316036 human GLUCO216_H Glucose level QTL 216 (human) 2 8.2E-4 1298257 D2S117 Glucose level Diagnosed as diabetic per the World Health Organization's 1985 guidelines abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 2315992 11916952 2 182327142 208327142 3 - by peak only
2316037 human GLUCO219_H Glucose level QTL 219 (human) 15 2.0E-5 1338535 D15S994 Glucose level Diagnosed as diabetic per the World Health Organization's 1985 guidelines abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 2315992 11916952 15 25369481 51369481 3 - by peak only
2316038 human GLUCO217_H Glucose level QTL 217 (human) 7 0.008 1340763 D7S517 Glucose level Diagnosed as diabetic per the World Health Organization's 1985 guidelines abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 2315992 11916952 1351287 PRKAR1B 7 1 17464692 3 - by peak only
2316326 human GLUCO230_H Glucose level QTL 230 (human) 18 3.79 1331566 D18S976 1336163 D18S391 Glucose level Diagnosed as type 2 diabetic abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 2316292 11246890 732421 MC5R 18 5238944 5771405 1 - by flanking markers
2316328 human GLUCO237_H Glucose level QTL 237 (human) 20 1335995 D20S103 Glucose level Diagnosed as type 2 diabetic abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 738115 11246891 20 1 13507306 3 - by peak only
2316329 human GLUCO229_H Glucose level QTL 229 (human) 18 1.0 0.02 1341487 D12S1042 Glucose level Diagnosed as type 2 diabetic abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 2316270 15161769 12 14538701 40538701 3 - by peak only
2316330 human GLUCO235_H Glucose level QTL 235 (human) 4 1337880 D4S1501 Glucose level Diagnosed as type 2 diabetic abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 738115 11246891 4 167524249 191273063 3 - by peak only
2316331 human GLUCO231_H Glucose level QTL 231 (human) 1 2.38 1341601 D1S3462 Glucose level Diagnosed as type 2 diabetic abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 2316292 11246890 1 217017269 243017269 3 - by peak only
2316332 human GLUCO228_H Glucose level QTL 228 (human) 12 1.99 0.0012 1341487 D12S1042 Glucose level Diagnosed as type 2 diabetic abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 2316270 15161769 12 14538701 40538701 3 - by peak only
2316333 human GLUCO238_H Glucose level QTL 238 (human) 8 2118328 D8S593 Glucose level Diagnosed as type 2 diabetic abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 738115 11246891 8 42887898 68887898 3 - by peak only
2316334 human GLUCO225_H Glucose level QTL 225 (human) 4 2.63 3.0E-4 1298161 D4S2394 1298110 D4S1644 Glucose level Diagnosed as type 2 diabetic abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 2316270 15161769 4 130517283 141971108 1 - by flanking markers
2316335 human GLUCO232_H Glucose level QTL 232 (human) 4 1.41 1337133 D4S2361 Glucose level Diagnosed as type 2 diabetic abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 2316292 11246890 1346979 NKX6-1 4 72224541 98224541 3 - by peak only
2316336 human GLUCO233_H Glucose level QTL 233 (human) 5 2.41 1340849 D5S816 Glucose level Diagnosed as type 2 diabetic abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 2316292 11246890 5 122329530 148329530 3 - by peak only
2316337 human GLUCO226_H Glucose level QTL 226 (human) 5 0.84 0.02 1340849 D5S816 Glucose level Diagnosed as type 2 diabetic abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 2316270 15161769 5 122329530 148329530 3 - by peak only
2316338 human GLUCO223_H Glucose level QTL 223 (human) 1 3.09 8.0E-5 2131 Apoa2 1339028 D1S194 Glucose level Diagnosed as type 2 diabetic abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 2316270 15161769 736633;735872;1343442 CRP;PLA2G4A;KCNJ9 1 137704127 163704127 4 - by one flank marker only
2316339 human GLUCO234_H Glucose level QTL 234 (human) 17 1.29 1298312 D17S1301 Glucose level Diagnosed as type 2 diabetic abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 2316292 11246890 69010;1344971 GCGR;GH2 17 57192606 78774742 3 - by peak only
2316340 human GLUCO222_H Glucose level QTL 222 (human) 11 0.0013 1340959 D11S905 Glucose level Diagnosed with type 2 diabetes per American Diabetes Association's 1997 criteria abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 2316083 15490285 11 27930988 53930988 3 - by peak only
2316342 human GLUCO236_H Glucose level QTL 236 (human) 20 1341027 D20S195 Glucose level Diagnosed as type 2 diabetic abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 738115 11246891 732277;69093 RPN2;HNF4A 20 18289479 44289479 3 - by peak only
2316343 human GLUCO221_H Glucose level QTL 221 (human) 6 0.0097 1298111 D6S462 Glucose level Diagnosed with type 2 diabetes per American Diabetes Association's 1997 criteria abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 2316083 15490285 6 77985454 103985454 3 - by peak only
2316344 human GLUCO227_H Glucose level QTL 227 (human) 6 1.91 0.002 1341899 D6S1277 1338225 D6S1027 Glucose level Diagnosed as type 2 diabetic abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 2316270 15161769 6 164217731 168951405 1 - by flanking markers
2316345 human GLUCO224_H Glucose level QTL 224 (human) 3 1.27 0.008 1339237 D3S4545 Glucose level Diagnosed as type 2 diabetic abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 2316270 15161769
2316346 human GLUCO240_H Glucose level QTL 240 (human) 2 1.64 0.01 1334687 D2S2166 Glucose level Diagnosed as type 2 diabetic abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 2316318 14747302 2 1 17859749 3 - by peak only
2316347 human GLUCO241_H Glucose level QTL 241 (human) 8 3.67 2.8E-5 1335322 D8S1742 Glucose level Diagnosed as type 2 diabetic abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 2316318 14747302 8 1 19201482 3 - by peak only
2316348 human GLUCO239_H Glucose level QTL 239 (human) 14 1339017 D14S605 Glucose level Diagnosed as type 2 diabetic abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 738115 11246891 14 82504179 106368585 3 - by peak only
2316042 human GLUCO200_H Glucose level QTL 200 (human) 20 6.0E-4 1335922 D20S196 Glucose level Diagnosed as type 2 diabetic, fasting plasma glucose greater than 7.8 mmol/l or greater than 11.1 mmol/l 2 hours after a 75g glucose load, and non-diabetics had fasting glucose less than 6.1 mmol/l and less than 7.8 mmol/l 2 hours after a glucose load, type 1, MODY and maternally inherited diabetic subjects excluded abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 2315942 11357482 20 35995245 61995245 3 - by peak only
2316044 human GLUCO197_H Glucose level QTL 197 (human) 12 0.03 1299944 D12S2070 1299909 D12S324 1339412 D12S304 Glucose level Previously diagnosed as diabetic, using oral antidiabetic medications or insulin, or with fasting glucose greater than 6.7 mmol/l or 2 hour post glucose challenge value greater than 8.5 mmol/l abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 1298353 11791216 12 114567092 125191356 1 - by flanking markers
2316046 human GLUCO192_H Glucose level QTL 192 (human) 20 1.8E-5 1299965 D20S119 1336753 D20S428 1335922 D20S196 Glucose level Diagnosed as diabetic or with impaired glucose tolerance according to WHO (1985) criteria 2315900 11118028 736208;1314347 CEBPB;DUSP15 20 43082465 54908025 2 - by one flank and peak markers
2316048 human GLUCO193_H Glucose level QTL 193 (human) 2 2.0 0.03 1298185 D2S286 1298104 D2S1790 1299929 D2S1777 Glucose level Previously diagnosed as diabetic, using oral antidiabetic medications or insulin, or with fasting glucose greater than 6.7 mmol/l or 2 hour post glucose challenge value greater than 8.5 mmol/l abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 1298353 11791216 2 75195641 84929094 1 - by flanking markers
2316049 human GLUCO211_H Glucose level QTL 211 (human) 16 0.039 1340592 D16S423 Glucose level Diagnosed as type 2 diabetic, fasting plasma glucose greater than 7.8 mmol/l or greater than 11.1 mmol/l 2 hours after a 75g glucose load, and non-diabetics had fasting glucose less than 6.1 mmol/l and less than 7.8 mmol/l 2 hours after a glucose load, type 1, MODY and maternally inherited diabetic subjects excluded abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 2315942 11357482 16 1 18983390 3 - by peak only
2316050 human GLUCO209_H Glucose level QTL 209 (human) 11 0.046 1338334 D11S935 Glucose level Diagnosed as type 2 diabetic, fasting plasma glucose greater than 7.8 mmol/l or greater than 11.1 mmol/l 2 hours after a 75g glucose load, and non-diabetics had fasting glucose less than 6.1 mmol/l and less than 7.8 mmol/l 2 hours after a glucose load, type 1, MODY and maternally inherited diabetic subjects excluded abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 2315942 11357482 11 22979936 48979936 3 - by peak only
2316051 human GLUCO202_H Glucose level QTL 202 (human) 4 0.013 1338152 D4S2964 Glucose level Diagnosed as type 2 diabetic, fasting plasma glucose greater than 7.8 mmol/l or greater than 11.1 mmol/l 2 hours after a 75g glucose load, and non-diabetics had fasting glucose less than 6.1 mmol/l and less than 7.8 mmol/l 2 hours after a glucose load, type 1, MODY and maternally inherited diabetic subjects excluded abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 2315942 11357482 4 67994452 93994452 3 - by peak only
2316052 human GLUCO208_H Glucose level QTL 208 (human) 9 4.73E-4 1342113 D9S175 Glucose level Diagnosed as type 2 diabetic, fasting plasma glucose greater than 7.8 mmol/l or greater than 11.1 mmol/l 2 hours after a 75g glucose load, and non-diabetics had fasting glucose less than 6.1 mmol/l and less than 7.8 mmol/l 2 hours after a glucose load, type 1, MODY and maternally inherited diabetic subjects excluded abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 2315942 11357482 69199;735936;1604403 ASIP;PLCG1;FXN 9 64137535 90137535 3 - by peak only
2316053 human GLUCO206_H Glucose level QTL 206 (human) 6 0.017 1337477 D6S446 Glucose level Diagnosed as type 2 diabetic, fasting plasma glucose greater than 7.8 mmol/l or greater than 11.1 mmol/l 2 hours after a 75g glucose load, and non-diabetics had fasting glucose less than 6.1 mmol/l and less than 7.8 mmol/l 2 hours after a glucose load, type 1, MODY and maternally inherited diabetic subjects excluded abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 2315942 11357482 6 157394327 170899992 3 - by peak only
2316054 human GLUCO199_H Glucose level QTL 199 (human) 17 0.03 1336435 D17S122 1299902 D17S953 Glucose level Previously diagnosed as diabetic, using oral antidiabetic medications or insulin, or with fasting glucose greater than 6.7 mmol/l or 2 hour post glucose challenge value greater than 8.5 mmol/l abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 1298353 11791216 17 15150070 16043344 1 - by flanking markers
2316055 human GLUCO207_H Glucose level QTL 207 (human) 9 1.19E-4 1340399 D9S171 Glucose level Diagnosed as type 2 diabetic, fasting plasma glucose greater than 7.8 mmol/l or greater than 11.1 mmol/l 2 hours after a 75g glucose load, and non-diabetics had fasting glucose less than 6.1 mmol/l and less than 7.8 mmol/l 2 hours after a glucose load, type 1, MODY and maternally inherited diabetic subjects excluded abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 2315942 11357482 9 11524300 37524300 3 - by peak only
2316056 human GLUCO195_H Glucose level QTL 195 (human) 4 0.01 1339077 D4S1595 1339707 D4S3047 1299897 D4S3015 Glucose level Previously diagnosed as diabetic, using oral antidiabetic medications or insulin, or with fasting glucose greater than 6.7 mmol/l or 2 hour post glucose challenge value greater than 8.5 mmol/l abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 1298353 11791216 4 174554403 185647461 1 - by flanking markers
2316057 human GLUCO198_H Glucose level QTL 198 (human) 16 0.05 1299903 D16S420 Glucose level Previously diagnosed as diabetic, using oral antidiabetic medications or insulin, or with fasting glucose greater than 6.7 mmol/l or 2 hour post glucose challenge value greater than 8.5 mmol/l abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 1298353 11791216 16 11143742 37143742 3 - by peak only
2316058 human GLUCO203_H Glucose level QTL 203 (human) 5 0.027 1336473 D5S426 Glucose level Diagnosed as type 2 diabetic, fasting plasma glucose greater than 7.8 mmol/l or greater than 11.1 mmol/l 2 hours after a 75g glucose load, and non-diabetics had fasting glucose less than 6.1 mmol/l and less than 7.8 mmol/l 2 hours after a glucose load, type 1, MODY and maternally inherited diabetic subjects excluded abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 2315942 11357482 5 21798808 47798808 3 - by peak only
2316059 human GLUCO213_H Glucose level QTL 213 (human) 20 0.04 1335497 D20S889 Glucose level Diagnosed as type 2 diabetic, fasting plasma glucose greater than 7.8 mmol/l or greater than 11.1 mmol/l 2 hours after a 75g glucose load, and non-diabetics had fasting glucose less than 6.1 mmol/l and less than 7.8 mmol/l 2 hours after a glucose load, type 1, MODY and maternally inherited diabetic subjects excluded abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 2315942 11357482 20 1 16895114 3 - by peak only
2316060 human GLUCO212_H Glucose level QTL 212 (human) 20 0.013 1335497 D20S889 Glucose level Diagnosed as type 2 diabetic, fasting plasma glucose greater than 7.8 mmol/l or greater than 11.1 mmol/l 2 hours after a 75g glucose load, and non-diabetics had fasting glucose less than 6.1 mmol/l and less than 7.8 mmol/l 2 hours after a glucose load, type 1, MODY and maternally inherited diabetic subjects excluded abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 2315942 11357482 20 1 16895114 3 - by peak only
2316061 human GLUCO194_H Glucose level QTL 194 (human) 3 0.02 1298316 D3S3038 1298325 D3S2409 1299934 D3S1561 Glucose level Previously diagnosed as diabetic, using oral antidiabetic medications or insulin, or with fasting glucose greater than 6.7 mmol/l or 2 hour post glucose challenge value greater than 8.5 mmol/l abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 1298353 11791216 3 21924508 50994028 2 - by one flank and peak markers
2316062 human GLUCO205_H Glucose level QTL 205 (human) 6 0.009 1336116 D6S276 Glucose level Diagnosed as type 2 diabetic, fasting plasma glucose greater than 7.8 mmol/l or greater than 11.1 mmol/l 2 hours after a 75g glucose load, and non-diabetics had fasting glucose less than 6.1 mmol/l and less than 7.8 mmol/l 2 hours after a glucose load, type 1, MODY and maternally inherited diabetic subjects excluded abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 2315942 11357482 6 11293951 37293951 3 - by peak only
2316063 human GLUCO204_H Glucose level QTL 204 (human) 5 0.033 1337571 D5S408 Glucose level Diagnosed as type 2 diabetic, fasting plasma glucose greater than 7.8 mmol/l or greater than 11.1 mmol/l 2 hours after a 75g glucose load, and non-diabetics had fasting glucose less than 6.1 mmol/l and less than 7.8 mmol/l 2 hours after a glucose load, type 1, MODY and maternally inherited diabetic subjects excluded abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 2315942 11357482 5 166921015 180857866 3 - by peak only
2316064 human GLUCO210_H Glucose level QTL 210 (human) 11 0.027 1298330 D11S987 Glucose level Diagnosed as type 2 diabetic, fasting plasma glucose greater than 7.8 mmol/l or greater than 11.1 mmol/l 2 hours after a 75g glucose load, and non-diabetics had fasting glucose less than 6.1 mmol/l and less than 7.8 mmol/l 2 hours after a glucose load, type 1, MODY and maternally inherited diabetic subjects excluded abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 2315942 11357482
2316065 human GLUCO196_H Glucose level QTL 196 (human) 9 0.002 1299940 D9S1874 1299927 D9S153 1299885 D9S166 Glucose level Previously diagnosed as diabetic, using oral antidiabetic medications or insulin, or with fasting glucose greater than 6.7 mmol/l or 2 hour post glucose challenge value greater than 8.5 mmol/l abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 1298353 11791216 9 37212295 80771302 1 - by flanking markers
2316066 human GLUCO201_H Glucose level QTL 201 (human) 2 0.008 1298307 D2S126 Glucose level Diagnosed as type 2 diabetic, fasting plasma glucose greater than 7.8 mmol/l or greater than 11.1 mmol/l 2 hours after a 75g glucose load, and non-diabetics had fasting glucose less than 6.1 mmol/l and less than 7.8 mmol/l 2 hours after a glucose load, type 1, MODY and maternally inherited diabetic subjects excluded abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 2315942 11357482 2 208725280 234725280 3 - by peak only
2316869 human GLUCO294_H Glucose level QTL 294 (human) 12 1.93 0.0027 1299909 D12S324 1336935 D12S1659 Glucose level Sex adjusted age at diagnosis of type 2 diabetes abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 2316768 14988275 12 125191131 127982460 1 - by flanking markers
2316871 human GLUCO292_H Glucose level QTL 292 (human) 5 1.56 0.0055 1340441 D5S1981 1334915 D5S406 Glucose level Sex adjusted age at diagnosis of type 2 diabetes abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 2316768 14988275 5 1207429 5047247 1 - by flanking markers
2316872 human GLUCO305_H Glucose level QTL 305 (human) 20 1.742 0.0073 1337931 D20S118 Glucose level Diagnosed as type 2 diabetic abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 2316815 15776287 20 3977420 29977420 3 - by peak only
2316873 human INSUL46_H Insulin level QTL 46 (human) 14 2.67 8.0E-4 1336750 D14S65 Insulin level fasting Fasting insulin abnormal circulating insulin level Diabetes Mellitus, Non-Insulin-Dependent 2316753 11032784 14 83691308 106368585 3 - by peak only
2316874 human GLUCO301_H Glucose level QTL 301 (human) 1 0.001 1331547 D1S3669 Glucose level Affected with type 2 diabetes or impaired glucose homeostasis before age 40 abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 2316801 14693720 1 4656345 30656345 3 - by peak only
2316876 human GLUCO299_H Glucose level QTL 299 (human) 6 0.01 1298306 D6S1056 Glucose level Affected with type 2 diabetes or impaired glucose homeostasis before 40 years of age abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 2316801 14693720 6 81154351 107154351 3 - by peak only
2316878 human GLUCO293_H Glucose level QTL 293 (human) 12 2.58 0.001 1340578 D12S310 Glucose level Sex adjusted age at diagnosis of type 2 diabetes abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 2316768 14988275 12 5864933 31864933 3 - by peak only
2316879 human GLUCO304_H Glucose level QTL 304 (human) 1 2.609 0.033 1338728 D1S196 1339394 D1S2851 Glucose level Diagnosed as type 2 diabetic abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 2316815 15776287 737360;737364;1312426 APOA2;PKLR;LMX1A 1 165870924 168583665 1 - by flanking markers
2316880 human GLUCO300_H Glucose level QTL 300 (human) 1 0.001 1336087 D1S1589 Glucose level Affected with type 2 diabetes or impaired glucose homeostasis before age 40 abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 2316801 14693720 1 159527826 185527826 3 - by peak only
2316881 human GLUCO297_H Glucose level QTL 297 (human) 6 0.001 1298242 D6S1040 Glucose level Affected with type 2 diabetes or impaired glucose homeostasis abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 2316801 14693720 6 118027578 144027578 3 - by peak only
2316883 human GLUCO296_H Glucose level QTL 296 (human) 6 0.003 1298296 D6S1009 Glucose level Affected with type 2 diabetes or impaired glucose homeostasis abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 2316801 14693720 6 124344004 150344004 3 - by peak only
2316884 human GLUCO303_H Glucose level QTL 303 (human) 1 3.103 0.005 1340957 D1S432 Glucose level Diagnosed as type 2 diabetic abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 2316815 15776287 735832 LEPR 1 26149898 52149898 3 - by peak only
2316885 human GLUCO291_H Glucose level QTL 291 (human) 4 1.61 0.0034 1341734 D4S2971 Glucose level Sex adjusted age at diagnosis of type 2 diabetes abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 2316768 14988275 4 40421545 66421545 3 - by peak only
2316886 human INSUL47_H Insulin level QTL 47 (human) 11 2.32 5.0E-4 1335315 D11S1311 Insulin level Insulin secretion index, fasting insulin divided by fasting glucose abnormal circulating insulin level Diabetes Mellitus, Non-Insulin-Dependent 2316753 11032784 11 79987735 105987735 3 - by peak only
2316888 human GLUCO295_H Glucose level QTL 295 (human) 14 1.71 0.003 1341752 D14S70 1337644 D14S288 Glucose level Sex adjusted age at diagnosis of type 2 diabetes abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 2316768 14988275 14 33528945 43171795 1 - by flanking markers
2316889 human GLUCO290_H Glucose level QTL 290 (human) 1 1.31 0.0089 1335516 D1S2836 Glucose level Sex adjusted age at diagnosis of type 2 diabetes abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 2316768 14988275 1 231936869 247249719 3 - by peak only
2316890 human GLUCO302_H Glucose level QTL 302 (human) 1 0.005 1339881 D1S1728 Glucose level Affected with type 2 diabetes or impaired glucose homeostasis before age 40 abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 2316801 14693720
2316891 human GLUCO298_H Glucose level QTL 298 (human) 6 0.013 1298242 D6S1040 Glucose level Affected with type 2 diabetes or impaired glucose homeostasis before 40 years of age abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 2316801 14693720 6 118027578 144027578 3 - by peak only
2316892 human INSUL44_H Insulin level QTL 44 (human) 3 3.13 1.0E-4 1342031 D3S1266 1298239 D3S1768 Insulin level Fasting C-peptide divided by fasting glucose abnormal insulin secretion Diabetes Mellitus, Non-Insulin-Dependent 2316753 11032784 3 27932392 34599593 1 - by flanking markers
2316894 human INSUL45_H Insulin level QTL 45 (human) 13 1.52 1341056 D13S263 Insulin level fasting Fasting insulin abnormal circulating insulin level Diabetes Mellitus, Non-Insulin-Dependent 2316753 11032784 13 27979051 53979051 3 - by peak only
2316660 human GLUCO254_H Glucose level QTL 254 (human) 6 3.45 0.017 1342414 D6S1569 Glucose level Diagnosed with type 2 diabetes, or with fasting glucose equal to or greater than 6.1 mmol/l, likely type 1 diabetic subjects excluded abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 2316508 17179727 6 126095507 152095507 3 - by peak only
2316662 human GLUCO251_H Glucose level QTL 251 (human) 7 3.85 1357237 D7S1802 Glucose level Diagnosed with diabetes after age 35, excluding steriod induced or gestational diabetes abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 2316485 14988270 7 7671918 33671918 3 - by peak only
2316664 human GLUCO249_H Glucose level QTL 249 (human) 20 2.63 1336000 D20S480 1342071 D20S171 Glucose level Fasting plasma glucose greater than or equal to 7 mmol/l or 2 hour post glucose load value of greater than or equal to 11.1 mmol/l, on more than one occasion abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 2316370 14988271 20 31241563 57241563 4 - by one flank marker only
2316666 human GLUCO252_H Glucose level QTL 252 (human) 12 3.65 1334755 D12S321 Glucose level Diagnosed with type 2 diabetes, or with fasting glucose equal to or greater than 6.1 mmol/l, 1 likely type 1 diabetic excluded abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 2316491 9792550 737153 HNF1A 12 105631982 131631982 3 - by peak only
2316668 human GLUCO244_H Glucose level QTL 244 (human) 12 1.92 1299944 D12S2070 1341328 D12S395 Glucose level Fasting plasma glucose greater than or equal to 7 mmol/l or 2 hour post glucose load value of greater than or equal to 11.1 mmol/l, on more than one occasion abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 2316370 14988271 737153 HNF1A 12 114567092 118673086 1 - by flanking markers
2316669 human GLUCO253_H Glucose level QTL 253 (human) 6 7.91 0.014 1340864 D6S445 1336207 D6S1601 Glucose level Diagnosed with type 2 diabetes, or with fasting glucose equal to or greater than 6.1 mmol/l, likely type 1 diabetic subjects excluded abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 2316508 17179727 6 82511547 85641498 1 - by flanking markers
2316670 human GLUCO243_H Glucose level QTL 243 (human) 4 1.37 1338978 D4S2623 1298161 D4S2394 Glucose level Fasting plasma glucose greater than or equal to 7 mmol/l or 2 hour post glucose load value of greater than or equal to 11.1 mmol/l, on more than one occasion abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 2316370 14988271 4 111109155 130517530 1 - by flanking markers
2316671 human GLUCO246_H Glucose level QTL 246 (human) 19 1.81 1342299 D19S588 1298168 D19S433 Glucose level Fasting plasma glucose greater than or equal to 7 mmol/l or 2 hour post glucose load value of greater than or equal to 11.1 mmol/l, on more than one occasion abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 2316370 14988271 19 15589231 35109072 1 - by flanking markers
2316672 human GLUCO250_H Glucose level QTL 250 (human) 6 2.69 1337949 D6S1035 Glucose level Diagnosed with diabetes after age 35, excluding steriod induced or gestational diabetes abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 2316485 14988270 6 146947193 170899992 3 - by peak only
2316673 human GLUCO247_H Glucose level QTL 247 (human) 20 1.24 1339271 D20S470 2156941 D20S477 Glucose level Fasting plasma glucose greater than or equal to 7 mmol/l or 2 hour post glucose load value of greater than or equal to 11.1 mmol/l, on more than one occasion abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 2316370 14988271 20 17320490 22360342 1 - by flanking markers
2316674 human GLUCO245_H Glucose level QTL 245 (human) 17 1.26 1298294 D17S1298 Glucose level Fasting plasma glucose greater than or equal to 7 mmol/l or 2 hour post glucose load value of greater than or equal to 11.1 mmol/l, on more than one occasion abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 2316370 14988271 17 1 16613421 3 - by peak only
2316675 human GLUCO248_H Glucose level QTL 248 (human) 20 1.8 1339243 D20S481 1336000 D20S480 Glucose level Fasting plasma glucose greater than or equal to 7 mmol/l or 2 hour post glucose load value of greater than or equal to 11.1 mmol/l, on more than one occasion abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 2316370 14988271 20 43201695 62435964 4 - by one flank marker only
2316676 human GLUCO242_H Glucose level QTL 242 (human) 5 2.9 1.29E-4 1299887 DG5S5 1299907 D5S429 1299914 D5S625 Glucose level Diagnosed as type 2 diabetic, or with impaired fasting glucose per 1997 American Diabetes Association guidelines abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 1298031 12851856 5 157102706 180857866 3 - by peak only
2316720 human GLUCO288_H Glucose level QTL 288 (human) 20 1.72 0.00432 1298199 D20S178 Glucose level Diagnosed with type 2 diabetes abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 1298348 11067779 20 32985515 58985515 3 - by peak only
2316721 human GLUCO285_H Glucose level QTL 285 (human) 16 1.39 0.00971 1299892 D16S3068 Glucose level Diagnosed with type 2 diabetes abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 1298348 11067779 16 12468197 38468197 3 - by peak only
2316722 human GLUCO278_H Glucose level QTL 278 (human) 11 1.25 0.01371 1337167 D11S1338 Glucose level Diagnosed with type 2 diabetes abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 1298348 11067779 11 1 18944680 3 - by peak only
2316723 human GLUCO286_H Glucose level QTL 286 (human) 18 1.75 0.00401 1339328 D18S478 Glucose level Diagnosed with type 2 diabetes abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 1298348 11067779 18 10401381 36401381 3 - by peak only
2316724 human GLUCO282_H Glucose level QTL 282 (human) 8 1.44 0.00865 1335449 D8S270 Glucose level Diagnosed with type 2 diabetes abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 1298348 11067779 8 80089758 106089758 3 - by peak only
2316725 human GLUCO287_H Glucose level QTL 287 (human) 20 1.86 0.00312 1340191 D20S186 Glucose level Diagnosed with type 2 diabetes abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 1298348 11067779 20 1 24471866 3 - by peak only
2316726 human GLUCO284_H Glucose level QTL 284 (human) 15 1.5 0.00753 1341689 D15S1007 Glucose level Diagnosed with type 2 diabetes abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 1298348 11067779 15 18525141 44525141 3 - by peak only
2316727 human GLUCO281_H Glucose level QTL 281 (human) 2 1.98 0.0023 1335210 D2S305 Glucose level Diagnosed with type 2 diabetes abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 1298348 11067779 2 6282068 32282068 3 - by peak only
2316728 human GLUCO279_H Glucose level QTL 279 (human) 19 1.26 0.01358 1299977 D19S221 Glucose level Diagnosed with type 2 diabetes abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 1298348 11067779 19 1 25573976 3 - by peak only
2316729 human GLUCO289_H Glucose level QTL 289 (human) X 1.67 0.00491 1341766 DXS991 Glucose level Diagnosed with type 2 diabetes abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 1298348 11067779 X 42535916 68535916 3 - by peak only
2316730 human GLUCO280_H Glucose level QTL 280 (human) 2 1.9 0.00278 1298126 D2S168 Glucose level Diagnosed with type 2 diabetes abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 1298348 11067779
2316731 human GLUCO283_H Glucose level QTL 283 (human) 12 1.41 0.00925 1340523 D12S345 Glucose level Diagnosed with type 2 diabetes abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 1298348 11067779
2316695 human GLUCO259_H Glucose level QTL 259 (human) 18 2.3 9.7E-4 1337583 D18S1163 1299942 D18S843 Glucose level Diagnosed with type 2 diabetes abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 1298537 12727978 18 7462347 8603953 1 - by flanking markers
2316697 human GLUCO258_H Glucose level QTL 258 (human) X 1.27 1335211 DXS1205 Glucose level Diagnosed with type 2 diabetes abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 2316511 14988269 X 127090165 153090165 3 - by peak only
2316698 human GLUCO260_H Glucose level QTL 260 (human) 2 1.5 0.0075 1299938 D2S436 1299936 D2S1888 Glucose level Diagnosed with type 2 diabetes abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 1298537 12727978 2 106609665 111111693 1 - by flanking markers
2316699 human GLUCO266_H Glucose level QTL 266 (human) 1 1.64 0.00533 1336704 D1S2785 Glucose level Diagnosed with type 2 diabetes abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 1298348 11067779 1 225943481 247249719 3 - by peak only
2316700 human GLUCO262_H Glucose level QTL 262 (human) 11 1.5 0.061 1335397 D11S2362 1338019 D11S1999 Glucose level Diagnosed with type 2 diabetes abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 1334497 14636289 11 4868745 10676696 1 - by flanking markers
2316701 human GLUCO261_H Glucose level QTL 261 (human) 19 1.5 0.0063 1299912 D19S400 1299939 D19S245 Glucose level Diagnosed with type 2 diabetes abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 1298537 12727978 19 38790201 46219373 1 - by flanking markers
2316702 human GLUCO263_H Glucose level QTL 263 (human) 12 1.7 0.029 1298304 D12S398 Glucose level Diagnosed with type 2 diabetes abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 1334497 14636289 12 38483417 64483417 3 - by peak only
2316703 human GLUCO255_H Glucose level QTL 255 (human) 6 2.66 1338388 D6S1546 Glucose level Diagnosed with type 2 diabetes abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 2316511 14988269 6 91786850 117786850 3 - by peak only
2316704 human GLUCO256_H Glucose level QTL 256 (human) 11 2.98 1.1E-4 1338869 D11S4172 Glucose level Diagnosed with type 2 diabetes abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 2316511 14988269 11 65553683 91553683 3 - by peak only
2316705 human GLUCO265_H Glucose level QTL 265 (human) 1 2.5 6.6E-4 1335027 D1S484 Glucose level Diagnosed with type 2 diabetes abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 1298348 11067779 1 146034261 172034261 3 - by peak only
2316706 human GLUCO264_H Glucose level QTL 264 (human) 1 1.48 0.00782 1341244 D1S206 Glucose level Diagnosed with type 2 diabetes abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 1298348 11067779 1 88458026 114458026 3 - by peak only
2316707 human GLUCO257_H Glucose level QTL 257 (human) 14 2.74 1.9E-4 1335355 D14S290 Glucose level Diagnosed with type 2 diabetes abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 2316511 14988269 14 49602738 75602738 3 - by peak only
2316709 human GLUCO277_H Glucose level QTL 277 (human) 10 1.69 0.00472 1342195 D10S212 Glucose level Diagnosed with type 2 diabetes abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 1298348 11067779 10 121299685 135374737 3 - by peak only
2316710 human GLUCO270_H Glucose level QTL 270 (human) 3 3.91 2.0E-5 1335890 D3S1262 1340874 D3S1601 1342246 D3S1580 Glucose level Diagnosed with type 2 diabetes abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 1298348 11067779 3 187706173 193160302 1 - by flanking markers
2316711 human GLUCO268_H Glucose level QTL 268 (human) 2 2.27 0.00116 1337364 D2S2259 1338927 D2S391 1337364 D2S2259 Glucose level Diagnosed with type 2 diabetes abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 1298348 11067779 2 42850145 46265152 1 - by flanking markers
2316712 human GLUCO269_H Glucose level QTL 269 (human) 2 1.22 0.01507 1336069 D2S2330 Glucose level Diagnosed with type 2 diabetes abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 1298348 11067779 2 153405912 179405912 3 - by peak only
2316713 human GLUCO273_H Glucose level QTL 273 (human) 5 1.67 0.00492 1337935 D5S410 1338437 D5S436 1337935 D5S410 Glucose level Diagnosed with type 2 diabetes abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 1298348 11067779 5 145184396 152755186 1 - by flanking markers
2316714 human GLUCO271_H Glucose level QTL 271 (human) 4 1.35 0.01087 1336688 D4S2935 1341533 D4S412 1336688 D4S2935 Glucose level Diagnosed with type 2 diabetes abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 1298348 11067779 4 3350738 6611978 1 - by flanking markers
2316715 human GLUCO272_H Glucose level QTL 272 (human) 4 2.09 0.00175 1335155 D4S1539 Glucose level Diagnosed with type 2 diabetes abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 1298348 11067779 4 162924838 188924838 3 - by peak only
2316716 human GLUCO275_H Glucose level QTL 275 (human) 9 1.22 0.01494 1339367 D9S158 Glucose level Diagnosed with type 2 diabetes abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 1298348 11067779 9 125239066 140273252 3 - by peak only
2316717 human GLUCO267_H Glucose level QTL 267 (human) 2 2.02 0.00212 1337470 D2S319 Glucose level Diagnosed with type 2 diabetes abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 1298348 11067779 2 1 16406134 3 - by peak only
2316718 human GLUCO274_H Glucose level QTL 274 (human) 7 1.68 0.00479 1299970 D7S669 Glucose level Diagnosed with type 2 diabetes abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 1298348 11067779 7 64710512 90710512 3 - by peak only
2316719 human GLUCO276_H Glucose level QTL 276 (human) 10 1.24 0.01427 1334795 D10S1655 Glucose level Diagnosed with type 2 diabetes abnormal glucose homeostasis Diabetes Mellitus, Non-Insulin-Dependent 1298348 11067779 10 117846048 135374737 3 - by peak only